

PROGRAM GUIDE

CROI 2022

Conference on Retroviruses
and Opportunistic Infections

—— February 12-16 ——

with Symposia on February 22, 23, and 24



 IAS-USA

International Antiviral Society-USA

Version 4 | Last Updated February 18, 2022

CONTENTS

GENERAL INFORMATION	ii
LIVE PRECONFERENCE SESSIONS	1
LIVE PLENARY, ORAL ABSTRACT, AND INTERACTIVE SESSIONS BY DAY	7
POSTER SESSIONS BY DAY	32
POSTER SESSIONS DAY 1	32
POSTER SESSIONS DAY 2	59
POSTER SESSIONS DAY 3	89
POSTER SESSIONS BY CATEGORY	120
LIVE SYMPOSIA SESSIONS BY DAY	124
SYMPOSIA SESSIONS DAY 1	124
SYMPOSIA SESSIONS DAY 2	126
SYMPOSIA SESSIONS DAY 3	129
ABSTRACT PROCESS	132
INDEX OF STUDIES RELATED TO WOMEN	134
INDEX OF PRESENTING AUTHORS	140
SCHEDULE AT A GLANCE	INSIDE BACK COVER

GENERAL INFORMATION

CONTINUING MEDICAL EDUCATION

For information, visit the [CROI Continuing Medical Education](#) webpage.

FUNDING AND GRANT SUPPORT

For information, visit the [CROI Funding and Grant Support](#) webpage.

CROI FOUNDATION

The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections.

To view the current CROI Foundation Board Members and their roles and responsibilities, visit the [CROI Foundation](#) webpage.

IAS–USA

The International Antiviral (formerly AIDS) Society–USA (IAS–USA) serves as the Conference Organizer for the logistical planning and organization for CROI in partnership with the CROI Foundation and Program Committee. The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

To access primary educational and informational programs sponsored by the IAS–USA, visit the [IAS–USA](#) website.

SCIENTIFIC PROGRAM COMMITTEE

To view current members, visit the [CROI Scientific Program Committee](#) webpage.

COMMUNITY LIAISON SUBCOMMITTEE

To view the current members, visit the [CROI Community Liaison Subcommittee](#) webpage.

FORMER MEMBERS

To view former members, visit the [Former Members of the CROI Scientific Program Committee](#) webpage.

EXTERNAL REVIEWERS

To view current external reviewers, visit the [CROI External Reviewers](#) webpage.

SCHOLARSHIP AWARDEES

To view CROI 2022 New Investigator, International Investigator, and Community Scholarship recipients, visit the [Scholarship Recipient](#) webpage.

AFFILIATED OR PROXIMATE ACTIVITIES

For information, visit the [CROI Affiliated or Proximate Activities](#) webpage.

EMBARGO AND PRESS RELEASE POLICIES

For information, visit the [CROI Embargo and Press Release Policies](#) webpage.

LIVE PRECONFERENCE SESSIONS

SATURDAY, FEBRUARY 12, 2022

Workshop-1 SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

CME

8:30 AM MT - 12:30 PM MT

Target Audience: This workshop is directed to new investigators and trainees (eg, postdoctoral fellows, physician fellows, undergraduate students, and graduate students). Attendance is mandatory for all scholarship recipients, but the workshop is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for fewer than 3 years.

Objectives: At the completion of the session, participants will be able to:

- Describe the current state of the art of selected areas of HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions, in terms of basic, epidemiologic, and clinical research
- List the leading research themes being presented at CROI 2022
- Navigate CROI 2022, maximize the knowledge gained, and interact with research colleagues
- Clarify their individual research interests in relation to the priorities discussed at the workshop and at CROI 2022 overall

Conveners

Nicolas Chomont, *Université de Montréal, Montreal, Canada*

Serena S. Spudich, *Yale University, New Haven, CT, USA*



1 SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

8:30 SESSION DEDICATION AND WELCOME

John W. Mellors, *University of Pittsburgh, Pittsburgh, PA, USA*



8:35 ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2

Theodora Hatzioannou, *Rockefeller University, New York, NY, USA*



9:10 ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY

Penny Moore, *University of the Witwatersrand, Johannesburg, South Africa*



9:45 BREAK

9:55 ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC

Carlos del Rio, *Emory University, Atlanta, GA, USA*



10:30 ADVANCES IN BIOMEDICAL PREVENTION OF HIV

Adaora Adimora, *University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*



11:05 BREAK

11:15

ADVANCES IN HIV CURE WITH CLINICAL PERSPECTIVES**Peter W. Hunt**, *University of California San Francisco, San Francisco, CA, USA*

11:50

LIVE QUESTIONS AND ANSWERS

SUNDAY, FEBRUARY 13, 2022

OPENING SESSION

CME

8:30 AM MT - 10:45 AM MT

Description: The Opening Session is directed to all CROI participants: researchers and clinicians in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions, as well as new investigators, community educators, and research trainees (eg, postdoctoral fellows, physician fellows' undergraduate students, and graduate students).

8:30 CHAIR'S WELCOME TO CROI 2022

Elaine J. Abrams*ICAP at Columbia University, New York, NY, USA***CROI 2022 Chair****James A. Hoxie***University of Pennsylvania, Philadelphia, PA, USA***CROI 2022 Vice Chair****Landon Myer***University of Cape Town, Cape Town, South Africa***CROI 2022 Vice Chair**

The Martin Delaney Presentation is designed annually by the CROI Community Liaison Subcommittee and held annually in honor of pioneering HIV/AIDS activist Martin Delaney (1945–2009). It recognizes the important contributions of community advocacy and engagement in research.

8:40 INTRODUCTION OF THE MARTIN DELANEY PRESENTATION

Ntando D. Yola, *University of Cape Town, Cape Town, South Africa*

2 8:45 WE'RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION

Marc Thompson, *PrEPster, London, UK*

The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields (1938–1995), is given during the Opening Session, usually by a basic scientist recognized for their important and relevant contributions to the fields of virology and viral pathogenesis.

9:10 INTRODUCTION OF THE BERNARD FIELDS LECTURE

James A. Hoxie, *University of Pennsylvania, Philadelphia, PA, USA*

3 VACCINE STRATEGIES FOR HIV-1 AND COVID-19

9:15 **Dan H. Barouch**, *Beth Israel Deaconess Medical Center, Boston, MA, USA*

The N'Galy-Mann Lecture recognizes an HIV/AIDS researcher for their important and relevant work in the fields of epidemiology or clinical research. The lecture is named in honor of Drs Bosenge N'Galy and Jonathan Mann for their crucial, pioneering work in HIV science and care in Africa.

9:40

INTRODUCTION OF THE N'GALY-MANN LECTURE

Landon Myer, *University of Cape Town, Cape Town, South Africa*



4

9:45

HIV PREVENTION IN VULNERABLE POPULATIONS: GENERATING EVIDENCE TO REDUCE INEQUALITIES

Beatriz Grinsztejn, *Fundação Oswaldo Cruz, Rio de Janeiro, Brazil*



A special moderated discussion with the 19th Director of the Centers for Disease Control and Prevention will focus on the US response to the COVID-19 pandemic.

10:15

THE COVID-19 EPIDEMIC IN THE UNITED STATES: A DISCUSSION WITH DR ROCHELLE P. WALENSKY

Moderator

Elaine J. Abrams, *ICAP at Columbia University, New York, NY, USA*



Rochelle P. Walensky, *Centers for Disease Control and Prevention, Atlanta, GA, USA*



Workshop-2 FRONTIERS IN LABORATORY TECHNOLOGIES

CME

11:00 AM MT - 1:00 PM MT

Target Audience: This session is directed to scientists, clinicians, funders, stakeholders, students, and members of the community at large, who are interested in understanding the impact of novel laboratory technologies.

Level of Knowledge: It is assumed that the participants are familiar with the main technologic and data analysis approaches used in research.

Objectives: At the completion of the session, participants will be able to:

- Describe the power of protein visualization for mapping protein function, defining sites of vulnerability, and developing drugs or vaccines
- List the emerging technologies used to track and predict viral evolution, their impact on virulence, infectivity, and escape from vaccine immunity
- Describe the overlap in artificial intelligence techniques involved in tracking epidemics as well as developing new therapeutics

Conveners

Galit Alter, *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA*

Frank Kirchhoff, *Ulm University Medical Center, Ulm, Germany*



5

POPULATION-LEVEL VIRAL SEQUENCING

11:00

Tulio de Oliveira, *University of KwaZulu-Natal, Durban, South Africa*



11:20

LIVE QUESTIONS AND ANSWERS

6 DEEP MUTATIONAL SCANNING TO INTERPRET VIRAL EVOLUTION

11:30

Jesse Bloom, *Fred Hutchinson Cancer Research Center, Seattle, WA, USA*



11:50 LIVE QUESTIONS AND ANSWERS

7 AI-INSPIRED MONOCLONAL THERAPEUTIC ANTIBODY DESIGN

12:00

Regina Barzilay, *Massachusetts Institute of Technology, Cambridge, MA, USA*



12:20 LIVE QUESTIONS AND ANSWERS

8 SINGLE-CELL PROTEOMICS

12:30

Nikolai Slavov, *Northeastern University, Boston, MA, USA*



12:50 LIVE QUESTIONS AND ANSWERS

Workshop-3 CASE-BASED LIVER WORKSHOP

CME

11:00 AM MT - 1:00 PM MT

Target Audience: This session is directed to physicians and researchers interested in obtaining a contemporary understanding of key issues in viral hepatitis and liver disease in people with and without HIV infection.

Level of Knowledge: It is assumed that the participants are familiar with the major viral causes of hepatitis and other key issues related to liver disease in people with and without HIV infection.

Objectives: At the completion of the session, participants will be able to:

- Identify individuals at risk for hepatitis C virus reinfection
- Describe how the hepatitis viruses are transmitted
- Describe testing strategies in high-risk vulnerable populations
- List the current treatment strategies for recently acquired hepatitis C virus infection

Conveners

David Wyles, *Denver Health Medical Center, Denver, CO, USA*

Marina B. Klein, *McGill University Health Centre, Montreal, Canada*



9 LIVER STEATOSIS IN PERSONS LIVING WITH HIV

11:00

Maud Lemoine, *Imperial College London, London, UK*



11:25 LIVE QUESTIONS AND ANSWERS

10 GETTING HEPATITIS C AGAIN

11:30

Maria Prins, *Public Health Service of Amsterdam, Amsterdam, Netherlands*



11 CONTROVERSIES IN HEPATITIS B

11:52

Chloe L. Thio, *The Johns Hopkins University School of Medicine, Baltimore, MD, USA*



12 THE ORIGINAL DELTA VIRUS OR D LIKE THE DEVIL

12:15

Markus Cornberg, *Medizinische Hochschule Hannover, Hannover, Germany*



12:37 LIVE QUESTIONS AND ANSWERS

Workshop-4 CLINICAL TRIAL DESIGN AND ANALYSIS**CME****11:00 AM MT - 1:00 PM MT**

Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and epidemiologic studies of HIV or SARS-CoV-2.

Objectives: At the completion of the session, participants will be able to:

- List some of the reasons for disparate results between different COVID-19 studies
- Describe how analyses can be used to identify correlates of vaccine efficacy
- Discuss the underlying principles behind test-negative study designs and other study designs of vaccine effectiveness

Conveners

Susan P. Buchbinder, *San Francisco Department of Public Health, San Francisco, CA, USA*

Richard E. Chaisson, *The Johns Hopkins University, Baltimore, MD, USA*



13 **STUDYING COVID TREATMENT OUTCOMES: WHY DISPARATE RESULTS?**

11:00

Eric J. Rubin, *New England Journal of Medicine, Boston, MA, USA*



11:25 **LIVE QUESTIONS AND ANSWERS**

14 **ANALYSIS APPROACHES TO CORRELATES OF VACCINE EFFICACY**

11:30

Peter Gilbert, *Fred Hutchinson Cancer Research Center, Seattle, WA, USA*



11:55 **LIVE QUESTIONS AND ANSWERS**

15 **ASSESSING VACCINE EFFICACY IN THE REAL WORLD**

12:00

Sheena G. Sullivan, *University of Melbourne, Melbourne, Australia*



12:25 **LIVE QUESTIONS AND ANSWERS AND PANEL DISCUSSION**

CONFERENCE DAYS

MONDAY, FEBRUARY 14, 2022

Plenary Session-1 MONDAY PLENARY SESSION

CME

8:30 AM MT - 9:30 AM MT

Session Hosts

Guido Silvestri, Emory University, Atlanta, GA, USA

Hermione Lyall, Imperial College Healthcare NHS Trust, London, UK



8:30 WELCOME AND DAILY ROADMAP

James A. Hoxie, University of Pennsylvania, Philadelphia, PA, USA



16 HIV NONHUMAN PRIMATE MODELS FOR STUDIES OF VIRUS PATHOGENESIS, PERSISTENCE, AND CURE

8:40

Michaela Müller-Trutwin, Institut Pasteur, Paris, France



17 CHILDREN EXPOSED TO HIV, BUT UNINFECTED: EVIDENCE FOR ACTION

9:05

Andrew J. Prendergast, Queen Mary University of London, London, UK



Oral Abstract Session-1 TARGETS AND BARRIERS TO VIRAL INFECTION

9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

John M. Coffin, Tufts University, Boston, MA, USA

Theodora Hatzioannou, The Rockefeller University, New York, NY, USA



9:45 INTRODUCTIONS

18 HIV INFECTION OF BRAIN ORGANOID MICROGLIA INDUCES INFLAMMATION AND NEURONAL DEATH

9:50

Weili Kong, Gang Zhang, Peter Sohn, Roland Schwarzer, Guorui Xie, Julie Frouard, Mauricio Montano, Nadia Roan, Li Gan, Warner Greene

19 MACROPHAGES ARE THE PRIMARY SOURCE OF VIRUS IN SEMEN IN ACUTELY INFECTED MACAQUES

9:58

Christine M. Fennessey, Catherine Brands, Simona Florea, Laura Newman, Leslie Lipkey, William Bosche, Randy Fast, Jeffrey D. Lifson, Brandon Keele, **Claire Deleage**

20 CyTOF-Lec REVEALS GLYCAN FEATURES DEFINING CELLS DIFFERENTIALLY SUSCEPTIBLE TO HIV

10:06

Tongcui Ma, Matthew McGregor, Leila B. Giron, Mohamed Abdel-Mohsen, Nadia Roan

21 MONOMERIC HIV-1 ENVELOPE CYTOPLASMIC TAILS ARE SUFFICIENT FOR Gag LATTICE RETENTION

10:14

Nicholas S. Groves, Yuta Hikichi, Merissa Bruns, Eric O. Freed, Schuyler van Engelenburg



10:22 **LIVE QUESTIONS AND ANSWERS**10:40 **INTRODUCTIONS****22 RAPALOGS DOWNMODULATE INTRINSIC IMMUNITY AND PROMOTE CELL ENTRY OF SARS-CoV-2**

10:45

Guoli Shi, Abhilash I. Chiramel, Saliha Majdoul, Kin Kui Lai, Swagata Kar, Sonja M. Best, **Alex A. Compton****23 IFITM DEPENDENCY OF SARS-CoV-2 VARIANTS OF CONCERN**

10:53

Rayhane Nchioua, Caterina Prelli Bozzo, Annika Schundner, Fabian Zech, Manfred Frick, Konstantin Sparrer, Frank Kirchhoff**24 INTERFERON RESISTANCE OF EMERGING SARS-CoV-2 VARIANTS**

11:01

Kejun Guo, Bradley S. Barrett, Kaylee Mickens, Eszter Vladar, James Morrison, Kim J. Hasenkrug, Eric M. Poeschla, **Mario L. Santiago****25 TYPE-I INTERFERON MODULATION IN VIVO BLOCKS SARS-CoV-2 REPLICATION AND INFLAMMATION**

11:09

**Timothy Hoang**, Elise G. Viox, Amit Upadhyay, Maria Pino, Arun Boddapati, Gregory Tharp, Zachary Strongin, Thomas H. Vanderford, Monica Vaccari, Jacob Estes, Daniel C. Douek, Gideon Schreiber, Steven Bosinger, Mirko Paiardini**26 SARS-CoV-2 SPIKE BINDS FIBRINOGEN-INDUCING ABNORMAL INFLAMMATORY BLOOD CLOTS**

11:17

Mauricio Montano, Jae Kyu Ryu, Elif G. Sozmen, Karuna Dixit, Yusuke Matsui, Yixin Liu, Ekram Wassim A. Helmy, Thomas J. Deerinck, Zhaoqi Yan, Renaud Schuck, Reuben Thomas, Alexander R. Pico, Mark H. Ellisman, Katerina Akassoglou, Warner Greene11:25 **LIVE QUESTIONS AND ANSWERS****Oral Abstract Session-2 MATERNAL AND CHILD HEALTH: NEW INSIGHTS INTO HEPATITIS, SARS-CoV-2, AND HIV**

9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators**Elaine J. Abrams**, Columbia University, New York, NY, USA**Landon Myer**, University of Cape Town, Cape Town, South Africa9:45 **INTRODUCTIONS****27 UNIVERSAL HEPATITIS C VIRUS SCREENING IN PREGNANCY: THE JUICE IS WORTH THE SQUEEZE**

9:50

Catherine A. Chappell, Samantha M. Mayo, John A. Grosko, Leslie A. Meyn, Scott Henzler, Naudia Jonassaint, Sharon L. Hillier**28 HBIG-FREE STRATEGY TO PREVENT HBV MOTHER-TO-CHILD TRANSMISSION: ANRS TA PROHM STUDY**

9:58

Olivier Segéral, Bunnet Dim, Christine Durier, Sovann Nhoeng, Kearena Chhim, Chantana Yay, Sothy Pech, Bunthoeun Nhem, Kay Huot, Chanlina Vong, Julia Guillebaud, Rattana Kim, Samsorphea Chhun, Laurence Borand, for the ANRS 12345 TA PROHM Study Group**29 THE IMPACT OF COVID-19 ON ADVERSE BIRTH OUTCOMES IN BOTSWANA BY HIV STATUS**

10:06

**Maya Jackson-Gibson**, Modiegi Diseko, Ellen Caniglia, Gloria Mayondi, Judith Mabuta, Rebecca Luckett, Sikhulile Moyo, Pamela F. Smith-Lawrence, Mogomotsi S. Matshaba, Mosepele Mosepele, Mompoti Mmalane, Shahin Lockman, Joseph Makhema, Rebecca Zash, Roger L. Shapiro

30 **GROWTH OF INFANTS WITH PERINATAL EXPOSURE TO MATERNAL DTG VS EFV AND TDF VS TAF**
 10:14 **Lynda Stranix-Chibanda**, Lauren Ziemba, Sean Brummel, Benjamin Johnston, Tapiwa G. Mbengeranwa, Haseena Cassim, Gerhard Theron, Sherika Hanley, Maxensia Owor, Katie McCarthy, Nahida Chakhtoura, Patrick Jean-Philippe, Lameck Chinula, Shahin Lockman, for the IMPAACT 2010/VESTED Study Team and Investigators

10:22 **LIVE QUESTIONS AND ANSWERS**

10:40 **INTRODUCTIONS**

31 **TWO-YEAR VIROLOGIC OUTCOMES OF VERY EARLY ART FOR INFANTS IN THE IMPAACT P1115 STUDY**
 10:45

Deborah Persaud, Ellen G. Chadwick, Bryan S. Nelson, Camlin Tierney, Mark F. Cotton, Anne Coletti, Diane Costello, Nicol Nicodimus, Lynda Stranix-Chibanda, Adeodata R. Kekitiinwa, Christina Reding, Sai Majji, Patrick Jean-Philippe, Yvonne Bryson, for the IMPAACT P1115 Study Team

32 **TREATMENT WITH BROADLY NEUTRALIZING ANTIBODIES IN CHILDREN WITH HIV IN BOTSWANA**
 10:53

Roger L. Shapiro, Kenneth Maswabi, Gbolahan Ajibola, Michael Hughes, Molly Pretorius Holme, Kathleen M. Powis, Sikhulile Moyo, Bryan S. Nelson, Marina Caskey, Lucio Gama, Patrick Jean-Philippe, Dwight E. Yin, Edmund Capparelli, Daniel Kuritzkes, Mathias Lichterfeld

33 **IMPACT OF POINT-OF-CARE HIV VIRAL LOAD TESTING IN KENYAN CHILDREN: A RANDOMIZED TRIAL**
 11:01

Rena Patel, Patrick Oyaro, Katherine K. Thomas, James Wagude, Irene Mukui, Eunice Kinywa, Frederick Oluoch, Leonard Kingwara, Evelyn Brown, Emericah C. Kariuki, Nashon Y. Odhiambo, Grace John-Stewart, Lisa Abuogi

11:09 **LIVE QUESTIONS AND ANSWERS**

Oral Abstract Session-3 MALIGNANCIES AND COMORBIDITIES: AN INCREASING BURDEN

9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Judith S. Currier, University of California Los Angeles, Los Angeles, CA, USA

Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA



9:45 **INTRODUCTIONS**

34 **GEOGRAPHICAL DIFFERENCES IN FUNCTIONAL IMPAIRMENT OF PEOPLE WITH HIV**
 9:50

Kristine Erlandson, Kathleen Fitch, Sara McCallum, Heather J. Ribaud, Edgar T. Overton, Gerald S. Bloomfield, Todd Brown, Carl J. Fichtenbaum, Sara Bares, Judith A. Aberg, Pamela S. Douglas, Laura Moran, Vidya Mave, Steven Grinspoon

35 **ANTICHOLINERGIC MEDICATIONS ASSOCIATED WITH FALLS AND FRAILTY IN PEOPLE WITH HIV**
 9:58

Jessica Doctor, Alan Winston, Jaime Vera, Frank A. Post, Marta Boffito, Patrick Mallon, Jane Anderson, Margarita Durkina, Ian Williams, Margaret Johnson, Manolis Bagkeris, Memory Sachikonye, Caroline Sabin, for the POPPY Study

36 INFLAMMATION AND KYNURENINE PATHWAY LINKED TO TYPE 2 DIABETES AND FAT FIBROSIS IN HIV

10:06

Diana L. Alba, Samuel R. Schnittman, Rachel T. Cheang, Gabriele B. Beck-Engeser, Fay Chan, Dave Glidden, Joseph A. Delaney, Amelia N. Deitchman, Fran Aweeka, Judy K. Shigenaga, Carl Grunfeld, Heidi Crane, Suneil K. Koliwad, Peter W. Hunt, for the CFAR Network of Integrated Clinical Systems Network

37 GUT MICROBIOTA, PLASMA METABOLOMICS, AND ATHEROSCLEROSIS IN HIV INFECTION

10:14

Zheng Wang, Wendy Post, Alan Landay, Kathleen Weber, Elizabeth T. Golub, Deborah Gustafson, Seble Kassaye, Bradley Aouizerat, Sabina Haberen, Carlos Malvestutto, Matthew Budoff, Kathryn Anastos, Robert Kaplan, Robert Burk, Qibin Qi

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

38 MACROPHAGE ARTERIAL INFILTRATION RELATES TO PLAQUE TYPE AND IMMUNE ACTIVATION IN HIV

10:45

Mabel Toribio, Moses Wilks, Sandeep Hedgire, Michael T. Lu, Madeline Cetlin, Melissa Wang, Iad Alhallak, Kevin S. White, Zoey K. Wallis, Takara Stanley, Georges El-Fakhri, Patrick Autissier, Markella V. Zanni, Kenneth Williams, Steven Grinspoon

39 TRENDS IN MYOCARDIAL INFARCTION RISK BY HIV STATUS IN TWO US HEALTHCARE SYSTEMS

10:53

Michael J. Silverberg, Asya Lyass, Leo Hurley, Rachel Ehrbar, Taylor Mahoney, Leila Borowsky, Wei He, Jorge Plutzky, Daniel Klein, Joseph M. Massaro, Ralph B. D'Agostino Sr, Virginia A. Triant

40 NONSMALL CELL LUNG CARCINOMA IN PLWH HARBORS IMMUNOREGULATORY TUMOR MICROENVIRONMENT

11:01



Syim Salahuddin, Ramsey Yusuf, Shruti Desai, Kishu Ranjan, Jianlei Gu, Daiwei Tang, Yong Kong, Hongyu Zhao, Yuval Kluger, Kurt Schalper, Brinda Emu

41 HPV GENOTYPING IN STUDY OF ADJUNCTIVE VACCINE FOR TREATMENT OF CERVICAL DYSPLASIA

11:09

Grant Ellsworth, Yvonne Perner, Mathilda Claaseen, Avril J. Swarts, Vuyokazi Jezile, Masangu Mulongo, Bridgette Goeieman, Sophie Williams, Mark Faesen, Pamela Michelow, Wolfgang Preiser, Timothy Wilkin, Cynthia S. Firnhaber

42 ANGIOGENIC FACTORS IN RNA-SEQ OF SKIN AND GASTROINTESTINAL KAPOSI SARCOMA LESIONS

11:17

Ramya Ramaswami, Takanobu Tagawa, Anna Serquina, Guruswamy Mahesh, Xiaofan Li, Vishal Koparde, Kathryn Lurain, Ralph Mangusan, Anaida Widell, Irene Ekwede, Laurie T. Krug, Robert Yarchoan, **Joseph Ziegelbauer**

11:25 LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-4 EVOLVING EPIDEMIOLOGY OF HIV AND SARS-CoV-2

9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

James A. McIntyre, Anova Health Institute, Johannesburg, South Africa



9:45 **INTRODUCTIONS****43** **ESTIMATING THE LIFETIME RISK OF A DIAGNOSIS OF HIV INFECTION IN THE UNITED STATES**

9:50

Sonia Singh, Xiaohong Hu, Kristen Hess**44** **LARGE HIV CLUSTERS AMONG MEN WHO HAVE SEX WITH MEN IN THE UNITED STATES**

9:58

Stephen Perez, Nivedha Panneer, Anne Marie France, Kathryn Curran, Alexandra M. Oster**45** **HIV-1 DIAGNOSES IN NORTH CAROLINA, 2018-21: INCIDENT INFECTIONS AND DRUG RESISTANCE**

10:06

Shuntai Zhou, Nathan Long, Matt Moeser, Collin Hill, Erika Samoff, Victoria Mobley, Simon Frost, Elizabeth Kelly, Scott Shone, William Glover, Michael Clark, Joseph J. Eron, Myron S. Cohen, Ronald Swanstrom, Ann M. Dennis**46** **SARS-CoV-2 PREVALENCE IN CHILDREN AND ADULTS IN 15 US COMMUNITIES: THE COMPASS STUDY**

10:14

Jessica E. Justman, Timothy M. Skalland, Ayana Moore, Christopher Amos, Mark Marzinke, Colleen F. Kelley, Rebecca M. Singer, Yael Hirsch-Moverman, Susanne Doblecki-Lewis, David Metzger, Elizabeth Barranco, Ken Ho, Margaret M. Powers-Fletcher, Patricia J. Kissinger, for the CoVPN 5002 COMPASS Study Team10:22 **LIVE QUESTIONS AND ANSWERS**10:40 **INTRODUCTIONS****47** **SAFETY AND EFFECTIVENESS OF THE Ad26.COVS.S VACCINE IN SOUTH AFRICA**

10:45

Glenda E. Gray, Nigel Garrett, Ameena Goga, Lara Fairall, Tarylee Reddy, Nonhlanhla Yende-Zuma, Shirley Collie, Ian Sanne, Harry Moultrie, Fatima Mayat, Andrew Boule, Simbarashe Takuva, Azwi Takalani, Lawrence Corey, Linda-Gail Bekker, for the Sisonke Research Group**48** **COVID-19 BOOSTER VACCINE EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION**

10:53

**Jing Sun**, Qulu Zheng, Alfred J. Anzalone, Alison G. Abraham, Jomol Mathew, Nasia Safdar, Jessica Y. Islam, Amy L. Olex, Roslyn B. Mannon, Christopher G. Chute, Rena Patel, Gregory D. Kirk, for the National COVID Cohort Collaborative**49** **INFECTIOUSNESS OF BREAKTHROUGH INFECTIONS AFTER VACCINATION AND NATURAL INFECTION**

11:01

Laith J. Abu-Raddad, Hiam Chemaitelly, for the National Study Group for COVID-19 Epidemiology in Qatar**50** **COVID-19 VACCINATION RATES IN A GLOBAL HIV COHORT**

11:09

Evelynne S. Fulda, Kathleen Fitch, Edgar T. Overton, Markella V. Zanni, Judith A. Aberg, Judith S. Currier, Michael T. Lu, Carlos Malvestutto, Carl J. Fichtenbaum, Esteban Martinez, Triin Umbleja, Pamela S. Douglas, Heather J. Ribaud, Steven Grinspoon, for the REPRIEVE Trial11:17 **LIVE QUESTIONS AND ANSWERS**

Interactive Session-1**VIRAL SURVIVAL STRATEGIES IN THE
FACE OF HOST IMMUNE RESPONSES:
IMPLICATIONS FOR VACCINES****CME****12:00 PM MT - 1:00 PM MT**

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include 5 rapid-fire presentations, followed by discussions and interactions with the moderators, experts, and audience.

Target Audience: This session is directed to researchers, clinicians, and translational scientists interested in why some vaccines have been successful and why some viruses have presented challenges to the development of effective vaccines.

Level of Knowledge: It is assumed that the participants are familiar with the importance of vaccine development and use and their infectious targets.

Objectives: At the completion of the session, participants will be able to:

- Explain how effective vaccines against SARS-CoV-2 were developed so quickly
- Describe why the most effective viral vaccine (ie, for human papillomavirus infection) achieves its success, especially against mucosal infection
- Describe the mechanisms by which certain important viruses (herpes simplex virus, influenza virus, and HIV) pose different impediments to the development of effective vaccines

Moderators

Douglas D. Richman, *University of California San Diego, San Diego, CA, USA*

Guido Silvestri, *Emory University, Atlanta, GA, USA*



12:00 **SESSION OVERVIEW**

12:05 **UNIQUE CHALLENGES OF VACCINATING DURING A PANDEMIC**

John P. Moore, *Weill Cornell Medicine, New York, NY, USA*



12:10 **HPV VACCINE: A SUCCESSFUL MODEL OF VACCINE-INDUCED MUCOSAL ANTIVIRAL IMMUNE RESPONSE**

Margaret A. Stanley, *University of Cambridge, Cambridge, UK*



12:15 **FLU VACCINES: THE GLASS HALF-FULL**

Florian Krammer, *Columbia University, New York, NY, USA*



12:20 **HERPES VIRUSES: VIRUSES THAT EVADE VACCINE-INDUCED HOST-IMMUNE RESPONSES**

Betsy Herold, *Albert Einstein College of Medicine, New York, NY, USA*



12:25 **HIV-1: THE ULTIMATE CHALLENGE FOR VACCINE DEVELOPMENT**

Alexandra Trkola, *University of Zurich, Zurich, Switzerland*



12:30 **LIVE PANEL DISCUSSION**

Interactive Session-2 COVID-19 TREATMENT: CONSENSUS AND CONTROVERSIES

CME

12:00 PM MT - 1:00 PM MT

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include case presentations with discussion from the expert panel, followed by discussions and interactions with the moderators, experts, and audience.

Target Audience: This session is directed to clinicians interested in the care of persons with COVID-19.

Level of Knowledge: It is assumed that the participants are familiar with the clinical expression of SARS-CoV-2 and general medical principles and practices.

Objectives: At the completion of the session, participants will be able to:

- Compare the therapeutics recommended by international guidelines for the management of serious COVID-19
- Compare the treatment of COVID-19 in pregnant women with nonpregnant adults
- Compare the treatment of COVID-19 in persons with HIV or otherwise immunocompromised with those without apparent immunologic deficits
- List the treatments available for persons with mild or moderate COVID-19

Moderators

Rajesh T. Gandhi, *Massachusetts General Hospital, Boston, MA, USA*

Annie Luetkemeyer, *University of California San Francisco, San Francisco, CA, USA*



Panelists

Ghady Haidar, *University of Pittsburgh, Pittsburgh, PA, USA*



Laura Riley, *Weill Cornell Medicine, New York, NY, USA*



David Lye, *National Centre for Infectious Diseases, Singapore, Singapore*



Sandra Wagner-Cardoso, *Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil*



- **CASE 1: AN IMMUNOCOMPROMISED PATIENT WITH HIV AND COVID-19**
- **CASE 2: A PREGNANT WOMAN WITH MODERATE TO SEVERE COVID-19**
- **CASE 3: A FULLY VACCINATED AND BOOSTED PATIENT WHO IS OPEN TO COVID-19 PrEP**

Interactive Session-3 (COVID-19) VACCINE MANDATES: THE PAST, THE PRESENT, AND THE WAY FORWARD

CME

12:00 PM MT - 1:00 PM MT

Description: This session is intended to be an engaging, lively, interactive, and scientifically fun discussion on the issue of mandating vaccinations for COVID-19. The session includes 3 presentations of 10 minutes each, followed by a discussion by the expert panel and responses to questions from the audience.

Target Audience: This session is directed at researchers, clinicians, translational scientists, and policymakers interested in the issue of mandated COVID-19 vaccination.

Level of Knowledge: It is assumed that the participants are familiar with COVID-19 vaccines and most may be working in environments where vaccination is or is not mandatory.

Objectives: At the completion of the session, participants will be able to:

- Describe the history of vaccine mandates
- Explain the causes of vaccine hesitancy and concern among members of some under-represented minority groups and solutions for overcoming this challenge
- Identify barriers to vaccine mandates and solutions for this problem

Moderators

Adaora Adimora, *University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*



Carlos del Rio, *Emory University, Atlanta, GA, USA*



12:00 VACCINE MANDATES: HISTORY IN THE UNITED STATES AND OTHER COUNTRIES

Ruth Macklin, *Albert Einstein College of Medicine, New York, NY, USA*



12:10 VACCINE HESITANCY AMONG MEMBERS OF RACIAL AND ETHNIC MINORITY GROUPS

Matifadza Hlatshwayo Davis, *City of St Louis Department of Health, Saint Louis, MO, USA*



12:20 LEGAL AND POLITICAL ISSUES RELATED TO VACCINE MANDATES IN THE US, AND SOLUTIONS FOR OVERCOMING THEM

Lawrence O. Gostin, *Georgetown University, Washington, DC, USA*



12:30 LIVE PANEL DISCUSSION

TUESDAY, FEBRUARY 15, 2022

Plenary Session-2 TUESDAY PLENARY SESSION

CME

8:30 AM MT - 9:30 AM MT

Session Hosts

Theodora Hatzioannou, *The Rockefeller University, New York, NY, USA***Wafaa M. El-Sadr**, *Columbia University, New York, NY, USA*

8:30 WELCOME AND DAILY ROADMAP

Landon Myer, *University of Cape Town, Cape Town, South Africa*

60 NEW INSIGHTS INTO HIV RNA BIOLOGY

8:40 **Michael Summers**, *University of Maryland Baltimore County, Baltimore, MD, USA*

61 UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE

9:05

Muge Cevik, *University of St Andrews, St Andrews, UK*

Oral Abstract Session-5 HIV RESERVOIRS AND CURE STRATEGIES

9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Nicolas Chomont, *Université de Montréal, Montreal, Canada***Katharine J. Bar**, *University of Pennsylvania, Philadelphia, PA, USA*

9:45 INTRODUCTIONS

62 THE IMPACT OF 3BNC117 AND ROMIDEPSIN TREATMENT AT ART INITIATION ON HIV-1 PERSISTENCE

9:50

Jesper D. Gunst, Marie H. Pahu, Miriam Rosás-Umbert, Thomas Benfield, Henrik Nielsen, Isik S. Johansen, Rajesh Mohey, Lars Østergaard, Mariane H. Schleimann, Martin Tolstrup, Julie Fox, Michel Nussenzweig, Marina Caskey, Sarah Fidler, Ole Sogaard

63 THERAPEUTIC EFFICACY OF COMBINED ACTIVE AND PASSIVE IMMUNIZATION IN SHIV+ MACAQUES

9:58

Victoria E. Walker-Sperling, Noe B. Mercado, Abishek Chandrashekar, Erica N. Borducchi, Jinyan Liu, Joseph P. Nkolola, Mark G. Lewis, Romas Geleziunas, Merlin Robb, Nelson L. Michael, Maria G. Pau, Hanneke Schuitemaker, Janet Siliciano, Robert Siliciano, Dan Barouch

64 AZD5582 PLUS SIV mAbs TO REDUCE TISSUE RESERVOIRS IN ART-SUPPRESSED MACAQUES

10:06

Amir Dashti, Sophia Sukkestad, Anna M. Horner, Margaret A. Neja, Nils Schoof, Maud Mavigner, Jeffrey D. Lifson, Shane D. Falcinelli, Hannah King, Rosemarie D. Mason, Richard M. Dunham, David M. Margolis, Mario R. Roederer, Guido Silvestri, Ann Chahroudi

65 HIV-1 REMISSION WITH CCR5Δ32Δ32 HAPLO-CORD TRANSPLANT IN A US WOMAN: IMPAACT P1107

10:14



JingMei Hsu, Koen Van Besien, Marshall J. Glesby, Anne Coletti, Savita G. Pahwa, Meredith Warshaw, Amanda Golner, Frederic Bone, Nicole Tobin, Marcie Riches, John W. Mellors, Renee Browning, Deborah Persaud, **Yvonne Bryson**, for the IMPAACT P1107 Study Team

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

66 UNBIASED AND MULTIOMIC ASSESSMENT OF HIV-1-INFECTED CELLS AT SINGLE-CELL RESOLUTION

10:45



Vincent H. Wu, Son Nguyen, Perla Mariana Del Rio Estrada, Fernanda Torres-Ruiz, Yara A. Luna-Villalobos, Santiago Ávila-Ríos, Gustavo Reyes-Teran, Katharine J. Bar, Laura A. Vella, Michael Betts

67 EXPANSION AND EXTENSIVE RECIRCULATION OF HIV-INFECTED CELLS IN MULTIPLE ORGANS

10:53



Caroline Dufour, Maria Julia Ruiz, Amélie Pagliuzza, Amélie Cattin, Tomas Raul Wiche Salinas, Syim Salahuddin, Stephanie Burke Schinkel, Cecilia Theresa Costiniuk, Mohammad-Ali Jenabian, Petronela Ancuta, Jean-Pierre Routy, Eric A. Cohen, Christopher Power, Jonathan B. Angel, Nicolas Chomont

68 SELECTION OF INTACT HIV-1 PROVIRUSES IN DEEP LATENCY DURING LONG-TERM ART

11:01



Kyra W. Seiger, Xiaodong Lian, Elizabeth Parsons, Ce Gao, Gregory T. Gladkov, Joshua M. Chevalier, Michael M. Lederman, Deborah K. McMahon, Ronald J. Bosch, Jeffrey M. Jacobson, Rajesh T. Gandhi, Michael J. Peluso, Steven G. Deeks, Xu Yu, Mathias Lichterfeld

69 SINGLE-CELL MULTIOMICS REVEALS HIV-1 PERSISTENCE IN EXPANDED CYTOTOXIC T-CELL CLONES

11:09

Jack A. Collora, Runxia Liu, Neal Ravindra, Delia M. Pinto-Santini, Siavash Pasalar, Carmela Ganoza, Javier R. Lama, Ricardo Alfaro, Serena S. Spudich, Karam Mounzer, Pablo Tebas, Luis J. Montaner, David Van Dijk, Ann C. Duerr, **Ya-Chi Ho**

70 DELAYED VIRAL REBOUND FOLLOWING ANTIBODY ADMINISTRATION IN INFANT MACAQUES

11:17

Jenna S. Powers, Katherine M. Bricker, Brianna Williams, Danielle Oliver, Veronica Obregon-Perko, Dormarie E. Rivera Rodriguez, Sophia Sukkestad, Amir Dashti, Rosemarie D. Mason, Mario R. Roederer, Ann Chahroudi

11:25 LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-6 TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HEPATITIS

9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Constance A. Benson, *University of California San Diego, San Diego, CA, USA*

David L. Thomas, *The Johns Hopkins School of Medicine, Baltimore, MD, USA*



9:45 INTRODUCTIONS

71 NOVEL qPCR APPROACH REVEALS DYNAMICS OF HBsAg DERIVED FROM INTEGRATED HBV (iDNA)

9:50

Tanner Grudde, Hyon S. Hwang, Mark S. Sulkowski, Maraake Taddese, Richard Sterling, Ashwin Balagopal, Chloe L. Thio

72 MODELING IMPACT OF THE COVID-19 PANDEMIC ON HEPATITIS C VIRUS ELIMINATION IN THE US

9:58

Ricardo E. Flores Ortega, Martin Hoenigl, Jaskaran S. Cheema, Nancy Reau, Natasha Martin

73 EFFECT OF DIRECT-ACTING ANTIVIRALS ON HCV INCIDENCE AMONG PEOPLE LIVING WITH HIV

10:06

Daniela K. van Santen, Rachel Sacks-Davis, Marc Van der Valk, Mark Stooze, Andri Rauch, Inma Jarrín, Karine Lacombe, Linda Wittkop, Gail Matthews, Joseph Doyle, Marina B. Klein, Maria Prins, Tim Spelman, Margaret Hellard, for the InCHEHC Collaboration

74 VORICONAZOLE OR AMPHOTERICIN B DEOXYCHOLATE: WHICH IS THE PREFERRED INDUCTION THERAPY

10:14

Yihong Zhou, Yuanyuan Qin, Yanqiu Lu, Jing Yuan, Jingmin Nie, Min Liu, Qun Tian, Ke Lan, Guoqiang Zhou, Yingmei Qin, Kaiyin He, Jianhua Yu, Jun Liu, Vijay Harypursat, **Yaokai Chen**

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

75 CLUSTER RCT OF A MID-LEVEL MANAGER INTERVENTION TO PROMOTE IPT UPTAKE IN UGANDA

10:45

Elijah Kakande, Canice Christian, Laura B. Balzer, Joshua R. Nugent, William Dileo, Derek Rast, Jane Kabami, Jason Johnson Peretz, Carol S. Camlin, Starley R. Shade, Elvin H. Geng, Dalsone Kwarisiima, Moses R. Kanya, Diane V. Havlir, Gabriel Chamie

76 RANDOMIZED CONTROLLED TRIAL OF ADJUNCTIVE ROSUVASTATIN FOR TUBERCULOSIS TREATMENT

10:53

Gail B. Cross, Intan Permata Sari, Cissy Kityo, Yogesh Pokharkar, Han-Nguyen Thi, Quyet Do, Emmanuel Gutierrez, Victoria Dalay, Vincent M. Jr, Henry Mugerwa, Ka-Lip Chew, Nicholas Paton, for the ROSETTA Trial Team

77 PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH RIFAMPICIN THERAPY IN ACTG A5375

11:01

Rosie Mngqibisa, Laura M. Smeaton, Maxine Olefsky, Anthony T. Podany, Elizabeth Barr, Pablo Belaunzaran, Sharlaa Badal-Faesen, Evans Kachale, Cecelia Kanyama, Marije Van Schalkwyk, Elizabeth Woolley, Susan E. Cohn, Catherine Godfrey, Kimberly K. Scarsi, for the AIDS Clinical Trials Group A5375 Study Team

78 DTG PK IN PEOPLE WITH HIV RECEIVING DAILY 1HP FOR LATENT TB TREATMENT (ACTG A5372)

11:09



Marjorie Z. Imperial, Annie Luetkemeyer, Rodney Dawson, Yoninah Cramer, Sue Rosenkranz, Susan Swindells, Irina Gelmanova, Anchalee Avihingsanon, Roberto C. Arduino, Wadzanai Samaneka, Kelly Dooley, Rada Savic, **Anthony T. Podany**, for the ACTG A5372 Protocol Team

79 TB-PRACTECAL RESULTS: 24 WEEK ALL-ORAL REGIMENS FOR RIFAMPICIN RESISTANT TUBERCULOSIS

11:17



Bern-Thomas Nyang'wa, Emil Kazounis, Ilaria Motta, Matthew Dodd, Katherine Fielding, Catherine Berry, for the TB-PRACTECAL Team

11:25 LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-7 HIV PREVENTION: FROM THE BENCH TO POPULATION

9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Sharon L. Hillier, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Jean-Michel Molina, University of Paris, Paris, France



9:45 **INTRODUCTIONS**

80 **LONG-ACTING INJECTABLE FOR PREVENTION OF HIV AND UNPLANNED PREGNANCY**

9:50



Isabella Young, Aryani Pallerla, Panita Maturavongsadit, Alka Prasher, Roopali Shrivastava, Stephanie Montgomery, Amanda Schauer, Mackenzie L. Cottrell, Angela Kashuba, Soumya R. Benhabbour

81 **PHASE I STUDY OF COMBINATION ANTI-HIV NEUTRALIZING ANTIBODIES IN HIV-NEGATIVE ADULTS**

9:58

Magdalena E. Sobieszczyk, Sharon Mannheimer, Yunda Huang, Carmen Paez, Theresa Gamble, Deborah A. Theodore, Wairimu Chege, Margaret Yacovone, Chenchen Yu, Lily Zhang, Jack Heptinstall, Kelly E. Seaton, Georgia Tomaras, David Montefiori, for the HVTN 130/HPTN 089 Study Team

82 **PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING**

10:06

Albert Liu, Holly Gundacker, Barbra A. Richardson, Beatrice Chen, Craig Hoesley, Ariane Van der Straten, May Beamer, Jennifer Robinson, Cindy Jacobson, Rachel Scheckter, Katherine Bunge, Andrea Thurman, Gustavo Doncel, Jeanna Piper, Mark Marzinke

83 **ISLATRAVIR DISTRIBUTION IN MUCOSAL TISSUES, PBMC, & PLASMA AFTER MONTHLY ORAL DOSING**

10:14

Craig W. Hendrix, Sharon L. Hillier, Linda-Gail Bekker, Sharlaa Badal-Faesen, Sharon A. Riddler, Edward J. Fuchs, Pippa J. Macdonald, Stacey Edick, Rebeca M. Plank, Cynthia M. Chavez-Eng, Barbara Evans, Xiaowei Zang, Ryan Vargo, Michael N. Robertson, Munjal Patel

10:22 **LIVE QUESTIONS AND ANSWERS**

10:40 **INTRODUCTIONS**

84 **THE BIDIRECTIONAL EFFECTS OF HORMONE THERAPY AND PrEP IN TRANSGENDER INDIVIDUALS**

10:45

Jill Blumenthal, Ravi Goyal, Leah Burke, Michael Dubé, Martin Hoenigl, David J. Moore, Karen Chow, Jordan Silva, Katya Corado, Richard H. Haubrich, Peter Anderson, Robert Bolan, Sheldon Morris

85 **PHASE IIA TRIAL OF ISLATRAVIR QM FOR HIV PrEP: WEEK 24 METABOLIC AND RENAL OUTCOMES**

10:53

Pippa J. Macdonald, Sharon A. Riddler, Sharlaa Badal-Faesen, Howard Schwartz, Johannes Lombaard, Yoseph Caraco, Avivit Peer, Ciaran McMullan, Keith D. Kaufman, Brenda Homony, Katherine Nedrow, Valerie Teal, Michael N. Robertson, Rebeca M. Plank

86 **COUNTERFACTUAL ESTIMATION OF CAB-LA EFFICACY AGAINST PLACEBO USING EXTERNAL TRIALS**

11:01

Deborah Donnell, Fei Gao, James Hughes, Brett Hanscom, Lawrence Corey, Myron S. Cohen, Srilatha Edupuganti, Nyaradzo M. Mgodi, Helen V. Rees, Jared Baeten, Glenda E. Gray, Linda-Gail Bekker, Mina C. Hosseini, Sinead Delany-Moretlwe

87 DIFFERENT HIV PROTECTION FOR TRADITIONAL AND MEDICAL CIRCUMCISION IN HPTN 071 (PopART)

11:09



Kidist B. Zewdie, Michael Pickles, Sian Floyd, Sarah Fidler, Helen Ayles, Peter Bock, Graeme Hoddinot, Nomtha Mandla, Ephraim Sakala, Kwame Shanaube, Musonda Simwinga, Estelle M. Piwowar-Manning, Richard Hayes, Deborah Donnell

88 CHOICE AND ADHERENCE TO DAPIVIRINE RING OR ORAL PrEP BY YOUNG AFRICAN WOMEN IN REACH

11:17



Kenneth Nguire, Gonasagrie Nair, Daniel Szydlo, Elizabeth R. Brown, Carolyne Akello, Pippa Macdonald, Thesla Palanee-Phillips, Bekezela Siziba, Sharon L. Hillier, Morgan Garcia, Sherri Johnson, Lisa Levy, Tara McClure, Lydia Soto-Torres, Connie L. Celum

11:25 LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-8 GLOBAL PERSPECTIVES ON HIV TESTING, TREATMENT, AND PREVENTION 9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Jonathan Mermin, *Centers for Disease Control and Prevention, Atlanta, GA, USA*

Landon Myer, *University of Cape Town, Cape Town, South Africa*



9:45 INTRODUCTIONS

89 TRENDS IN HIV TESTING AND LINKAGE TO HIV TREATMENT IN 41 COUNTRIES: 2016-2021

9:50

Bakary Drammeh, Anindya K. De, Amy Medley, Randy Yee, Shazad Ahmed, Helen Dale, Arielle Lasry, Vincent J. Wong, Michael Grillo, Emanny Sanchez, David A. Miller, Tiffany Aholou, Shahul Ebrahim, Stephanie Behel

90 DETECTING RECENT HIV INFECTIONS IN OUTPATIENT DEPARTMENTS: A MULTI-COUNTRY ANALYSIS

9:58

Suzue Saito, Lenhle D. Nsibandze, Samkelo Simelane, Dumile Sibandze, Vusie Lokotfwako, Munyaradzi Pasipamire, Peter Fonjungo, Aime Mboyo, Tania L. Tchissambou, Mugenyi Asimwe, Appolinaire Tiam, Tlhomola Mphotleng, Keisha Jackson, Michael Martin, Stephanie Behel

91 HIV AND VIREMIA PREVALENCE IN NONMIGRATING MEMBERS OF MIGRANT HOUSEHOLDS IN UGANDA

10:06



Ruth Young, Joseph Ssekasanvu, Fred Nalugoda, Joseph Kagaayi, Robert Ssekubugu, Godfrey Kigozi, Steven J. Reynolds, Lisa J. Nelson, Maria Wawer, Bareng A. Nonyane, Larry W. Chang, Caitlin E. Kennedy, Ligia Paina, David Serwadda, M. Kate Grabowski

92 THE IMPACT OF FREE ANTIRETROVIRAL THERAPY FOR NONCITIZEN PREGNANT WOMEN IN BOTSWANA

10:14



Christina Fennell, Daniel J. Escudero, Rebecca Zash, Modiegi Diseko, Gloria Mayondi, Judith Mabuta, Tumulano Sekoto, Tendani Gaolathe, Mompoti Mmalane, Shahin Lockman, Joseph Makhema, Roger L. Shapiro

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

- 93**
10:45 **DO INCENTIVE VOUCHERS IMPROVE HIV TREATMENT OUTCOMES AMONG KEY POPULATIONS IN INDIA?**
Sunil S. Solomon, Allison M. McFall, Aylur K. Srikrishnan, Vasudevan C. Kesavan, Rifa Khan, Anand Santhanam, Saravanan Shanmugam, Paneerselvam Nandagopal, David C. Celentano, Shruti H. Mehta, Gregory M. Lucas
- 94**
10:53 **THE COOPERATIVE RE-ENGAGEMENT CONTROLLED TRIAL: DURABLE VIRAL SUPPRESSION ASSESSMENT**
Jesse O'Shea, Robyn Fanfair, George Khalil, Tiffany Williams, Kathleen Brady, Alfred DeMaria, Heidi Jenkins, Liisa Randall, Nasima Camp, Crystal Lucas, Marianne Buchelli, Taraz Samandari, Paul Weidle
- 96**
11:01 **UPDATED EFFICACY, SAFETY, AND CASE STUDIES IN HPTN 083: CAB-LA VS TDF/FTC FOR PrEP**
Raphael J. Landovitz, Deborah Donnell, Ha Tran, Esper G. Kallas, Many Magnus, Mark Marzinke, Susan Eshleman, Brett Hanscom, Adeola Adeyeye, James F. Rooney, Alex R. Rinehart, Myron S. Cohen, Marybeth McCauley, Beatriz Grinsztejn, for the HPTN 083 Study Team
- 95**
11:09 **CAB-LA PrEP: EARLY DETECTION OF HIV INFECTION MAY REDUCE InSTI RESISTANCE RISK**
Susan Eshleman, Jessica M. Fogel, Elias K. Halvas, John W. Mellors, Estelle M. Piwowar-Manning, Alex R. Rinehart, Marybeth McCauley, Adeola Adeyeye, Juan C. Hinojosa, Robinson Cabello, Keren Middelkoop, Myron S. Cohen, Beatriz Grinsztejn, Raphael J. Landovitz, for the HPTN 083 Study Team
- 11:17 **LIVE QUESTIONS AND ANSWERS**

Oral Abstract Session-9 SARS-CoV-2 ANTIVIRALS AND OUTCOMES
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Robert T. Schooley, *University of California San Diego, La Jolla, CA, USA*

Huldrych F Günthard, *University Hospital Zurich, Zurich, Switzerland*



- 9:45 **INTRODUCTIONS**
- 97**
9:50 **SYMPTOM DURATION IN COVID-19 CONVALESCENT PATIENTS: REGIONAL & CLINICAL ASSOCIATIONS**
Jorge A. Gallardo-Cartagena, Juan J. Montenegro-Idrogo, Sue Li, Jiani Hu, Abhishek B. Amin, Portia Hunidzarira, Paul Goepfert, Megan Jones, Vicky Kim, Robert De La Grecca, Azwi Takalani, Simbarashe Takuva, Lawrence Corey, Shelly Karuna, for the HVTN 405/HPTN 1901 Study Team
- 98**
9:58 **POST-ACUTE SEQUELAE OF SARS-CoV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT**
Michael A. Horberg, Eric S. Watson, Celeena R. Jefferson, Julia M. Certa, Keri N. Althoff, Carolyn F. Williams, Richard Moore
- 99**
10:06 **INFLAMMATION, EXERCISE CAPACITY, CHRONOTROPY, AND SYMPTOMS IN POST-ACUTE COVID-19**
Matthew S. Durstenfeld, Michael J. Peluso, Punita Kaveti, Christopher Hill, Danny Li, Erica Sander, Shreya Swaminathan, Victor M. Arechiga, Victor Zepeda, Yoojin Lee, Mandar Aras, Donald J. Grandis, Carlin S. Long, Steven G. Deeks, Priscilla Hsue

100 SALIVA, NASAL & TEAR PK OF EIDD-1931 IN PATIENTS WITH COVID-19 RECEIVING MOLNUPIRAVIR

10:14

Richard FitzGerald, **Laura Dickinson**, Laura Else, Thomas Fletcher, Colin Hale, Aliou Amara, Lauren Walker, Sujana D. Penchala, Rebecca Lyon, Victoria Shaw, Helen Reynolds, Wendy P. Painter, Sean Ewings, Gareth Griffiths, Saye Khoo

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

101 PHASE III TRIAL OF MOLNUPIRAVIR IN ADULTS WITH MILD SARS-CoV-2 INFECTION IN INDIA

10:45

Nagalingeswaran Kumarasamy, Bibhuti Saha, Atul Jindal, Veer Bahadur Singh, Naveen Chander Reddy Podduturi, Shubhadeep Sinha, Sreenivasa Chary Sriramadasu

102 INTRAMUSCULAR SOTROVIMAB IS NONINFERIOR TO INTRAVENOUS SOTROVIMAB FOR COVID-19

10:53



Adrienne E. Shapiro, Elias Sarkis, Jude Acloque, Yaneicy Gonzalez-Rojas, Rubaba (Ruby) Hussain, Erick Juarez, Jaynier Moya, David Inman, Andrew Skingsley, Daren Austin, Amanda Peppercorn, Jennifer E. Sager, Elizabeth Alexander, **Leah A. Gaffney**, Anita Kohli

103 EFFECT OF SEROSTATUS ON THE EFFICACY OF SOTROVIMAB IN PREVENTING COVID-19 PROGRESSION

11:01



Anil Gupta, Elias Sarkis, Andrea L. Cathcart, Elizabeth Alexander, Wendy W. Yeh, Megan Smithey, Nicola Scott, Andrew Skingsley, Helen Watson, Melissa Aldinger, **Adrienne E. Shapiro**

104 CASIRIVIMAB AND IMDEVIMAB COMBINATION PROVIDES LONG-TERM PROTECTION AGAINST COVID-19

11:09



Meagan P. O'Brien, Gary Herman, Eduardo Forleo Neto, Neena Sarkar, Flonza Isa, Peijie Hou, Kuo-Chan Chen, Ruanne Barnabas, Myron S. Cohen, John D. Davis, Kenneth C. Turner, Andrea T. Hooper, George D. Yancopoulos, David M. Weinreich, for the COVID-19 Phase III Prevention Trial Team

105 CAMOSTAT IS NOT EFFECTIVE FOR MILD-MODERATE COVID-19 IN A PHASE II TRIAL OF ACTIV-2

11:17



Nikolaus Jilg, Kara W. Chew, Mark Giganti, Eric S. Daar, David A. Wohl, Arzhang Cyrus Javan, Amy Kantor, Atasi Jana, Philip A. Hart, Joseph J. Eron, Judith S. Currier, Michael Hughes, Davey M. Smith, Jonathan Li, for the ACTIV-2/A5401 Study Team

11:25 LIVE QUESTIONS AND ANSWERS

Interactive Session-4 LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND

CME

12:00 PM MT - 1:00 PM MT

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include a 10-minute overview, 3 rapid-fire presentations of 5 minutes each, and interactions with the moderators, experts, and audience.

Target Audience: This session is directed to clinical and basic scientists interested in understanding the mechanisms of postacute sequelae of SARS-CoV-2 infection, or long COVID.

Level of Knowledge: It is assumed that the participants are familiar with the fundamental aspects of viral infection and the immune response to it.

Objectives: At the completion of the session, participants will be able to:

- Describe the symptoms and clinical consequences of long COVID
- Describe the challenges associated with research to understand the virologic and immunologic basis of this condition
- Identify potential strategies being considered for treatment

Moderators

Galit Alter, *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA*

Karine Lacombe, *Sorbonne Université, Paris, France*



12:00 PUTTING LONG COVID IN CONTEXT

Steven G. Deeks, *University of California San Francisco, San Francisco, CA, USA*



12:10 THEMES IN NEUROLOGY

Avindra Nath, *National Institutes of Health, Bethesda, MD, USA*



12:15 THEMES IN VIROLOGY

Susan R. Weiss, *University of Pennsylvania, Philadelphia, PA, USA*



12:20 THEMES IN IMMUNOLOGY

Akiko Iwasaki, *Yale University, New Haven, CT, USA*



12:25 LIVE PANEL DISCUSSION

Interactive Session-5 WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK?

CME

12:00 PM MT - 1:00 PM MT

Description: This session will discuss the status of scale-up of risk-informed use of preexposure prophylaxis (PrEP) in adolescent girls and young women, focusing on the challenges faced as well as learning lessons from successful experiences. Expanded opportunities for postexposure prophylaxis (PEP) use will also be discussed. This session is intended to be engaging, lively, interactive, and scientifically fun. Moderators will introduce the session, followed by rapid-fire presentations and discussion, and end with responses to questions from the audience.

Target Audience: This session is directed to policymakers and implementers, clinicians, epidemiologists, and researchers with an interest in HIV prevention.

Level of Knowledge: It is assumed that the participants are familiar with the HIV field and, in particular, with PrEP and PEP to prevent HIV acquisition.

Objectives: At the completion of the session, participants will be able to:

- Describe the challenges with achieving appropriate, risk-informed PrEP use in adolescent girls and young women
- List some potential solutions and how they might be implemented
- Describe the potential role of greater use of PEP

Moderators

Susan P. Buchbinder, *San Francisco Department of Public Health, San Francisco, CA, USA*

Moses R. Kamya, *Makerere University College of Health Sciences, Kampala, Uganda*

12:00 **SESSION OVERVIEW**12:05 **GLOBAL PrEP UPTAKE IN ADOLESCENT GIRLS AND YOUNG WOMEN**

Rachel Baggaley, *World Health Organization, Geneva, Switzerland*

12:10 **EXPERIENCE WITH OFFERING PEP ALONGSIDE PrEP**

James Ayieko, *Kenya Medical Research Institute, Nairobi, Kenya*

12:15 **PrEP IMPLEMENTATION IN ADOLESCENT GIRLS AND YOUNG WOMEN**

Nicolette Naidoo, *Wits Reproductive Health and HIV Institute, Johannesburg, South Africa*

12:20 **PrEP IMPLEMENTATION IN YOUNG SEX WORKERS IN ZIMBABWE**

Primrose Matambanadzo, *Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe*

12:25 **LIVE PANEL DISCUSSION**
Special Session ANAL CANCER PREVENTION AND MANAGEMENT
1:15 PM MT - 2:00 PM MT
Moderator

Ronald Mitsuyasu, *University of California Los Angeles, Los Angeles, CA, USA*

1:15 **WELCOME AND SESSION OVERVIEW**
106 TREATMENT OF ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS TO PREVENT ANAL CANCER
 1:17

Joel Palefsky, Jeannette Lee, Teresa Darragh, Stephen Goldstone, Naomi Jay, Hillary Dunlevy, Timothy Wilkin, Isabella Rosa-Cunha, Abigail Arons, Julia Pugliese, Gary Bucher, Lisa Flowers, Rebecca Levine, Michael Berry-Lawhorn, for the ANCHOR Investigators Group

1:37 **LIVE QUESTIONS AND ANSWERS AND PANEL DISCUSSION****Panelists**

Elizabeth Chiao, *The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

David Henry, *University of Pennsylvania, Philadelphia, PA, USA*

Richard Little, *National Cancer Institute, Bethesda, MD, USA*

WEDNESDAY, FEBRUARY 16, 2022

Plenary Session-3 WEDNESDAY PLENARY SESSION

CME

8:30 AM MT - 9:30 AM MT

Session Hosts

Joseph J. Eron, *University of North Carolina at Chapel Hill, Chapel Hill, NC, USA***Susan P. Buchbinder**, *San Francisco Department of Public Health, San Francisco, CA, USA*

8:30 WELCOME AND DAILY ROADMAP

Elaine J. Abrams, *ICAP at Columbia University, New York, NY, USA*

116 NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTION

8:40

Chloe L. Orkin, *Queen Mary University of London, London, UK*

117 PAST AND FUTURE OF HIV VACCINES

9:05

Mark Feinberg, *International AIDS Vaccine Initiative, Amsterdam, Netherlands*

Oral Abstract Session-10

IMMUNE RESPONSES TO HIV AND SARS-CoV-2 IN TREATMENT, PREVENTION, AND PATHOGENESIS

9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Galit Alter, *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA***Richard A. Koup**, *National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA*

9:45 INTRODUCTIONS

118 INFLAMMASOMES AND IL-1 β : AN INNATE IMMUNE AXIS IN CD4+ T CELLS DRIVING HIV INFECTION

9:50

Jeffrey A. Tomalka, *Khader Ghneim, Margaret Costanzo, Susan Pereira Ribeiro, Nelson L. Michael, Merlin Robb, Michael Eller, Rafick-Pierre Sékaly*

119 RAPID LOSS OF CD4+ T CELLS BY PYROPTOSIS IN ACUTELY SIV-INFECTED RHESUS MACAQUES

9:58

**Xuan He**, *Malika M. Boudries, John D. Ventura, Erica N. Borducchi, Abishek Chandrashekar, Michelle Lifton, Jinyan Liu, Dan Barouch*

120 EXPERIMENTAL MICROBIAL DYSBIOSIS ENHANCES RECTAL SIV ACQUISITION IN RHESUS MACAQUES

10:06

Alexandra Ortiz, *Phillip Baker, Charlotte Langner, Jennifer Simpson, Jacob Flynn, Carly E. Starke, Carol Vinton, Brandon Keele, Jason Brenchley*

121 PHASE IIB EFFICACY TRIAL OF MOSAIC HIV-1 VACCINE REGIMEN IN AFRICAN WOMEN: IMBOKODO

10:14

Glenda E. Gray, *Kathy Mngadi, Ludo Lavreys, Alex Luedtke, Steven Nijis, Daniel Stieh, Michal Juraska, Olivier Hyrien, Edith Swann, Georgia Tomaras, Julie McElrath, Maria G. Pau, Susan P. Buchbinder, Frank Tomaka, for the Imbokodo Study Group*

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

122 ADMINISTRATION OF 3BNC117 AT ART INITIATION INDUCES LONG-TERM HIV CD8 T-CELL IMMUNITY

10:45



Miriam Rosás-Umbert, Jesper D. Gunst, Rikke Olesen, Marina Caskey, Michel Nussenzweig, Martin Tolstrup, Ole Søgaard

123 CD8+ LYMPHOCYTES MODULATE STEMNESS AND SURVIVAL PATHWAYS IN HIV-INFECTED CD4+ T CELLS

10:53

Lavinia Franchitti, Ashish A. Sharma, Jack Yoon, Erick R. White, Hong Wang, Maura Statzu, Abigail Willemse, Rafick-Pierre Sékaly, Mirko Paiardini, Guido Silvestri, Deanna Kulpa

124 HIGH NEUTRALIZING CONVALESCENT PLASMA RESULTS IN RAPID CLEARANCE OF SARS-CoV-2

11:01

Irene A. Abela, Maddalena Marconato, Anthony Hauser, Magdalena Schwarzmüller, Dominique Braun, Selina Epp, Annette Audigé, Jacqueline Weber, Eméry Schindler, Michael Huber, Beat M. Frey, Roger Kouyos, Huldrych F. Günthard, Markus G. Manz, Alexandra Trkola

125 SARS-CoV-2 ANTIBODY RESPONSES IN INDIVIDUALS FOLLOWING mRNA BOOSTER VACCINATION

11:09



Frauke Muecksch, Zijun Wang, Alice Cho, Christian Gaebler, Victor Ramos, Tarek Ben Tanfous, Eva Bednarski, Justin Da Silva, Dennis Schaefer-Babajew, Irina Shiimeliovich, Anna Gazumyan, Marina Caskey, Paul Bieniasz, Theodora Hatziioannou, Michel Nussenzweig

11:17 LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-11 CROSSING THE CNS BORDER: HIV, SIV, AND SARS-CoV-2
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Dennis L. Kolson, University of Pennsylvania, Philadelphia, PA, USA

Serena S. Spudich, Yale University, New Haven, CT, USA



9:45 INTRODUCTIONS

126 HIV-1 RNA TRANSCRIPTS IN CSF CD4+ T CELLS, NOT MONOCYTES, ARE LINKED TO BRAIN INJURY

9:50

Kazuo Suzuki, **John Zaunders**, Thomas Gates, Angelique Levert, Shannen Butterly, Zhixin Liu, Takaomi Ishida, Chin-Shiou Huang, Caroline Rae, Lauriane Jugé, Lucette A. Cysique, Bruce Brew

127 PBR28 PET IMAGING IN PEOPLE WHO STARTED ART DURING ACUTE VERSUS CHRONIC HIV INFECTION

9:58



Jasmini Alagaratnam, Jaime Vera, Zhen Fan, John Thornhill, Jonathan Underwood, David Owen, Paul Edison, Sarah Fidler, Alan Winston

128 LONGITUDINAL MODELING OF EARLY HIV BURDEN IN THE CENTRAL NERVOUS SYSTEM

10:06



Victor D. Armengol, Veronika Shabanova, Lars Hagberg, Richard Price, Magnus Gisslen, Serena S. Spudich

129 CD4+ DEPLETION RESULTS IN ROBUST CNS REBOUND AND LARGER MACROPHAGE RESERVOIRS

10:14

Rebecca T. Veenhuis, Celina Abreu, Edna Ferreira, Janaysha Ratliff, Suzanne Queen, Erin Shirk, Joseph Mankowski, Lucio Gama, Janice Clements

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

130 NEUROSYPMTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS

10:45

Laura Kincer, Ameet N. Dravid, Paola Cinque, Mattia Trunfio, Andrea Calcagno, Serena S. Spudich, Magnus Gisslen, Richard Price, Sarah B. Joseph

131 SARS-CoV-2 CSF N-ANTIGEN DETECTION IS ASSOCIATED WITH CNS INFLAMMATION IN NEUROCOVID

10:53

Arvid Eden, Anna Grahn, Daniel Bremell, Pradeepthi Bathala, Dietmar Fuchs, Johanna Gostner, Salvia Mishagian, Navaratnam Manjula, Staffan Nilsson, Michael Schöll, George Sigal, Erika Stentoft, Martin Stengelin, Henrik Zetterberg, Magnus Gisslen

132 IS THERE A ROLE OF NOVEL ART REGIMENS IN THE DECLINING PREVALENCE OF HAND?

11:01



Ilaria Mastroianni, Anna Clelia Brita, Annalisa Mondì, Giulia Del Duca, Patrizia Lorenzini, Alessandra Vergori, Valentina Mazzotta, Roberta Gagliardini, Marta Camici, Rita Bellagamba, Federico De Zottis, Marisa Fusto, Stefania Cicalini, Andrea Antinori, Carmela Pinnetti

133 ACTG A5324: A RANDOMIZED TRIAL OF ART INTENSIFICATION FOR COGNITIVE IMPAIRMENT IN PWH

11:09

Scott L. Letendre, Jhoanna Roa, Huichao Chen, Ashley McKhann, Christina M. Marra, Eric S. Daar, Peter W. Hunt, Thomas Campbell, Shobha Swaminathan, Belinda Ha, Beverly Alston-Smith, Robert Paul, Serena S. Spudich, for the A5324 Study Team

11:17 LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-12 HIV ANTIVIRALS AND OUTCOMES

9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Joseph J. Eron, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Angela Kashuba, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA



9:45 INTRODUCTIONS

134 IMPROVING INTESTINAL BARRIER USING GLP-2 AGONIST REDUCES ARTERIAL INFLAMMATION IN PWH

9:50



Caroline E. Diggins, Shibani Mukerji, Douglas S. Kwon, Charles F. Saylor, Lediya Cheru, Jae Sim, Meaghan Flagg, Bjoern Corleis, Emily Rudmann, Shady Abohashem, Ahmed Tawakol, **Janet Lo**

135 DOLUTEGRAVIR WITH RECYCLED nRTIs IS NONINFERIOR TO PI-BASED ART: VISEND TRIAL

9:58

Lloyd B. Mulenga, Sombo Fwoloshi, Aggrey Mweemba, Mpanji Siwingwa, Suilanji Sivile, Davies Kampamba, Danielle C. Engamba, Nyuma Mbewe, Henry Phiri, Aaron Shibemba, Bryony Simons, C. William Wester, Lameck Chirwa, Andrew Hill, for the VISEND Study Team

136 A RANDOMIZED TRIAL OF SWITCHING TREATMENT-EXPERIENCED ADULTS FROM PI/r TO DTG

10:06

Loice A. Ombajo, Jeremy Penner, Joseph Nkuranga, Jared Mecha, Margaret Mburu, Collins Odhiambo, Florentius Ndinya, Rukia Aksam, Richard Njenga, Simon Wahome, Peter Muiruri, Catherine Ngugi, Anton Pozniak

137 NUCLEOSIDES AND DARUNAVIR/DOLUTEGRAVIR IN AFRICA (NADIA) TRIAL: OUTCOMES AT 96 WEEKS

10:14



Nicholas Paton, Joseph Musaaazi, Cissy Kityo, Stephen I. Walimbwa, Apolo Balyegisawa, Anne Hoppe, Arvind Kaimal, Grace Mirembe, Gilbert Ategeka, Henry Mugerwa, Margaret Borok, Abraham Siika, Barbara Castelnuevo, Andrew D. Kambugu, for the Nucleosides and Darunavir/Dolutegravir in Africa (NADIA) Trial Team

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

138 LENACAPAVIR AS PART OF A COMBINATION REGIMEN IN TREATMENT NAIVE PWH: WEEK 54 RESULTS

10:45

Samir Gupta, James Sims, Cynthia Brinson, Frederick A. Cruickshank, Godson Oguchi, Javier Morales, Theo Hodge, Craig Dietz, Angela S. Liu, Laurie VanderVeen, Hadas Dvory-Sobol, Martin Rhee, Jared Baeten, Ellen Koenig

139 VIRAL ESCAPE DURING TRIPLE BROADLY NEUTRALIZING ANTIBODY THERAPY AGAINST HIV-1

10:53

Boris Juelg, Kathryn E. Stephenson, Kshitij Wagh, Victoria E. Walker-Sperling, Tom Hassell, Allen DeCamp, Elena E. Giorgi, Richard A. Koup, John R. Mascola, Roberto C. Arduino, Edwin DeJesus, Nicole L. Yates, Michael Seaman, Bette Korber, Dan Barouch

140 PHASE I STUDY OF LONG-ACTING 3BNC117 AND 10-1074 IN VIREMIC ADULTS LIVING WITH HIV

11:01

Marina Caskey, Katrina Millard, Martina Turroja, Christian Gaebler, Erin Logue, Caroline S. Jiang, Leah Todd, Jacqueline D. Reeves, Christos Petropoulos, Timothy Wilkin, Pablo Tebas, Michel Nussenzweig

11:09 LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-13 SHIFTING PARADIGMS IN HIV TESTING 9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Wafaa M. El-Sadr, Columbia University, New York, NY, USA

Andrew N. Phillips, University College London, London, UK



9:45 INTRODUCTIONS

141 PREVALENCE OF SYPHILIS AND HIV/SYPHILIS COINFECTION IN 5 SUB-SAHARAN COUNTRIES

9:50

Rose Killian, Mansoor Farahani, Giles Reid, Godfrey Musuka, Samuel Biraro, Harriet Nuwagaba-Biribonwoha, Wafaa M. El-Sadr, Jessica E. Justman

142 CHANGES IN HIV AND STI TESTING AND DIAGNOSES DURING THE COVID-19 PANDEMIC

9:58

Jennifer J. Chang, Qiaoling Chen, Rulin C. Hechter, Jodie Dionne-Odom, Katia Bruxvoort

143 CDC'S DIRECT-TO-CONSUMER DISTRIBUTION OF 100,000 HIV SELF-TESTS

10:06

Pollyanna R. Chavez, Brian Emerson, Emily Lilo, Jennie Johnston Gayden, Euna August, Christopher Voegeli, Revae Downey, Emily Pingel, Kevin P. Delaney

144 HIV SELF-TESTING UNCOVERS HIGH BURDEN OF HIDDEN INFECTIONS IN INDIA

10:14

Jalpa H. Thakker, Aditya Singh, Rose Pollard, Jade Bell, Allison M. McFall, Mahender Taduri, Vikrant Gupta, Sangeeta Kaul, Jagadish T. Patil, Subash Ghosh, Ajay K. Enugu, Anthony Reddy, Shruti H. Mehta, Sunil S. Solomon

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

145 HIGH HIV SELF-TESTING OF MALE PARTNERS OF WOMEN LIVING WITH HIV IN RURAL SOUTH AFRICA

10:45

Dvora Joseph Davey, Kristin Wall, Nireshni Naidoo, Dhirisha Naidoo, Gugu Xaba, Claire Serrao, Silinganiso Chatikobo, Todd Malone, Kathryn Dovel

146 SIX-MONTH PrEP WITH HIV SELF-TESTING TO IMPROVE DELIVERY KENYA: A RANDOMIZED TRIAL

10:53

Kenneth Ngunjiri, Katrina Ortblad, Peter A. Mogere, Ashley Bardon, Dorothy Mangale, Catherine Kiptinness, Stephen Gakuo, Sarah Mbaire, Jacinta Nyokabi, Katherine K. Thomas, Nelly R. Mugo, Jared Baeten

147 SUCCESS OF ASSISTED PARTNER NOTIFICATION AMONG PATIENTS WITH PRIOR HIV DIAGNOSES

11:01

Gillian L. O'Bryan, **Harugumi Chirairo**, Farai Munyayi, Alison L. Ensminger, Gena L. Barnabee, Edington Dzinotyiweyi, Leonard Mwadingi, Laimi Ashipala, Norbert Forster, Gabrielle L. O'Malley, Matthew R. Golden

148 LOW RISK OF ADVERSE EVENTS FOLLOWING ASSISTED PARTNER NOTIFICATION IN MOZAMBIQUE

11:09

Matthew R. Golden, Allend Mamudo, Ferruccio Vio, Erin Branigan, Zulmira Paredes, Adelina Maiela, Orvalho Augusto, Aleny Couto, Guita Amane, Noelia Chicuecue, Joaquim Wate

11:17 LIVE QUESTIONS AND ANSWERS

Interactive Session-6 CHIMERIC ANTIGEN RECEPTORS (CARs): WHAT'S NEXT?

12:00 PM MT - 1:00 PM MT

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include 4 rapid-fire presentations of 5 to 7 minutes each, followed by discussions and real-time interactions with the moderators, experts, and audience.

Target Audience: This session is directed to a broad audience of basic science experts and clinicians in the field of HIV virology and AIDS.

Level of Knowledge: It is assumed that the participants are familiar with many aspects of HIV pathogenesis and persistence and with the challenges of eliminating HIV reservoirs. Clinicians who attend should be familiar with HIV-associated malignancies, including B cell lymphomas.

Objectives: At the completion of the session, participants will be able to:

- Describe the basic science of a CAR and how it can function on diverse cell backgrounds to target HIV-infected and malignant cells
- List current challenges in maintaining functional CAR cells in vivo with respect to their expansion, persistence, and sustaining their function, and appreciating how these challenges are being addressed with ongoing basic and translational research
- Describe the active areas of research in the HIV/AIDS and cancer fields as well as clinical trials where CAR cellular therapy is having an impact on patient care or could have an impact in the future

Moderators

Richard A. Koup, *National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA*


James A. Hoxie, *University of Pennsylvania, Philadelphia, PA, USA*



12:00 SESSION OVERVIEW

12:05 NEW AND IMPROVED T CELL CARs FOR HIV ERADICATION OR CONTROL

James L. Riley, *University of Pennsylvania, Philadelphia, PA, USA*



12:10 GENERATING CAR T CELLS IN VIVO

Hans-Peter Kiem, *Fred Hutchinson Cancer Research Center, Seattle, WA, USA*



12:15 NATURAL KILLER CELL CARs: NEW APPROACHES TO CURE LEUKEMIA AND LYMPHOMA

Katy Rezvani, *University of Texas MD Anderson Cancer Center, Houston, TX, USA*



12:20 STIMULATING CARs WITH mRNA VACCINES

Benjamin Rengstl, *BioNTech, Mainz, Germany*



12:25 LIVE PANEL DISCUSSION

Interactive Session-7 HIV CONTROVERSIES: CASE-BASED APPROACH TO PATIENTS WHO ARE TREATMENT OR PREVENTION EXPERIENCED

CME

12:00 PM MT - 1:00 PM MT

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include 3 case presentations, followed by a discussion of each case from the expert panel and answers to questions from the audience. The cases are focused on people with HIV who are treatment experienced in the context of therapy or preexposure prophylaxis (PrEP).

Target Audience: This session is directed to adult and pediatric HIV clinicians and clinical investigators as well as trainees in these areas.

Level of Knowledge: It is assumed that the participants are familiar with antiretroviral regimens commonly used for HIV treatment and prevention.

Objectives: At the completion of the session, participants will be able to:

- Describe new antiretroviral agents that now are or will soon be available for HIV treatment and HIV prevention
- Identify drug resistance risks of oral and long-acting PrEP and how they may impact HIV treatment of individuals who become infected during PrEP
- Design treatment regimens for people with HIV who have multidrug-resistant HIV

Moderators

Joseph J. Eron, *University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*

Hermione Lyall, *Imperial College Healthcare NHS Trust, London, UK*



Panelists

Mina C. Hosseinipour, *University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*



Natella Rakhmanina, *Children's National Hospital, Washington, DC, USA*



Annemarie M. Wensing, *University Medical Center Utrecht, Utrecht, Netherlands*



Timothy J. Wilkin, *Weill Cornell Medicine, New York, NY, USA*



Interactive Session-8

IMPACT OF VIRAL LOAD IN TRANSMISSION AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION

CME

12:00 PM MT - 1:00 PM MT

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include 4 presentations of 8 minutes each, followed by a 20-minute panel discussion and interactions with the moderators, experts, and audience.

Target Audience: This session is directed to clinicians, epidemiologists, public health officials, and clinical virologists interested in the transmission of SARS-CoV-2 and the progression of COVID-19.

Level of Knowledge: It is assumed that the participants are familiar with the global epidemiology of COVID-19, the route of transmission of SARS-CoV-2, the clinical presentation of SARS-CoV-2 infection, data supporting the use of monoclonal antibodies and other antiviral treatments of SARS-CoV-2 infection, and data supporting the efficacy of vaccination.

Objectives: At the completion of the session, participants will be able to:

- Describe how the viral load of SARS-CoV-2 influences outcomes such as transmission and possibly virulence
- Assess whether monitoring viral load is useful in the clinical management of COVID-19
- Describe the impact of vaccination on viral kinetics during SARS-CoV-2 infection

Moderators

Jean-Michel Molina, *University of Paris, Paris, France*

Monica Gandhi, *University of California San Francisco, San Francisco, CA, USA*



12:00 **SESSION OVERVIEW**

12:02 **ROLE OF VARIANTS AND VIRAL LOAD IN SARS-CoV-2 TRANSMISSION**

Arnaud Fontanet, *Institut Pasteur, Paris, France*



12:12 **IS SARS-CoV-2 VIRAL LOAD ASSOCIATED WITH DISEASE PROGRESSION AND RESPONSE TO TREATMENT?**

Matthew Spinelli, *University of California San Francisco, San Francisco, CA, USA*



12:22 **ARE NEW SARS-CoV-2 VARIANTS ASSOCIATED WITH MORE SEVERE DISEASE?**

Fiona Havers, *Centers for Disease Control and Prevention, Atlanta, GA, USA*



12:32 **VIRAL LOAD KINETICS IN PARTIALLY OR FULLY VACCINATED INDIVIDUALS INFECTED WITH SARS-CoV-2**

Annelies Wilder-Smith, *London School of Hygiene & Tropical Medicine, London, UK*



12:42 **LIVE PANEL DISCUSSION**

POSTER SESSIONS BY DAY

MONDAY, FEBRUARY 14, 2022

Poster Session-A01 INFECTION AND ENVELOPE

2:00 PM MT - 3:30 PM MT

158 **WITHDRAWN**

159 **INFECTION OF FORESKIN MYELOID CELLS BY SUBTYPE C TRANSMITTED FOUNDER HIV-1 STRAINS**



Bokani Nleya, Ebrahim Steenkamp, Lester Sigauke, Sonwabile Dzanibe, Clive Gray, Frank Kirchhoff, David G. Russell, Nyaradzo T. Tsikiwa-Chigorimbo

160 **MIGRATORY T CELLS ARE MORE SUSCEPTIBLE TO HIV-1 INFECTION VIA INCREASED VIRAL ENTRY**

Paul G. Lopez, Oluwaseun E. Ajibola, Amélie Pagliuzza, Romaniya Zayats, Wan Hon Koh, Alon Herschhorn, Nicolas Chomont, Thomas T. Murooka

161 **ACCUMULATION OF HIV-1 Env MUTATIONS LEADS TO HIGH-LEVEL RESISTANCE TO DOLUTEGRAVIR**



Yuta Hikichi, Jennifer L. Groebner, Ann Wiegand, John W. Mellors, Mary F. Kearney, Eric O. Freed

162 **N-GLYCOSYLATION SITE SIGNATURES OF HIV ENVELOPE IN POST-TREATMENT CONTROLLERS**



Elmira Esmaeilzadeh, Behzad Etemad, Yijia Li, Lavine L. Christy, James Regan, Colline Wong, Elizabeth Connick, Paul Volberding, Michael Seaman, Jonathan Li

163 **FUNCTIONALIZATION OF ENVELOPED PROTEIN NANOCAGES VIA DESIGNED TRANSMEMBRANE PROTEINS**

Daniel Humphrys, Wesley I. Sundquist, Neil King, Ben Schmitz

164 **MOLECULAR DETERMINANTS OF SARS-CoV-2 CELLULAR TROPISM IN VITRO**



Maritza N. Puray-Chavez, Kyle M. LaPak, Shawn J. Mohammed, Dana Q. Lawson, Dennis Goldfarb, M. Ben Major, Sebla B. Kutluay

165 **SPIKE MUTATION T403R ALLOWS BAT CORONAVIRUS RaTG13 TO USE HUMAN ACE2**

Fabian Zech, Daniel Schniertshauer, Christoph Jung, Alexandra Herrmann, Arne Cordsmeier, Janis Müller, Jana Krueger, Sandra Heller, Steffen Stenger, Alexander Kleger, Timo Jacob, Karl-Klaus Conzelmann, Armin Ensser, Konstantin Sparrer, Frank Kirchhoff

166 **D614G AND OTHER MUTATIONS ARE CRITICAL FOR FITNESS OF NOVEL SPIKE VARIANTS**

Leonid Yurkovetskiy, Ann Dauphin, Matteo Bosso, Thomas Nyalile, Jeremy Luban

167 **SARS-CoV-2 VARIANTS INCREASE KINETIC STABILITY OF OPEN SPIKE CONFORMATIONS**

Ziwei Yang, Yang Han, Shilei Ding, Wei Shi, Tongqing Zhou, Andrés Finzi, Peter D. Kwong, Walther Mothes, **Maolin Lu**

168 **MANNANOSE-BINDING LECTIN (MBL) INHIBITS SARS-CoV-2 INFECTION AND REPLICATION IN VITRO**

Isabel Pagani, Matteo Stravalaci, Daniela Cesana, Pierangela Gallina, Nicoletta Pedemonte, Valeria Capurro, Nicola Clementi, Nicasio Mancini, Barbara Bottazzi, Alberto Mantovani, Elisa Vicenzi, Cecilia Garlanda

169 SARS-CoV-2 SPIKE EXPRESSION AT THE SURFACE OF INFECTED HUMAN AIRWAY EPITHELIAL CELLS

Shilei Ding, Damien Adam, Guillaume Beaudoin-Bussi res, Alexandra Tauzin, Shang Yu Gong, Romain Gasser, Annemarie Laumaea, Sai Priya Anand, Anik Priv , Catherine Bourassa, Halima Medjahed, J r mie Pr vost, Jonathan Richard, Emmanuelle Brochiero, Andr s Finzi

Poster Session-B01 NONHUMAN PRIMATE MODELS OF HIV INFECTION

2:00 PM MT - 3:30 PM MT

188 VIRAL AND IMMUNE PREDICTORS OF TIME TO VIRAL REBOUND IN SHIV-INFECTED INFANT MACAQUES

Veronica Obregon-Perko, Achal Awasthi, Richard Barfield, Stella J. Berendam, Bhruyu Yagnik, Fan Bu, Tiffany M. Styles, Mithra R. Kumar, Emily J. Fray, Janet Siliciano, Rama R. Amara, Genevieve Fouda, Sallie Permar, Cliburn Chan, Ann Chahroudi

189 IMPACT OF CD4 BINDING SITE bNABs ON BARCODED TF-SHIV-D REBOUND IN MACAQUES AT ATI



Elise G. Viox, Sadia Samer, Kevin Nguyen, Emily Lindemuth, Felicity Mampe, Steffen Docken, Mykola Pinkevych, M. Betina Pampana, Brandon Keele, Michael Betts, Miles P. Davenport, Mirko Paiardini, Katharine J. Bar

190 DEVELOPMENT OF VIRAL BIOMARKERS IN SHIV INFECTED NONHUMAN PRIMATES

Luca Sardo, Guoxin Wu, Jessica Lewis, Carl J. Balibar, Paul Zuck, Daria Hazuda, Bonnie Howell

191 ANTI- 4 7 ANTIBODY REDUCES INTESTINAL MYELOID CELL TURNOVER IN SIV-INFECTED MACAQUES



Samuel D. Johnson, Lindsey Knight, Omalla Olwenyi, Michellie Thurman, Siddappa N. Byrareddy

192 INNATE IMPAIRMENT DURING SIV INFECTION ALTERS ZIKV VIRAL PATHOGENESIS

Jennifer Tisoncik-Go, Thomas B. Lewis, Skyler Groenier, Daniel Newhouse, Kathleen M. Voss, Erin Broderick, Karina Wang, Naoto Iwayama, Chul Ahrens, Robert Murnane, Kathryn A. Guerriero, Michael Gale, Deborah H. Fuller, **Megan A. O'Connor**

Poster Session-B02 SARS-CoV-2 PATHOGENESIS

2:00 PM MT - 3:30 PM MT

193 SARS-CoV-2 SPIKE PROTEIN DESTABILIZES MICROVASCULAR HOMEOSTASIS



Soumya Panigrahi, Tamal Goswami, Brian Ferrari, Christopher J. Antonelli, Douglas A. Bazdar, Hannah Gilmore, Michael L. Freeman, Michael M. Lederman, Scott F. Sieg

194 UNIQUE SARS-CoV-2 FURIN-CLEAVAGE SITE VARIANTS IN URINE OF SEVERE COVID-19 PATIENTS

Tatianna Travieso, Sneha Mahesh, Kelly Hughes, Lingye Chen, Lyra B. Olson, Feng Gao, Bryan D. Kraft, Christina Wyatt, Mary Klotman, **Maria Blasi**

195 GALECTIN-9 PROTECTS HUMANIZED ACE2-IMMUNOCOMPETENT MICE FROM SARS-CoV-2 INFECTION

Stephen T. Yeung, Thomas A. Premeaux, Toshiro Niki, Satish Pillai, Kamal M. Khanna, Lishomwa Ndhlovu

196 SARS-CoV-2 PLASMA VIREMIA AND DYSREGULATED IMMUNITY IN SEVERE COVID-19



Roberta Rovito, Valeria Bono, Matteo Augello, Camilla Tincati, Federica Mainoldi, Guillaume Beaudoin-Bussi res, Silvia Bianchi, Mohamad Hadla, Vaibhav Yellenki, Stefano Casola, Elisa Borghi, Andr s Finzi, Antonella D'Arminio Monforte, Giulia Marchetti

197 SARS-CoV-2 N-ANTIGEN SERA LEVELS ARE ASSOCIATED WITH COVID-19 PROGNOSTIC VALUE

Houssein R. Chenane, Reyene Menidjel, Samuel Lebourgeois, Cedric Louenan, Sarah Tubiana, Diane Descamps, Laurent Abel, J r mie Guedj, Surbhi Malhotra, Samir Kumar-Singh, Jade Ghosn, **Beno t Visseaux**

198 SARS-CoV-2 RNAEMIA AS A BIOMARKER OF LOWER RESPIRATORY VIRAL LOAD IN COVID-19

Jana L. Jacobs, Asma Naqvi, Faraaz A. Shah, Bryan J. McVerry, Barbara Meth , Janet S. Lee, Alison Morris, Georgios D. Kitsios, William Bain, John W. Mellors

199 SARS-CoV-2–INFECTED MACAQUES EXHIBIT MICROBIAL TRANSLOCATION ACROSS INTESTINAL MUCOSA

Kelsie Brooks, Christine Nelson, Cynthia Aguilar, Charlotte Langner, Sophia Vrba, Alexandra Ortiz, Ornella Sortino, Kevin Vannella, Timothy Hoang, Mirko Paiardini, Daniel Chertow, Irini Sereti, Heather Hickman, Daniel Barber, Jason Brenchley

200 PULMONARY CMV REACTIVATION FOLLOWING SARS-CoV-2: IMPLICATIONS FOR IMMUNOPATHOLOGY



Jamin Roh, Peter A. Barry, Peter W. Hunt, Smita S. Iyer

Poster Session-B04 HIV TRANSMISSION

2:00 PM MT - 3:30 PM MT

208 INHIBITION OF HIV-1 INFECTION IN SICKLE CELL DISEASE

Sergei Nekhai, Namita Kumari, Asrar Ahmad, Marina Jerebtsova, Andrey I. Ivanov, Sharmin Diaz, James G. Taylor

209 THE GUT MICROBIOTA IMPACTS SUSCEPTIBILITY TO HIV



Danting Jiang, Ria Goswami, Sedem Dankwa, Sallie Permar, Neeraj K. Surana

210 EFda OFFERS COMPLETE PROTECTION FROM REPEATED PENILE HIV CHALLENGES

Martina Kovarova, Sarah E. Wessel, Claire E. Johnson, Myron S. Cohen, J. Victor Garcia-Martinez

211 VAGINAL PROTEOME ALTERATIONS ASSOCIATED WITH HIV ACQUISITION IN THE VOICE TRIAL

Christina Farr Zuend, Samantha Knodel, Laura No l-Romas, Sausan Azzam, Marlon De Leon, Kateryna Kratzer, Zvavahera Chirenje, Sharon L. Hillier, Jeanne Marrazzo, Adam D. Burgener

212 VAGINAL MICROBIOME PROFILES IN YOUNG WOMEN AT RISK FOR HIV INFECTION

Yiran Wang, Laura No l-Romas, Michelle Perner, Samantha Horne, Sarah Hoger, Kenzie Birse, Christina Farr Zuend, Lyle R. McKinnon, Adam D. Burgener

213 STROMAL FIBROBLASTS FROM FEMALE GENITAL TRACT DIMINISH THE IN VITRO EFFICACY OF PrEP



Ashley F. George, Matthew McGregor, Jason Neidleman, Warner Greene, Nadia Roan

Poster Session-D01 HIV VACCINES

2:00 PM MT - 3:30 PM MT

235 STRUCTURAL CHARACTERIZATION OF DNA-ENCODED HIV VACCINES INDUCED NEUTRALIZING ANTIBODY**Ziyang Xu**, Susanne Walker, Megan C. Wise, Neethu Chokkalingam, Mansi Purwar, Alan Moore, Jesper Pallesen, Daniel W. Kulp, David Weiner**236 HIV VACCINE CANDIDATE EFFICACY MEDIATED BY CAMP-DEPENDENT EFFEROCYTOSIS AND V2-ADCC****Massimiliano Bissa**, Sohyoung Kim, Veronica Galli, Slim Fourati, Isabela Silva de Castro, Saori I. Fujiwara, Mohammad Arif Rahman, Guido Ferrari, Alexei V. Lobanov, George W. Nelson, Margaret C. Cam, Leonid Margolis, Rafick-Pierre Sékaly, Gordon L. Hager, Genoveffa Franchini**237 IMMUNOGENICITY AND PROPHYLACTIC EFFICACY OF ARENAVIRUS-BASED SIV VACCINE IN MACAQUES****Archana V. Boopathy**, Bhawna Sharma, Daniela Deutschmann, Hoa Truong, Johnny Lee, Jeffrey Murry, Christian Callebaut, Romas Gelezianas, Wade Blair, Klaus Orlinger, Sarah Schmidt, Henning Lauterbach, Tariro Makadzange, Sarah Ahmadi-Erber**238 SAMT-247 SYNERGIZES WITH ALVAC-BASED VACCINE TO PROTECT AGAINST SIVmac251 ACQUISITION****Mohammad Arif Rahman**, Sabrina Helmsold Hait, Isabela Silva de Castro, James D. Stamos, Ruth Hunegnaw, Melvin N. Doster, Tanya Hoang, Lisa M. Jenkins, David Venzon, Manjula Gunawardana, Marc Baum, Ettore Appella, Daniel H. Appella, Marjorie Robert-Guroff, Genoveffa Franchini**239 IL-7 AND IL-15 IMPROVE HUMORAL RESPONSES OF A SHIV DNA VACCINE IN ANIMAL MODELS****Laury Anne Leroy**, Alice Mac Donald, Aditi Kandlur, Deepanwita Bose, Peng Xiao, Jean Gagnon, François Villinger, Yahia CHEBLOUNE**240 PROTECTION FROM A PATHOGENIC HETEROLOGOUS SIV BY ELITE CONTROLLERS OF SIVmac239ΔGY**Pyone Aye, Faith Schiro, Amitinder Kaur, Marissa D. Fahlberg, Lara A. Doyle-Meyers, Ronald S. Veazey, Christine M. Fennessey, Brandon Keele, Jeffrey D. Lifson, Khader Ghneim, Rafick-Pierre Sékaly, Michael Gale, Mark Marsh, James Hoxie, **Nicholas Maness**

Poster Session-D02 SARS-CoV-2 VACCINES

2:00 PM MT - 3:30 PM MT

241 TEMPORAL ASSOCIATIONS OF B AND T CELL IMMUNITY IN A 16-WEEK INTERVAL BNT162b2 REGIMEN**Manon Nayrac**, Mathieu Dubé, Gérémy Sannier, Alexandre Nicolas, Alexandra Tauzin, Olivier Tastet, Shang Yu Gong, Lorie Marchitto, Nathalie Brassard, Guillaume Beaudoin-Bussièrès, Jonathan Richard, Cécile Tremblay, Valérie Martel-Laferrrière, Andrés Finzi, Daniel E. Kaufmann**242 A LONG-INTERVAL VACCINE REGIMEN LEADS TO STRONG HUMORAL RESPONSES AGAINST SARS-CoV-2****Alexandra Tauzin**, Shang Yu Gong, Guillaume Beaudoin-Bussièrès, Lorie Marchitto, Annemarie Laumaea, Manon Nayrac, Gérémy Sannier, Renée Bazin, Jonathan Richard, Marceline Côté, Cécile Tremblay, Ralf Duerr, Valérie Martel-Laferrrière, Daniel E. Kaufmann, Andrés Finzi

- 243 IMMUNE RESPONSES AFTER ChAdOx1 OR BNT162b2 BOOSTERS IN PRIMARY CORONAVAC VACCINATION**
Watsamon Jantarabenjakul, Pimpayao Sodsai, Napaporn Chantasrisawad, Anusara Jitsatja, Vichaya Ruenjaiman, Jiratchaya Sophonphan, Supaporn Wacharapluesadee, Thanyawee Puthanakit, Nattiya Hirankarn, Opass Putcharoen
- 244 INTRADERMAL AND INTRAMUSCULAR ADMINISTRATION OF THE BOOSTER COVID-19 VACCINATION**
Suvimol Niyomnaitam, Somruedee Chatsiricharoenkul, Nasikarn Angkasekwinai, Sansnee Senawong, Kulkanya Choekhaibulkit
- 245 DURABILITY AND BOOSTABILITY OF Ad26.COv2.S IN RHESUS MACAQUES**
Xuan He, Abishek Chandrashekar, Jingyou Yu, Katherine McMahan, Frank Wegmann, Huahua Wan, Daniel Sellers, Jinyan Liu, Michelle Lifton, Hanne Andersen, Mark G. Lewis, Galit Alter, Hanneke Schuitemaker, Roland Zahn, Dan Barouch
- 246 S mRNA PRIME S+N DNA BOOST VACCINATION ELICITS ROBUST IMMUNE RESPONSES IN MICE**
 Adrian Rice, **Mohit Verma**, Emily Voigt, Peter Battisti, Sam Beaver, Kyle Dinkins, Shivani Mody, Wendy Higashide, Brett Morimoto, Elizabeth R. Gabitzsch, Jeffrey T. Safrit, Patricia R. Spilman, Christopher Fox, Corey Casper, Patrick Soon-Shiong
- 247 PROTECTIVE EFFICACY OF A GASTROINTESTINAL SARS-CoV-2 VACCINE**
Jingyou Yu, Natalie Collins, Hanne Andersen, Christian Hofer, Donald S. Burke, Erica K. Barkei, Hannah King, Diane Bolton, Kayvon Modjarrad, Nelson L. Michael, Dan Barouch
- 248 LONG-TERM IMMUNOGENICITY AND EFFECTIVENESS OF CD40-TARGETING VACCINATION IN COVID-19**
Véronique Godot, Lea Dupaty, Florence Picard, Ana Zarubica, Amandine Sansoni, Sylvain Cardinaud, Sandra Zurawski, Craig Fenwick, Mireille Centlivre, Mathieu Surenaud, Christine Lacabaratz, Giuseppe Pantaleo, Bernard Malissen, Gerard Zurawski, Yves Levy
- 249 ARMY LIPOSOMAL SPIKE FERRITIN NANOPARTICLE VACCINE INDUCES DURABLE IMMUNE RESPONSES**
Shikha Shrivastava, Joshua M. Carmen, Zhongyan Lu, Rajeshwer S. Sankhala, Shraddha Basu, Alexander Anderson, Hung V. Trinh, Gary R. Matyas, Nelson L. Michael, M. G. Joyce, Kayvon Modjarrad, Jeffrey R. Currier, Elke Bergmann Leitner, Allison M. Malloy, Mangala Rao
- 250 AAVCOVID: A SINGLE-DOSE, THERMOSTABLE COVID-19 VACCINE WITH DURABLE IMMUNOGENICITY**
Nerea Zabaleta, Urja Bhatt, Cécile Herate, Pauline Maisonnasse, Jessica A. Chichester, Julio Sanmiguel, Cheikh Diop, Dawid Maciorowski, James M. Wilson, Roger Le Grand, Luk H. Vandenberghe
- 251 SPIKE PLUS NUCLEOCAPSID VACCINE PROTECTS AGAINST SARS-CoV-2 DELTA INFECTION IN NHPs**
Nanda Kishore Routhu, Sailaja Gangadhara, Lilin Lai, Ayalnesh Shiferaw, Stephanie Fischinger, Bartsch Yannic, Sheikh A. Rahman, Sherrie M Jean, Chelsea Wallace, Rachelle L Stammen, Pamela A. Kozlowski, Galit Alter, Mehul Suthar, Rama R. Amara
- 252 INVESTIGATING CONSERVED SEQUENCE IN THE SARS-CoV-2 GENOME AS NOVEL VACCINE IMMUNOGEN**
Gabriel Dagotto, John D. Ventura, David R. Martinez, Tochi Anioke, Benjamin S. Chung, Mazuba Siamatu, Julia Barrett, Jingyou Yu, Lisa H. Tostanoski, Alexandra Schaefer, Ralph Baric, Bette Korber, Dan Barouch

253 ANTIGENICITY OF THE MU (B.1.621) AND A.2.5 SARS-CoV-2 SPIKES

Debashree Chatterjee, Shang Yu Gong, Alexandra Tausin, Annemarie Laumaea, Guillaume Goyette, Gabrielle Gendron-Lepage, Halima Medjahed, Jonathan Richard, Sandrine Moreira, Marceline Côté, Andrés Finzi

254 OPTIMIZATION OF NONCODING REGIONS IMPROVES mRNA SARS-CoV-2 VACCINE IN NHPs

Makda Gebre, Susanne Rauch, Nicole Roth, Jingyou Yu, Abishek Chandrashekar, Noe B. Mercado, Xuan He, Jinyan Liu, Katherine McMahan, Amanda Martinot, Xiaowen Liu, Mark G. Lewis, Stefan Mueller, Benjamin Petsch, Dan Barouch

255 IgG GLYCOSYLATION PREDICTS COVID-19 DISEASE SEVERITY AND VACCINE ANTIBODY RESPONSE

Michelle Ash, Pavan Bhimalli, Byoung-Kyu Cho, Basil Baby Mattamana, Stephanie Gambut, Imad Tarhoni, Cristina Fhied, Thomas Hope, Beverly Sha, Young Ah Goo, Lena Al-Harathi, Joao Mamede, Jeffrey Borgia, Neil Kelleher, **Jeffrey Schneider**

Poster Session-D08 HIV IMMUNOLOGY: NK CELLS AND CYTOKINES
2:00 PM MT - 3:30 PM MT
304 SEX DIFFERENCES IN CYTOKINE PROFILES DURING SUPPRESSIVE ANTIRETROVIRAL THERAPY

Christophe Vanpouille, Alan Wells, Timothy Wilkin, Jyoti S. Mathad, Sheldon Morris, Leonid Margolis, **Sara Gianella**

305 DOWNREGULATION OF CD155 RESULTS IN HIV-1 RESTRICTION BY KIR2DL5+ NK CELLS

Pia Fittje, Angelique Hölzemer, Wilfredo F. Garcia-Beltran, Annika Niehrs, Sarah Vollmers, Glòria Martrus, Christian Körner, Frank Kirchhoff, Daniel Sauter, Marcus Altfeld

306 THE ROLE OF ADAPTIVE NK CELLS DURING ACUTE HIV-1 INFECTION WITH DIFFERENT SUBTYPES

Aljawharah Alrubayyi, Amin Hassan, Jonathan Hare, Jill Gilmour, Joakim Esbjörnsson, Eduard Sanders, Sarah Rowland-Jones, Dimitra Peppas

307 CHARACTERIZATION OF NK CELLS IN ELITE CONTROLLERS LOSING HIV CONTROL

Nerea Sánchez-Gaona, Ana Gallego Cortés, Antonio Astorga Gamaza, Norma Rallón, José M. Benito, Vicenç Falcó, Meritxell Genescà, Maria José Buzón

Poster Session-D10 EBOLAVIRUS VACCINES
2:00 PM MT - 3:30 PM MT
323 PREVAC RCT: EFFECTS OF 3 EBOLA VACCINE STRATEGIES IN WEST AFRICAN ADULTS AND CHILDREN

Mark Kieh, Laura Richert, Abdoul Habib Beavogui, Birgit Grund, Bailah Leigh, Eric D'Ortenzio, Seydou Doumbia, Samba Sow, Lisa Hensley, Yves Levy, Cliff Lane, Deborah Watson-Jones, James Neaton, **Yazdan Yazdanpanah**, for the PREVAC Study Team

324 EBOLA VACCINE-INDUCED STRONG-BINDING ANTIBODY RESPONSES IN PEOPLE LIVING WITH HIV-1

Thembi Mdluli, Suzanne Wollen-Roberts, Dominic Paquin-Proulx, Jay Hooper, Betty Mwesigwa, Josphat Kosgei, Janet Oyieko, Nyanda Ntinginya, Ilesh Jani, Michael Iroezindu, Lucy Ward, Kerstin Luhn, Cynthia Robinson, Julie Ake, Morgane Rolland

Poster Session-E03

INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND

2:00 PM MT - 3:30 PM MT

347 BRAIN PENETRANT CSF1R INHIBITOR REDUCES BRAIN VIRUS BURDEN IN SIV-INFECTED MACAQUES

Laurent D. Zablocki-Thomas, Evan S. Leung, Jinbum K. Dupont, Julian B. Hattler, Diana G. Bohannon, Jolanta Kowalewska, Marcelo J. Kuroda, Woong-Ki Kim

348 COMBINATION OF PD-1 BLOCKADE AND AZD5582 THERAPY IN SIV+ MONKEYS

Bhruhu Yagnik, Sheikh A. Rahman, Gordon J. Freeman, Rafi Ahmed, Rama R. Amara

349 VIRAL AND BIOMARKER OUTCOMES OF AN ENGINEERED bNAb IN ART-SUPPRESSED PARTICIPANTS

Yanhui Cai, Lisa Selzer, Peter J. Ruane, Eric S. Daar, Princy N. Kumar, Laurie VanderVeen, Liao Zhang, Jeffrey Wallin, Devi SenGupta, Sean E. Collins, Kimberly Workowski, Joseph J. Eron, Edwin DeJesus

350 DNA-ECD4-IG DECREASED HIV-1 RESERVOIR ON ART DELAYED VIRAL REBOUND IN HUMANIZED MICE

Zhe Yuan, Mansi Purwar, Opeyemi S. Adeniji, Ziyang Xu, Colin Hart, Kwasi Gyampoh, Guorui Zu, Abhijeet J. Kulkarni, Mohamed Abdel-Mohsen, David Weiner, Luis J. Montaner

351 EFFICACY OF Ad26/MVA + Env + VESATOLIMOD THERAPEUTIC VACCINATION IN RHESUS MACAQUES

John D. Ventura, Joseph P. Nkolola, Abishek Chandrashekar, Erica N. Borducchi, Jinyan Liu, David L. Hope, Victoria M. Giffin, Katherine McMahan, Romas Geleziunas, Jeffrey Murry, Mark G. Lewis, Maria G. Pau, Merlin Robb, Dan Barouch

352 BEAT2: peg-IFN- α 2b + 3BNC117 AND 10-1074 KEEPS HIV AT <20 C/ML DURING 26 WEEK ATI

Pablo Tebas, Livio Azzoni, Emmanouil Papasavvas, Grace Choi, Susan S. Ellenberg, Marina Caskey, Bonnie Howell, Daria Hazuda, Christos Petropoulos, Kenneth Lynn, Linden Lalley-Chareczko, Jay R. Kostman, William R. Short, Karam Mounzer, Luis J. Montaner

353 SMAC MIMETICS REACTIVATE HIV AND REDUCE THE VIRAL RESERVOIR IN HUMANIZED MICE

Jaspreet Jain, **Tram N. Pham**, Nicolas Bellini, Frédéric Dallaire, Thomas T. Murooka, Rémi Fromentin, Nicolas Chomont, Eric A. Cohen

354 INDUCIBLE RESERVOIR IN TISSUES, BUT NOT IN PERIPHERY, PREDICTS FUNCTIONAL CURE OF SIV

Adam J. Kleinman, Sindhuja Sivanandham, Ranjit Sivanandham, Paola Sette, Benjamin B. Policicchio, Cuiling Xu, Quentin Le Hingrat, Egidio Brocca-Cofano, Dongzhu Ma, Ivona Pandrea, Cristian Apetrei

355 EFFECT OF HIGH-DOSE VITAMIN D3 ON THE HIV RESERVOIR: A RANDOMIZED CONTROLLED TRIAL

Matthew C. Pitman, Niamh Meagher, David J. Price, Ajantha Rhodes, Judy Chang, Barbara Scher, Brent Allan, Alan Street, James McMahon, Thomas A. Rasmussen, Paul U. Cameron, Jennifer Hoy, Stephen J. Kent, Sharon Lewin

356 CARD8 SENSITIZATION THROUGH DPP9 INHIBITION ENHANCES KILLING OF HIV-INFECTED CELLS

Kolin Clark, Qiankun Wang, Josh Kim, Liang Shan

357 HIV-1 VIRAL RESERVOIR DISRUPTION WITH PANOBINOSTAT AND IFN- α 

Marie Armani-Touret, Ciputra A. Hartana, Yelizaveta Rassadkina, Ce Gao, Katrina Shea, Amy Sbrolla, Xu Yu, Rajesh T. Gandhi, Daniel Kuritzkes, Mathias Lichterfeld

358 IMPACT OF INFLUENZA AND PNEUMOCOCCUS VACCINES ON CELLULAR HIV RNA TRANSCRIPTION

Sara Gianella, Alan Wells, Susanne May, Christy Anderson, Gemma Caballero, Laura Layman, Brianna Scott, Joseph Lonergan, Leticia Muttera, Liliana Harkness, Susan J. Little, Davey M. Smith

359 PHASE II CLINICAL TRIAL OF VEDOLIZUMAB AND ART IN SUBJECTS WITH NO PREVIOUS ART

Maria Reyes Jimenez Leon, Carmen Gasca-Capote, Cristina Roca-Oporto, Nuria Espinosa-Aguilera, Salvador Sobrino, María Fontillón, Inmaculada Rivas-Jeremias, Karin Neukam, Jose German Sanchez-Hernandez, Raul Rigo-Bonnin, Antonio J. Cervera, Rosario Mesones, Pompeyo Viciano, Luis Fernando López Cortés, Ezequiel Ruiz-Mateos

360 CARD8 ACTIVATION BY HIV-1 PR TRIGGERS GSDMD-DEPENDENT AND -INDEPENDENT CELL DEATH

Qiankun Wang, Liang Shan

361 PROLONGED VIRAL SUPPRESSION BY IMMUNOTHERAPY WITH ANTI-HIV ANTIBODIES 3BNC117/10-1074

Christian Gaebler, Lilian Nogueira, Elina Stoffel, Thiago Oliveira, Katrina Millard, Martina Turroja, Allison Butler, Victor Ramos, Michael Seaman, Jacqueline D. Reeves, Johannes F. Scheid, Rajesh T. Gandhi, Tae-Wook Chun, Marina Caskey, Michel Nussenzweig

Poster Session-E04**CONTROLLERS AND POST-TREATMENT CONTROLLERS****2:00 PM MT - 3:30 PM MT****362 POST-TREATMENT CONTROLLERS LIMIT COMPLETED AND SPLICED HIV TRANSCRIPTS AFTER ATI**

Adam Wedrychowski, Holly A. Martin, Sushama Telwatte, Gayatri Nikhila Kadiyala, Elizabeth Connick, Jeffrey Jacobson, David M. Margolis, Daniel J. Skiest, Paul Volberding, Frederick M. Hecht, Steven G. Deeks, Joseph K. Wong, Jonathan Li, Steven A. Yukl

363 IMMUNOLOGICAL AND GLYCOMIC CORRELATES OF TIME-TO-HIV-REBOUND IN VIREMIC CONTROLLERS

Yanhui Cai, Steven G. Deeks, Liao Zhang, Leila B. Giron, Jane Koshy, Zongbo Shang, Susan Guo, Christiaan de Vries, Elena Vendrame, Devi SenGupta, Mohamed Abdel-Mohsen, Jeffrey Wallin

364 POST-TREATMENT CONTROLLERS MAINTAIN A LIMITED INTACT RESERVOIR AFTER ART INTERRUPTION

Yijia Li, Behzad Etemad, Meghan Melberg, Radwa Sharaf, Wendy Hartogensis, Ronald J. Bosch, Jeffrey Jacobson, Elizabeth Connick, Paul Volberding, Daniel J. Skiest, David M. Margolis, Steven G. Deeks, Michael M. Lederman, Frederick M. Hecht, Jonathan Li

365 LIMITED EVOLUTION OF THE VIRAL RESERVOIR IN A NONHUMAN PRIMATE MODEL OF ELITE CONTROL

Kyle Rhodehouse, Mithra R. Kumar, Emily J. Fray, Christine M. Fennessey, Pyone Aye, Faith Schiro, Amitinder Kaur, Marissa D. Fahlberg, Lara A. Doyle-Meyers, Jeffrey D. Lifson, Brandon Keele, James Hoxie, Nicholas Maness, Janet Siliciano, Robert Siliciano

366 CD8 RECOGNITION OF AUTOLOGOUS VIRUS IN HIV-ELITE CONTROLLERS DESPITE ESCAPE MUTATIONS

Maria A Navarrete-Muñoz, Alejandro Calderón, Ricardo Ramos, África Holguín, Alfonso Cabello Úbeda, Miguel Górgolas, José M. Benito, **Norma Rallón**

Poster Session-F03 HIV, SIV, AND SARS-CoV-2 NEUROPATHOGENESIS MODELING

2:00 PM MT - 3:30 PM MT

401 HIV-1 Nef IMPAIRS MYELIN AND DISRUPTS GLIAL CELLS IN THE CENTRAL NERVOUS SYSTEM

Jessica K. Schenck, Michael I. Bukrinsky, Robert H. Miller

402 NLRP3 INFLAMMASOME SIGNALING PATHWAY IS UPREGULATED IN BRAINS OF PEOPLE WITH HIV-1



Alice K. Min, Amara Plaza-Jennings, Susan Morgello, Schahram Akbarian, Talia H. Swartz

403 CONCOMITANT CARDIAC PATHOLOGY WITH ENCEPHALITIS IN SIV-INFECTED ANIMALS WITH AIDS

Kevin S. White, Joshua A. Walker, Patrick Autissier, Andrew Miller, Qingsheng Li, Rachel Burrack, Woong-Ki Kim, Kenneth Williams

404 EVIDENCE OF BRAIN HYPOXIA IN NEUROPATHOLOGY OF SARS-CoV-2-INFECTED NONHUMAN PRIMATES

Ibolya Rutkai, Meredith G. Mayer, Linh Hellmers, Bo Ning, Zhen Huang, Nicholas Maness, Kasi Russell-Lodrigue, Tony Hu, Chad Roy, Robert Blair, Rudolf Bohm, Lara A. Doyle-Meyers, Jay Rappaport, **Tracy Fischer**

405 375W MUTATION ENHANCES CD4 BINDING AND CHANGES TROPISM IN SOME CLADES



Odette Verdejo-Torres, Tania Allin Vargas Pavia, Zhongming Mou, Paul R. Clapham, Maria Duenas Decamp

Poster Session-F04 BLOOD AND CSF BIOMARKERS OF BRAIN INTEGRITY AND FUNCTION

2:00 PM MT - 3:30 PM MT

406 H/L-FERRITINS AND TIM-1 ASSOCIATED WITH NEUROCOGNITIVE FUNCTION IN PEOPLE WITH HIV

Harpreet Kaur, Kunling Wu, Robert Kalayjian, Frank Palella, Susan L. Koletar, Corri Lynn O. Hileman, William Bush, Kristine Erlandson, Ronald J. Ellis, Roger Bedimo, Babafemi O. Taiwo, Katherine Tassiopoulos, **Asha R. Kallianpur**, for the ACTG A5322 Study Team

407 CSF EXOSOME A β 42 AND TAU/AB42 RATIO ASSOCIATED WITH COGNITIVE DISORDERS IN OLDER PWH

Debjani Guha, Vikas Misra, David Lorenz, Dana Gabuzda

408 HIGH PROTEIN CARBONYL LEVELS CORRELATE WITH ABNORMAL WHITE MATTER IN PEOPLE WITH HIV

Patricia K. Riggs, Albert M. Anderson, Bin Tang, Leah H. Rubin, Susan Morgello, Christina M. Marra, Benjamin B. Gelman, David Clifford, Donald Franklin, Robert K. Heaton, Ronald J. Ellis, Christine Fennema-Notestine, Scott L. Letendre

- 409 INTRA-INDIVIDUAL STABILITY OF CSF BIOMARKERS OVER 12 YEARS IN PEOPLE WITH HIV (PWH)**
Asante R. Kamkwala, Ankita Garg, Upal Roy, Avery Matthews, Patricia K. Riggs, Leah H. Rubin, Christina M. Marra, Susan Morgello, Benjamin B. Gelman, David Clifford, Donald Franklin, Debra Cookson, Robert K. Heaton, Ronald J. Ellis, Scott L. Letendre
- 410 DECREASING CNS MYELOID ACTIVATION RELATES TO DECREASING NEURODEGENERATION IN HIV**
Azin Tavasoli, Scott L. Letendre, Benjamin B. Gelman, Christina M. Marra, David Clifford, Susan Morgello, Jennifer Iudicello, Leah H. Rubin, Ronald J. Ellis
- 411 SERUM AND CSF ULTRASENSITIVE DETECTION OF NFL AND ALZHEIMER BIOMARKERS IN PLWH**
Mattia Trunfio, Miriam Antonucci, Jessica Cusato, Daniela Vai, Daniele Imperiale, Antonio D'Avolio, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno
- 412 ASSOCIATIONS BETWEEN PLASMA BIOMARKERS AND NEUROCOGNITION IN ART-TREATED PWH**
Robert Kalayjian, Corri Lynn O. Hileman, Ronald J. Ellis, Asha R. Kallianpur, Roger Bedimo, Kristine Erlandson, Susan L. Koletar, Babafemi O. Taiwo, Kunling Wu, Frank Palella, Katherine Tassiopoulos
- 413 SERUM NEUROFILAMENT AS A MARKER OF WHITE MATTER INJURY IN HIV DISEASE**
Christina S. Meade, Sheri L. Towe, David M. Murdoch, Ryan P. Bell
- 414 PLASMA D-DIMER, A MARKER OF INFLAMMATION, IS INCREASED WITH POLYNEUROPATHY IN HIV**
Ronald J. Ellis, David Clifford, Christina M. Marra, Ann C. Collier, Benjamin B. Gelman, Jessica Robinson-Papp, Scott L. Letendre, J Allen McCutchan, Robert K. Heaton
- 415 mtDNA HAPLOGROUPS AND COGNITIVE FUNCTION IN BLACK AND HISPANIC WOMEN WITH HIV**
 Todd Hulan, Tebeb Gebretsadik, **Karen E. Volpe**, Leah H. Rubin, Pauline Maki, Gayle Springer, Asha R. Kallianpur, Bradley Aouizerat, David Samuels

Poster Session-G01 WHAT'S NEW IN PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS

2:00 PM MT - 3:30 PM MT

- 429 IV PUSH ADMINISTRATION OF IBALIZUMAB: PHARMACOKINETICS, SAFETY, AND EFFICACY**
Edwin DeJesus, Gary Richmond, Mezgebe Berhe, Anthony Mills, Tanya Schreiber, Charlotte-Paige Rolle, Kuei-Ling Kuo, Mohammed Zogheib, Olivia G. Goss, Robert B. Cash, YingAn Lai, Martin Markowitz, Pedro M. Mesquita
- 430 DEEPHIV: DEEP LEARNING TO PREDICT DDI RELEVANCE FOR ARVs**
Thao Pham, Mohamed Ghafoor, Justin Chiong, Dennis Wang, Marco Siccardi
- 431 PK & SAFETY OF DARUNAVIR/COBICISTAT WITH ONCE-WEEKLY ISONIAZID/RIFAPENTINE**
Kristina M. Brooks, Alice K. Pau, Doris Swaim, Haden T. Bunn, Lilian Adejo, Charles A. Peloquin, Parag Kumar, Joseph A. Kovacs, Jomy M. George

- 432 ISLATRAVIR DOES NOT PROLONG QTC IN A THOROUGH QT STUDY IN HEALTHY PARTICIPANTS**
Randolph P. Matthews, Yang Liu, Catherine Matthews, Kristin Butterfield, Terry O'Reilly, Selwyn A. Stoch, Marian Iwamoto
- 433 EVALUATION OF POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ISLATRAVIR AND LENACAPAVIR**
Haeyoung Zhang, Eva Mortensen, Martin Rhee, Luxi Cao, Aaron M. Share, John Ling, Ramesh Palaparthi
- 434 PHARMACOKINETICS OF LENACAPAVIR IN PARTICIPANTS WITH SEVERE RENAL IMPAIRMENT**
Elijah Weber, Hiba Graham, Steve West, John Ling, Martin Rhee, Ramesh Palaparthi
- 435 REMOVAL OF DORAVIRINE BY HEMODIALYSIS IN HIV-INFECTED PATIENTS**
Jose Molto, Fredzzia Graterol, Adrià Curran, Natalia Ramos, Arkaitz Imaz, Diego Sandoval, Francisco Perez, Lucia Bailon, Saye Khoo, Laura Else, Bonaventura Clotet
- 436 PHARMACOKINETICS OF DOLUTEGRAVIR AND BICTEGRAVIR IN OBESE PEOPLE LIVING WITH HIV**
 **Mattia Berton**, Sara Bettonte, Laurent Decosterd, Manuel Battegay, Matthias Cavassini, Felix Stader, Catia Marzolini
- 437 STUDY 31/A5349 POPULATION PHARMACOKINETIC ANALYSIS OF RIFAPENTINE AND MOXIFLOXACIN**
Vincent Chang, Marc Weiner, Marjorie Z. Imperial, Nan Zhang, William Whitworth, Kia Byrant, Melissa Engle, Susan Dorman, Payam Nahid, Susan Swindells, Richard E. Chaisson, Pheona Nsubuga, Kelly Dooley, Rada Savic, for the AIDS Clinical Trials Group and the Tuberculosis Trials Consortium
- 438 PHARMACOGENETICS OF BEDAQUILINE AND CLOFAZIMINE PLASMA CLEARANCE AMONG SOUTH AFRICANS**
David W. Haas, Mahmoud T. Abdelwahab, Stijn W. van Beek, Paxton Baker, Gary Maartens, Yuki Bradford, Marylyn D. Ritchie, Sean Wasserman, Graeme Meintjes, Neel R. Gandhi, Elin Svensson, Paolo Denti, James C. Brust
- 439 PHARMACOGENETICS OF DOLUTEGRAVIR PLASMA EXPOSURE AMONG SOUTH AFRICANS LIVING WITH HIV**
 **Zinhle Cindi**, Aida N. Kawuma, Gary Maartens, Roeland E. Wasmann, Paolo Denti, Lubbe Wiesner, Yuki Bradford, Francois Venter, Simiso M. Sokhela, Nomathemba Chandiwana, Marylyn D. Ritchie, David W. Haas, Phumla Sinxadi

Poster Session-H05 NOVEL AGENTS: INTRIGUING RESULTS
2:00 PM MT - 3:30 PM MT

- 498 DURABLE HUMAN HIV-SPECIFIC bNAb PRODUCTION 3 YEARS AFTER AAV8-MEDIATED GENE TRANSFER**
Joseph P. Casazza, Evan M. Cale, Sandeep Narpala, Laura Novik, Galina V. Yamshchikov, Bob C. Lin, Janardan P. Pandey, Adrian McDermott, Mario R. Roederer, Alejandro Balazs, David Baltimore, Richard A. Koup, Julie E. Ledgerwood, John R. Mascola, for the VRC603 Team

- 499 MECHANISMS OF HOPEAPHENOL INHIBITION OF HIV PROVIRUS FOLLOWING DISCONTINUATION**
Ian Tietjen, Amanda Sciorillo, Maya E. Naidu, Cole Schonhofer, Zahra Haq, Toshitha Kannan, Andrew Kossenkov, Karam Mounzer, Colin Hart, Kwasi Gyampoh, Zhe Yuan, Karren D. Beattie, Topul Rali, Rohan A. Davis, Luis J. Montaner
- 500 INTRINSIC RESISTANCE OF HIV-2 AND SIV TO THE MATURATION INHIBITOR GSK2838232**
Robert A. Smith, Dana N. Raugi, Robbie Nixon, Jennifer Song, Moussa Seydi, Geoffrey S. Gottlieb, for the University of Washington-Senegal HIV-2 Study Group
- 501 HIV-1 NONGROUP M PHENOTYPIC SUSCEPTIBILITY TO IBALIZUMAB (ANTI-CD4)**
 Lucie Poisson-Arnaud, Quentin Le Hingrat, Jean-Christophe Plantier, **Elodie Alessandri-Gradt**
- 432 ISLATRAVIR DOES NOT PROLONG QTc IN A THOROUGH QT STUDY IN HEALTHY PARTICIPANTS**
Randolph P. Matthews, Yang Liu, Catherine Matthews, Kristin Butterfield, Terry O'Reilly, Selwyn A. Stoch, Marian Iwamoto

Poster Session-I01

PROFILING THE SENSITIVITY OF HIV TO NEUTRALIZING ANTIBODIES IN VIVO

2:00 PM MT - 3:30 PM MT

- 503 SUSCEPTIBILITY TO 3BNC117 AND 10-1074 IN ART-SUPPRESSED CHRONICALLY INFECTED PERSONS**
Luis J. Montaner, Kenneth Lynn, Livio Azzoni, Emmanouil Papasavvas, Matthew Fair, Giorgio Cocchella, Amanda Sciorillo, Charles Kang, Jacqueline D. Reeves, Linden Lalley-Chareczko, Jay R. Kostman, William R. Short, Karam Mounzer, Christos Petropoulos, Pablo Tebas
- 504 PERFORMANCE OF A PHENOTYPE AND 2 GENOTYPE ALGORITHMS FOR bNab SENSITIVITY PREDICTION**
 **Marie H. Pahus**, Jesper D. Gunst, Victor Ramos, Martin Tolstrup, Jacqueline D. Reeves, Christos Petropoulos, Michel Nussenzweig, Marina Caskey, Ole Sogaard
- 505 MUTATIONAL LANDSCAPE OF 10-1074 AND 3BNC117 SENSITIVITY IN A UK POPULATION WITH PHI**
 **Penny Zacharopoulou**, Lilian Nogueira, Thiago Oliveira, Helen Brown, Nicola Robinson, Sabine Kinloch-de Loes, Amanda Clarke, John Thornhill, Marina Caskey, Michel Nussenzweig, Julie Fox, Sarah Fidler, M. A. Ansari, John Frater, for the RIO and HEATHER Trial Investigators

Poster Session-I02

IMPACT OF HIV MUTATIONS ON FITNESS, DRUG RESISTANCE, AND TREATMENT RESPONSE

2:00 PM MT - 3:30 PM MT

- 506 EFFECT OF L74I POLYMORPHISM ON FITNESS OF HIV-1 SUBTYPE A6 RESISTANT TO CABOTEGRAVIR**
Zixin Hu, Trevor Cordwell, Jerry Jeffrey, Daniel Kuritzkes
- 507 HOW MUTATIONS IN THE HIV-1 3'-POLYPURINE TRACT CONFER DOLUTEGRAVIR RESISTANCE**
 **Jose Dekker**, Bep Klaver, Ben Berkhout, Atze Das

- 508 ABSENCE OF CROSS-RESISTANCE TO LENACAPAVIR IN HIV ENTRY INHIBITOR-RESISTANT ISOLATES**
Nicolas Margot, Vidula Naik, Laurie VanderVeen, Martin Rhee, Christian Callebaut
- 509 HIV DRUG RESISTANCE IN WOMEN RANDOMIZED TO DTG VS EFV OR TDF VS TAF IN PREGNANCY**
Ceejay L. Boyce, Sean Brummel, Lauren Ziemba, Katie McCarthy, Kevin Knowles, Sheila Styrchak, Renee Browning, Nahida Chakhtoura, Sikhulile Moyo, Tichaona Vhembo, Violet Korutaro, José H. Pilotto, Lameck Chinula, Shahin Lockman, Lisa M. Frenkel
- 510 A RANDOMIZED TRIAL OF DTG PLUS DRV/c AS A SWITCH STRATEGY IN SUBJECTS WITH MDR HIV-1**
José Ramón Santos, Pere Domingo, Joaquín Portilla, Félix Gutiérrez, Arkaitz Imaz, Helem H. Vilchez, Adrià Curran, Nieves Valcarce, Antoni Payeras, Enrique Bernal, Marta Montero, Miguel Ysusi, Roger Paredes
- 511 LOW-LEVEL RESISTANCE MUTATIONS CORRELATE WITH HIV THERAPY FAILURE IN PREGNANT WOMEN**
Rachel M. Burdorf, Shuntai Zhou, Claire Amon, Collin Hill, Lily Adams, Gerald Tegha, Maganizo Chagomerana, Allan Jumbe, Madalitso Maliwichi, Shaphil Wallie, Sarah B. Joseph, Ronald Swanstrom, Mina C. Hosseinipour
- 512 CHANGES IN THE HIV-1 3'-PPT IN PATIENTS FAILING DOLUTEGRAVIR IN BRAZIL**
Jeroen J. van Kampen, Rob Gruters, Saye Khoo, Daniel Kuritzkes, Ricardo S. Diaz, James Hunter, Thibault Mesplede, David van de Vijver, Jolanda Voermans, Ben Berkhout, Atze Das, Mauro Schechter

Poster Session-J01 FATTY LIVER: NAFL, MAFL, AND NASH

2:00 PM MT - 3:30 PM MT

- 518 IMPACT OF NASH ON THE SURVIVAL OF PEOPLE LIVING WITH HIV**
Juan Macias, Antonio Rivero-Juarez, Alejandro Gonzalez-Serna, Mario Frías, MARTA SANTOS, Ignacio Perez-Valero, Anaïs Corma-Gomez, Antonio Rivero, Miguel Garcia-Deltoro, Luis M. Real, Juan A. Pineda
- 519 NONINVASIVE PREDICTION OF HEPATIC DECOMPENSATION IN PATIENTS WITH HIV**

Amine Benmassaoud, Juan Macias, Anaïs Corma-Gomez, Giovanni Guaraldi, Jovana Milic, Jürgen K. Rockstroh, Kathrin Van Bremen, Emmanuel Tsochatzis, Akhilesh Mulay, Jennifer Price, Lucy J. Garvey, Dana Kablawi, Juan A. Pineda, Victor De-Ledinghen, Giada Sebastiani
- 520 NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS**
Carl J. Fichtenbaum, Heather J. Ribaudo, Jana Taron, Jorge T. Leon-Cruz, Netanya S. Utay, Ken Ho, Annie Luetkemeyer, Shobha Swaminathan, Carrie Johnston, Evelynne S. Fulda, Emma Kileel, Michael T. Lu, Steven Grinspoon, Jordan Lake, for the REPRIEVE Trial Investigators
- 521 FROM NAFLD TO MAFLD: IMPLICATIONS OF CHANGE IN TERMINOLOGY IN PWH**
Giovanni Guaraldi, Jovana Milic, Stefano Renzetti, Federico Motta, Licia Gozzi, Adriana Cervo, Giulia Burastero, Vittorio Iadiseria, Bertrand Lebouché, Alshaima Alhinai, Marc Deschenes, Paolo Raggi, Stefano Calza, Cristina Mussini, Giada Sebastiani

522 THE PATHWAY OF NAFLD VS MAFLD TOWARD SIGNIFICANT FIBROSIS



Jovana Milic, Stefano Renzetti, Federico Motta, Licia Gozzi, Giulia Besutti, Giulia Burastero, Vittorio Iadiseria, Bertrand Lebouché, Alshaima Alhinai, Marc Deschenes, Stefano Calza, Cristina Mussini, Giada Sebastiani, Giovanni Guaraldi

523 HIGH INCIDENCE RATE OF CT-MEASURED NAFLD IN MEN WITH AND WITHOUT HIV INFECTION

Jennifer Price, Gayle Springer, Eric C. Seaberg, Matthew Budoff, Susan L. Koletar, Claudia Hawkins, Mallory Witt, Wendy Post, Chloe L. Thio

524 DETERMINANTS OF LIVER STEATOSIS IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY



Carlotta Riebenschahm, Annalisa Berzigotti, Bernard Surial, Huldrych F. Günthard, Philip Tarr, Hansjakob Furrer, Andri Rauch, Gilles Wandeler

525 CANNABIS USE AND HEPATIC STEATOSIS BY MRI-PDF

Janet Diaz-Martinez, Javier A. Tamargo, Ivan Delgado-Enciso, Richard Ehman, Jun Chen, Kenneth E. Sherman, Leslie Seminario, Jupshy Jasmin, Marianna K. Baum, for the MASH Cohort

526 METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND ITS ASSOCIATION WITH EPICARDIAL FAT

Win Min Han, Tanakorn Apornpong, Sasiwimol Ubolyam, Stephen J. Kerr, Anchalee Avihingsanon

527 NONOBESE NAFLD IS ASSOCIATED WITH HIGHER sCD14 CONCENTRATIONS IN ADULTS WITH HIV

Jordan Lake, Han Feng, Hongyu Miao, Paula Debroy, Anoma Somasunderam, Netanya S. Utay

Poster Session-K01 CANCER RISK, TREATMENT, AND EPIDEMIOLOGY 2:00 PM MT - 3:30 PM MT

552 DISTINCT CANCERS HAVE DISTINCT INFLAMMATORY PREDICTORS IN TREATED HIV

Samuel R. Schnittman, Gabriele B. Beck-Engeser, Dave Glidden, Robin M. Nance, Vanessa York, Joseph A. Delaney, Amelia N. Deitchman, Fran Aweeka, Judy K. Shigenaga, Michael Saag, Carl Grunfeld, Franklin W. Huang, Heidi Crane, **Peter W. Hunt**, for the CFAR Network of Integrated Clinical Systems Network

553 PROINFLAMMATORY GLYCOMIC DYSREGULATIONS PRECEDE CANCER ONSET DURING HIV INFECTION

Leila B. Giron, Jane Koshy, Jianyi Ding, David Lu, Geoffrey A. Feret, Ted Barrell, Alan Landay, Qin Liu, Robert Gross, Mohamed Abdel-Mohsen

554 USING NEXT-GENERATION SEQUENCING TO DETECT GENES RELATED TO CANCER IN WOMEN WITH HIV

Stephanie Jo, Alicia Golembieski, Dwayne Baxa

555 DELAYED ART LEADS TO IRREVERSIBLE DEPLETION OF SKIN AND MUCOSA RESIDENT MEMORY T CELL

Simona Saluzzo, Ram Vinay Pandey, Laura M. Gail, Lisa Kleissl, Johanna Strobl, Veronique Touzeau-Römer, Armin Rieger, Matthias Farlik, Wolfgang Weninger, Georg Stingl, Georg Stary

- 556 CD4+ AND RISK OF ADVERSE EVENTS IN PARTICIPANTS RECEIVING IMMUNOTHERAPY FOR CANCER**
Thomas Odeny, Kathryn Lurain, Julius Strauss, Thomas S. Uldrick, Steven Fling, Elad Sharon, Anna K. Wright, James Gulley, Robert Yarchoan, Ramya Ramaswami
- 557 EXCESS MORTALITY ASSOCIATED WITH CANCER IN A PRIVATE HIV CARE PROGRAM IN SOUTH AFRICA**
Yann Ruffieux, Hannes Mouton, Andreas D. Haas, Matthias Egger, Gary Maartens, Eliane Rohner
- 558 AGE AND CANCER INCIDENCE IN 5.2 MILLION PEOPLE LIVING WITH HIV IN SOUTH AFRICA**
Yann Ruffieux, Mazvita Muchengeti, Victor Olago, Tafadzwa G. Dhokotera, Julia Bohlius, Matthias Egger, Elvira Singh, Eliane Rohner
- 559 TRENDS IN CANCER INCIDENCE IN DIFFERENT MODERN ART ERAS AMONG PEOPLE LIVING WITH HIV**
Lauren Greenberg, for the RESPOND Cohort Consortium and the D:A:D Study
- 560 THE SOUTH AFRICAN HIV CANCER MATCH STUDY: COHORT PROFILE**
Mazvita Muchengeti, Victor Olago, Matthias Egger, Tafadzwa G. Dhokotera, Elvira Singh, **Julia Bohlius**

Poster Session-L01 RISK FACTOR AND INFLAMMATORY MEDIATORS OF CARDIOVASCULAR DISEASE
2:00 PM MT - 3:30 PM MT

- 575 PREVALENCE AND CARDIOVASCULAR OUTCOME OF CLONAL HEMATOPOIESIS IN MEN LIVING WITH HIV**
Sergiu Pasca, Shiyu Wang, Susan Langan, Aparna Pallavajjala, Lisa Haley, Christopher Gocke, Wendy Post, Matthew Budoff, Sabina Haberen, Todd Brown, Richard F. Ambinder, Joseph B. Margolick, Lukasz P. Gondek
- 576 CLONAL HEMATOPOIESIS, INFLAMMATION, AND CORONARY ARTERY DISEASE IN PERSONS WITH HIV**
 **Andreas D. Knudsen**, Andreas Fuchs, Alvaro H. Borges, Christian Eskeland, Sisse R. Ostrowski, Joachim Weischenfeldt, Marco Gelpi, Cavan Reilly, James Pankow, Kirsten Grønbaek, Lars Køber, Marius Trøseid, Klaus F. Kofoed, Susanne D. Nielsen
- 577 SUBCLINICAL ATHEROSCLEROSIS AND IMMUNE ACTIVATION AMONG US FEMALES VS MALES WITH HIV**
Markella V. Zanni, Borek Foldyna, Kenneth Williams, Tricia H. Burdo, Sara McCallum, Sara E. Looby, Patrick Autissier, Kathleen Fitch, Judith S. Currier, Michael T. Lu, Pamela S. Douglas, Heather J. Ribaldo, Steven Grinspoon, for the REPRIEVE Investigators
- 578 INFLAMMATORY CLUSTERS PREDICT MULTIMORBIDITY AND CVD IN PEOPLE WITH HIV ON ART**
 **Padraig McGettrick**, Willard Tinago, Alejandro A. Garcia, Stefano Savinelli, Eoin Feeney, Eavan G. Muldoon, Tara McGinty, John S. Lambert, Gerard Sheehan, Aoife G. Cotter, Alan Landay, Patrick Mallon
- 579 GDF15 IS A MARKER OF HIGH-RISK CORONARY ATHEROSCLEROTIC PLAQUE IN PLWH**
 **Léna Royston**, Stéphane Isnard, Nils Perrin, John Lin, Brandon Fombuena, Manel Sadouni, Nicolas Chomont, Mohammad-Ali Jenabian, Benoit Trottier, Jean-Guy Baril, Carl Chartrand-Lefebvre, Cécile Tremblay, Madeleine Durand, Jean-Pierre Routy, for the Canadian HIV and Aging Cohort Study

580 **ROLE OF RENIN-ANGIOTENSIN-ALDOSTERONE ACTIVATION IN ARTERIAL INFLAMMATION IN HIV**



Grace Shen, Teresa S. Thomas, Allie R. Walpert, Kathleen Fitch, Christopher R. deFilippi, Gail K. Adler, Steven Grinspoon, Suman Srinivasa

581 **STATIN USE IN ART-TREATED HIV REVEALS AN ALTERED MACROPHAGE TRANSCRIPTOMIC PROFILE**



Jeeda Ismail, Cheryl M. Cameron, Manonmani Kumar, Banumathi Tamilselvan, Ken Riedl, Aya Cannon, Emily Bowman, Grace A. McComsey, Nicholas Funderburg, Mark J. Cameron

582 **HIGH-SENSITIVE TROPONINS AND CORONARY CALCIUM SCORE IN OLDER ASIAN HIV**

Pairoj Chattranukulchai, Sarawut Siwamogsatham, **Hay Mar Su Lwin**, Tanakorn Apornpong, Win Min Han, Sivaporn Gatechompol, Opass Puthcharoen, Anchalee Avihingsanon, for the HIV-NAT 006/207 Study Team

583 **CORONARY FLOW RESERVE ON DTG/ABC/3TC AT BASELINE AND AFTER SWITCH TO BIC/FTC/TAF**

Daniel M. Huck, Brittany Weber, Sean Parks, Sanjay Divakaran, Jenifer M. Brown, Courtney Bibbo, Leanne Barrett, Camden Bay, Laura Kogelman, Virginia A. Triant, Jacqueline Chu, Nina Lin, Kathleen Melbourne, Paul E. Sax, Marcelo Di Carli

Poster Session-M04 **FRAILITY AND SLEEP DISTURBANCES**

2:00 PM MT - 3:30 PM MT

615 **ASSOCIATION OF PHENOTYPIC AGING WITH COMORBIDITIES, FRAILITY, AND INFLAMMATORY MARKER**

Win Min Han, Tanakorn Apornpong, Sivaporn Gatechompol, Sasiwimol Ubolyam, Stephen J. Kerr, Kristine Erlandson

616 **L-FERRITIN AND TIM-1 ARE ASSOCIATED WITH FRAILITY MEASURES IN PEOPLE WITH HIV**

Harpreet Kaur, Robert Kalayjian, Kunling Wu, Katherine Tassiopoulos, Frank Palella, Babafemi O. Taiwo, William Bush, Corri Lynn O. Hileman, Roger Bedimo, Susan L. Koletar, Ronald J. Ellis, Kristine Erlandson, **Asha R. Kallianpur**, for the ACTG A5322 Study Team

617 **MUSCLE QUALITY AND PHYSICAL FUNCTION IN MEN WITH AND WITHOUT HIV**

Jing Sun, Todd Brown, Susan Langan, Frank Palella, Jordan Lake, Lawrence A. Kingsley, Wendy Post, Kristine Erlandson, for the MACS/WIHS Combined Cohort Study

618 **THE FUNCFAIL SCORE TO DISCRIMINATE FRAILITY IN OLDER ADULTS WITH HIV**

Matilde Sánchez-Conde, Antonio Antela, Jorge Vergas, Margarita Ramírez, Pablo Ryan, Fernando Dronda, Maria José Galindo, Miguel Torralba, Maria Jesús Bustinduy, Alfonso Cabello Úbeda, Carmen Busca Arenzana, Isabel Machuca, Fatima Brañas

619 **ASSOCIATION OF SLEEP DISRUPTION WITH KYNURENINE PATHWAY ACTIVATION IN WOMEN WITH HIV**



Andrea C. Rogando, Kathleen Weber, Jiaqian Xing, Xiaonan Xue, Tsion Yohannes, Ralph Morack, Qibin Qi, Clary Clish, Kevin Bullock, Deborah Gustafson, Kathryn Anastos, Anjali Sharma, Helen J. Burgess, Audrey L. French

620 SLEEP AND FRAILTY AMONG MEN WITH AND WITHOUT HIV

Mary Clare C. Masters, Benjamin Barrett, Gypsyamber D'Souza, Joshua Hyong-Jin Cho, Sanjay R. Patel, Valentina Stosor, Naresh M. Punjabi, Frank Palella

621 POOR SLEEP IS LINKED TO CVD RISK IN PLWH IN A SOUTHWESTERN US CLINIC

Rita A. Bedrossian, Julia Fisher, Ryan Weltzer, Rachel Briggs, Anna C. Ressel, Marine Khachatryan, Jacob C. Matthews, Bao Q. Thai, Jagteshwar Tung, Michael Grandner, Freda Patterson, Elizabeth Connick

Poster Session-M05 BIOMARKERS AND COMORBIDITIES**2:00 PM MT - 3:30 PM MT****622 EXTERNAL VALIDATION OF BIOMARKER CLUSTERS BASED ON PROTEIN BIOMARKERS**

Nicholas Bakewell, Caroline Sabin, Nicki D. Doyle, Alejandro A. Garcia, Riya Negi, Frank A. Post, Jane Anderson, Jaime Vera, Marta Boffito, Lewis Haddow, Memory Sachikonye, Alan Winston, Patrick Mallon, Ken Kunisaki

623 NETWORK ANALYSIS HIGHLIGHTS DIFFERENTIAL CLINICAL AND OMICS PROFILES IN HIV INFECTION

Flora Mikaeloff, Marco Gelpi, Andreas D. Knudsen, Beate Vestad, Julie Høgh, Johannes R. Hov, Thomas Benfield, Daniel Murray, Marius Trøseid, Susanne D. Nielsen, Ujjwal Neogi

624 EFFECT OF TENOFOVIR ON T-CELL MATURATIONAL SUBSETS IN LONG-TERM AVIREMIC HIV ADULTS

Javier Rodriguez-Centeno, Andrés Esteban-Cantos, Julen Cadiñanos, Rocio Montejano, Natalia Stella-Ascariz, Rosa De Miguel, Beatriz Mena-Garay, Gabriel Saiz-Medrano, Belen Alejos, Maria Jimenez-Gonzalez, Jose I. Bernardino, Juan M. Castro-Álvarez, Berta Rodes, Jose R. Arribas

625 TENOFOVIR ALAFENAMIDE IS ASSOCIATED WITH SHORTER TELOMERE LENGTH IN PEOPLE WITH HIV

Upal Roy, Avery Matthews, Asante R. Kamkwala, Ankita Garg, Hansapani Rodrigo, David Clifford, Benjamin B. Gelman, Christina M. Marra, Susan Morgello, Leah H. Rubin, Donald Franklin, Robert K. Heaton, Jue Lin, Ronald J. Ellis, Scott L. Letendre

Poster Session-N01 POSTACUTE SEQUELAE OF SARS-CoV-2 INFECTION**2:00 PM MT - 3:30 PM MT****626 POST-ACUTE SEQUELAE OF SARS-CoV-2 IN NONHOSPITALIZED ACTIV-2 TRIAL PARTICIPANTS**

Teresa H. Evering, Busola Sanusi, Nikolaus Jilg, Eunice Yeh, Carlee B. Moser, David A. Wohl, Eric S. Daar, Paul Klekotka, Arzhang Cyrus Javan, Joseph J. Eron, Judith S. Currier, Michael Hughes, Davey M. Smith, Kara W. Chew, for the ACTIV-2/A5401 Study Team

627 CLINICAL CONDITIONS ASSOCIATED WITH PASC IN KAISER PERMANENTE MID-ATLANTIC STATES

Eric S. Watson, Michael A. Horberg, Celeena R. Jefferson, Julia M. Certa, Keri N. Althoff, Carolyn F. Williams, Richard Moore

628 PERSISTENT COVID-19 SYMPTOMS ARE HIGHLY PREVALENT 12 MONTHS AFTER HOSPITALIZATION

Catherine Chirouze, Delphine Bachelet, Jean sebastien Hulot, Minerva Cervantes-Gonzalez, Francois Goehringer, Adrien Lemaigen, Mylene Maillot, Pierre Delobel, Matthieu Revest, Xavier Duval, Cedric Laouenan, **Jade Ghosn**, for the French COVID Study Group and Investigators Group

629 CHEST CT BODY COMPOSITION CHANGES AT 3 AND 6 MONTHS AFTER SEVERE COVID-19 PNEUMONIA

Giulia Besutti, Jovana Milic, Giovanni Dolci, Marta Ottone, Marco Massari, Guido Ligabue, Filippo Monelli, Massimo Pellegrini, Efrem Bonelli, Paolo Giorgi Rossi, Giovanni Guaraldi

630 POST-COVID19 QUALITY OF LIFE: LOW SATISFACTION WITH PHYSICAL AND MENTAL HEALTH STATUS

Ilaria Mastrorosa, Carmela Pinnetti, Giulia Del Duca, Patrizia Lorenzini, Alessandra Vergori, Marta Camici, Anna Clelia Brita, Valentina Mazzotta, Pierangelo Chinello, Paola Mencarini, Maria Letizia Giancola, Amina Abdeddaim, Enrico Girardi, Francesco Vaia, Andrea Antinori

631 NEUROLOGIC AND IMMUNOLOGIC BIOMARKERS ASSOCIATED WITH POST-COVID NEUROLOGIC SYMPTOMS

Michael J. Peluso, Hannah M. Sans, Carrie A. Forman, Ahmed Chenna, Brandon C. Yee, John W. Winslow, Christos Petropoulos, Jeffrey N. Martin, John D. Kelly, Meredith Greene, Felicia C. Chow, Joanna Hellmuth, Timothy J. Henrich, Dave Glidden, Steven G. Deeks

Poster Session-004**NOVEL INSIGHTS IN CRYPTOCOCCAL MENINGITIS EPIDEMIOLOGY, TREATMENT, AND OUTCOMES****2:00 PM MT - 3:30 PM MT****663 THE DREAMM PROJECT: EPIDEMIOLOGICAL FINDINGS AND CRYPTOCOCCAL MENINGITIS OUTCOMES**

Cecelia Kanyama, Charles Kouanfack, Sayoki Mfinanga, Saulos Nyirenda, Aude Sturny-Leclere, Emma Beaumont, Sokoine Lesikari, Timothée Boyer-Chamard, Olivier Lortholary, Shabbar Jaffar, John Bradley, Sile Molloy, Tom Harrison, Angela Loyse, for the DREAMM Consortium

664 COST-EFFECTIVENESS OF THE AMBITION REGIMEN FOR HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS

Charles Muthoga, David S. Lawrence, David Meya, Henry Mwandumba, Cecelia Kanyama, Graeme Meintjes, Conrad Muzoora, Mosepele Mosepele, Chiratidzo E. Ndhlovu, Tinevimbo Shiri, Shabbar Jaffar, Tom Harrison, Joseph N. Jarvis, Louis W. Niessen, for the AMBITION Study Group

665 RAPID SEMI-QUANTITATIVE ANTIGEN TESTING AND MORTALITY IN CRYPTOCOCCAL MENINGITIS

Tshepo B. Leeme, Kwana Lechiile, Cheusisime Kajanga, Melanie Moyo, Henry Mwandumba, Nabila Youssouf, Mosepele Mosepele, Tshepiso Mbangiwa, Alexandre Alanio, Aude Sturny-Leclere, Timothée Boyer-Chamard, Olivier Lortholary, David S. Lawrence, Tom Harrison, Joseph N. Jarvis

Poster Session-005 CMV AND FUNGAL OPPORTUNISTIC INFECTIONS

2:00 PM MT - 3:30 PM MT

666



ACTG A5351S: EFFECT OF IMMUNE-MODULATORY INTERVENTIONS ON CMV REPLICATION DURING ART

Elizabeth Hastie, Carlee B. Moser, Xin Sun, Jeff L. Lennox, Priscilla Hsue, Ronald J. Bosch, Steven G. Deeks, Milenka Vargas, Michael M. Lederman, Peter W. Hunt, Timothy J. Henrich, Vincent Marconi, Sara Gianella

667

CYTOMEGALOVIRUS VIREMIA AS A RISK FACTOR FOR MORTALITY IN HIV-ASSOCIATED MENINGITIS

Caleb Skipper, Katherine Hullsieck, Kiiza Tadeo, Michael Okirwoth, Nelmary Hernandez-Alvarado, Claudia Fernandez-Alarcon, Emily Martyn, Jayne Ellis, Kenneth Ssebambulidde, Lillian Tugume, Edwin Nuwagira, Fiona Cresswell, David Meya, David R. Boulware, Mark R. Schleiss

668



CMV VIREMIA AND DISEASE IN VERY ADVANCED LATE PRESENTERS: AN ADVANZ-4 TRIAL SUBSTUDY

Paula Suanzes, Adrià Curran, Ferran Torres, Maria A. Marcos, Pere Domingo, María Saumoy, Roger Paredes, Christian Manzardo, Lluís Force, Eva Bonfill, Nuria Climent, Montserrat Plana, Vicenç Falcó, Jose M. Miro, for the Advanz-4 Study Group

669

A MORE INDIVIDUALIZED ANTIFUNGAL TREATMENT REGIMEN FOR MODERATE TO SEVERE HIV/PCP

Yinqiu Huang, Xiaoqing He, presented by **Yaokai Chen**

Poster Session-P03 EVOLVING INSIGHTS: MTCT RISK TO MATERNAL HEALTH

2:00 PM MT - 3:30 PM MT

684

PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION

Jeanne Sibiude, Jerome Le Chenadec, Laurent Mandelbrot, Alexandre Hocht, Catherine Dollfus, Albert Faye, Eida Bui, Emmanuelle Pannier Metzger, Jade Ghosn, Valérie Garrait, Véronique Avettand-Fenoël, Pierre Frange, Josiane Warszawski, Roland Tubiana, for the ANRS-EPF Study Group

685

WITHDRAWN

686



PBPK MODELING OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN PREGNANCY

Shakir A. Atoyebi, Fazila S. Bunglawala, Nicolas Cottura, Maiara C. Montanha, Marco Siccardi, Catriona Waitt

687

PREGNANCY HEMOGLOBIN A1c AND GLUCOSE WITH DTG VS EFV, TDF VS TAF: IMPAACT 2010

Lameck Chinula, Evan Goldberg, Lauren Ziemba, Katie McCarthy, Chelsea Krotje, Kevin Knowles, Jyoti S. Mathad, Maria Leticia Santos Cruz, Risa M. Hoffman, Patrick Jean-Philippe, Tsungai Chipato, Deo Wabwire, Judith S. Currier, Shahin Lockman, Nahida Chakhtoura

688 WEIGHT GAIN WITH RALTEGRAVIR VS EFAVIRENZ DURING PREGNANCY

Conrado M. Coutinho, Meredith Warshaw, Geraldo Duarte, Alice M. Stek, Avy Violari, Cristina B. Hofer, Jaime Deville, James S. Ngocho, José H. Pilotto, Mario D. Correa, Trevon Fuller, Nahida Chakhtoura, Mark Mirochnick, Esau Joao, for the NICHD P1081 Study Team

689 GESTATIONAL WEIGHT GAIN IN SOUTH AFRICAN PREGNANT WOMEN LIVING WITH HIV

Hlengiwe P. Madlala, Landon Myer, Azetta Fisher, Mushi Matjila, Gregory Petro, Zandile Maqwatini, Angela Bengtson

690 UNIQUE PROFILE OF INFLAMMATION AND IMMUNE ACTIVATION IN PREGNANT US WOMEN WITH HIV

Stephanie Shiao, Denise Jacobson, Yanling Huo, Deborah Kacanek, Lynn M. Yee, David B. Williams, Lisa Haddad, Lena Serghides, Kathleen M. Powis, Paige L. Williams, Jennifer Jao, for the Pediatric HIV/AIDS Cohort Study

691 EPITOPES ASSOCIATED WITH ALTERED PATHOGENESIS IN VERTICAL HIV-1 TRANSMISSION

Zak A. Yaffe, Kevin Sung, Jared Galloway, Ruth Nduati, Frederick Matsen IV, Julie Overbaugh

Poster Session-P04**NEW PERSPECTIVES ON THE HEALTH OF CHILDREN EXPOSED TO HIV IN UTERO****2:00 PM MT - 3:30 PM MT****692 ASSOCIATION OF MATERNAL TDF-BASED ART WITH BONE MINERAL CONTENT IN BREASTFED INFANTS**

Tichaona Vhembo, Kristin Baltrusaitis, Camlin Tierney, Maxensia Owor, Sufia Dadabhai, Avy Violari, Gerhard Theron, Dhayendre Moodley, Cynthia Mukwasi-Kahari, Kathleen George, John Shepherd, George K. Siberry, Renee Browning, Mary G. Fowler, Lynda Stranix-Chibanda

693 SIMILAR EARLY GROWTH IN HEU AND HUU INFANTS WITH MATERNAL ART OPTIMIZATION

Maureen M. King'e, Irene Njuguna, Christine J. McGrath, Michelle Bulterys, Hellen Moraa, Alvin Onyango, Sarah Benki-Nugent, Dalton C. Wamalwa, Grace John-Stewart

694 MATERNAL IPT IN PREGNANCY AND GROWTH FALTERING AMONG HIV-EXPOSED UNINFECTED INFANTS

Ashenafi S. Cherkos, Sylvia LaCourse, Daniel A. Enquobahrie, Grace Montepiedra, Carol Onyanog, Blandina T. Mmbaga, Tichaona Vhembo, Gaerolwe Masheto, Gerhard Theron, Adriana Weinberg, Amita Gupta, Grace John-Stewart

695 PREDICTORS OF NEURODEVELOPMENT IN HIV-EXPOSED—UNINFECTED INFANTS

Michelle Bulterys, Maureen M. King'e, Irene Njuguna, Daisy J. Chebet, Hellen Moraa, Jessica Dyer, Laurén Gomez, Melissa Gladstone, Christine J. McGrath, Anjuli D. Wagner, Dalton C. Wamalwa, Grace John-Stewart, Sarah Benki-Nugent

696 MITOCHONDRIAL PROTON LEAK IN INFANTS WITH IN UTERO HIV AND ART EXPOSURE IN BOTSWANA

Jennifer Jao, Shan Sun, Lauren C. Balmert, Justine Legbedze, Keolebogile N. Mmasa, Gosego N. Masasa, Samuel N. Kgole, Sikhulile Moyo, Joseph Makhema, Mitchell E. Geffner, Elaine J. Abrams, Irwin J. Kurland, Anastasia Andrukhiv, Kathleen M. Powis, Mariana Gerschenson

- 697 HEARING LOSS AND FETAL EXPOSURE TO ANTIRETROVIRAL DRUGS IN HIV-UNINFECTED CHILDREN**
Peter Torre, Zhongli Zhang, Toinette Frederick, Murli Purswani, Howard J. Hoffman, Paige L. Williams, Tzy-Jyun Yao, for the Pediatric HIV/AIDS Cohort Study
- 698 Mtb INFECTION IN CHILDREN WITH AND WITHOUT HIV-EXPOSURE IN THE FIRST YEAR OF LIFE**
Sylvia LaCourse, Jerphason O. Mecha, Jaclyn Escudero, Barbra A. Richardson, Elizabeth Maleche-Obimbo, Daniel Matemo, John Kinuthia, Grace John-Stewart
- 699 IDENTIFYING HIV-POSITIVE MOTHERS AND EXPOSED INFANTS IN MATERNAL CHILD SERVICES**
Chloe A. Teasdale, Michelle Choy, Fatima Tsiouris, Eduarda Pimental de Gusmao, Etelvino Banqueiro, Nicole Flowers, Marilena Urso, Mirriah Vitale, Elaine J. Abrams

Poster Session-Q01 TIMING OF AND TESTING FOR HIV IN INFANTS, CHILDREN, AND YOUTH
2:00 PM MT - 3:30 PM MT

- 706 EVALUATION OF AN HIV-1/HIV-2 QUALITATIVE TEST FOR HIV EARLY INFANT DIAGNOSIS**
Shuyi Li, Guoqing Zhang, Katrina Sleeman, Shon Nguyen, Demetrius Mathis, Heather Alexander, Clement Zeh
- 707 ESTIMATING TIME OF HIV-1 INFECTION IN INFANTS USING VIRAL SEQUENCE DIVERSITY**
Magdalena Russell, Carolyn S. Fish, Sara Drescher, Noah Cassidy, Julie Overbaugh, Sarah Benki-Nugent, Jennifer Slyker, Dorothy Mbori-Ngacha, Rose Bosire, Dalton C. Wamalwa, Elizabeth Maleche-Obimbo, Grace John-Stewart, Frederick Matsen IV, Dara A. Lehman
- 708 COST OF AN HIV TEST-AND-TREAT STRATEGY AT BIRTH AND ITS EFFECT ON ART INITIATION**
Kira Elsbernd, Issa Sabi, Joaquim Lequechane, Sirel Boniface, Chishamiso Mudenyanga, Chris W. Buck, Arlete Mahumane, Bindiya Meggi, Kassia Pereira, Mariana Müller, Till Bärnighausen, Michael Hoelscher, Arne Kroidl, Ilesh Jani, Stefan Kohler
- 709 VALIDATION OF A PEDIATRIC SCREENING TOOL TO IDENTIFY HIV-POSITIVE CHILDREN IN ZAMBIA**
Jessica Joseph, Felton Mpasela, Isaac Banda, Patricia M. Bobo, Stephanie Dowling, Prudence Haimbe, Pamfred Hasweeka, Gertrude S. Kampekete, Fredrick Mumba, Charles Sakulanda, Hilda Shakwelele, Mwanei Simasiku, Kanchana Suggu, Gloria Munthali
- 710 COMMUNITY-BASED, PEER-LED SRH SERVICES INCREASE COVERAGE IN AYP (YATHU YATHU TRIAL)**
 Mwelwa Phiri, Albertus Schaap, Lucheka Sigande, Rosemary Zulu-Phiri, Louis Mwape, Melvin Simuyaba, Sian Floyd, Sarah Fidler, Richard Hayes, Musonda Simwinda, Bernadette Hensen, **Helen Ayles**, for the Yathu Yathu Trial

Poster Session-Q04 COMORBIDITIES AND COMPLICATIONS OF HIV AND ART IN CHILDREN AND YOUTH

2:00 PM MT - 3:30 PM MT

- 726 ESTIMATING ATHEROSCLEROTIC RISK IN SOUTH AFRICAN YOUTH WITH PERINATALLY ACQUIRED HIV**
Sana Mahtab, Lisa Frigati, Mothabisi Nyathi, Nana Akua Asafu-Agyei, Ntobeko Ntusi, Landon Myer, Heather Zar, Jennifer Jao
- 727 LONGITUDINAL CHANGES IN SUBCLINICAL VASCULAR DISEASE IN UGANDAN YOUTH WITH HIV**
Sahera Dirajlal-Fargo, Chenya Zhao, Abdus Sattar, Christine Karungi, Rashidah Nazzinda, Danielle Labbato, Nicholas Funderburg, Emmy Okello, Victor Musiime, Grace A. McComsey
- 728 MENTAL HEALTH AND TREATMENT OUTCOMES IN ADOLESCENTS LIVING WITH HIV IN WEST AFRICA**
Désiré Lucien Dahourou, Marc Harris Dassi Tchoupa Revegue, Marie-Sylvie N'Gbeche, Caroline Yonaba, Corinne Moh, Kouakou Kouadio, Patricia Nindjin, Karen Malateste, Jean-Claude Azani, Julie Jesson, Eulalie Kangah, Elisabeth Thio, Philippe Msellati, Valériane Leroy, for the leDEA West-African Collaboration
- 729 MENTAL HEALTH DISORDERS IN HIV-POSITIVE ADOLESCENTS AND YOUTHS: DATA FROM MOZAMBIQUE**
 **Francesco Di Gennaro**, Anton Pozniak, Claudia Marotta, Lucy Ramirez, Hamilton Cardoso, Vasco Cinturao, Natalia Chimundi, Andrea Atzori, Izilda Chaguruca, Francesca Tognon, Giovanna De Meneghi, Edson Namarime, edoardo Ocça, Giovanni Putoto, Annalisa Saracino
- 730 PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE VERTICALLY HIV-INFECTED YOUTHS**
Itziar Carrasco, María Luisa Navarro, Sonia Alcolea, Antonio Oliveira, Angel Lancharro, Maria Luisa Montes, Cristina Díez, Luis Escosa, Maria Jose Mellado, Carmen Busca Arenzana, Talia Sainz
- 731 WEIGHT GAIN AMONG ADOLESCENTS ON DOLUTEGRAVIR: A REAL CONCERN?**
Jesus Riscart, Eva Soria, Luis Prieto, Luis Escosa, Claudia Fortuny, Dolores Falcon, Antoinette Frick, Jose Tomas Ramos Amador, Matilde Bustillo, Maria Penin, Pilar Collado, María Luisa Navarro, Santiago Jiménez de Ory, **Talia Sainz**, for CORISPE

Poster Session-R04 HIV CLUSTERS AND OUTBREAKS

2:00 PM MT - 3:30 PM MT

- 781 PRIORITIZING HIV-1 TRANSMISSION CLUSTERS FOR INTERVENTION: A PHYLOGENETIC APPROACH**
 **Rachel L. Miller**, Angela McLaughlin, Richard Liang, Delphine Duhirwe, Anh Le, Chanson Brumme, Julio S. Montaner, Jeffrey B. Joy
- 782 PHYLOGENETIC TRACKING OF HIV EPIDEMIC GROWTH IN QUEBEC FROM 2014 TO 2020**
Bluma G. Brenner, Réjean Thomas, Isabelle Hardy, Ruxandra-Ilinca Ibanescu, Jean-Pierre Routy, Michel Roger, for the Montreal Primary HIV Infection Cohort

783



MOLECULAR ANALYSIS SUGGESTS LOW ONWARD HIV-1 TRANSMISSION AMONG MIGRANTS IN GREECE

Evangelia G. Kostaki, Stefanos Limnaios, Maria Chini, George Adamis, Vasileios Papastamopoulos, Anastasia Antoniadou, Simeon Metallidis, Vasileios Paparizos, Dimitrios Chatzidimitriou, Dimitra Paraskeva, Pagona Lagiou, Angelos Hatzakis, Gkikas Magiorkinis, Lemonia Skoura, Dimitrios Paraskevīs

784

DEEP LEARNING APPROACHES TO INFORM NETWORK-BASED HIV INTERVENTIONS AMONG PWID

Steven J. Clipman, Shruti H. Mehta, Shoba Mohapatra, Aylur K. Srikrishnan, Katie Zook, Priya Duggal, Saravanan Shanmugam, Paneerselvam Nandagopal, Muniratnam S. Kumar, Gregory M. Lucas, Carl Latkin, Sunil S. Solomon

785

HIGH HIV INCIDENCE AMONG PWID ON THE US/MEXICO BORDER DURING THE COVID-19 PANDEMIC

Britt Skaathun, Cho-Hee Shrader, Annick Borquez, Antoine Chaillon, Tetyana Vasylyeva, Irina Artamanova, Alicia Harvey-Vera, Gudelia Rangel, Steffanie Strathdee

786

MISSED OPPORTUNITIES: PREVENTION & CARE FOR PWID IN A WEST VIRGINIA HIV OUTBREAK

Robert A. Bonacci, Anne C. Moorman, Danae Bixler, McKenna Penley, Suzanne Wilson, Alana G. Hudson, Stephen Perez, Phillip P. Salvatore, Kathryn Curran, Rebecca Hershow, Alexandra M. Oster, Robert P. McClung, for the Kanawha County HIV Outbreak Investigation Team

Poster Session-R06 HIV EPIDEMIOLOGY

2:00 PM MT - 3:30 PM MT

797

GREEK MSM: 95-95-95 TARGET IS NOT ENOUGH TO MEET THE HIV INCIDENCE REDUCTION GOAL

Ilias Gountas, Kyriakos Souliotis, Georgios Nikolopoulos, **Giota Touloumi**

798

URBAN VERSUS RURAL ACHIEVEMENTS OF 90:90:90 TARGETS IN 12 AFRICAN COUNTRIES

Suhani Patel, Mansoor Farahani, Rachel Bray, Jessica E. Justman, Wafaa M. El-Sadr

799

AWARENESS OF HIV STATUS AMONG ADULTS LIVING WITH HIV IN 12 AFRICAN COUNTRIES

Ling Guo, Mansoor Farahani, Jessica E. Justman, Wafaa M. El-Sadr

800

DISCORDANT COUPLES' KNOWLEDGE AND DISCLOSURE OF HIV STATUS IN 10 AFRICAN COUNTRIES

Mahad Magan, Mansoor Farahani, Rachel Bray, Domonique M. Reed, Jessica E. Justman, Wafaa M. El-Sadr

801

DIVERSE TIME TRENDS IN SEXUAL BEHAVIOR AFTER HIV DIAGNOSIS OVER 20 YEARS FOLLOW-UP

Kalongo Hamusonde, Dunja Nicca, Huldrych F. Günthard, Marcel Stöckle, Katharine E. Darling, Alexandra L. Calmy, Roger Kouyos, Andri Rauch, Luisa Salazar-Vizcaya, for the Swiss HIV Cohort Study

802

AUTHORSHIP INEQUALITIES IN GLOBAL HEALTH RESEARCH INITIATIVE

Veronika W. Skrivankova, Stefanie Hossmann, Carole Dupont, Morna Cornell, Marie Ballif, Matthias Egger

Poster Session-T04 ADVANCES IN SARS-CoV-2 DIAGNOSTICS

2:00 PM MT - 3:30 PM MT

818 LIMIT OF DETECTION OF SARS-CoV-2 ANTIBODY ASSAYS



Evan Beck, Santosh Dhakal, Sharada Saraf, Reinaldo Fernandez, Owen R. Baker, Sabra L. Klein, Thomas Quinn, Oliver Laeyendecker

819 MSD V-PLEX SARS-CoV-2 ASSAY TO IDENTIFY VACCINATED AND INFECTED INDIVIDUALS



Evan Beck, Andrew Karaba, Xianming Zhu, Ruchee Shrestha, Aaron M. Milstone, Andrew Redd, Aaron Tobian, Evan M. Bloch, Emily Egbert, Joel Blankson, Yu-Hsiang Hsieh, Richard Rothman, Thomas Quinn, Oliver Laeyendecker

820 COMPARISON OF SARS-CoV-2 LIVE VIRUS NEUTRALIZATION AND SEROLOGIC IMMUNOASSAYS



Owen R. Baker, Eshan U. Patel, Andrew Pekosz, Kirsten Littlefield, Reinaldo Fernandez, Aaron Tobian, Evan M. Bloch, Yu-Hsiang Hsieh, Richard Rothman, Andrew Redd, Thomas Quinn, Oliver Laeyendecker

821 DEVELOPMENT OF A HIGH-THROUGHPUT NGS WORKFLOW FOR SARS-CoV-2 WHOLE-GENOME SEQUENCING

Sun Hee Rosenthal, Anna Gerasimova, Rolando Ruiz-Vega, Kayla Livingston, **Ron M. Kagan**, Yan Liu, Ben P. Anderson, Renius Owen, Laurence E. Bernstein, Alla Smolgovsky, Dong Xu, Rebecca Chen, Andrew Grupe, Pranoot Tanpaiboon, Felicitas L. Lacbawan

822 ORAL SALIVA SWAB RT-PCR AS A FIT-FOR-PURPOSE DIAGNOSTIC TEST FOR COVID-19 IN CHILDREN

Cinta Moraleda, Sara Domínguez-Rodríguez, Juan Miguel Mesa, Paula García, Jose Antonio Alonso, Amanda Bermejo, Gema Sabrido, Leticia Martínez-Campos, María De la Serna, Arantxa Gonzalez, Álvaro Ballesteros, Juan Carlos Galán, Francisco Llorente, Alfredo Tagarro, for the EPICO-AEP Working Group

Poster Session-V01 PrEP: SERVICES, COST-EFFECTIVENESS, BONE LOSS, AND ARV RESISTANCE

2:00 PM MT - 3:30 PM MT

829 DIFFERENCES IN SEXUAL HEALTH CLINIC SERVICES BY AGE AND GENDER IN METROPOLITAN BOSTON

Anne M. Neilan, Yiqi Qian, Grace Chamberlin, Fatma M. Shebl, Kevin L. Ard

830 ASSESSING THE BENEFITS OF PREVENTION VERSUS CARE CONTINUUM INTERVENTIONS IN BALTIMORE

Melissa Schnure, Parastu Kasaie, David Dowdy, Maunank Shah, Ruchita Balasubramanian, Anthony T. Fojo

831 COST-EFFECTIVENESS OF HIV PrEP AMONG YOUNG MEN WHO HAVE SEX WITH MEN IN THE US

Alyssa K. Amick, G Ege Eskibozkurt, Sybil Hosek, Clare Flanagan, Raphael J. Landovitz, Kenneth Freedberg, Craig M. Wilson, Milton C. Weinstein, David Paltiel, Andrea Ciaranello, Anne M. Neilan

832 OUT-OF-POCKET PAYMENTS FOR PrEP DRUGS DECREASED ONLY MODESTLY IN 2021

Ya-Lin A. Huang, Weiming Zhu, Karen W. Hoover

- 833 PRESCRIPTIONS FOR BRAND AND GENERIC PrEP MEDICATIONS IN THE UNITED STATES**
Duygu Islek, Weiming Zhu, Ya-Lin A. Huang, Karen W. Hoover
- 834 RURAL HIV PrEP USERS AND PROVIDERS IN THE UNITED STATES: 2014-2020**
Weiming Zhu, Ya-Lin A. Huang, Athena Kourtis, Karen W. Hoover
- 835 EFFECT OF NAVIGATION ON LINKAGE TO HIV PREEXPOSURE PROPHYLAXIS AMONG US MSM**
Anne A. Kimball, Weiming Zhu, Kashif Iqbal, Mary Tanner, Karen W. Hoover
- 836 ESTIMATING BENEFITS FROM USING ON-DEMAND ORAL PrEP BY MSM IN US: A MODELING STUDY**
 Sarah Stansfield, Mia Moore, Marie-Claude Boily, James Hughes, Deborah Donnell, Dobromir Dimitrov
- 837 PrEP INDICATIONS AND PrEP KNOWLEDGE, ACCESS, AND INTEREST AMONG INDIVIDUALS WITH HCV**
Kristi C. Hill, Rachel Silk, Rahwa Eyasu, Onyinyechi Ogbumbadiugha, Emade Ebah, Amelia A. Cover, Ashley Davis, David Sternberg, Phyllis Bijole, Junfeng Sun, Henry Masur, Shyam Kottiril, Sarah Kattakuzhy, Elana S. Rosenthal
- 838 PrEP LONG-TERM ENGAGEMENT AMONG MSM AND TGW IN LATIN AMERICA: THE ImPrEP STUDY**
Valdilea Veloso, Ronaldo I. Moreira, Kelika A. Konda, Brenda Hoagland, Hamid Vega-Ramirez, Iuri C. Leite, Juan V. Guanira, Sergio Bautista-Arredondo, Heleen Vermandere, Marcos R. Benedetti, Maria Pimenta, Thiago S. Torres, Beatriz Grinsztejn, Carlos F. Caceres, for the ImPrEP Study Group
- 839 DRUG RESISTANCE AND CLUSTERING PATTERNS AMONG PREVIOUS PrEP USERS WHO SEROCONVERTED**
Angela McLaughlin, Junine Toy, Vincent Montoya, Paul Sereda, Jason Trigg, Amanda Granados, Sakshi Khanna, Chanson Brumme, Rolando Barrios, Julio S. Montaner, Jeffrey B. Joy
- 840 A RETROSPECTIVE ANALYSIS OF BONE LOSS IN EMTRICITABINE/TENOFOVIR THERAPY FOR HIV PrEP**
Joseph C. Chang, Duy Do, Hector M. Delgado, An Huynh
- 841 TRENDS IN THE PREEXPOSURE PROPHYLAXIS CONTINUUM AMONG US LATINX MSM**
Michael Barry, David Katz, Roxanne P. Kerani, Travis Sanchez, Jane J. Lee

Poster Session-X01 SEXUAL AND REPRODUCTIVE HEALTH IN THE TIME OF COVID-19

2:00 PM MT - 3:30 PM MT

- 869 TRENDS IN STI SCREENING DURING COVID-19 AND MISSED CASES AMONG ADOLESCENTS**
 Stephen Bonett, Daniel Teixeira da Silva, Danielle Petsis, Jungwon Min, Spandana Makeneni, Anjali Mahajan, Sarah M. Wood
- 870 STI TRANSMISSION DYNAMICS DURING THE COVID-19 PANDEMIC AMONG URBAN SEXUAL MINORITIES**
Christina Schumacher, Nicole Thornton, Jessica Duchon, Carla Tilchin, Khalil Ghanem, Matthew M. Hamill, Carl Latkin, Anne Rompalo, Sebastian Ruhs, Adena Greenbaum, Jacky Jennings

871 WITHDRAWN

Poster Session-Y07 HIV AND SURVIVAL

2:00 PM MT - 3:30 PM MT

935 CHARACTERISTICS OF DEATHS IN A PEPFAR HIV PROGRAM IN DEMOCRATIC REPUBLIC OF THE CONGO

Dany Malaba, **Michelle Selim**, Paola Chanes-Mora, Hilary T. Wolf

936 SURVIVAL AFTER HIV INFECTION IN THE ERA OF DECENTRALIZED DRUG DISTRIBUTION MODELS

Amobi Onovo, David Onime, Jemeh Pius, Thomas Minior, Sena Woldetensay, Moses Katbi, Kalaiwo Abiye, Adeoye Adegboye, Onyeka Igboelina, Chika Obiora-Okafo, Helina Meri, Rachel Goldstein

Poster Session-Y08 COVID-19 AND HIV

2:00 PM MT - 3:30 PM MT

937 TELEMEDICINE AND HIV CARE QUALITY MEASURES DURING THE COVID-19 PANDEMIC

Mary Clare C. Masters, Juan Rivera, Mia Calamari, Katherine Wright, Patrick Janulis, Laura Rusie, Jacqueline Bannon, Patrick Milne, Shannon Galvin, Elena Molina, Lisa R. Hirschhorn, Frank Palella, Rebecca N. Kumar, Cory Brown, Claudia Hawkins

938 DID COVID-19 RESTRICTIONS IMPACT HIV TREATMENT AMONG MSM IN CHINA?

**Yinghui Sun**, Weiran Zheng, Hui Li, Yanxiao Gao, Yuewei Zhan, Hui Chen, Yong Cai, Huachun Zou

939 PANDEMIC ERA CHANGES IN HIV/STI DIAGNOSES AND PrEP USE IN AN URBAN US HEALTH CENTER

Kenneth H. Mayer, Sy Q. Gitin, Douglas Krakower, Chris H. Grasso, Katie Biello

940 COVID-19–RELATED DISRUPTIONS IN THE HIV CARE CONTINUUM IN A LARGE URBAN COHORT OF PWH

Amanda Castel, Shannon K. Barth, Michael A. Horberg, Jiayang Xiao, Anne Monroe, Alan E. Greenberg, for the DC Cohort Executive Committee

941 SARS-CoV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH

Vera Portillo, Pilar Ustero, **Chiara Fedeli**, Ianis Petignat, Ellen Cristina Mereles Costa, Adi Sulstarova, Cyril Jaksic, Sabine Yerly, Alexandra L. Calmy

942 IMPACT OF COVID OUTBREAK ON PREVENTION AND CARE FOR HIV AND STIs AT A LARGE HOSPITAL

Esteban Martinez, Elisa de Lazzari, Ivan Chivite, Ana Gonzalez-Cordon, María M. Mosquera, Montserrat Laguno, Jordi Bosch, Jose L. Blanco, Miriam Alvarez-Martinez, Berta Torres, Juan C. Hurtado, Josep Mallolas, Jose M. Miro, Maria A. Marcos

943 CHARACTERIZING THE SCOPE AND DRIVERS OF THE IMPACT OF COVID-19 ON LOCAL HIV EPIDEMICS

Anthony T. Fojo, Emma Wallengren, Melissa Schnure, Ruchita Balasubramanian, David Dowdy, Maunank Shah, Parastu Kasaie

- 944 HEALTHCARE ACCESS AMONG SOUTH AFRICAN YOUTH LIVING WITH & WITHOUT HIV DURING COVID-19**
 **Danielle Giovenco**, Audrey Pettifor, Stephanie Chung, Gina Itzikowitz, Yamkela Qayiya, Linda-Gail Bekker
- 945 COVID-19 AND THE HIV CARE CONTINUUM IN C3PNO COHORTS**
Catherine R. Lesko, Jeanne C. Keruly, Richard Moore, Nikki Shen, Jarratt D. Pytell, Bryan Lau, Anthony T. Fojo, Shruti H. Mehta, Michele Kipke, Marianna K. Baum, Steve Shoptaw, Pamina M. Gorbach, Brian Mustanski, Marjan Javanbakht, Geetanjali Chander
- 946 IMPACT OF THE COVID-19 PANDEMIC ON HIV OUTPATIENT CARE AND VIRAL SUPPRESSION IN NYC**
Shaoli Chaudhuri, Judith A. Aberg, Rachel Chasan, Emma Kaplan-Lewis, Keith Sigel
- 947 THE IMPACT OF THE COVID-19 LOCKDOWN ON HIV CARE CONTINUUM IN CHINA**
 **Xinsheng Wu**, Ganfeng Luo, Yuanyi Chen, Yi-Fan Lin, Yiguo Zhou, Yanxiao Gao, Yuwei Zhan, Huachun Zou
- 948 COVID-19 PANDEMIC IMPACT ON HIV PrEP PROGRAM ENGAGEMENT IN BRITISH COLUMBIA**
Junine Toy, Cora Keeney, Raquel M. Espinoza, Wendy Zhang, Diana Kao, Erin Ready, Jason Trigg, Katherine J. Lepik, Mark Hull, Taylor McLinden, Viviane D. Lima, Paul Sereda, David Moore, Rolando Barrios, Julio S. Montaner

TUESDAY, FEBRUARY 15, 2022

Poster Session-A02 IMMUNE CELL INFECTION AND RESPONSES

2:00 PM MT - 3:30 PM MT

- 170 RESTRICTED INFECTION OF MACROPHAGES BY SARS-CoV-2 INDUCES PROINFLAMMATORY RESPONSES**
 **Sallieu Jalloh**, Judith Olejnik, Jacob Berrigan, Ellen L. Suder, Annuurun Nisa, Sanjay Tyagi, Yuri Bushkin, Elke Mühlberger, Suryaram Gummuluru
- 171 NEUROPILIN-1 MEDIATES SARS-CoV-2 INFECTION OF ASTROCYTES PROMOTING NEURON DYSFUNCTION**
 **Weili Kong**, Mauricio Montano, Michael J. Corley, Ekram Wassim A. Helmy, Nadia Roan, Melanie M. Ott, Lishomwa Ndhlovu, Warner Greene
- 172 GALECTIN-9 INDUCES SARS-CoV-2 REPLICATION AND INFLAMMATION IN AIRWAY EPITHELIAL CELLS**
 **Li Du**, Mohamed Bouzidi, Akshay Gala, Fred H. Deiter, Jean-Noël Billaud, Stephen T. Yeung, Prerna Dabral, Jing Jin, Graham Simmons, Zain Y. Dossani, Toshiro Niki, Lishomwa Ndhlovu, John Greenland, Satish Pillai
- 173 THE EFFECTS OF TYPE I & II IFNs DISCLOSE A ROLE FOR DOPAMINE IN SARS-CoV-2 INFECTION**
 **Fiona Limanaqi**, Gioia Cappelletti, Micaela Garziano, Sergio Strizzi, Claudia Vanetti, Claudio Fenizia, Daria Trabattoni, Mario Clerici, Mara Biasin
- 174 CHARACTERIZATION OF HIV AND SARS-CoV-2 COINFECTION: ROLE OF IL-10**
 **Claudia Vanetti**, Daria Trabattoni, Marta Stracuzzi, Antonella Amendola, Clara Fappani, Valeria Rubinacci, Claudio Fenizia, Mara Biasin, Anna Dighera, Irma Saulle, Francesco Ardizzone, Elisabetta Tanzi, Mario Clerici, Gian V. Zuccotti, Vania Giacommet
- 175 CHARACTERIZING MECHANISMS OF TRANSCRIPTIONAL CONTROL IN HIV-INFECTED MACROPHAGES**
Rachel Van Duyne, Stephanie Matt, Alexis Brantly, Michael R. Nonnemacher, Peter J. Gaskill, Zachary A. Klase

Poster Session-B03 CORRELATES OF SARS-CoV-2 OUTCOMES

2:00 PM MT - 3:30 PM MT

- 201 IDENTIFICATION OF KEY BIOMARKERS FOR THE PREDICTION OF CRITICAL COVID-19 OUTCOMES**
 **Laia Reverté Calvet**, Elena Yeregui Etxeberria, Monsterrat Olona Cabases, Maria José Buzón, Anna Martí, Frederic Gómez-Bertomeu, Teresa Auguet, Clara Benavent-Bofill, Carme Boqué, Ezequiel Ruiz-Mateos, Maria Teresa Mestre, Francesc Vidal, Joaquin Peraire, Anna Rull, for the COVIDOMICS Study Group
- 202 MACHINE LEARNING ANALYSIS OF DNA METHYLATION IN COVID-19 DISEASE**
Scott Bowler, Giorgos Papoutsoglou, Aristides Karanikas, Ioannis Tsamardinos, Michael J. Corley, Lishomwa Ndhlovu
- 203 IMMUNE EXHAUSTION IS ASSOCIATED WITH PERSISTENT SARS-CoV-2 VIREMIA AND SEVERE DISEASE**
Yijia Li, Arnav Mehta, Matteo Gentili, Julian A. Villalba, Moshe Sade-Feldman, Kyle R. Kays, Nir Hacohen, Marcia B. Goldberg, Michael R. Filbin, Mari Mino-Kenudson, Jonathan Li

204 CIRCULATING LEVELS OF TYPE I, TYPE II, AND TYPE III INTERFERONS AND COVID-19 SEVERITYAlejandro A. Garcia, **Riya Negi**, Camille Heckmann, Grace Kenny**205 TGF- β 2 IS ASSOCIATED WITH ASYMPTOMATIC/MILD SARS-CoV-2 INFECTION DURING PREGNANCY**Rachel Pope, Muhammad B. Latif, Gabriela Pacheco Sanchez, Meredith Gardner, Ruth Farrell, Kelly Gibson, Sarah O'Connell, Suprabhath Gajjaia, Adrian McDermott, Robert Balderas, Michael Konstan, Mehul Suthar, Rafick-Pierre Sékaly, **Susan Pereira Ribeiro****206 GDF-15 AS A PREDICTOR OF MORTALITY IN COVID-19: IMPLICATIONS FOR TREATMENT****Valeria Bono**, Paola Ciceri, Matteo Sala, Lorenza Magagnoli, Roberta Rovito, Luisa Artioli, Mohamad Hadla, Vaibhav Yellenki, Antonella D'Arminio Monforte, Andrea Galassi, Camilla Tincati, Giulia Marchetti, Mario Cozzolino**207 ANGIOTENSIN II CAUSES T LYMPHOPENIA VIA REACTIVE OXYGEN SPECIES IN SEVERE COVID-19**Lucy Kundura, Sandrine Gimenez, Renaud Cezar, Sonia André, Yea-Lih Lin, Clément Mettling, Philippe Pasero, Laurent Muller, Pierre-Géraud Claret, Sandra Duvnjak, Paul Loubet, Albert Sotto, Tu-Anh Tran, Jérôme Estaquier, **Pierre Corbeau****Poster Session-B05 HIV REPLICATION IN VIVO****2:00 PM MT - 3:30 PM MT****214 GERMINAL CENTER B CELLS AUGMENT HIV REPLICATION IN T FOLLICULAR HELPER CELLS****Matthew T. Ollerton**, Joy Folkvord, David Parry, Elizabeth Connick**215 HIV DNA AND ACTIVATION DIFFER FOR LONG-LIVED CD4 CELLS IN LYMPH NODES AND PBMC ON ART****Christina Mallarino-Haeger**, Maria Pino, Elise G. Viox, Amélie Pagliuza, Sol del Mar Aldrete, Keith A. Delman, Michael C. Lowe, Nicolas Chomont, Vincent Marconi, Mirko Paiardini**216 SINGLE-CELL ANALYSIS OF A HUMAN TONSIL EXPLANT HISTOCULTURE MODEL OF HIV-1 INFECTION****Connie A. Zhao**, Tracey Freeman, Nadine Schrode, Sanjana Shroff, Benjamin Tweel, Robert Sebra, Kristin Beaumont, Talia H. Swartz**217 TEMSAVIR PROTECTS BYSTANDER CELLS FROM ADCC AND BLOCKS CYTOKINE BURST BY MONOCYTES**Jérémy Prévost, **Jonathan Richard**, Halima Medjahed, Romain Gasser, Nathalie Brassard, Catherine Bourassa, Gabrielle Gendron-Lepage, Amos Smith III, Marzena Pazgier, Daniel E. Kaufmann, Walther Mothes, Andrés Finzi**218 EFFECT OF HIV INFECTION AND ART INITIATION ON GENOME-WIDE DNA METHYLATION****Andrés Esteban-Cantos**, Javier Rodriguez-Centeno, Juan C. Silla, Pilar Barruz, Fátima Sánchez, Gabriel Saiz-Medrano, Maria Jimenez-Gonzalez, Rosa De Miguel, Jose I. Bernardino, Rocio Montejano, Cédric Wallet, François Raffi, Berta Rodes, Jose R. Arribas, for NEAT001/ANRS143 Study Group**219 ESTROGEN EXPOSURE MAY ENHANCE TOLL-LIKE RECEPTOR 4 ACTIVATION IN HIV****Aaren E. Kettelhut**, Emily Bowman, Janelle Gabriel, Manjusha Kulkarni, Jordan Lake, Nicholas Funderburg

Poster Session-D03 HIV IMMUNOLOGY: T CELLS

2:00 PM MT - 3:30 PM MT

256 EVALUATING VIRUS-SPECIFIC CD8+ T CELLS FROM MULTIPLE ANATOMICAL SITES

Jennifer Simpson, Carly E. Starke, Carol Vinton, Alexandra Ortiz, Amy Ransier, Sam Darko, Daniel C. Douek, Jason Brencley

257 CD8+ T-CELL REPROGRAMMING TO BOOST ANTI-HIV POTENTIAL

Federico Perdomo-Celis, Caroline Passaes, Stevonn Volant, Faroudy Boufassa, Pierre De Truchis, Morgane Marcou, Katia Bourdic, Laurence Weiss, Corinne Jung, Christine Bourgeois, Cécile Goujard, Laurence Meyer, Michaela Müller-Trutwin, Olivier Lambotte, Asier Sáez-Cirión

258 CD8 RESPONSE TO HIV PROVIRUS IN ELITE CONTROLLERS IMPROVES EXPECTATIONS OF HIV CURE

Maria A. Navarrete-Muñoz, Jaime Valentin, José M Ligos, Alfonso Cabello Ubeda, Miguel Górgolas, **José M. Benito**, Norma Rallón

259 HIGHLY DAMPENED HIV-SPECIFIC CYTOLYTIC T-CELL RESPONSE DEFINE VIREMIC NONPROGRESSION

Amit Kumar Singh, Varsha Padwal, Harsha Palav, Shilpa Velhal, Vidya Nagar, Priya Patil, Vainav Patel

260 T CELLS EXPRESSING MULTIPLE INHIBITORY RECEPTORS PERSIST ON LONG-TERM ART

Bernard J. Macatangay, Deborah K. McMahon, Hanna Mar, Ronald J. Bosch, Joshua Cyktor, Ann C. Collier, Sharon A. Riddler, Evelyn Hogg, Joseph J. Eron, John W. Mellors, Rajesh T. Gandhi, Charles R. Rinaldo

261 INHIBITORY RECEPTOR EXPRESSION CORRELATES WITH HIV PERSISTENCE AND IMMUNE RESPONSES

Bernard J. Macatangay, Deborah K. McMahon, R. Brad Jones, Adam R. Ward, Hanna Mar, Ronald J. Bosch, Joshua Cyktor, Sharon A. Riddler, Ann C. Collier, Evelyn Hogg, Joseph J. Eron, John W. Mellors, Rajesh T. Gandhi, Charles R. Rinaldo

262 INVESTIGATING ANTIGEN-INDEPENDENT CD8+ T-CELL ENFORCEMENT OF HIV LATENCY

Talia M. Mota, Jared Weiler, Louise Leyre, Sandra Terry, Lynsay MacLaren Ehui, Avery Wimpelberg, Christopher M. Cannon, Sarah Henn, Erika Benko, Colin Kovacs, R. Brad Jones

263 HLA-II-ASSOCIATED VIRAL ADAPTATION IMPACTS CD4+ T-CELL RESPONSES IN HIV-1 VACCINES

Jacob K. Files, Sarah Sterrett, Timothy Fram, Nathan Erdmann, Anju Bansal, Paul Goepfert

264 TFH-SPECIFIC FEATURES ASSOCIATED WITH NEUTRALIZATION IN CHRONIC HIV-1 INFECTION

Eirini Moysi, Ashish A. Sharma, Sijy O'Dell, Clarisa Buckner, Perla Mariana Del Rio Estrada, Gustavo Reyes-Teran, Alexander J. Chassiakos, Margaret H. Beddall, Nicole Doria-Rose, Susan Moir, Rafick-Pierre Sékaly, John R. Mascola, Richard A. Koup, Constantinos Petrovias

265 HIV-SPECIFIC T-CELL FREQUENCIES AND FUNCTION AFTER ART DURING ACUTE OR EARLY HIV

Scott F. Sieg, Joseph A. Puleo, Lu Zheng, Brian Claggett, Javier R. Lama, Lawrence Fox, Jintanat Ananworanich, Kiat Ruxrungham, Beatriz Grinsztejn, Roberto C. Arduino, Joseph J. Eron, John W. Mellors, Eric S. Daar, Trevor A. Crowell, for the AIDS Clinical Trials Group A5354 Study Team

266



TREATMENT INTERRUPTION AND T-CELL IMMUNITY IN ART-TREATED PRIMARY HIV INFECTION

Timothy L. Tipoe, Ane T. Ogbe, Helen Brown, Nicola Robinson, Ming J. Lee, Rebecca Hall, Claire Petersen, Heather Lewis, John Thornhill, Julianne Lwanga, Fiona Ryan, Julie Fox, Sarah Fidler, John Frater

267



PBMC TRANSCRIPTOME REVEALED A BENEFICIAL IMMUNE ACTIVATION AGAINST HIV-1 IN LGMD1F

Francisco Diez-Fuertes, Sara Rodríguez-Mora, Javier García-Pérez, Esther Calonge, Mercedes Bermejo, María Rosa López-Huertas, Mayte Coiras, José Alcamí

268

ASSOCIATIONS BETWEEN MATERNAL HIV AND INFANT IMMUNE ACTIVATION

Ceri Evans, Bernard Chasekwa, Jonathan Broad, Christie Noble, Kuda Mutasa, Sandra Rukobo, Margaret Govha, Patience Mushayanembwa, Florence D. Majo, Naume V. Tavengwa, Jean H. Humphrey, Robert Ntozini, Claire D. Bourke, Andrew J. Prendergast

269

IMPACT OF ANTIMICROBIALS ON PENILE IMMUNOLOGY: A RANDOMIZED CLINICAL TRIAL

Ronald Galiwango, Brenda Okech, Vineet Joag, Sanja Huibner, Victoria M. Biribawa, Juliet Mpendo, Moses Muwanga, Daniel Park, Tony Pham, Cindy Liu, Aaron Tobian, Lane Buchanan, Jessica Prodder, **Rupert Kaul**, for the APM Trial Group

270

COCAINE AND PERIPHERAL SEROTONIN DRIVE IMPAIRED T-CELL FUNCTION AND HIV PERSISTENCE

Mehul Sharma, Maggie Fu, Xuan Xu, Daniela Schlatzer, Rebeka Bordi, Susan Pereira Ribeiro, Joumana Zeidan, Mark Chance, Marianna K. Baum, Rafick-Pierre Sékaly, **Ashish A. Sharma**

Poster Session-D09 SARS-CoV-2 IMMUNOLOGY: T CELLS, NK CELLS, AND CYTOKINES

2:00 PM MT - 3:30 PM MT

308



TGF- β SIGNALING PATHWAY SHAPES ADAPTIVE IMMUNITY IN EARLY SARS-CoV-2 INFECTION

Yulong Wei, Jack A. Collora, Runxia Liu, Jon Klein, Carolina Lucas, Akiko Iwasaki, Ya-Chi Ho, for the Yale IMPACT Team

309

SYSTEMATIC ANALYSIS OF INNATE IMMUNE ANTAGONISM OF SARS-CoV-2 AND ITS EVOLUTION

Lennart Koepke, Rayhane Nchioua, Manuel Hayn, Maximilian Hirschenberger, Annika Schundner, Fabian Zech, Susanne Klute, Steffen Stenger, Karl-Klaus Conzelmann, Jan Muench, Dorota Kmiec, Manfred Frick, Frank Kirchhoff, Konstantin Sparrer

310



DETECTION OF CIRCULATING AND AIRWAY AUTOANTIBODIES TO IFN IN SEVERE COVID-19 PATIENTS

Federica Frasca, Mirko Scordio, Giuseppe Oliveto, Leonardo Sorrentino, Agnese Viscido, Camilla Bitossi, Alessandra Pierangeli, Luigi Celani, Giancarlo Ceccarelli, Letizia Santinelli, Claudio M. Mastroianni, Gabriella D'Ettore, Guido Antonelli, Carolina Scagnolari

311



DIFFERENTIAL IFN GENES EXPRESSION IN THE UPPER AIRWAYS OF CHILDREN AND ADULTS

Leonardo Sorrentino, Federica Frasca, Giuseppe Oliveto, Mirko Scordio, Agnese Viscido, Matteo Fracella, Fabio Midulla, Raffaella Nenna, Gabriella D'Ettore, Giancarlo Ceccarelli, Ombretta Turriziani, Massimo Gentile, Guido Antonelli, Alessandra Pierangeli, Carolina Scagnolari

312 DIFFERENTIALLY EXPRESSED IMMUNOLOGICAL GENES IN MILD AND SEVERE CASES OF COVID-19



Gabriel Gonzalez, Michael J. Carr, Alejandro A. Garcia, Rachel MacCann, John S. Lambert, Eoghan De Barra, Eoin Feeney, Obada Yousif, Peter Doran, Alan Landay, Aoife G. Cotter, William W. Hall, Patrick Mallon

313 DIMENSIONALITY REDUCTION FOR STEPWISE ANALYSIS OF IMMUNE RESPONSE DYNAMICS IN COVID19

Elsa Brunet-Ratnasingham, Sacha Morin, Marjorie Labrecque, Lorie Marchitto, Amélie Pagliuzza, Nathalie Brassard, David R. Morrisson, Brent Richards, Madeleine Durand, Nicolas Chomont, Andrés Finzi, Matrine Tétreault, Guy Wolf, Daniel E. Kaufmann

314 T-CELL RESPONSE QUALITY TO ACUTE SARS-CoV-2 INFECTION, IMMUNE MEMORY, AND HCoV



Alberto L. Perez-Gomez, Carmen Gasca-Capote, Joana Vitale Andrade, Francisco José Ostos, María Trujillo Rodríguez, Cristina Roca-Oporto, Nuria Espinosa-Aguilera, Alicia Gutiérrez Valencia, Mohammed Rafii-El-Idrissi Benhnia, Daniela Weiskopf, Shane Crotty, Alessandro Sette, Luis Fernando López Cortés, Eva Poveda, Ezequiel Ruiz-Mateos

315 IMPAIRED CYTOTOXIC IMMUNE RESPONSE AND EBV REACTIVATION IN PATIENTS WITH LONG COVID19



Lorena Vigón, Miguel Galán, Elena Mateos, Javier García-Pérez, Montserrat Torres, Sara Rodríguez-Mora, María Aranzazu Murciano-Antón, José Alcamí, Mayte Pérez-Olmeda, María Rosa López-Huertas, Mayte Coiras

316 SARS-CoV-2—SPECIFIC T CELLS ASSOCIATED WITH LUNG DYSFUNCTION IN LONG COVID-19

Katherine M. Littlefield, Renée Watson, Jennifer Schneider, Charles Neff, Eiko Yamada, Min Zheng, Thomas Campbell, Sarah Jolley, Andrew Fontenot, Brent Palmer

317 TCR SEQUENCING OF EPITOPE-SPECIFIC T CELLS FROM SARS-CoV-2 CONVALESCENT INDIVIDUALS

Kristin L. Boswell, Phillip A. Swanson, Amy Ransier, Jasmine Roberts-Torres, David R. Ambrozak, Giune Padilla, Sam Darko, Lauren Bowman, Christian Wake, Allison Kirk, Paul G. Thomas, Adrian McDermott, Martin R. Gaudinski, Daniel C. Douek, Richard A. Koup

318 CROSS-RECOGNITION OF A CONSERVED CD4+ T-CELL EPITOPE PRESENT IN DIVERSE CORONAVIRUSES



Bezawit A. Woldemeskel, Arbor G. Dykema, Caroline C. Garliss, Saphira Cherfils, Kellie N. Smith, Joel Blankson

319 DEFINING IMMUNOGENIC PEPTIDES TARGETING SARS-CoV-2 VARIANTS OF CONCERN



Eunok Lee, Gabriel Duette, Gabriela Martins Costa Gomes, Katie Tungatt, Chloe Doyle, Ashley Lee, Vicki Stylianou, Rajiv Khanna, Kerrie Sandgren, Anthony Cunningham, Sarah Palmer

320 PREDICTING COVID-19 CLINICAL PROTECTIVE IMMUNITY FROM SARS-CoV-2 T-CELL RESPONSES

Amanda M. Buck, Darra Drucker, Michael J. Peluso, Steven G. Deeks, Rachel L. Rutishauser, Timothy J. Henrich, Amelia N. Deitchman

321 NATURAL KILLER CELL-MEDIATED ADCC IN SARS-CoV-2 INFECTION AND VACCINATION



Kerri Hagemann, Johannes Jung, Heike Hildebrandt, Stephan Menzel, Madeleine Bunders, Friedrich Koch-Nolte, Fabian Heinrich, Sven Peine, Julian Schulze Zur Wiesch, Thomas T. Brehm, Marylyn M. Addo, Marc Lütgehetmann, Marcus Altfeld

322 DIVERGENT ADAPTIVE IMMUNE RESPONSES DEFINE 2 TYPES OF LONG COVID

Kervevan Jérôme, Isabelle Staropoli, Dorsaf SLAMA, Raphaël Jeger-Madiot, Delphine Planas, Marie-Pierre Pietri, Rémy Robinot, Faroudy Boufassa, Olivier Schwartz, Dominique Salmon, **Lisa A. Chakrabarti**

Poster Session-E01 SINGLE-CELL ANALYSES OF HIV RESERVOIRS**2:00 PM MT - 3:30 PM MT****325 SINGLE-CELL IMAGING CORROBORATES THE LINK BETWEEN HIV INTEGRATION AND TRANSCRIPTION**

Julie Janssens, Flore De Wit, Nagma Parveen, Frauke Christ, Zeger Debyser

326 SINGLE-CELL PROFILING OF LEAKY LATENT HIV-1 RESERVOIRS IN ART-TREATED DONORS

Mathieu Dubé, Nathalie Brassard, Rémi Fromentin, Gérémy Sannier, Gloria G. Delgado, Amélie Pagliuzza, Jean-Pierre Routy, Nicolas Chomont, Daniel E. Kaufmann

327 TRANSLATION-COMPETENT HIV RESERVOIRS ARE HIGHLY EXPANDED AND PHENOTYPICALLY DIVERSE

Caroline Dufour, Corentin Richard, Rémi Fromentin, Marion Pardons, Marta Massanella, Ben Murrell, Bertrand Routy, Jean-Pierre Routy, Nicolas Chomont

328 LONG-READ SEQUENCING ASSAY ALLOWS ACCURATE CHARACTERIZATION OF THE HIV-1 RESERVOIR

Laurens Lambrechts, Rita Verstraeten, Noah Bonine, Ytse Noppe, Marion Pardons, Basiel Cole, Linos Vandekerckhove

329 HIV-1 PROVIRUS-HOST CHROMATIN INTERACTIONS AT THE INTEGRATION SITE

Jack A. Collora, Sandra Springer, Yuval Kluger, Ya-Chi Ho

330 SINGLE-CELL MULTIOMICS ANALYSIS OF HIV RESERVOIR CELLS BY NOVEL T-TRACE APPROACH

Julie Frouard, Jason Neidleman, Rebecca Hoh, Steven G. Deeks, Warner Greene, Nadia Roan

331 CD4+ T-CELL SUBSET-SPECIFIC DIFFERENCES IN HIV LATENCY ESTABLISHMENT

Eun Hye G. Kim, Lara Manganaro, Michael Schotsaert, Lubbertus C. Mulder, Viviana Simon

Poster Session-E06 DYNAMICS OF HIV RESERVOIRS AND VIRAL REBOUND**2:00 PM MT - 3:30 PM MT****376 IMPACT OF TREATMENT INTERRUPTION ON COLONIC MUCOSA IN ACUTELY TREATED PARTICIPANTS**

Alexandra Schuetz, Catherine Brands, David Morcock, Donn J. Colby, Trevor A. Crowell, Rungsun Rerknimitr, Carlo Sacdalan, Suteeraporn Pinyakorn, Yuwadee Phuang-Ngern, Brandon Keele, Jeffrey D. Lifson, Jintanat Ananworanich, Denise C. Hsu, **Claire Deleage**, for the RV411/397 Study Groups

377 HIV-1 RESERVOIRS ESTABLISHED PRIOR TO THERAPY CONTRIBUTE TO REBOUND VIRUS

Katie Fisher, Xiao Qian Wang, Ashley Lee, Vincent Morcilla, Anneke de Vries, Eunok Lee, John-Sebastian Eden, Steven G. Deeks, Anthony Kelleher, Sarah Palmer

- 378 Vpr SHAPES THE PROVIRAL LANDSCAPE AND POLYCLONAL HIV-1 REACTIVATION PATTERNS IN VITRO**
Edmond Atindaana, Sarah Emery, Cleo Burnett, Jake Pitcher, Jeffrey M. Kidd, Alice Telesnitsky
- 379 SIZE AND ACTIVITY OF THE HIV RESERVOIR PREDICT REBOUND TIMING AFTER ART INTERRUPTION**
Jonathan Li, Autumn Kittilson, Meghan Melberg, Elizabeth R. Wonderlich, Jennifer Kinslow, Evgenia Aga, Ronald J. Bosch, Robert Coombs, Steven G. Deeks, Rajesh T. Gandhi, Michael P. Busch, Alan Landay, Bernard J. Macatangay, Davey M. Smith, for the AIDS Clinical Trials Group A5345 Study Team
- 380 DECAY KINETICS OF FREE VIRUS, INTACT & DEFECTIVE PROVIRUSES, & 2LTR CIRCLES ON ART**
Jennifer A. White, Francesco R. Simonetti, Subul Beg, Niklas Bachmann, Natalie McMyn, Weiwei Dai, William Ford, Jun Lai, Christina Bunch, Joyce Jones, Ruy M. Ribeiro, Alan S. Perelson, Janet Siliciano, Robert Siliciano
- 381 FORMATION OF THE LONG-LIVED EARLY RESERVOIR IS PUNCTUATED BY EPISODIC SEEDING**
Olivia D. Council, Melissa-Rose Abrahams, Sarah B. Joseph, Nigel Garrett, Matt Moeser, Ean Spielvogel, Amy Sondgeroth, Lynn Tyers, David Matten, Sergei L. Kosakovsky Pond, Nancie Archin, David M. Margolis, Salim S. Abdool Karim, Ronald Swanstrom, Carolyn Williamson
- 382 MEASURING HIV-1 RESERVOIR DYNAMICS DURING LONG-TERM ANTIRETROVIRAL THERAPY**
Thuy Nguyen, Mary E. Zipparo, Lindsey Adams, Shawn Hill, Matthew A. Adan, Erin Madeen, Chuen-Yen Lau, Frank Maldarelli
- 383 HIV PROVIRUSES MIMIC THE CLONALITY OF HIGHLY EXPANDED CD4+ T CELLS IN PEOPLE ON ART**
Daniel B. Reeves, Danielle N. Rigau, Francesco R. Simonetti, Hao Zhang, Leah H. Rubin, Stephen Gange, Nadia Roan, Phyllis Tien, Joseph B. Margolick, Frederick M. Hecht, Steven G. Deeks, Joshua Schiffer, Janet Siliciano, Robert Siliciano, **Annukka A. Antar**
- 384 PREDICTORS OF HIGH TOTAL AND INTACT HIV RESERVOIR AMONG CHILDREN WITH HIV IN KENYA**
 **Jillian Neary**, Carolyn S. Fish, Noah Cassidy, Dalton C. Wamalwa, Agnes Langat, Evelyn Ngugi, Sarah Benki-Nugent, Hellen Moraa, Barbra A. Richardson, Jennifer Slyker, Dara A. Lehman, Grace John-Stewart
- 385 PROVIRUSES WITH 5'-LEADER DELETIONS ARE A CAUSE OF NONSUPPRESSIBLE HIV-1 VIREMIA**
Francesco R. Simonetti, Jennifer A. White, Saif Yasin, Joseph Varriale, Milica Moskovljevic, Jiayi Duan, Kyle Rhodehouse, Andrei Gheorghe, Alison L. Hill, Hao Zhang, Christin Kilcrease, Christopher Hoffmann, Michael Summers, Janet Siliciano, Robert Siliciano
- 386 INTACT HIV TRANSCRIPTS ARE RARE IN ART-SUPPRESSED INDIVIDUALS**
 **Holly A. Martin**, Gayatri Nikhila Kadiyala, Sushama Telwatte, Adam Wedrychowski, Tsui-Hua Chen, Sara Moron-Lopez, Rebecca Hoh, Steven G. Deeks, Joseph K. Wong, Steven A. Yuki
- 387 EARLY ANTIRETROVIRAL THERAPY REDUCES BUT DOES NOT ELIMINATE HIV DNA IN BLOOD**
Trevor A. Crowell, Justin Ritz, Lu Zheng, Asma Naqvi, Joshua Cyktor, Scott F. Sieg, Javier R. Lama, James F. Rooney, Lawrence Fox, Jintanat Ananworanich, Joseph J. Eron, Gert Van Zyl, John W. Mellors, Eric S. Daar, for the AIDS Clinical Trials Group A5354 Study Team

388 INTACT NONINDUCIBLE PROVIRUSES ARE GENERATED DURING ACUTE HIV AND CAN PERSIST ON ART

Pierre Gantner, Supranee Buranapraditkun, Caroline Dufour, Amélie Pagliuzza, Corentin Richard, Rémi Fromentin, Julie Mitchell, Eugene Kroon, Suteeraporn Pinyakorn, Merlin Robb, Nittaya Phanuphak, Denise C. Hsu, Sandhya Vasan, Lydie Trautmann, Nicolas Chomont

389 EXPRESSION OF HIV-1 ANTISENSE TRANSCRIPTS IN DONORS ON ART

Rachel Sklutuis, Jennifer L. Groebner, Valerie F. Boltz, Wei Shao, Rui Li, Steven G. Deeks, Brandon Keele, Fabio Romero, Mary F. Kearney

Poster Session-F01 CNS RESERVOIRS, REGULATION, AND ESCAPE
2:00 PM MT - 3:30 PM MT
390 EVALUATION OF GLIAL HIV RESERVOIRS USING A HUMANIZED BLOOD AND BRAIN MOUSE

Saumi Mathews, Edward Makarov, Lili Guo, Li Wu, Larisa Y. Poluektova, Santhi Gorantla

391 ALTERED MICROGLIAL GENOME STRUCTURE AND TRANSCRIPTION IN HIVE IMPACT HIV INTEGRATION

Amara Plaza-Jennings, Brandon Pratt, Benjamin K. Chen, Lotje De Witte, Susan Morgello, Hyejung Won, Schahram Akbarian

392 COMPARTMENTALIZED CLONAL EXPANSIONS OF CD8+ T CELLS IN CSF DURING ACUTE HIV INFECTION

Julie Mitchell, Caroline Subra, A Julian Pacheco Mendez, Faria Fatmi, Blake Colton, Supranee Buranapraditkun, Suteeraporn Pinyakorn, Carlo Sacdalan, Somporn Tipsuk, Nittaya Phanuphak, Denise C. Hsu, Sandhya Vasan, Serena S. Spudich, Lydie Trautmann, for the SEARCH010/RV254 Study Group

393 SIV-INFECTED CD4+ T CELLS CARRY VIRUS TO THE BRAIN

Howard S. Fox, Brenda M. Morsey, Meng Niu, Katy Emanuel, Benjamin G. Lamberty, Andrew J. Trease

394 MULTI-COMPARTMENT FRESH SINGLE-CELL STUDIES IN AN INTERNATIONAL HIV RESEARCH SETTING

Michael J. Corley, Supranee Buranapraditkun, Panadda Sawangsinth, Alexandra Schuetz, Sodsai Tovanabuttra, Alina Pang, Shelli F. Farhadian, Nittaya Phanuphak, Carlo Sacdalan, Denise C. Hsu, Sandhya Vasan, Serena S. Spudich, Lishomwa Ndhlovu, for the RV254/SEARCH010 and RV304/SEARCH013 Study Group

Poster Session-F06 NEUROCOGNITION: PREDICTIONS, TRAJECTORIES, AND THERAPEUTICS
2:00 PM MT - 3:30 PM MT
422 ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH HIV AND COGNITIVE ISSUES

Kate Alford, Stephanie Daley, Sube Banerjee, Elizabeth Hamlyn, Daniel Trotman, Jaime Vera

423 PRESCRIBED DRUGS DISTINGUISH DATA-DRIVEN COGNITIVE PROFILES IN PEOPLE WITH HIV (PWH)

Raha Dastgheyb, Yanxun Xu, Alison Buchholz, Donald Franklin, Ronald J. Ellis, Susan Morgello, David Clifford, Benjamin B. Gelman, Christina M. Marra, Robert K. Heaton, David J. Moore, Scott L. Letendre, Qing Ma, **Leah H. Rubin**

424 PREVALENCE AND CHARACTERISTICS OF HIV-ASSOCIATED STROKE IN A SOUTH AFRICAN SETTING

Craig Corbett, Naeem Brey, Richard D. Pitcher, Suzanne O'Hagan, Tonya M. Esterhuizen, Felicia C. Chow, Eric Decloedt

425 ABNORMAL COGNITIVE AGING IS DETECTED DESPITE CLINICALLY DEFINED COGNITIVE STABILITY

Htein Linn Aung, Thomas Gates, Limin Mao, Bruce Brew, Krista J. Siefried, Andrew Carr, Lucette A. Cysique

426 COGNITIVE PREDICTORS OF EVERYDAY FUNCTIONING IN THE WOMEN'S INTERAGENCY HIV STUDY

David Vance, Pauline Maki, Danyang Yu, Raha Dastgheib, Gayle Springer, Kathryn Anastos, Deborah Gustafson, Kathleen Weber, Derek M. Dykxhoorn, Joel Milam, Monica M. Diaz, Seble Kassaye, Drenna Waldrop, Yanxun Xu, Leah H. Rubin

427 A NOVEL COMORBIDITY INDEX PREDICTS COGNITIVE CHANGE IN PEOPLE WITH CHRONIC HIV

Ronald J. Ellis, Bin Tang, Sara Gianella, Christina M. Marra, David Clifford, Igor Grant, Benjamin B. Gelman, Susan Morgello, J. Allen McCutchan, Scott L. Letendre, Robert K. Heaton

428 RECREATIVE DRUGS: NEW SUSPECTS IN HAND MYSTERY GAME

Sophie Henrard, Nicola Trotta, Antonin Rovai, Tim Coolen, Hichem Slama, Jean-Christophe Goffard, Serge Goldman, Xavier De Tiège

**Poster Session-G02 HIV PREVENTION AND MUCOSAL
COMPARTMENT PHARMACOLOGY**
2:00 PM MT - 3:30 PM MT
440 ANTI-INFECTIVES' PENETRATION IN UPPER AND LOWER FEMALE GENITAL TISSUES

Fan Wang, Olivie C. Namuju, Katelyn A. Pastick, Kizito Abdusalaamu, Usha Mishra, Lindsey B. Collins, David R. Boulware, Robert Lukande, David Meya, Melanie R. Nicol

441 ORAL TDF/FTC PROVIDES EARLY MUCOSAL PROTECTION IN BOTH ON-DEMAND AND DAILY REGIMEN

Sylvain Chawki, Audrey Gabassi, Mayssam El Mouhebb, Milad Taouk, Lambert Assoumou, Iris Bichard, Skander Benothmane, Ali Amara, Rhonda Brand, Aaron Siegel, Lauriance Goldwirt, Ian McGowan, Dominique Costagliola, Jean-Michel Molina, Constance Delaunay, for the PREVENIR Study

442 PK/PD RESULTS OF CHAPS ORAL PREEXPOSURE PROPHYLAXIS TRIAL IN FORESKIN TISSUE

Carolina Herrera, Laura Else, Emily Webb, Azure-Dee A. Pillay, Thabiso B. Seiphetlo, Limakatso Lebina, Jennifer Serwanga, Christian Callebaut, Robin Shattock, Francesca Chiodi, Clive Gray, Saye Khoo, Neil A. Martinson, Julie Fox, for the CHAPS Study Team

443 ANAL SEX & TENOFOVIR DOUCHE SEQUENCE IMPACT COLORECTAL DISTRIBUTION OF HIV & DOUCHE

Lynn N. Bertagnolli, Sandra Abdul Massih, Craig W. Hendrix, Sridhar Nimmagadda, Edward J. Fuchs

444 PHARMACOKINETIC STUDY OF ISLATRAVIR & ETONOGESTREL IMPLANTS IN MACAQUES

Michele B. Daly, Andres Wong-Sam, Linying Li, Archana Krovi, Gregory Gatto, Victoria Mrotz, Catalina Forero, Joy Gary, James Mitchell, Ariane Van der Straten, Walid Heneine, Gerardo Garcia-Lerma, Charles Dobard, Leah Johnson

445 NEXT-GENERATION ISLATRAVIR/ETONOGESTREL/ETHINYL ESTRADIOL MPT INTRAVAGINAL RING

Isabella Young, Roopali Shrivastava, Rima Januszewicz, Craig Sykes, Mackenzie L. Cottrell, Cynthia Cabrales, Angela Kashuba, David Katz, Richard Pyles, Kathleen L. Vincent, **Rahima Benhabbour**

446 LONG-ACTING DORAVIRINE FOR TREATMENT AND PREVENTION OF VAGINAL HIV TRANSMISSION

Martina Kovarova, Manse Kim, Sarah E. Wessel, J. Victor Garcia-Martinez

Poster Session-H01 CLINICAL TRIALS OF THERAPY FOR SARS-CoV-2: ANTIVIRALS AND IMMUNE MODIFIERS
2:00 PM MT - 3:30 PM MT

453 WITHDRAWN**454 PHASE-2 STUDY OF SAB-185, A POLYCLONAL ANTIBODY TREATMENT FOR COVID-19 IN ACTIV-2**

Babafemi O. Taiwo, Kara W. Chew, Mark Giganti, David A. Wohl, Eric S. Daar, Maxine Olefsky, Rick Finnegan, Jake Miles, Arzhang Cyrus Javan, Jonathan Li, Judith S. Currier, Joseph J. Eron, Michael Hughes, Davey M. Smith, for the ACTIV-2/ACTG A5401 Study Team

455 MODELING REMDESIVIR ANTIVIRAL EFFICACY IN COVID-19 HOSPITALIZED PATIENTS

Guillaume Lingas, Nadège Néant, Alexandre Gaymard, Drifa Belhadi, Maya Hites, Dominique Costagliola, Yazdan Yazdanpanah, Florent Wallet, Amandine Gagneux-Brunon, France Mentré, Florence Ader, Charles Burdet, Jérémie Guedj, Maude Bouscambert-Duchamp, for the Discovery Study Group

456 SAFETY OF REMDESIVIR VS PLACEBO IN NONHOSPITALIZED PATIENTS WITH COVID-19

Bradon Webb, Godson Oguchi, Yessica Sachdeva, John Cafardi, Alan S Go, Kavita Juneja, Santosh Davies, Shuguang Chen, Chen-Yu Wang, Anu O. Osinusi, Frank Duff, Pablo Ryan, Carlos Vaca, Jorge Mera

457 EFFECTS OF CASIRIVIMAB + IMDEVIMAB ON SYMPTOM OUTCOMES IN OUTPATIENTS WITH COVID-19

Yuhuan Wang, Mohamed Hussein, Diana Rofail, Kuan-Ju Lin, Daniela J. Conrado, Kenneth C. Turner, Samit Ganguly, Hazem E. Hassan, Qian Huang, Zhichao Lyu, Hong Yan, Thomas Norton, Shazia Ali, John D. Davis, Nidal Al-Huniti

458 REMDESIVIR IN AN OUTPATIENT SETTING IMPROVES BIOMARKERS FOR PROGRESSION OF COVID-19

David Z. Pan, Pamela Odorizzi, Andre Schoenichen, Mazin Abdelghany, Shuguang Chen, Chris Blair, Henry N. Hulter, Scott D. Patterson, Anu O. Osinusi, Kavita Juneja, Jeffrey Wallin

459 A RANDOMIZED CONTROLLED TRIAL OF CAMOSTAT IN OUTPATIENTS WITH COVID-19

Nikolaus Jilg, Janet Nuttall, Atasi Jana, David Maislin, Susan Lewis, Bob Szurgot, Philip A. Hart

460 TDF/FTC FOR HIGH-RISK PATIENTS WITH COVID-19: THE PANCOVID RANDOMIZED CLINICAL TRIAL

María Velasco, Rocio Montejano, Gonzalo Sierra, Javier Queiruga, Patricia Martínez, Ane Goikoetxea, Angela Gutierrez, Miguel Torralba, Pablo Ryan, Pilar Vizcarra, Sofía Ibarra, Maria Jimenez-Gonzalez, Javier Marcos, **Jose R. Arribas**, for the PANCOVID Study Group

461 VIRAL KINETICS IN COVID-19 OUTPATIENTS TREATED WITH CASIRIVIMAB+IMDEVIMAB COMBINATION

Daniela J. Conrado, Kashyap Patel, Kuan-Ju Lin, Yuhuan Wang, Jiraganya Bhongsatiern, Mohamed A. Kamal, Kenneth C. Turner, Samit Ganguly, Hazem E. Hassan, Hong Yan, Cynthia Portal-Celhay, John D. Davis, Patrick F. Smith, Jérémie Guedj, Nidal Al-Hunuti

462 A REAL-WORLD COMPARISON OF BAM/ETE VS CAS/IMD FOR COVID-19 CLINICAL PROGRESSION RISK

Valentina Mazzotta, Francesca Colavita, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Silvia Rosati, Ilaria Mastroianni, Eleonora Lalle, Claudia Cimaglia, Alessandra Vergori, Angela Corpolongo, Concetta Castilletti, Enrico Girardi, Francesco Vaia, Emanuele Nicastri, Andrea Antinori

463 BARICITINIB FOR HIGH-RISK PATIENTS WITH COVID-19: THE PANCOVID RANDOMIZED TRIAL

Alberto Borobia, Fernando de la Calle, Carlos Guijarro, Patricia González-Ruano, Marta Ibarrola, Marianela Ciudad, Ana Díaz-Brasero, Antonio de Pablo, Cristina Marcelo, Cristina Díez, Esperanza Merino, Vicente Estrada, María Novella Mena, Jose R. Arribas, for the PANCOVID Study Group

464 RECOVERY AND SURVIVAL IN COVID-19 RESPIRATORY FAILURE WHEN TREATED WITH AVIPTADIL

Dushyantha Jayaweera, Jihad G. Youssef, Richard A. Lee, Philip T. Lavin, Rainer Lenhardt, David J. Park, Javier P. Fernandez, Melvin L. Morganroth, Jonathan C. Javitt

465 DO ALL CRITICALLY ILL COVID-19 PATIENTS BENEFIT FROM INTENSIFYING WITH TOCILIZUMAB?

Cristina Mussini, Alessandro Cozzi-Lepri, Jovana Milic, Andrea Cossarizza, Gianluca Cuomo, Adriana Cervo, Federica Carli, Sara Volpi, Giovanni Guaraldi

466 SARILUMAB PLUS STANDARD OF CARE (SOC) VERSUS SOC FOR SEVERE COVID-19 (ESCAPE STUDY)

Ilaria Mastroianni, Roberta Gagliardini, Francesco Vladimiro Segala, Annalisa Mondì, Patrizia Lorenzini, Carlotta Cerva, Eleonora Taddei, Francesca Bai, Maria Maddalena Plazzi, Loredana Sarmati, Emanuele Nicastri, Antonella D'Arminio Monforte, Fabrizio Palmieri, Antonella Cingolani, Andrea Antinori

467 CONVALESCENT PLASMA FOR OUTPATIENTS WITH EARLY COVID-19: A RANDOMIZED TRIAL

Arvind Gharbharan, Pere Millat-Martinez, Andrea Alemany, Casper Rokx, Corine H. Geurts van Kessel, Grigorios Papageorgiou, Carlijn Jordans, Marc Corbacho-Monné, Quirke Bassat, Bonaventura Clotet, Bàrbara Baro, Jaap Jan Zwaginga, Oriol Mitjà, Bart J. Rijnders, for the COMPILEhome Investigators

468 ENPATORAN SAFETY AND EFFICACY IN COVID-19 PNEUMONIA: ANEMONE TRIAL



John McKinnon, Joel Santiaguel, Claudia Murta, Dongzi Yu, Mukhy Khursheed, Flavie Moreau, Sanjeev Roy, Amy Kao

469 IMPACT OF TENOFOVIR ON SARS-CoV-2 INFECTION AMONG PEOPLE LIVING WITH HIV



Daniel Kwakye Nomah, Juliana Reyes-Urueña, Yesika Diaz, Sergio Moreno Fornés, Jordi Aceiton, Andreu Bruguera, Rosa M. Vivanco-Hidalgo, Jordi Casabona, Pere Domingo, Jordi Navarro, Arkaitz Imaz, Elisabet Deig, Gemma Navarro, Josep M Llibre, Jose M. Miro

Poster Session-H02 NEW ANTIVIRALS FOR SARS-CoV-2: ACTIVITY IN VITRO AND IN VIVO

2:00 PM MT - 3:30 PM MT

470 PBI-0451 AN ORALLY ADMINISTERED 3CL PROTEASE INHIBITOR OF SARS-CoV-2 FOR COVID-19



Brian P. Kearney, Andrew Plummer, Grushenka Wolfgang, David Turnquist, Mark R. Marshall, Mark Denison, Christian Schwabe, Uri Lopatin, Lee Arnold

471 MOLNUPIRAVIR INCREASES RANDOM SARS-CoV-2 RNA ERRORS WITHOUT SELECTION FOR RESISTANCE



Arthur Fridman, Nicholas J. Murgolo, Andy Liaw, Ying Zhang, Shunbing Zhao, Hong Wan, Alison Pedley, Min Xu, Daria Hazuda, Jay A. Grobler, **Julie M. Strizki**

472 WITHDRAWN

473 GUNNERA PERPENZA ELLAGITANNINS SYNERGISTICALLY INHIBIT MULTIPLE SARS-CoV-2 VARIANTS

Ian Tietjen, Luke Invernizzi, Phanankosi Moyo, Joel Cassel, Emery T. Register, Frederick Keeney, Joseph M. Salvino, Freddie J. Isaacs, Vinesh Maharaj, Luis J. Montaner

474 INTERIM ANALYSIS OF A PHASE I STUDY OF PRTX007: SAFETY, PK, AND PD RESPONSE

Charlotte R. Lemeck, **Curtis L. Scribner**, Richard Daniels, James R. Appleman

475 CETYLPYRIDINIUM CHLORIDE MOUTHWASHES TO REDUCE THE SHEDDING OF VIABLE SARS-CoV-2



Jordana Muñoz-Basagoiti, Andrea Alemany, Daniel Perez-Zsolt, Dan Ouchi, Dalia Raich-Regué, Benjamin Trinité, Edwards Pradenas, Julià Blanco, Ruben León, Vanessa Blanc, Joan Gispert, Bonaventura Clotet, Oriol Mitjà, Nuria Izquierdo-Useros, for the CPC Study Group

476 A NOVEL CLASS OF ANTIVIRAL COMPOUNDS WITH POTENT ACTIVITY AGAINST SARS-CoV-2

David E. Gordon, Eugene Stavtsev, Anatolii Demchenko

477 DESIGN OF NOVEL AND HIGHLY SELECTIVE SARS-CoV-2 MAIN PROTEASE INHIBITORS

Joseph M. Salvino, Ian Tietjen, Adi Narayana Reddy R. Poli, Joel Cassel, Troy E. Messick, Emery T. Register, Frederick Keeney, Luis J. Montaner

478 EFFECT OF ASTODRIMER SODIUM AGAINST SARS-CoV-2 VARIANTS (A, B, Γ, Δ, K) IN VITRO

Philippe Gallay, Carolyn Luscombe, Winston Stauffer, Michael D. Bobardt, Graham Heery, Alex Castellarnau, Aynaz Seta, Jeremy R. Paull

Poster Session-I03 NEW TECHNOLOGIES TO DETECT HIV DRUG RESISTANCE

2:00 PM MT - 3:30 PM MT

513 TEMPORAL VARIABILITY OF MULTI-CLASS RESISTANT HIV-1 IN PROVIRAL DNA

Christian Hoffmann, Eva Wolf, Patrick Braun, Markus Bickel, Albrecht Stoehr, Silke Heldwein, Heribert Knechten, Stefan Esser, Christoph Mayr, Christoph Wyen, Markus Mueller, Jan-Christian Wasmuth, Maximilian Münchhoff, Alexander Thielen, Martin Daeumer

514 COMPARATIVE ANALYSIS OF HIV-1 RNA AND ARCHIVED PROVIRAL HIV-1 DNA GENOTYPING

Noah C. Gaitan, Michelle L. D'Antoni, Rima K. Acosta, Susan J. Little, Antoine Chaillon

515 POINT-OF-CARE URINE TENOFOVIR TESTING TO DETECT HIV DRUG RESISTANCE

Suzanne McCluskey, Katya Govender, John Adamson, Monica Gandhi, Matthew A. Spinelli, Mahomed-Yunus Moosa, Henry Sunpath, Pravikrishnen Moodley, Melendhran Pillay, Selvan Pillay, Winnie R. Muyindike, Godfrey Masette, Bethany Hedt-Gauthier, Vincent Marconi, Mark Siedner

Poster Session-I04 TRANSMITTED HIV DRUG RESISTANCE

2:00 PM MT - 3:30 PM MT

516 TRANSMITTED DRUG RESISTANCE TO INTEGRASE-BASED FIRST-LINE TREATMENT IN EUROPE

Adolfo De Salazar, Laura Viñuela, Ana Fuentes, Elisa Teyssou, Charlotte Charpentier, Sidonie Lambert-Niclot, Lavinia Fabeni, Carlo F. Perno, Dimitrios Paraskevis, Perpetua Gomes, Maria M. Santoro, Francesca Ceccherini-Silberstein, Anne Genevieve Marcelin, **Federico Garcia**, for the MeditRes HIV Collaboration

517 STATEWIDE TRENDS OF TRANSMITTED HIV-1 DRUG RESISTANCE IN RHODE ISLAND OVER 2004-2020

Vlad Novitsky, Jon Steingrimsson, Fizza S. Gillani, Mark Howison, Su Aung, Cindy Y. Won, Amy Brotherton, Rajeev Shah, Thomas Bertrand, Anna Civitarese, Katharine Howe, Utpala Bandy, Nicole Alexander-Scott, Joseph Hogan, Rami Kantor

Poster Session-J02 HCV TREATMENT AND DISEASE

2:00 PM MT - 3:30 PM MT

528 EFFICACY & SAFETY OF RAVIDASVIR + SOFOSBUVIR IN HEPATITIS C: STORM-C-1 FINAL RESULTS



Soek-Siam Tan, Sombat Thanprasertsuk, Satawat Thongsawat, Nicolas Salvadori, **Caroline Menétrey**, for the STORM-C-1 Research Team

529 TREATMENT WITH SOF/VEL/VOX IN HIV/HCV-COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs

Luz Martin Carbonero, Angela Gil-Martin, Teresa Aldámiz-Echevarría, Vicente Estrada, Carlos Barros, Rebeca Font, Pablo Ryan, Carmen Quereda, Beatriz Alvarez, Rafael Mican, Juan Berenguer, Jorge Vergas, Maria Luisa Montes, Juan C. Lopez, for the Madrid-CoRe Study Group

530 ADHERENCE IN THE ACTG A5360 HCV MINIMAL MONITORING (MINMON) TRIAL

Leonard Sowah, Laura M. Smeaton, Irena Brates, Debika Bhattacharya, Benjamin Linas, Bruce Kreter, Sandra Wagner-Cardoso, Sunil S. Solomon, Mark S. Sulkowski, Gregory K. Robbins

531 IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS

Teresa Aldámiz-Echevarría, **Juan Berenguer**, Victor Hontañón, Chiara Fanciulli, Carmen Quereda, Carmen Busca Arenzana, Lourdes Domínguez, Cristina Hernandez Gutierrez, Jorge Vergas, Gabriel Gaspar, Lucio Jesús García-Fraile Fraile, Marta De Miguel, José M. Bellón, Juan González-García, for the GeSIDA 10318-Marathon Study Team

532 HIGHER MORTALITY OF PLWH CURED OF HCV BY DAAs: RESULTS FROM THE ANRS-CO4-FHDH COHORT

Maria B. Requena, Sophie Grabar, Gilles Pialoux, Dominique Costagliola, Karine Lacombe

533 DIAGNOSIS OF ESOPHAGEAL VARICES IN VIRUS-RELATED ADVANCED CHRONIC LIVER DISEASE

Jordana Serero, Amine Zoughlami, Stephen E. Congly, Irene Zhao, Julie Zhu, Alnoor Ramji, Curtis Cooper, Philip Wong, Robert Bailey, Carla S. Coffin, Giada Sebastiani, for the Canadian HBV Network

534 HIV/HBV/HCV TRIPLE INFECTION, END-STAGE LIVER DISEASE, AND ALL-CAUSE MORTALITY

Amanda Mocroft, Adam Geressu, Charles Béguelin, Josep Maria Llibre, Jeffrey V. Lazarus, Janez Tomazic, Jelena Smidt, Milosz Parczewski, Johanna Brännström, Dalibor Sedlacek, Olaf Degen, Marc Van der Valk, Dmitry Paduta, Lars Peters, for the EuroSIDA Study Group

535 IMPACT OF HCV CURE ON DEPRESSIVE SYMPTOMS IN THE HIV-HCV COINFECTED POPULATION

Gayatri J. Marathe, Erica E. Moodie, Marie-Josée Brouillette, Charlotte Lanièce Delaunay, Joseph Cox, Curtis Cooper, M. John Gill, Valérie Martel-Laferrrière, Neora Pick, Marie-Louise Vachon, Sharon Walmsley, Marina B. Klein, for the Canadian Co-infection Cohort

Poster Session-J03 HCV ELIMINATION AND CARE CASCADE**2:00 PM MT - 3:30 PM MT****536 HCV DIAGNOSIS PRECEDING AN HIV OUTBREAK AMONG PWID IN KANAWHA COUNTY, WV: 2019-2021**

Alana G. Hudson, Robert A. Bonacci, Anne C. Moorman, McKenna Penley, Suzanne Wilson, Robert P. McClung, Jessica Hoffman, Erica Thomasson, Danae Bixler

537 THE HEPATITIS C CARE CONTINUUM IN THE DAA ERA AMONG TRANSGENDER WOMEN WITH HIV

Jimmy Ma, Stephanie A. Ruderman, Bridget M. Whitney, Rob J. Fredericksen, John D. Scott, Robin M. Nance, Sari L. Reisner, Kenneth H. Mayer, Jamaica R. Robinson, Joseph A. Delaney, Edward R. Cachay, Geetanjali Chander, H. Nina Kim, Lydia N. Drumright, for the CNICS Cohort

538 PROGRESS TOWARD HCV MICROELIMINATION AMONG HIV-POSITIVE PATIENTS IN TAIWAN

Shu-Yuan Ho, Li-Hsin Su, Hsin-Yun Sun, Miao-Hui Huang, Yu-Shan Huang, Sung-Hsi Huang, Yi-Chia Huang, Wen-Chun Liu, Yi-Ching Su, Sui-Yuan Chang, **Chien-Ching Hung**

539 THE IMPACT OF COVID-19 ON HCV MICRO-ELIMINATION IN MSM IN GERMANY

Patrick Ingiliz, Thomas Lutz, Knud C. Schewe, Stefan Mauss, Stefan Christensen, Natasha Martin, Sonia Jain, Feng He, Michael Sabranski, Jukka Hartikainen, Markus Bickel, Jürgen K. Rockstroh, Christoph Boesecke

540 WITHDRAWN**541 PERFORMANCE OF HCV ANTIGEN ASSAY IN THE DIAGNOSIS OF ACUTE HCV INFECTION AMONG PLWH**

Hsin-Yun Sun, Li-Hsin Su, Yi Ting Chen, Wen-Chun Liu, Yi-Ching Su, Yu-Chung Chuang, Yu-Shan Huang, Wan-Da Liu, Po-Liang Lu, Chien-Ching Hung, Ming-Lung Yu

542 HCV MICROELIMINATION AMONG PEOPLE LIVING WITH HIV IN SAN DIEGO: ARE WE ON TRACK?

Jaskaran S. Cheema, William C. Mathews, Adriane Wynn, Laura Bamford, Francesca Torriani, Lucas Hill, Amutha Rajagopal, Jeffrey Yin, Edward R. Cachay, Natasha Martin

**Poster Session-K02 CERVICAL CANCER AND ANAL CANCER:
PREVALENCE AND SCREENING**
2:00 PM MT - 3:30 PM MT
561 PREVALENCE AND SEVERITY OF HPV-ASSOCIATED ANAL DISEASE IN PWH YOUNGER THAN 35

Keith Sigel, Michael M. Gaisa, Yuxin Liu

562 FACTORS ASSOCIATED WITH ANAL DYSPLASIA AMONG YOUNG MSM AND TW WITH HIV IN ATLANTA

Leah Loerinc, Amy Scheel, Amelia Thompson, Kristin Wall, Scott Gillespie, Molly McCallum, Lisa Flowers, Andres Camacho-Gonzalez

563 GENITAL AND ANAL CYTOLOGY: HPV COTESTING RESULTS FROM 381 WOMEN LIVING WITH HIV

Michael M. Gaisa, Kevin Weiss, Keith Sigel, Yuxin Liu

564 EVALUATING HPV TESTING FOR CERVICAL CANCER SCREENING IN 4 COUNTRIES' HIV PROGRAMS

Jessica Joseph, Owen Demke, Lola Ameyan, Joseph Bitilinyu-Bango, Jibrin Kama, Marvin Lubega, Bernard Madzima, Tasimba Mhizha, Andrew Musoke, Timothy Tchereni, Shaukat Khan

Poster Session-K03 BASIC SCIENCE OF HPV, KSHV, AND HIV-ASSOCIATED LYMPHOMAS

2:00 PM MT - 3:30 PM MT

565



IMMUNOLOGICAL BIOMARKERS ASSOCIATED WITH ANAL DYSPLASIA IN PEOPLE LIVING WITH HIV

Joaquin Burgos-Cibrian, **Cristina Mancebo Pérez**, Nuria Massana, Antonio Astorga Gamaza, Stefania Landolfi, Vicenç Falcó, Maria José Buzón, Meritxell Genescà

566



EXPRESSION OF IFN RECEPTORS IN ANAL CELLS FROM HIV-POSITIVE MEN DURING HPV INFECTION

Mirko Scordio, Federica Frasca, Giuseppe Oliveto, Leonardo Sorrentino, Agnese Viscido, Matteo Fracella, Letizia Santinelli, Eugenio Nelson Cavallari, Paolo Gozzo, Gabriella D'Ettorre, Guido Antonelli, Alessandra Pierangeli, Carolina Scagnolari

567

HPV DIFFERENTLY HIJACKS ANAL INTERFERON RESPONSE IN HIV-POSITIVE AND HIV-NEGATIVE MSM

Eugenio Nelson Cavallari, Letizia Santinelli, Mirko Scordio, Federica Frasca, Giuseppe P. Innocenti, Luca Maddaloni, Gabriella De Girolamo, Giancarlo Ceccarelli, Claudio M. Mastroianni, Alessandra Pierangeli, Carolina Scagnolari, Gabriella D'Ettorre

568

WHOLE-GENOME SEQUENCING OF KSHV REVEALS EVIDENCE FOR 2 AFRICAN LINEAGES

Razia Moorad, Angelica Juarez, Justin T. Landis, Linda J. Pluta, Megan V. Perkins, Avery Cheves, Dirk P. Dittmer

569



IDENTIFICATION OF PROVIRAL INTEGRATIONS WITHIN HIV-ASSOCIATED B-CELL LYMPHOMAS

Michael P. Rist, Machika Kaku, Tyler Colson, Michael Freeman, John M. Coffin

Poster Session-L02 HYPERTENSION, HEART FAILURE, AND OTHER CARDIOVASCULAR DISEASE OUTCOMES

2:00 PM MT - 3:30 PM MT

584

HIV INFECTION AND INCIDENT ABDOMINAL AORTIC ANEURYSM AMONG 143,327 VETERANS

Alexandra M. Filipkowski, Suman Kundu, Charles W. Alcorn, Joshua A. Beckman, Matthew Freiberg, Aaron W. Aday

585

HYPERTENSION CARE CASCADE DURING COVID IN VETERANS WITH HIV

Lewis S. Musoke, Sandra Woolson, Julie Schexnayder, Chris T. Longenecker, Elizabeth Strawbridge, Hayden Bosworth, Puja Van Epps

586

HYPERTENSION PREVALENCE AMONG PERSONS LIVING WITH HIV: ZAMBIA, JULY 2020–JUNE 2021

Jonas Hines, Jose Tomas Prieto, Sombo Fwoloshi, Peter Minchella, Cecilia Chitambala, Dalila Zachary, Megumi Itoh, Khozya D. Zyambo, Lloyd B. Mulenga, Simon Agolory

587

ATRIAL FIBRILLATION RISK FACTORS AMONG PATIENTS IN HIV CARE IN THE UNITED STATES

Robin M. Nance, Joseph A. Delaney, James S. Floyd, Michael Saag, Richard Moore, Jeanne C. Keruly, Mari M. Kitahata, Bridget M. Whitney, William C. Mathews, Edward R. Cachay, Greer Burkholder, Amanda Willig, Sonia Napravnik, Heidi Crane, Susan Heckbert

588 ELEVATED METHYLGLYOXAL TRIGGERS HEART FAILURE DURING HIV-1 INFECTION

Prasanta K. Dash, Fadhel Alomar, Jesse Cox, Bryan T. Hackfort, Howard S. Fox, Howard E. Gendelman, Santhi Gorantla, Keshore R. Bidasee

589 ACTIVATED MONOCYTES AND MYOCARDIAL FIBROSIS AMONG PERSONS WITH HIV IN SOUTH AFRICA

Tess Peterson, Muki Shey, Nomawethu Masina, Lye-Yeng Wong, Scott Shuldiner, Julian Wolfson, Stephen Jermy, Hadil Saad, Achita Singh, Mbalabu Lumbamba, Graeme Meintjes, Ntobeko Ntusi, Mpiko Ntsekhe, Jason Baker

590 IMPACT OF RHEUMATOLOGIC THERAPIES ON CARDIOVASCULAR OUTCOMES IN PEOPLE WITH HIV

Boghuma K. Titanji, Shumpei Nagatomi, Julia Gallini, Xiangqin Cui, Vincent Marconi

591 IMPAIRED RESPONSE OF MEMORY TREG TO HDL IS ASSOCIATED WITH HIGHER CARDIOVASCULAR RISK

Laura O. Atehortua, Carl J. Fichtenbaum, W. S. Davidson, Mirza Baig, Sarah Trentman, Claire A. Chougnet

592 ASSOCIATION OF IP-10 AND FAT ATTENUATION INDEX IN PWH AND CONTROLS WITHOUT CVD

Michael L. Freeman, Nivya George, Shana Burrows, Jean Jeudy, Pratik Patel, Daniela Moisi, Sarah E. Mitchell, Mariam Khambaty, Kapil Saharia, Robert G. Weiss, Thomas Mathew, Michael M. Lederman, Shashwatee Bagchi

Poster Session-M03 OTHER COMORBIDITIES**2:00 PM MT - 3:30 PM MT****607 PROTEINURIA IS COMMON AMONG PEOPLE WITH HIV WITH CONTROLLED HIV VIREMIA**

Edgar T. Overton, Amy Kantor, Kathleen Fitch, Paul M. Muntner, Mosepele Mosepele, Judith A. Aberg, Carl J. Fichtenbaum, Grace A. McComsey, Carlos Malvestutto, Michael T. Lu, Pamela S. Douglas, Steven Grinspoon, Heather J. Ribaud, Christina Wyatt, for the REPRIEVE Trial Investigators

608 APOL1 VARIANTS, SICKLE CELL TRAIT, AND KIDNEY FAILURE IN AFRICANS WITH HIV

Frank A. Post, Rachel K. Hung, Julie Fox, Burns Fiona, Andrew Ustianowski, Lisa Hamzah, Sarah Schoeman, Amanda Clarke, Caroline Sabin, Cheryl Winkler, for the GEN-AFRICA Study Group

609 PETRAM RESULTS: BONE TURNOVER CHANGES ON 18F-PET/CT AFTER A RANDOMIZED SWITCH TO TAF

Amelia E. Moore, James E. Burns, Deidre Sally, Ana Milinkovic, Georgios Krokos, Joemon John, Christopher Rookyard, Erica Pool, Richard Gilson, Alejandro Arenas-Pinto, Gary Cook, David Dunn, Glen Blake, Sarah L. Pett

610 ROSUVASTATIN WORSENS VITAMIN K2 STATUS WHICH IMPAIRS BENEFICIAL EFFECT ON BONE IN HIV

Jared C. Durieux, Sokratis N. Zisis, Christian F. Mouchati, Grace A. McComsey

611 HIV-ASSOCIATED COPD IS CHARACTERIZED BY INCREASED SMALL AIRWAYS DYSFUNCTION ON CT

Sarath Raju, Andrew Gearhart, Nicole L. Brown, Michael B. Drummond, Robert Brown, Meredith McCormack, Gregory D. Kirk

- 612 HIV AND TB DRIVE NONCOMMUNICABLE LUNG DISEASE IN URBAN WEST AFRICA**
 **Douglas Fink**, David Oladele, Abigail L. Slack, Oluwatosin Odubela, Tomilola Musari-Martins, Adaobi Okechukwu, Kemi Adetayo, Sola Opaneye, Rufai Abubakar, Agatha David, Shumonta Quaderi, Marc Lipman, John Hurst, Oliver Ezechi
- 613 HIV INFECTION DOES NOT EXPLAIN HIGHER NICOTINE METABOLISM IN PEOPLE WITH HIV (PWH)**
Robert Gross, Warren B. Bilker, Xiaoyan Han, Michael Plankey, Deanna Ware, Mackey Friedman, Gypsyamber D'Souza, Steven Wolinsky, Robert Schnoll, Rachel F. Tyndale, Rebecca L. Ashare
- 614 PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA**
 **Raynell Lang**, M. John Gill, Richard Moore, Michael J. Silverberg, Amy Justice, Amanda Willig, Angel Mayor, Marina B. Klein, Michael A. Horberg, Kelly Gebo, Ronald J. Bosch, Laura Bamford, Jennifer S. Lee, Keri N. Althoff, for the North American AIDS Cohort Collaboration on Research and Design of leDEA

Poster Session-N02 NEUROCOGNITIVE MANIFESTATIONS OF COVID-19

2:00 PM MT - 3:30 PM MT

- 632 NEUROPSYCHOLOGIC PERFORMANCE FOLLOWING COVID-19: PREVALENCE AND PREDICTORS**
Alessandra Vergori, Carmela Pinnetti, Giulia Del Duca, Anna Clelia Brita, Ilaria Mastrososa, Patrizia Lorenzini, Valentina Mazzotta, Marta Camici, Pierangelo Chinello, Paola Mencarini, Maria Letizia Giancola, Amina Abdeddaim, Enrico Girardi, Francesco Vaia, Andrea Antinori
- 633 MENTAL HEALTH & ALCOHOL USE IN PEOPLE WITH & WITHOUT HIV BEFORE & DURING COVID-19**
Sara Bares, Pamela May, Harlan Sayles, Renae Furl, Tony Wilson
- 634 QUINOLINIC ACID IS A BIOMARKER OF COVID-19–ASSOCIATED COGNITIVE IMPAIRMENT**
Lucette A. Cysique, Sophia Bracken, Yasmin Allen-Davidian, Benjamin Heng, Sharron Chow, Mona Dehghani, Ananda Staats Pires, David Darley, Anthony Byrne, Anthony Kelleher, Greg Dore, Gail Matthews, Gilles Guillemin, Bruce Brew
- 635 CSF AND BLOOD ANALYSES IN PARTICIPANTS WITH POST-COVID-19 NEUROPSYCHIATRIC SYMPTOMS**
 **Lindsay S. McAlpine**, Jennifer Chiarella, Hannah Walsh, Sharon Shin, Eunice Baik, Jennifer Yoon, Aroma Naeem, Michael Wilson, Samuel Pleasure, Christopher M. Bartley, Serena S. Spudich, Shelli F. Farhadian, for the COVID Mind Study at Yale

Poster Session-002 PHARMACOLOGIC RELATIONSHIPS ASSOCIATED WITH TB DRUGS AND OUTCOMES

2:00 PM MT - 3:30 PM MT

- 651 RIFABUTIN FORMULATION THAT DELIVERS DRUG 4 MONTHS PREVENTS AND TREATS Mtb INFECTION**
Manse Kim, Claire E. Johnson, Alan A. Schmalstig, Ayano Annis, Sarah E. Wessel, Miriam Braunstein, J. Victor Garcia-Martinez, Martina Kovarova

652 ISONIAZID AND RIFAMPIN PLASMA EXPOSURE ARE ASSOCIATED WITH TB TREATMENT OUTCOMES

Lauren S. Peetluk, Edward Acosta, David W. Haas, Brian Hachey, Gustavo Amorim, Marcelo Cordeiro-Santos, Afrânio L. Kritski, Marina C. Figueiredo, Leticia Linhares, Megan Turner, Felipe Ridolfi, Bruno B. Andrade, Valeria Cavalcanti Rolla, Timothy Sterling, for the RePORT Brazil Consortium

653 ALCOHOL USE AND SUBOPTIMAL ADHERENCE TO ISONIAZID IN PERSONS WITH HIV AND LATENT TB

Winnie R. Muyindike, Robin Fatch, Debbie M. Cheng, Nneka I. Emenyonu, Leah Forman, Christine Ngabirano, Julian Adong, Benjamin Linas, Karen R. Jacobson, Judith A. Hahn

654 DOSE SELECTION OF RIFAPENTINE IN PEDIATRIC PATIENTS BASED ON PBPK MODELLING

Maiara C. Montanha, Shakir A. Atoyebi, Fazila S. Bunglawala, Kamunkhwala Gausi, Hannah Kinvig, Paolo Denti, Marco Siccardi, Catriona Waitt

655 CONCENTRATION-QT MODELING OF BEDAQUILINE, CLOFAZIMINE, AND PRETOMANID IN TB PATIENTS

Mahmoud T. Abdelwahab, Elin Svensson, Andreas Diacon, Almari Conradie, Morounfolu Olugbosi, Rodney Dawson, Gary Maartens, Paolo Denti

656 CLOFAZIMINE DRUG LEVELS AND CARDIAC TOXICITY IN CHILDREN WITH RIFAMPICIN-RESISTANT TB

Ali M. Ali, Belen P. Solans, Jana Winckler, Anneke Hesseling, Heather Draper, Simon Schaaf, Louvina van der Laan, Jennifer Hughes, Anthony Garcia-Prats, Rada Savic

Poster Session-003 TB EPIDEMIOLOGY, TREATMENT, AND IMPLEMENTATION SCIENCE
2:00 PM MT - 3:30 PM MT
657 SEX DIFFERENCES IN RATES OF TUBERCULOSIS IN PEOPLE WITH HIV IN RIO DE JANEIRO, BRAZIL

Lelia H. Chaisson, Betina Durovni, Eileen P. Scully, Solange Cavalcante, Jonathan Golub, Richard E. Chaisson, Valeria Saraceni

658 SEX DIFFERENCES IN LATENT TUBERCULOSIS INFECTION AMONG CLOSE CONTACTS IN BRAZIL

Paul Y. Wada, Peter F. Rebeiro, Allyson Guimarães da Costa, Rebeca C. Araújo, Mariana Araújo-Pereira, Beatriz Barreto-Duarte, Alexandra B. Souza, Michael S. Rocha, Megan Turner, Valeria Cavalcanti Rolla, Afrânio L. Kritski, Marcelo Cordeiro-Santos, Bruno B. Andrade, Timothy Sterling, for the Regional Prospective Observational Research in Tuberculosis Brazil Consortium

659 MODELING THE IMPACT OF HIV AND TB INTERVENTIONS ON SOUTH AFRICAN TB TRENDS: 1990-2019

Mmamapudi Kubjane, Muhammad Osman, Rory Dunbar, Andrew Boulle, Leigh Johnson, for the Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine

660 CLINICAL AND LABORATORY PREDICTORS OF TUBERCULOSIS RECURRENCE

Sonya Krishnan, Nikhil Gupte, Shreyas Desmukh, Padma Priyadarshini, Sanjay Gaikwad, Vijay Vishwanathan, Madhusudan Barthwal, Amita Gupta, Hardy Kornfeld, Jonathan Golub, Vidya Mave, for the RePORT India Study Team

661 PATIENT-LEVEL POOLED ANALYSIS OF STUDY 31/A5349, A STRATIFIED MEDICINE APPROACH

Vincent Chang, Marjorie Z. Imperial, Patrick P. Phillips, Wendy Carr, Ekaterina Kurbatova, Andrew Vernon, Marc Weiner, Kelly Dooley, Susan Dorman, John Johnson, Susan Swindells, Richard E. Chaisson, Payam Nahid, Rada Savic, for the AIDS Clinical Trials Group and the Tuberculosis Trials Consortium

662 LATENT TB INFECTION TREATMENT ACCELERATES IMMUNE RECOVERY AMONG PLWH ON ART

Eduarda Grinsztejn, Luciane Velasque, Sandra Wagner-Cardoso, Brenda Hoagland, Sandro Nazer, Beatriz Grinsztejn, Valdilea Veloso

Poster Session-P01 COVID-19 IN MOTHERS AND THEIR CHILDREN 2:00 PM MT - 3:30 PM MT

670 HIV AND SARS-CoV-2 INFECTION AMONG POSTPARTUM KENYAN WOMEN AND THEIR INFANTS



Emily R. Begnel, Bhavna Chohan, Ednah Ojee, Judith A. Onyango, Prestone Owiti, LaRinda A. Holland, Barbra A. Richardson, Adam K. Khan, Rabia Maqsood, Efrem S. Lim, Dara A. Lehman, Jennifer Slyker, John Kinuthia, Dalton C. Wamalwa, Soren Gantt

671 ADVERSE PREGNANCY OUTCOMES ASSOCIATED WITH COVID-19 INFECTION IN WESTERN KENYA

Victor Akelo, Gregory Ouma, Joyce Were, Sammy Khagayi, Dickson Gethi, Richard Omore, Feiko ter Kuile, Marc Bulterys, Dickens Onyango, Beth A. T. Barr

672 SARS-CoV-2 INFECTION AND PREGNANCY IN AFRICA: A 6-COUNTRY RETROSPECTIVE COHORT STUDY

Jean Nachega, Nadia Sam-Agudu, Rhoderick Machezano, Philip J. Rosenthal, Onesmus Gachuno, John Kinuthia, Nancy Mwongeli, Philippa Musoke, Musa Sekikubo, Jean-Jacques Muyembe-Tamfum, Denis Mukwege, John W. Mellors, Lynne Mofenson, Eduard J. Langenegger, for the AFREhealth COVID-19 Pregnancy Research Collaboration Working Group

673 LONGITUDINAL SARS-CoV-2 ANTIBODY RESPONSE IN PREGNANCY AND TRANSPLACENTAL TRANSFER

Sylvia LaCourse, Morgan Aurelio, Jaclyn Escudero, Sascha R. Ellington, Lauren B. Zapata, Margaret C. Snead, Viral Upadhyay, Krissy Yamamoto, Carol Salerno, Alex Greninger, Alisa Kachikis, Janet A. Englund, Alison L. Drake

674 IMMUNE SYSTEM PROFILE AND CYTOKINE LEVELS OF SARS-CoV-2 IN PREGNANCY AND NEWBORNS



Elena Vázquez Alejo, Laura Tarancon-Diez, Itziar Carrasco, Sara Vigil-Vazquez, Mar Muñoz-Chapuli, Elena Rincón López, Jesús Saavedra-Lozano, Mar Santos Sebastián, Juan Antonio De León Luis, Manuel Sánchez-Luna, María Luisa Navarro, María Ángeles Muñoz-Fernández

675 NEUTRALIZING ANTIBODY RESPONSE AND TRANSPLACENTAL TRANSFER IN COVID-19 IN PREGNANCY

Mary C. Cambou, **Christine M. Liu**, Thalia Mok, Viviana Fajardo Martinez, Sophia G. Paiola, Francisco J. Ibarrondo, Tara Kerin, Nicole Tobin, Gustavo Garcia, Debika Bhattacharya, Grace M. Aldrovandi, Vaithilingaraja Arumugaswami, Rashmi Rao, Otto Yang, Karin Nielsen-Saines

676 IMPAACT 2032: REMDESIVIR PK & SAFETY IN PREGNANT AND NON-PREGNANT WOMEN WITH COVID-19

Kristina M. Brooks, Kristin Baltrusaitis, Jeremiah Momper, Elizabeth Greene, Frederic Bone, Kira Bacon, Rita Humeniuk, Dwight E. Yin, Nahida Chakhtoura, Alice M. Stek, Edmund Capparelli, Mark Mirochnick, Diana F. Clarke, Brookie M. Best, for the IMPAACT 2032 Study Team

Poster Session-P02 HIV, ART, AND PREGNANCY OUTCOMES: EPIDEMIOLOGY AND MECHANISMS

2:00 PM MT - 3:30 PM MT

677 NEURAL TUBE DEFECTS AND PRENATAL EXPOSURE TO DOLUTEGRAVIR: UNITED STATES, 2008-2019



Athena Kourtis, Weiming Zhu, Margaret Lampe, Ya-Lin A. Huang, Karen W. Hoover

678 BIRTH OUTCOMES FOLLOWING PRENATAL EXPOSURE TO DOLUTEGRAVIR: THE DOLOMITE-EPPICC STUDY

Claire Thorne, Karoline Aebi-Popp, Luminita Ene, Marco Floridia, Anna Maria Gamell, Marta Illan, Helen Peters, Anna Samarina, Leigh Ragone, Carlo Giaquinto, Vani Vannappagari, for the Dolomite-EPPICC Study Group

679 RISK-BENEFIT TRADE-OFF FOR PREGNANCY AND INFANT OUTCOMES: DTG, EFV, TAF, AND TDF

Sean Brummel, Lauren Ziemba, Anne Coletti, Lameck Chinula, Chelsea Krotje, Renee Browning, Esau Joao, Mpho Raesi, James S. Ngocho, Linda Aurpibul, Lynda Stranix-Chibanda, Roger L. Shapiro, Jeff Stringer, Shahin Lockman

680 ADVERSE OUTCOMES IN SUBSEQUENT PREGNANCIES IN THE IMPAACT 2010 TRIAL

Lee Fairlie, Sean Brummel, Lauren Ziemba, Anne Coletti, Lameck Chinula, Roger L. Shapiro, Jeff Stringer, Renee Browning, Nahida Chakhtoura, Blandina T. Mmbaga, Tsungai P. Mhembere, Ayotunde Omoz-Oarhe, Beatrice Naggadya, Megeshinee Naidoo, Shahin Lockman

681 SOME InSTIs INDUCE TOXICITY AND DIFFERENTIATION IN HUMAN EMBRYONIC STEM CELLS



Marie-Soleil R. Smith, Ronil Patel, Lou Martineau, Helene C. Cote

682 IMPACT OF MATERNAL HIV/HBV COINFECTION ON PREGNANCY AND INFANT OUTCOMES

Flavia K. Matovu, Camlin Tierney, Audrey Chang, Dhayendre Moodley, Vani Govender, Tichaona Vhembo, Kathleen George, Neaka Z. Mohtashemi, Philippa Musoke, Dingase Dula, Nahida Chakhtoura, Marion Peters, Mary G. Fowler, Judith S. Currier, Debika Bhattacharya

683 HIV-RELATED DIFFERENCES IN PLACENTAL IMMUNOLOGY: DATA FROM THE PRACHITI COHORT

Jyoti S. Mathad, Ramesh Bhosale, Mallika Alexander, Shilpa Naik, Vandana Kulkarni, Lisa Marie Cranmer, Andrea Chalem, Jin Liu, Jun Lei, Anna Chudnovets, Anguo Liu, Rupak Shivakoti, Amita Gupta, Irina Burd

Poster Session-Q02 EARLY TREATMENT AND HIV RESERVOIRS IN CHILDREN

2:00 PM MT - 3:30 PM MT

711 2-YEAR OUTCOME OF EARLY TREATED INFANTS IN SUB-SAHARAN AFRICA

Alfredo Tagarro, Sara Domínguez-Rodríguez, Louise Kuhn, Tacilta Nhampossa, Kennedy Otworld, Anita Janse van Rensburg, Nigel Klein, Maria Grazia Lain, Almoustapha I. Maiga, Camille Brehin, Carlo Giaquinto, Paolo Rossi, Pablo Rojo, for the EPIICAL Consortium

712 HIV-1 RESERVOIR CELL EVOLUTION IN EARLY-TREATED CHILDREN IN BOTSWANA



Ciputra A. Hartana, Pilar Garcia-Broncano, Yelizaveta Rassadkina, Xiaodong Lian, Chenyang Jiang, Kevin B. Einkauf, Sikhulile Moyo, Terence Mohammed, Comfort Maphorisa, Joseph Makhema, Ce Gao, Xu Yu, Daniel Kuritzkes, Roger L. Shapiro, Mathias Lichterfeld

713 DIFFERENTIAL CLEARANCE OF INTACT AND DEFECTIVE HIV DNA IN THE PEDIATRIC RESERVOIR

Makayla Poindexter, Carolyn S. Fish, Noah Cassidy, Elizabeth R. Duke, Dalton C. Wamalwa, Agnes Langat, Daisy J. Chebet, Hellen Moraa, Jennifer Slyker, Sarah Benki-Nugent, Grace John-Stewart, Joshua Schiffer, Dara A. Lehman, **Daniel B. Reeves**

714 LOWER RESERVOIR CONTRIBUTION OF NAIVE VS MEMORY T CELLS IN PERINATAL HIV INFECTION

Adit Dhumakupt, Yuyang Huang, Joseph Szewczyk, Priya R. Khetan, Ya Chen, Hao Zhang, Bareng A. Nonyane, Thuy Anderson, Mareike Haaren, Vicki Tepper, Allison Agwu, Deborah Persaud

715 EARLY ANTIRETROVIRAL THERAPY IN NEONATES AND MATURATION OF THE GUT MICROBIOME

Louise Kuhn, Fan Li, Renate Strehlau, Nicole Tobin, Faezeh Patel, Stephanie Shiao, Shuang Wang, Elaine J. Abrams, Caroline T. Tiemessen, Grace M. Aldrovandi, for the LEOPARD Study Team

716 DNA METHYLATION SIGNATURES ASSOCIATED WITH HIV SUPPRESSION AFTER TREATMENT IN INFANTS

Stephanie Shiao, Ziyi Wang, Renate Strehlau, Ashraf Coovadia, Carmen Marsit, Shuang Wang, Michael T. Yin, Stephen M. Arpadi, Elaine J. Abrams, Louise Kuhn, for Neverest Study Team

717 THE SUBPHENOTYPES OF EARLY-TREATED CHILDREN LIVING WITH HIV-1



Sara Domínguez-Rodríguez, Alfredo Tagarro, Caroline Foster, Paolo Palma, Nicola Cotugno, Anita De Rossi, Annalisa Dalzini, Savita G. Pahwa, Eleni Nastouli, Kathleen Gärtner, Anne Genevieve Marcelin, Paolo Rossi, Carlo Giaquinto, Pablo Rojo, for the EPIICAL Consortium

718 IS ROUTINE PCP PROPHYLAXIS NEEDED IN VERY EARLY-TREATED INFANTS WITH HIV?

Bryan S. Nelson, Camlin Tierney, Deborah Persaud, Jennifer Jao, Mark F. Cotton, Yvonne Bryson, Kira Bacon, Diane Costello, Charlotte Perlowski, Maria Leticia Santos Cruz, Josphat Kosgei, Sai Majji, Dwight E. Yin, Ellen G. Chadwick, for the IMPAACT P1115 Team

Poster Session-Q06 ALL THINGS COVID-19 IN CHILDREN

2:00 PM MT - 3:30 PM MT

740 COVID-19 IN CHILDREN: WORSENING OUTCOMES DURING DELTA VARIANT WAVE



Christiana Smith-Anderson, Lori Silveira, Monika Jelic, Sean Lang, Shane Curran-Hays, Ye Ji Choi, JoEllen Fresia, Brian Carter, Shea Boyer, Lisa Abuogi

741 LONGITUDINAL STUDY OF ANTI-SPIKE ANTIBODIES IN CHILDREN AFTER SARS-CoV-2 INFECTION



Federica Frasca, Leonardo Sorrentino, Giuseppe Oliveto, Mirko Scordio, Matteo Fracella, Agnese Viscido, Fabio Midulla, Raffaella Nenna, Alessandra Febbo, Luigi Matera, Guido Antonelli, Carolina Scagnolari, Alessandra Pierangeli

742 HUMORAL AND CELLULAR RESPONSE TO mRNA SARS-CoV-2 VACCINATION IN HIV-INFECTED CHILDREN

Jose Tomas Ramos Amador, Arantxa Berzosa Sanchez, Marta Illan, Alba Ruedas, Kauzar M. Mohamed Mohamed, Luis Prieto, Sara Guillén, Ignacio Callejas, Ana Belén Jiménez, Santiago Jiménez de Ory, María Luisa Navarro, Silvia Sanchez-Ramon

743 BAMLANIVIMAB PLUS ETESEVIMAB FOR THE TREATMENT OF COVID-19 IN PEDIATRIC PATIENTS

Himanshu P. Upadhyaya, Jenny Chien, Martin Bohm, Lisa Macpherson, Dipak R. Patel, Matthew M. Hufford, **Mark Williams**

744 REMDESIVIR TREATMENT FOR COVID-19 IN HOSPITALIZED CHILDREN: CARAVAN INTERIM RESULTS

Amina Ahmed, Pablo Rojo, Allison Agwu, David Kimberlin, Jaime Deville, Ana Mendez-Echevarria, Paul Sue, Luisa Galli, Zongbo Shang, Kavita Juneja, Henry N. Hult, Charlotte Hedskog, Kathryn Kersey, William Muller, Flor Munoz

745 TREATMENTS FOR MIS-C IN CHILDREN: DISCHARGE, FEVER, AND SECOND-LINE THERAPIES

Alfredo Tagarro, Sara Domínguez-Rodríguez, Juan Miguel Mesa, Cristina Epalza, Carlos Grasa, María Isabel Iglesias-Bouzas, María Fernández-Pascual, Jesús Saavedra, Beatriz Soto, Jacques G. Rivière, Victoria Fumadó, Leticia Martínez-Campos, Álvaro Ballesteros, Cinta Moraleta, for the EPICO-AEP Working Group

Poster Session-R01 SARS-CoV-2 EPIDEMIOLOGY

2:00 PM MT - 3:30 PM MT

746 ASYMPTOMATIC SARS-CoV-2 INFECTION IS EXTREMELY COMMON AMONG PEOPLE WITH HIV

Isabelle R. Weir, **Edgar T. Overton**, Markella V. Zanni, Stephanie Fischinger, Kathleen Fitch, Judith A. Aberg, Carl J. Fichtenbaum, Gerald S. Bloomfield, Carlos Malvestutto, Sara McCallum, Pamela S. Douglas, Galit Alter, Heather J. Ribaud, Steven Grinspoon, for the REPRIEVE Trial Investigators

747 SARS-CoV-2 ANTIBODY CORRELATES AMONG PWID LIVING WITH AND WITHOUT HIV IN KENYA

Shradha J. Doshi, Hanley Kingston, Ashley Tseng, Bhavna Chohan, Betsy Sambai, Brandon Guthrie, Aliza Monroe-Wise, Loice Mbogo, Sarah Masyuko, William Sinkele, Paul Macharia, David Bukusi, Joshua Herbeck, Carey M. Farquhar

- 748 HIGHER COVID-19 POSITIVITY AND LOWER VACCINATIONS AMONG PEOPLE WHO USE DRUGS**
Javier A. Tamargo, Janet Diaz-Martinez, Ivan Delgado-Enciso, Mary J. Trepka, David R. Brown, Nana A. Garba, Eneida Roldan, Yolangel Hernandez, Aileen M. Marty, Adriana Campa, Haley R. Martin, Jose A. Bastida Rodriguez, Yongjun Huang, Marianna K. Baum, for the MASH Cohort
- 749 DAY-TO-DAY IMPACT OF COVID-19 ASSOCIATED WITH RISK OF OVERDOSE: C3PNO COHORT FINDINGS**
Soroush Moallem, Becky L. Genberg, Kanna Hayashi, Shruti H. Mehta, JinCheol Choi, Kora DeBeck, Michele Kipke, Richard Moore, Marianna K. Baum, Steve Shoptaw, Pamina M. Gorbach, Brian Mustanski, Marjan Javanbakht, Sue Siminski, M. J. Milloy
- 750 SEROPREVALENCE AND RISK FACTORS FOR SARS-CoV-2 AMONG INCARCERATED ADULT MEN IN QUEBEC**
Nadine Kronfli, Camille Dussault, Mathieu Maheu-Giroux, Alexandros Halavrezos, Sylvie Chalifoux, Jessica P. Sherman, Hyejin Park, Lina Del Balso, Matthew P. Cheng, Sebastien Poulin, Joseph Cox
- 751 RACIAL/ETHNIC AND NEIGHBORHOOD SOCIAL VULNERABILITY DISPARITIES IN COVID-19**
 Usama Bilal, **Florence Momplaisir**, Alina Schnake-Mahl, Kathleen Murphy, John Jemmott
- 752 ASSOCIATION BETWEEN THE NEIGHBORHOOD BUILT ENVIRONMENT AND COVID-19 HOSPITALIZATION**
Sarah E. Rowan, Alessandro Rigolon, Jeremy Nemeth, Cory Hussain, Brian Montague, Brenn Anderson-Gregson, Priyanka deSouza, Kristine Erlandson
- 753 A NATIONAL SEROPREVALENCE SURVEY OF SARS-CoV-2 ANTIBODIES IN SOUTH AFRICA: 2020-2021**
Leickness C. Simbayi, Sizulu Moyo, Adrian Puren, Penny Moore, Samuel Manda, Nompumelelo Zungu, Khangelani Zuma, Edmore Marinda, Sean Jooste, Tarylee Reddy, Lynn Morris, Ameena Goga, Musawenkosi Mabaso, Whadi-ah Parker, Inbarani Naidoo, for the NCAS Study Group
- 754 LOCAL-SCALE SPATIAL VARIABILITY IN SARS-CoV-2 SEROPREVALENCE IN AN INDIAN MEGACITY**
Eshan U. Patel, Rifa Khan, Matt Hitchings, Aylur K. Srikrishnan, Mark Anderson, K. S. Kumar, Amy Wesolowski, Syed H. Iqbal, Mary A. Rodgers, Shruti H. Mehta, Gavin Cloherty, Derek A. Cummings, Sunil S. Solomon
- 755 PHYLODYNAMIC OF SARS-CoV-2 TRANSMISSION IN FRANCE: 2020**
 Romain Coppée, François Blanquart, Aude Jary, Valentin Leducq, Anna-Maria Franco-Yusti, Léna Daniel, Charlotte Charpentier, Karen Zafilaza, Vincent Calvez, Diane Descamps, Anne Genevieve Marcelin, **Benoît Visseaux**, Antoine Bridier-Nahmias
- 756 MAIN SARS-CoV-2 CIRCULATING VARIANTS IN SPAIN DURING THE FIRST YEAR OF THE PANDEMIC**
Paloma Troyano-Hernández, Roberto Reinoso, África Holguín
- 757 MOLECULAR EPIDEMIOLOGY OF THE COVID-19 PANDEMIC IN CHICAGO**
Ted Ling Hu, Lacy M. Simons, Egon A. Ozer, Ramon Lorenzo-Redondo, Judd F. Hultquist
- 758 CHARACTERISTICS AND OUTCOMES CHANGES IN COVID-19 INPATIENTS: A COMPARISON OF 4 WAVES**
Martin Martinot, Magali Eyriey, Simon Gravier, Ciprian Ion, Mahsa Mohseni-Zadeh, Estelle Rougier, Jean-Claude Ongagna, Anaïs Henric, Anne Schieber, Christian Kempf

759 EFFICACY OF NATURAL IMMUNITY AGAINST REINFECTION WITH SARS-CoV-2 B.1.351 VARIANT

Laith J. Abu-Raddad, Hiam Chemaitelly, for the National Study Group for COVID-19 Epidemiology in Qatar

760 CLINICAL OUTCOME IN PEOPLE WITH COVID-19 BY HIV-STATUS: A NATIONWIDE REGISTER STUDY

Isabela Möller, Magnus Gisslen, Philippe Wagner, Pär Sparén, Anders Sönnernborg, Christina Carlander

Poster Session-R05 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION
2:00 PM MT - 3:30 PM MT
787 EMPIRICAL ESTIMATES OF ADULT HIV INCIDENCE ACROSS 12 COUNTRIES IN SUB-SAHARAN AFRICA

Nora E. Rosenberg, Bonnie Shook-Sa, Mincen Liu, Lynda Stranix-Chibanda, Marcel Yotebieng, Nadia Sam-Agudu, Sam J. Phiri, Willbroad Mutale, Linda-Gail Bekker, Manhattan E. Charurat, Jessica E. Justman, Benjamin Chi

788 EDUCATION AND HIV RISK: EVIDENCE FROM 12 SUB-SAHARAN AFRICAN COUNTRIES, 2015-2018

Elizabeth Gummerson, Daniela Quigee, Delivette Castor, Andrea Low

789 HEAVY RAINFALL IS ASSOCIATED WITH HIGHER HIV PREVALENCE ACROSS SUB-SAHARAN AFRICA

Karly Hampshire, Jason Nagata, Adrienne Epstein, Edwin D. Charlebois, Alexander C. Tsai, Denis Nash, Sheri D. Weiser

790 HIV RISK BEHAVIORS AMONG BLACK AND HISPANIC TRANSGENDER WOMEN IN THE UNITED STATES

Xinyi Li, Evelyn J. Olansky, Kathryn Lee, Janet Burnett, for the NHBS-Trans Study Group

791 GENDER IDENTITY, STIGMA, AND SEXUALLY TRANSMITTED INFECTIONS IN NIGERIA

Elyse LeeVan, Fengming Hu, Andrew Mitchell, Afoke Kokogho, Sylvia Adebajo, Haoyu Qian, Julie Ake, Merlin Robb, Manhattan E. Charurat, Stefan Baral, Rebecca G. Nowak, Trevor A. Crowell, for the TRUST/RV368 Study Group

792 PREVALENCE OF UNTREATED HIV AND HIV INCIDENCE AMONG OCCUPATIONAL GROUPS IN UGANDA

Victor O. Popoola, Joseph Kagaayi, Joseph Ssekasanvu, Robert Ssekubugu, Anthony Ndyababo, Fred Nalugoda, Larry W. Chang, Godfrey Kigozi, Justin Lessler, Maria Wawer, Donna Kabatesi, Lisa Mills, Steven J. Reynolds, David Serwadda, M. Kate Grabowski

793 MEDIATORS OF HIV/STI IN NON-US-BORN VS US-BORN HETEROSEXUAL ADULTS IN 22 US CITIES

Laura Platt, Fatma M. Shebl, Katherine K. Hsu, Kevin L. Ard, Catlainn Sioneau, Johanna Chapin-Bardales, Bridget A. Bunda, Ingrid V. Bassett, Monina Klevens

794 SOURCES OF HIV TRANSMISSION IN THE ERA OF UNIVERSAL TEST AND TREAT: A MODELING STUDY

Adam Akullian, Joshua Herbeck, Anna Bershteyn

795 HIV INCIDENCE AND IMPACT OF INTERVENTIONS IN FEMALE SEX WORKERS IN MENA

Hiam Chemaitelly, Houssein H. Ayoub, Ryosuke Omori, Shereen El Feki, Joumana G. Hermez, Helen A. Weiss, Laith J. Abu-Raddad

796 ASSOCIATION THE HIV STATUS OF HOUSEHOLD HEAD AND THEIR YOUTHS IN 10 AFRICAN COUNTRIES

Matthew A. Weisberg, Mansoor Farahani, Rachel Bray, Jessica E. Justman, Wafaa M. El-Sadr

Poster Session-T03 HIV DIAGNOSTICS**2:00 PM MT - 3:30 PM MT****814 3-IN-1 RAPID BLOOD SELF-TESTING FOR HIV, HBV, AND HCV: ACCEPTABILITY AND FEASIBILITY**

Nicolas Salvadori, Jullapong Achalapong, Chonlatorn Boontan, Surachet Arunothong, Wootichai Khamduang, Phornphimon Moolnoi, Sakorn Pornprasert, Sumet Ongwandee, Jean Yves Mary, Gonzague Jourdain, Nicole Ngo-Giang-Huong, for the Napneung Project Team

815 INCREASE IN FALSE POSITIVE 4TH GENERATION HIV TESTS IN PATIENTS WITH COVID-19 DISEASE

Anita Shallal, **Smitha Gudipati**, Edward Peterson, Bernard Cook, Robert Tibbetts, Norman Markowitz

816 NEW MOLECULAR ASSAY BASED ON NANOTECHNOLOGY FOR THE EARLY DETECTION OF HIV-1 p24

Ana Rodríguez Galet, Sergio García López, Priscila Kosaka, África Holguín

817 INTERPRETATION OF HIV SELF-TEST RESULTS AMONG PrEP USERS IN KENYA

Peter A. Mogere, Ashley Bardon, Dorothy Mangale, Catherine Kiptinness, Richard Magara, Snaidah Ongachi, Sarah Mbaire, Stephen Gakuo, Nelly R. Mugo, Jared Baeten, Katrina Ortblad, Kenneth Ngunjiri

Poster Session-V02 PrEP IN ADOLESCENTS AND PREGNANT PEOPLE**2:00 PM MT - 3:30 PM MT****842 A TOOL TO ASSESS HIV PREVENTION READINESS OF ADOLESCENT GIRLS AND YOUNG WOMEN**

Geetha Beauchamp, Sybil Hosek, Deborah Donnell, Gary Chan, Bonnie Dye, Brian Flaherty, Peter Anderson, Nyaradzo M. Mgodi, Linda-Gail Bekker, Sinead Delany-Moretlwe, Connie L. Celum

843 PrEP DISCONTINUATION AMONG ADOLESCENTS PrEP USERS IN BRAZIL

Diana R. Zeballos Rivas, Fabiane Soares, Laio Magno, Marcos Eustorgio, Leila Amorim, Dirceu Greco, Alexandre Grangeiro, Ines Dourado, for the PrEP1519 Brazil Study Group

844 ECOLOGICAL MOMENTARY ASSESSMENT TO EXPLORE THE POTENTIAL OF ON-DEMAND PrEP FOR YMSM

Lisa Hightow-Weidman, Zachary Soberano, Bryce Stamp, Kimberly Powers, **Sybil Hosek**, Jacob Stocks, Matthew Rosso, Alyssa Vecchio, Keith J. Horvath

845 PrEP USE PERSISTENCE AMONG KENYAN WOMEN WHO INITIATED PrEP DURING PREGNANCY

Jillian Pintye, John Kinuthia, **Anna Larsen**, Felix Abuna, Ben Ochieng, Nancy Ngumbau, Julia Dettinger, Laurén Gomez, Jessica E. Haber, Grace John-Stewart, Jared Baeten

846 ORAL PrEP USE AMONG SOUTH AFRICAN WOMEN WITH PLANS FOR PREGNANCY

Lynn T. Matthews, Manjeetha Jaggernath, Yolandie Kriel, Christina Psaros, Patricia M. Smith, Kara Bennett, David R. Bangsberg, Craig W. Hendrix, Norma Ware, Jared Baeten, Kathleen E. Hurwitz, Jessica E. Haber, Jennifer Smit

847 GEOGRAPHIC CLUSTERING AND PROGRESS IN PrEP USE AMONG WOMEN IN THE US: 2012-2019

Brady W. Bennett, Sanjana Pampati, Marisol Valenzuela-Lara, Patrick S. Sullivan, Jodie L. Guest

Poster Session-V03 HIV PREVENTION: NALTREXONE, PEP, AND PrEP FOR TRANSGENDER PEOPLE
2:00 PM MT - 3:30 PM MT
848 EXTENDED-RELEASE NALTREXONE LOWERS INJECTION USE IN JUSTICE-INVOLVED PERSONS WITH HIV

Audun J. Lier, Nikhil Seval, Brent Vander Wyk, Angela Di Paola, Sandra Springer

849 SELF-START HOME PEPSE TO REDUCE UPTAKE TIME AND INCREASE PEPSE EFFICACY: RCT

Julie Fox, Julianne Lwanga, Achyuta Nori, Amanda Clarke, Ming J. Lee, Orla McQuillan, Lesedi M. Ledwaba-Chapman, Suna Mantori, Cassie Fairhead, Fiona Ryan, Yanzhong M. Wang, Anatole Menon Johansson, for HOME PEPSE

850 IMPLEMENTATION OF A POST-EXPOSURE PROPHYLAXIS HOTLINE IN WASHINGTON, DC

Megan Coleman, Jason Beverley, Annika Bergstrom, Kate Drezner, Rachel Harold, Michael Kharfen, Amanda B. Spence, Camilla Stanley, Ashlee Wimberly, Adam Visconti

851 RCT OF ITAB PLUS MOTIVATIONAL INTERVIEWING FOR PrEP ADHERENCE IN TRANSGENDER PERSONS

Sheldon Morris, Sonia Jain, Jill Blumenthal, Robert Bolan, Michael Dubé, Philip Henderson, Katya Corado, Feng He, Leah Burke, Peter Anderson, David J. Moore

852 HIV TESTING AND PrEP AMONG US TRANSGENDER WOMEN AND MEN: 2012-2019

Karen W. Hoover, Ya-Lin A. Huang, Weiming Zhu, Anne A. Kimball, Evelyn J. Olansky, Asa Radix

853 PrEP NEED AND SERVICES FOR TRANSGENDER PERSONS IN THE THRIVE PROJECT: 2015-2020

Maria Zlotorzynska, **Weiming Zhu**, Ya-Lin A. Huang, Kashif Iqbal, Mary Tanner, Karen W. Hoover

Poster Session-X03 THE PLOT THICKENS: SEXUAL AND REPRODUCTIVE HEALTH ISSUES IN PEOPLE WITH HIV
2:00 PM MT - 3:30 PM MT
881 HIGH LEVEL OF HIV VIRAL SUPPRESSION IN UGANDAN MEN WITH URETHRITIS AND BACTERIAL STI

Evan Beck, Oliver Laeyendecker, Sharada Saraf, Annet Onzia, Johan H. Melendez, Peter Kyambadde, Tza-Huei Wang, Ethan Gough, Yukari C. Manabe, **Matthew M. Hamill**

882 HIV, ASYMPTOMATIC STI, AND THE RECTAL MUCOSAL IMMUNE ENVIRONMENT AMONG YOUNG MSM



Vanessa E. Van Doren, S A. Smith, Yi-Juan Hu, Gregory Tharp, Steven Bosinger, Cassie G. Ackerley, Phillip M. Murray, Rama R. Amara, Praveen K. Amancha, Robert A. Arthur, Henry R. Johnston, Colleen F. Kelley

883 SYPHILIS REINFECTIONS AMONG HIV+ AND HIV- PATIENTS: A RETROSPECTIVE STUDY



Giorgio Tiecco, Valentina Marchese, Samuele Storti, Melania Degli Antoni, Silvia Amadasi, Maurizio Gulletta, Francesca Viola, Emanuele Focà, Francesco Castelli, Maria Eugenia Quiros-Roldan

884 DOUBLE-DOSE ETONOGESTREL CONTRACEPTIVE IMPLANT OVERCOMES INTERACTION WITH EFAVIRENZ

Catherine A. Chappell, Mohammed Lamorde, Shadia Nakalema, Isabella Kyohairwe, Pauline Byakika-Kibwika, Leslie A. Meyn, Michelle Pham, Kimberly K. Scarsi

885 DISPARITIES IN PRENATAL SYPHILIS RISK AMONG PREGNANT WOMEN LIVING WITH HIV IN BRAZIL

Jessica L. Castilho, Fernanda F. Fonseca, Ahra Kim, Emilia M. Jalil, Andrea M. Beber, Valdilea Veloso, Carmen S. Domingues, Catherine McGowan, Angelica E. Miranda, Beatriz Grinsztejn, Adele S. Benzaken, Bryan Shepherd, Gerson Fernando M. Pereira, for the National Cohort Study of Dolutegravir and Pregnancy Outcomes in Brazil

886 SCREENING OF STIs IN PREGNANCY AND PREGNANCY OUTCOMES IN WOMEN WITH AND WITHOUT HIV



Dorothy C. Nyemba, Remco P. Peters, Andrew Medina-Marino, Jeffrey D. Klausner, Phuti Ngwepe, Landon Myer, Leigh Johnson, Dvora Joseph Davey

Poster Session-Y04 SUBSTANCE USE

2:00 PM MT - 3:30 PM MT

912 MAINTAINED ACCESS TO PREVENTION & CARE FOR PWID DESPITE COVID-19 IN HAIPHONG, VIETNAM

Delphine Rapoud, Duc Q. Nguyen, Trang T. Nguyen, Huong T. Duong, Oanh T. Khuat, Nicolas Nagot, Don C. Des Jarlais, Khue M. Pham, Vinh H. Vu, Didier Laureillard, Mai S. Le, Laurent Michel, Jean-Pierre Molès, Thanh T. Nham, Giang T. Hoang

913 SUBSTANCE USE AND HIV OUTCOMES AMONG PRISON RELEASEES IN ZAMBIA: A COHORT STUDY

Michael E. Herce, Helene J. Smith, Vivien Mai, Chilambwe Mwila, Mirriam Nanyangwe, Lillian Kashela, Tina Kayumba, Yotam Lungu, Clement Moonga, Sisa Hatwiinda, Stewart E. Reid, Monde Muyoyeta

914 SUBSTANCE USE TREATMENT UTILIZATION AMONG WOMEN WITH AND AT RISK FOR HIV IN THE SOUTH



Aditi Ramakrishnan, Wendy A. Fujita, Cyra C. Mehta, Tracey Wilson, Steve Shoptaw, Adam W. Carrico, Adaora Adimora, Ellen F. Eaton, Mardge Cohen, Jennifer Cohen, Adebola Adedimeji, Michael Plankey, Deborah Jones Weiss, Aruna Chandran, Anandi N. Sheth

Poster Session-Y05 HIV PREVENTION

2:00 PM MT - 3:30 PM MT

- 915** **RANDOMIZED TRIAL OF PATIENT ACTOR TRAINING TO IMPROVE PrEP SERVICES FOR AGYW IN KENYA**
 **Pamela Kohler**, John Kinuthia, Anna Larsen, Felix Abuna, George Owiti, Joseph Sila, Tamara Owens, Valerie Kemunto, Harrison Lagat, Melissa Vera, Barbra A. Richardson, Jillian Pintye, Grace John-Stewart
- 916** **PROJECTED IMPACT OF EXPANDED LONG-ACTING INJECTABLE PrEP USE ON LOCAL HIV EPIDEMICS**
Ruchita Balasubramanian, Parastu Kasaie, Melissa Schnure, David Dowdy, Maunank Shah, Anthony T. Fojo
- 917** **GET2PrEP3: RCT OF PROVIDER MESSAGING TO IMPROVE LINKAGE TO HIV PREVENTION SERVICES**
Jason Zucker, Deborah A. Theodore, Caroline Carnevale, Eshiemomoh Osilama, Norman Archer, Lily Bonadonna, Elena Wadden, Nicholas Morley, Simian Huang, Kathrine Meyers, Alwyn Cohall, Peter Gordon, Delivette Castor, Magdalena E. Sobieszczyk
- 918** **PrEP RATHER THAN COVID-19 INFLUENCED SEXUAL ACTIVITY AMONG MSM IN TOKYO**
Daisuke Mizushima, Misao Takano, Yasuaki Yanagawa, Takahiro Aoki, Koji Watanabe, Shinichi Oka
- 919** **SEXUAL HEALTHCARE USE, PrEP USE, AND THE INCIDENCE OF STI AMONG MSM DURING COVID-19**
 Feline De IL Court, Anders Boyd, Liza Coyer, Mark van den Elshout, Henry J. de Vries, Amy Matser, Elske Hoornenborg, Maria Prins
- 920** **ACCEPTABILITY AND ELIGIBILITY FOR PrEP AMONG MEDICAL MALE CIRCUMCISION CLIENTS**
Tendesayi Kufa-Chakezha, Ocean Tobaiwa, Sean M. Patrick, Khumbulani Moyo, Phil Dorrell, Nichola Lutchman, Erushka Pillay, Adrian Puren
- 921** **HEALTH OF LONG-TERM PrEP USERS IN AUSTRALIA: FINDINGS FROM THE X-PLORE COHORT**
Vincent J. Cornelisse, Dean Murphy, Michael Traeger, Mark Stooove, Brian Price, Edwina J. Wright, for the X-PLORE Study Team
- 922** **DEFERRING CREATININE CLEARANCE TESTING TO SUPPORT PrEP UPTAKE IN YOUNG WOMEN**
 **Craig J. Heck**, Lara Lewis, Natasha Samsunder, Quarraisha Abdool Karim
- 923** **A COMPARISON OF SELF-REPORTED PrEP ADHERENCE AND OBJECTIVE MEASURES IN KENYA**
 **Ashley Bardon**, Kenneth Ngunjiri, Peter A. Mogere, Dorothy Mangale, David Chege, Catherine Kiptinness, Stephen Gakuo, Sarah Mbaire, Peter Anderson, Nelly R. Mugo, Jared Baeten, Katrina Ortblad
- 924** **PrEP ROLLOUT AND COVID-19 ARE IMPACTING COMMUNITY-BASED TESTING FOR HIV & OTHER STIs**
Christoph Boesecke, Torben Kimhofer, Christopher Tocha, Oliver Schubert, Rainer Rybak, Klaus Kuhlen, Christoph Klaes, Jürgen K. Rockstroh
- 925** **PrEP DISCONTINUATION AMONG WOMEN IN US COMMUNITY HEALTH CENTERS**
Whitney Irie, Jonathan Todd, Kenneth H. Mayer, Elvin H. Geng, Douglas Krakower, Julia Marcus

- 926 USING SAFE SPACE MODEL TO SCALE UP HIV PREVENTION IN ADOLESCENT GIRLS AND YOUNG WOMEN**
Andrew W. Wafula, Philip Masaulo, Jane Thiomi, Benard Ogony, Peris M. Nasimiyu, Paul Musingila, Carol Kambona
- 927 HIGH PrEP UPTAKE AND LOW HIV VIREMIA WHEN PrEP IS INTEGRATED INTO UGANDAN ART CLINICS**
Renee Heffron, Timothy Muwonge, Dorothy Thomas, Florence Nambi, Lylian Nakabugo, Joseph Kibuuka, Erika L. Feutz, Allison A. Meisner, Katherine K. Thomas, Norma Ware, Jane A. Simoni, Ingrid T. Katz, Herbert Kadama, Andrew Mujugira, for the Partners PrEP Program Team
- 928 PHARMACY-BASED PrEP INITIATION AND CONTINUATION IN KENYA: FINDINGS FROM A PILOT STUDY**
Katrina Ortblad, Peter A. Mogere, Victor Omollo, Alexandra Kuo, Magdaline Asewe, Stephen Gakuo, Hilma N. Nakambale, Melissa Mugambi, Andy Stergachis, Josephine Odoyo, Elizabeth A. Bukusi, Kenneth Ngunjiri, Jared Baeten
- 929 COST-EFFECTIVENESS OF A COLLABORATIVE DATA-TO-CARE INTERVENTION FOR HIV PREVENTION**
Ram Shrestha, Robyn Fanfair, Liisa Randall, Crystal Lucas, Lisa Nichols, Nasima Camp, Kathleen Brady, Heidi Jenkins, Frederick Altice, Alfred DeMaria, Mercedes Villanueva, Paul Weidle

Poster Session-Y06 MENTAL HEALTH AND STIGMA

2:00 PM MT - 3:30 PM MT

- 930 COGNITIVE BEHAVIORAL THERAPY FOR HIV & DEPRESSION: COST-EFFECTIVENESS IN SOUTH AFRICA**
Aditya R. Gandhi, Emily P. Hyle, Justine Scott, Jasper S. Lee, Fatma M. Shebl, John Joska, Lena S. Andersen, Conall O'Leirigh, Steven A. Safren, Kenneth Freedberg
- 931 AGRICULTURAL LIVELIHOOD INTERVENTION REDUCES HIV STIGMA: RESULTS FROM A CLUSTER RCT**
Sheri D. Weiser, Edward A. Frongillo, Adrienne R. Mocello, Elly Weke, Lila A. Sheira, Rachel L. Burger, Pauline Wekesa, Harsha Thirumurthy, Shari Dworkin, Lisa Butler, Alexander C. Tsai, Elizabeth A. Bukusi, Craig R. Cohen
- 932 PSYCHOSOCIAL FACTORS INTERACT WITH RACE DURING COUNTYWIDE PERSONALIZED HIV CARE**
Michael J. Li, Brendon Chau, Wendy Garland, Sona Oksuzyan, Robert E. Weiss, Sae Takada, Uyen Kao, Sung-Jae Lee, Steve Shoptaw
- 933 MENTAL HEALTH AND PrEP ADHERENCE AMONG MSM/NON-CISGENDER PEOPLE FROM LATIN AMERICA**
Hamid Vega-Ramirez, Centli Guillén-Díaz-Barriga, Dulce Diaz, Kelika A. Konda, Thiago S. Torres, Oliver A. Elorreaga, Brenda Hoagland, Juan V. Guanira, Marcos R. Benedetti, Sergio Bautista-Arredondo, Beatriz Grinsztejn, Carlos F. Caceres, Valdilea Veloso, for the ImPrEP Study Group
- 934 EFFECTS OF THE COVID-19 LOCKDOWN ON MENTAL HEALTH CARE USE IN PEOPLE LIVING WITH HIV**
Anja E. Wettstein, Mpho Tlali, John Joska, Morna Cornell, Veronika W. Skrivankova, Soraya Seedat, Hannes Mouton, Leigh Van den Heuvel, Nicky Maxwell, Mary-Ann Davies, Gary Maartens, Matthias Egger, Andreas D. Haas

WEDNESDAY, FEBRUARY 16, 2022

Poster Session-A03 VIRUS REPLICATION AND HOST FACTORS
2:00 PM MT - 3:30 PM MT
176 WITHDRAWN**177 SPECIFIC DETECTION AND REPLICATION KINETICS OF SARS-CoV-2 USING smRNA-FISH**

Rajiv Pathak, Carolina Eliscovich, Updesh Dixit, Nacho Mena, Adolfo Garcia-Sastre, James M. Pullman, Robert H. Singer, Ganjam V. Kalpana

178 QUANTIFYING SARS-CoV-2 INFECTION KINETICS FROM UNVACCINATED AND VACCINATED PERSONS

Ruian Ke, Pamela Martinez, Rebecca L. Smith, Christopher B. Brooke

179 MUTATIONS IN PERSISTENT SARS-CoV-2 CASES

Lacy M. Simons, Judd F. Hultquist, Ramon Lorenzo-Redondo, Egon A. Ozer, Michael G. Ison, Chad J. Achenbach

180 ORF1 REGION OF SARS-CoV-2 GENOMIC RNA AS A PROMISING TARGET FOR siRNA-BASED THERAPY

Shubhankar Ambike, Cho-Chin Cheng, Martin Feuerherd, Domizia Baldassi, Stoyan Velkov, Gerald Burgstaller, Olivia M. Merkel, Thomas Michler

181 ROLE OF ACTIN REGULATORS IN HIV-1, IAV, & SARS-CoV-2 VIRUS-LIKE PARTICLES PRODUCTION

Manon Gourdelier, Peggy Merida, Jitendriya Swain, Delphine Muriaux

182 REDUCING HIV-1 HXB2 env GENE CpG FREQUENCY INCREASES VIRUS REPLICATION CAPACITY

Ana Jordan-Paiz, Sandra Franco, **Miguel A. Martinez**

183 UNRAVELING THE ANTIVIRAL ACTIVITY OF PLITIDEPSIN BY ULTRASTRUCTURAL ANALYSIS

Martin Sachse, Raquel Tenorio, Isabel Fernández de Castro, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Alejandro Losada, Pablo Avilés, Carmen Cuevas, Roger Paredes, Joaquim Segalés, Bonaventura Clotet, Júlia Vergara-Alert, **Nuria Izquierdo-Useros**, Cristina Risco, for the SARS-CoV-2 Study Team

184 REPURPOSING SINGLE-CELL RNA SEQ DATA TO QUANTIFY HIV SPLICING DURING LATENCY REVERSAL

Ann L. Emery, Jackson Peterson, Edward P. Browne, Ronald Swanstrom

185 HYDROGEN SULFIDE BLOCKS HIV REBOUND BY MAINTAINING CELLULAR REDOX HOMEOSTASIS

Virender K. Pal, Ragini Agrawal, Amit Singh

186 DEFECTIVE RNA-DIRECTED STRAND DISPLACEMENT DUE TO HIV-1 RIBONUCLEASE H INACTIVATION

Samara Martín Alonso, Dongwei Kang, Javier Martínez del Río, Joanna Luczkowiak, Çağıl Urhan, Estrella Frutos Beltrán, Xinyong Liu, Peng Zhan, Luis Menéndez Arias

187 INTERACTOME OF HIV PROTEINS AND THEIR HOST RNA INTERACTION PARTNERS

Tinus Schynkel, W. J. Van Snippenberg, Kimberly Verniers, Eric J. de Bony de Lavergne, Gwendolyn M. Jang, Nevan J. Krogan, Pieter Mestdag, Linos Vandekerckhove, Wim Trypsteen

Poster Session-B06 OUTCOMES OF HIV INFECTION

2:00 PM MT - 3:30 PM MT

220 EXTENSIVE TRANSCRIPTIONAL PERTURBATIONS IN THE COLON VERSUS BLOOD DURING CHRONIC HIV

Stephanie Dillon, Kejun Guo, Emily Cooper, Cheyret Wood, Katerina Kechris, Mario L. Santiago, Cara Wilson

221 GUT BARRIER INTEGRITY AND MICROBIOTA IN HIV PATIENTS RECEIVING ORAL BACTERIOTHERAPY



Letizia Santinelli, Giacomo Rossi, Giorgia Gioacchini, Ranieri Verin, Giuseppe P. Innocenti, Federica Frasca, Mirko Scordio, Francesca Lombardi, Alessandra Piccirilli, Stefano Fiorucci, Adriana Carino, Carolina Scagnolari, Giancarlo Ceccarelli, Claudio M. Mastroianni, Gabriella D'Ettorre

222 TNF- α AND IFN- γ -PRODUCING CD4+ T CELLS MODULATE GUT REGENERATION IN HIV-1 INFECTION



Ana Jordan-Paiz, Martin E. Baumdick, Johannes Jung, Pia Fittje, Marcus Altfeld, Madeleine Bunders

223 HIV-INDUCED CELLULAR SENESENCE IN PLWH IS DECREASED EX VIVO BY D+Q SENOLYTIC DRUGS



Nuria Climent, Víctor Casanova, Maria Jose Maleno, Andrea Rodríguez-Agustín, Sonsoles Sánchez-Palomino, Tània González, Carmen Hurtado, Esteban Martinez, Josep Mallolas, Juan Ambrosioni, Jose M. Miro, José Alcamí

224 REDUCED Nef BUT NOT Vpu FUNCTION IN AFRICAN LONG-TERM HIV SURVIVORS VS PROGRESSORS



Gisele Umvilighozo, Hua-Shiuan Hsieh, Jacklyn K. Mann, Steven W. Jin, Francis Mwimanzu, Hanwei Sudderuddin, Zabrina L. Brumme, Mark A. Brockman

225 IL-18 AND IL-3 IN EXTRACELLULAR VESICLES: BIOMARKERS FOR A DURABLE ELITE CONTROL

Eva Poveda, Wendy Fitzgerald, Cristina Reglero, Manuel Crespo, Ana Mariño, Hortensia Álvarez, Nieves Valcarce, Ezequiel Ruiz-Mateos, Leonid Margolis, Michael M. Lederman, Michael L. Freeman, for the ECRIS Integrated in the Spanish AIDS Research Network

226 SURVIVAL AND DISEASE PROGRESSION IN ART-NAIVE LTNP WITH UNDETECTABLE HIV REPLICATION



Francisco Diez-Fuertes, Ruben A. Ayala-Suarez, Humberto Erick De La Torre-Tarazona, José Alcamí, **Laura Capa**

Poster Session-B07 HIV INFECTION AND INFLAMMATION

2:00 PM MT - 3:30 PM MT

227 METABOLIC SHIFTS POTENTIATE ACCELERATED AGING IN SUCCESSFUL LONG-TERM HIV TREATMENT

Flora Mikaeloff, Sara Svensson Akusjärvi, George M. Ikomey, Soham Gupta, Alejandra Escós, Luke E. Hanna, Kamal Singh, Rui Benfeitas, **Ujjwal Neogi**

228 HIGH-THROUGHPUT TARGETED PLASMA PROTEOMICS SHOWS SYSTEMIC DYSREGULATION IN PWH ON ART

Nadira Vadaq, Vasiliki Matzaraki, Yue Zhang, Quirijn De Mast, Leo A. Joosten, Mihai Netea, Jingyuan Fu, Andre van der Ven

229 TARGETED INFLAMMATORY PLASMA PROTEOMICS SHOWS UPREGULATION OF DISTINCT PATHWAYS

Nadira Vadaq, Vasiliki Matzaraki, Lisa Van de Wijer, Louise van Eekeren, Leo A. Joosten, Mihai Netea, Quirijn De Mast, Andre van der Ven

230 UPREGULATION OF INTERFERON-STIMULATED GENES PERSISTS DURING TREATED HIV-1 INFECTION

Yunqi Li, Cheryl M. Cameron, Banumathi Tamilselvan, Manonmani Kumar, Brian Richardson, Jared Baeten, Andrew Mujugira, Nelly R. Mugo, Connie L. Celum, Jairam R. Lingappa, Florian Hladik, Mark J. Cameron, Romel D. Mackelprang

231 INFLAMMATION AND IMMUNE ACTIVATION NOT DRIVEN BY ON-ART HIV-SPECIFIC IMMUNE RESPONSES

Adam R. Ward, Allison S. Thomas, Eva Stevenson, Szu-Han Huang, Sheila M. Keating, Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Bernard J. Macatangay, Joshua Cyktor, Joseph J. Eron, John W. Mellors, R Brad Jones, for the AIDS Clinical Trials Group A5321 Team

232 RECTAL TISSUE HIV RNA IS ASSOCIATED WITH SYSTEMIC INFLAMMATION IN PERSONS WITH HIV

Cecile D. Lahiri, Kehmia Titanji, Monica D. Reece, Ruby K. Taylor, Renata M. Shaw, Shelby Collins, Cyra C. Mehta, Jessica Ingersoll, Igbo Ofotokun, Susan Pereira Ribeiro, Rafick-Pierre Sékaly, Christina Gavegnano

233 LONGITUDINAL ASSOCIATION OF SYSTEMIC INFLAMMATION WITH FRAILTY IN HIV-INFECTED MEN

Weiyang Zhang, Jay H. Bream, Sean Leng, Tricia Nilles, Huifen Li, Joseph B. Margolick

234 ASSOCIATION OF PLASMA BIOMARKERS WITH EARLY MORTALITY IN ADVANCED HIV INFECTION

Victor Riitho, Roisin Connon, Agnes Gwela, Josephine Namusanje, Ruth Nhema, Abraham Siika, James Hakim, Victor Musiime, James A. Berkley, Alexander Szubert, Nigel Klein, A S. Walker, Diana Gibb, Andrew J. Prendergast, for the REALITY Trial Team

Poster Session-D04 SARS-CoV-2 IMMUNOLOGY: B CELLS AND ANTIBODIES**2:00 PM MT - 3:30 PM MT****271 LOSS OF TOLERANCE AND ANERGY IN HUMAN PERIPHERAL B CELLS DURING SARS-CoV-2 INFECTION**

Moriah J. Castleman, Megan Stumpf, Nicholas Therrien, Brenda Martinez, Roberta Pelanda, Raul Torres

272 STRAIN-SPECIFIC SEROLOGICAL RESPONSE FOLLOWING SARS-CoV-2 VOC INFECTION

Karljin van der Straten, Denise Guerra, Meliawati Poniman, Dirk Eggink, Marloes Grobбен, Chantal Reusken, Hugo D. van Willigen, Elke Wynberg, Menno D. de Jong, Maria Prins, Tim Beaumont, Godelieve De Bree, Rogier W. Sanders, Marit J. van Gils

273 SARS-CoV-2 NEUTRALIZING RESPONSE BEYOND 1 YEAR AFTER INFECTION

Benjamin Trinité, Edwards Pradenas, Victor Urrea, Silvia Marfil, Ferran Tarrés-Freixas, Raquel Ortiz, Carla Roviroso, Jorge Carrillo, Roger Paredes, Anna Chamorro, Ruth Toledo, Marta Massanella, Bonaventura Clotet, Julià Blanco

274 ESTABLISHMENT OF AN ANTI-RBD THRESHOLD THAT PREDICTS ROBUST NEUTRALIZING ACTIVITY

Grace Kenny, Sophie O'Reilly, Riya Negi, Alejandro A. Garcia, Obada Yousif, John S. Lambert, Aoife G. Cotter, Eoghan De Barra, Eoin Feeney, Peter Doran, Virginie W. Gautier, Patrick Mallon

275 HIGHER CORONAVIRUS ANTIBODY RESPONSES PREPANDEMIC IN AFRICA THAN IN THAILAND

Yifan Li, Mélanie Merbah, Bradley Beckman, Thembi Mdluli, Heather Liu, Nittaya Phanuphak, Jonah Maswai, John Owuoth, Hannah Kibuuka, Michael Iroezindu, Emmanuel Bahemana, Sandhya Vasan, Julie Ake, Kayvon Modjarrad, Morgane Rolland

276 PERSISTENCE OF SARS-CoV-2 ANTIBODIES IN CHILDREN AND ADULTS 1 YEAR AFTER INFECTION

Costanza Di Chiara, Anna Cantarutti, Paola Costenaro, Chiara Cosma, Bonfante Francesco, Sandra Cozzani, Maria Raffaella Petrara, Francesco Carmona, Cecilia Liberati, Paolo Palma, Anita De Rossi, Mario Plebani, Carlo Giaquinto, Andrea Padoan, Daniele Donà

Poster Session-D05 HIV IMMUNE THERAPY**2:00 PM MT - 3:30 PM MT****277 IMMUNOAGONIST CONVERTS CMV-SPECIFIC T CELLS INTO MORE POTENT HIV-SPECIFIC CAR-T CELLS**

Hang Su, Christopher Hiner, Moriah Rabin, Danica Lee, Stephanie Sabido, Scott J. Garforth, Jianhua Zheng, Kim Anthony-Gonda, Boro Dropulić, Steven C. Almo, Harris Goldstein

278 PRECLINICAL STUDIES TOWARD A PHASE I/IIA TRIAL USING ANTI-HIV DuoCAR-T CELL THERAPY

Kim Anthony-Gonda, Alex Ray, Yuge Wang, Hang Su, Ariele Block, Danica Lee, Sarah Kleinsorge-Block, Jane Reese, Marcos de Lima, Dimiter S. Dimitrov, Rimas Orentas, Steven G. Deeks, Harris Goldstein, Boro Dropulić

279 CD64 GENE-MODIFIED PRIMARY NK CELLS LOADED WITH ANTI-HIV bNAbs TRIGGER HIGH ADCC

Costin Tomescu, Hong Kong, Meizan Lai, James L. Riley, Luis J. Montaner

280 TARGETING SIGLEC IMMUNE CHECKPOINTS POTENTIATE NK CLEARANCE OF HIV-INFECTED CELLS

Opeyemi S. Adeniji, Leticia Kuri-Cervantes, Chenfei Yu, Ziyang Xu, Glen Chew, Costin Tomescu, Ashley F. George, Nadia Roan, Lishomwa Ndhlovu, Qin Liu, Kar Muthumani, David Weiner, Michael Betts, Han Xiao, Mohamed Abdel-Mohsen

281 IMMUNE RESPONSES FOLLOWING ANTI-PD-1 MONOCLONAL ANTIBODY INFUSION IN PERSONS WITH HIV

Bernard J. Macatangay, Cynthia Gay, Ashley McKhann, Ronald J. Bosch, Chanelle Wimbish, Patrick Mehta, Raymond Cha, Kendall F. Moseley, Cheryl Jennings, Danielle Campbell, Elizabeth Miller, Randall Tressler, Daniel Kuritzkes, Joseph J. Eron, David W. Hardy

282 CDK INHIBITORS IMPACT HIV-1 SUSCEPTIBILITY BY MODULATING IN VIVO IMMUNOLOGIC RESPONSE



Lucía Gutiérrez Chamorro, Eudald Felip, Ifeanyi J. Ezeonwumelu, Bonaventura Clotet, Mireia Margelí, Ester Ballana

283 PROMOTING RESIDENT MEMORY CD8+ T-CELL PHENOTYPES TO ENHANCE HIV RESERVOIR ELIMINATION

Sebastián G. Kuguel, Nuria Massana, Jon Cantero-Pérez, Marina Suppi, Judith Grau-Expósito, Josep Castellví, Laura Mañalich-Barrachina, Cristina Centeno-Mediavilla, Jordi Navarro, Adrià Curran, Vicenç Falcó, Maria José Buzón, Meritxell Genescà

284 INCLUDING Env IN AN HIV THERAPEUTIC VACCINE BLUNTS Gag/Pol-SPECIFIC T-CELL RESPONSES

Kara W. Chew, Emma Reuschel, Mansi Purwar, Megan C. Wise, Nilu Goonetilleke, Elizabeth R. Wonderlich, Faraz Zaidi, Drew Frase, Jean Boyer, Laurent Humeau, Rafick-Pierre Sékaly, David Weiner, Dave Glidden, Steven G. Deeks, Rachel L. Rutishauser

285 CONSERVED-REGION MVA VACCINES REDIRECT HIV T-CELL IMMUNODOMINANCE IN PWH ON ART

Nilu Goonetilleke, Yinyan Xu, Shahryar Samir, Ann Marie Weideman, Sallay Kallon, Joanna Warren, Maria Abad, Alison Crook, Lawrence Fox, Michael Hudgens, David M. Margolis, Tomas Hanke, JoAnn D. Kuruc, Cynthia Gay, for the M&M Study Team

286 DENDRITIC CELL VACCINATION AGAINST HIV ALTERS NK CELL FREQUENCY AND PHENOTYPE

Thessa Laeremans, Cynthia Lungu, Sabine Den Roover, Sigrid D'Haese, Rob Gruters, Sabine D. Allard, Joeri L. Aerts

287 EX VIVO ASSAY PREDICTS HIV-1 SUPPRESSION BY bNAbs INFUSED IN A PHASE I CLINICAL TRIAL

Sabrina Helmold Hait, Sarah E. Lovelace, Emily E. Coates, Grace Chen, Martin R. Gaudinski, Ro Shauna Rothwell, Eileen Donaghy, Jhoanna Roa, Carl J. Fichtenbaum, Jorge Santana, Rachel Presti, Pablo Tebas, Julie E. Ledgerwood, Amarendra Pegu, John R. Mascola

Poster Session-D06 SARS-CoV-2 VACCINE RESPONSES IN SPECIAL POPULATIONS

2:00 PM MT - 3:30 PM MT

288 ChAdOx1 nCoV-19 VACCINATION IN PWH: IMMUNE RESPONSES TO SARS-CoV-2, VOCs, AND HCoV



Ane T. Ogbe, Matthew Pace, Mustapha Bittaye, Stephanie Longet, Tom Tipton, Wanwisa Dejnirattisai, Katie J. Ewer, Gavin R. Screaton, Sarah C. Gilbert, Miles Carroll, Andrew J. Pollard, Sarah Fidler, Julie Fox, Teresa Lambe, John Frater

289 HIGH SEROCONVERSION RATE AND DELTA NEUTRALIZATION IN PLWHIV VACCINATED WITH BNT162b2

Valérie Pourcher, Lisa Belin, Cathia Soulie, Michelle Rosenzweig, Stéphane Marot, Karine Lacombe, Nadia Valin, Gilles Pialoux, Ruxandra Calin, Roland Tubiana, Marc Antoine Valantin, David Klatzmann, Vincent Calvez, Noémie Simon-Tillaux, Anne Genevieve Marcelin

- 290 HOW HIV MODULATES THE SAFETY AND IMMUNOGENICITY OF THE BNT162b2 COVID-19 VACCINE**
Ludovica Ferrari, Lorenzo Piermatteo, Federica Caldara, Eleonora Andreassi, Ada Bertoli, Harrison Austin, Diletta Meloni, Elisabetta Teti, Mirko Compagno, Marco Iannetta, Francesca Ceccherini-Silberstein, Loredana Sarmati, Massimo Andreoni, Anna Maria Geretti, for the PTVAX Study
- 291 DURABILITY OF SARS-CoV-2 mRNA VACCINE IMMUNE RESPONSE IN PLWH WITH ADVANCED DISEASE**
 Stefania Cicalini, Alessandra Vergori, Alessandro Cozzi-Lepri, Silvia Meschi, Veronica Bordoni, Simone Lanini, Daniele Lapa, Davide Mariotti, Lidya De Pascale, Veronica D'aquila, Concetta Castilletti, Chiara Agrati, Enrico Girardi, Francesco Vaia, **Andrea Antinori**
- 292 SARS-CoV-2 VACCINE IMMUNOGENICITY IN PLWH IN THE NETHERLANDS**
 Kathryn S. Hensley, Marlou Jongkees, Corine H. Geurts van Kessel, Virgil A. Dalm, Jan G. den Hollander, Wouter F W Bierman, Eliane M. Leyten, Emile F. Schippers, Heidi S. Ammerlaan, Marc Van der Valk, Bart J. Rijnders, **Kees Brinkman**, Anna Roukens, Casper Rokx, for the COVH Study Group
- 293 IMMUNOGENICITY TO COVID-19 mRNA VACCINE BOOSTER SHOT IN PLWH BY CURRENT CD4+ COUNT**
Alessandra Vergori, Stefania Cicalini, Alessandro Cozzi-Lepri, Giulia Matusali, Veronica Bordoni, Simone Lanini, Francesca Colavita, Eleonora Cimini, Roberta Iannazzo, Lidya De Pascale, Concetta Castilletti, Chiara Agrati, Enrico Girardi, Francesco Vaia, Andrea Antinori, for the HIV-VAC Study Group
- 294 ALTERED FEATURES OF B AND T CELL RESPONSES TO BNT162 VACCINE IN HEMODIALYSIS PATIENTS**
 **Alexandre Nicolas**, G  r  my Sannier, Lorie Marchitto, Manon Nayrac, Nathalie Brassard, Shilei Ding, Alexandra Tauzin, Mathieu Dub  , C  cyle Tremblay, Val  rie Martel-Laf  rri  re, R  mi Goupil, William Beaubien-Souigny, Andr  s Finzi, Rita Suri, Daniel E. Kaufmann
- 295 ANTIBODY RESPONSE TO SARS-CoV-2 VACCINES AND IMMUNODEFICIENCY: A RANDOMIZED TRIAL**
Fr  d  rique Chammartin, Benjamin Speich, Irene A. Abela, Patrizia Amico, Marcel St  ckle, Anna L. Eichenberger, Mac   M. Schuurmans, Thomas M  ller, Michael Tamm, Huldrych F. G  n  thard, Michael T. Koller, Alexandra Trkola, Matthias Briel, Katharina Kusejko, Heiner C. Bucher
- 296 ANTIBODIES IN SOLID ORGAN TRANSPLANT RECIPIENTS 6 MONTHS AFTER BNT162b2 VACCINATION**
 **Sebastian Hamm**, Dina Leth M  ller, Laura P  rez-Al  s, Rasmus Bo Hasselbalch, Zitta Barrella Harboe, Ruth Frikke-Schmidt, Sisse R. Ostrowski, Michael Perch, S  ren Schwartz S  rensen, Allan Rasmussen, Henning Bundgaard, Peter Garred, Kasper Karmark Iversen, Susanne D. Nielsen, for VACCIM
- 297 HUMORAL RESPONSE TO SARS-CoV-2 mRNA VACCINE IN HEART TRANSPLANT RECIPIENTS**
Valentine M. Ferr  , Zohra Brouk, H  lo  ise Flament, Caroline Kern  is, Charlotte Charpentier, Vania Da Silva, Constance Verdonk, Eric Vicaut, Luc De Chaisemartin, Diane Descamps, Nadhira Houhou-Fidouh, Richard Dorent

298 IMMUNE PARAMETERS ASSOCIATED WITH LOWER SARS-CoV-2 VACCINATION RESPONSE IN OLD PEOPLE



Joana Vitale Andrade, Alberto L. Perez-Gomez, Maria Reyes Jimenez Leon, Carmen Gasca-Capote, Sara Bachiller, Francisco José Ostos, Inmaculada Rivas-Jeremias, María del Mar Silva-Sánchez, Anabel Ruiz-Mateos, Luis Fernando López Cortés, Mohammed Rafii-El-Idrissi Benhnia, Ezequiel Ruiz-Mateos

Poster Session-D07 SARS-CoV-2 IMMUNE THERAPY

2:00 PM MT - 3:30 PM MT

299 DUAL MONOCLONAL ANTIBODIES IN COVID-19 PATIENTS: CLINICAL AND VIROLOGICAL EFFICACY

Valentine M. Ferré, Nathan Peiffer-Smadja, Laura Kramer, Aïcha Kanté, Margaux Debarge, Christophe Choquet, Romain Coppée, Donia Bouzid, Jonathan Messika, Jennifer Le Grand, Michael Thy, Solen Kernéis, Diane Descamps, Benoît Visseaux, Jade Ghosn

300 IN VIVO EFFICACY OF ENGINEERED ACE2-Fc IN PREVENTING LETHAL SARS-CoV-2 INFECTION

Yaozong Chen, Lulu Sun, Irfan Ullah, Guillaume Beaudoin-Bussièrès, Andrew Hederman, William D. Tolbert, Rebekah Sherburn, Dung N. Nguyen, Priti Kumar, Margaret E. Ackerman, Walther Mothes, Andrés Finzi, Pradeep D. Uchil, Frank J. Gonzalez, Marzena Pazgier

301 A FC-ENHANCED NON-NEUTRALIZING ANTIBODY DELAYS SARS-CoV-2-INDUCED DEATH IN MICE

Guillaume Beaudoin-Bussièrès, Yaozong Chen, Irfan Ullah, Jérémie Prévost, William D. Tolbert, Kelly Symmes, Shilei Ding, Mehdi Benlarbi, Fei Zhou, Edwin Pozharski, Priti Kumar, Walther Mothes, Pradeep D. Uchil, Marzena Pazgier, Andrés Finzi

302 REAL-LIFE USE OF HIGH-DOSE ANAKINRA IN COVID-19 PATIENTS TREATED WITH REMDESIVIR



Roberta Monardo, Andrea Mastrangelo, Laura Galli, Alessandro Tomelleri, Vincenzo Spagnuolo, Chiara Oltolini, Giacomo Ponta, Corrado Campochiaro, Lorenzo Dagna, Giulio Cavalli, Fabio Ciceri, Paola Cinque, Paolo Scarpellini, Antonella Castagna, Marco Ripa

303 METHYLPREDNISOLONE PULSES IN HOSPITALIZED PATIENTS WITH SEVERE COVID-19 PNEUMONIA



Giovanni Dolci, Carlo Salvarani, Marco Massari, Gabriella L. Mariani, Massimo Costantini, Franco Merlo, Pierluigi Viale, Stefano Nava, Emanuele A. Negr, Chiara Barbieri, Luisa Savoldi, Mariagrazia Catanoso, Luca Boni, Nicola Facciolo, for the RCT-MP-COVID19 Study Group

Poster Session-E02 MECHANISMS OF HIV LATENCY: MAINTENANCE AND REVERSAL

2:00 PM MT - 3:30 PM MT

332 GLUTAMINOLYSIS ALTERS CD4+ T-CELL IMMUNOMETABOLISM AND INHIBITS HIV TRANSCRIPTION

Leila B. Giron, Toshitha Kannan, Jane Koshy, Clovis S. Palmer, Alan Landay, Andrew Kossenkov, Mohamed Abdel-Mohsen

333 IDENTIFICATION OF THE HIV-1 Δ 8 RNA DOMAINS INVOLVED IN PROMOTING VIRAL LATENCY

Rui Li, Kaveh Daneshvar, Biplab Paul, Michelle Pleet, Rachel Barclay, Isabella Caico, Zahra Gholizadeh, Mohd Shameel Iqbal, Fatah Kashanchi, Alan Mullen, Fabio Romerio

- 334 HIV LATENCY REVERSAL VIA IAP ANTAGONISM AND TARGETED BET BROMODOMAIN INHIBITION**
Shane D. Falcinelli, Jackson Peterson, Anne-Marie Turner, David Irlbeck, Samuel Raines, Katherine James, Cameron Sutton, Anthony Sanchez, Edward P. Browne, Richard M. Dunham, Nancie Archin, David M. Margolis
- 335 HIV-INDUCED TYPE I INTERFERONS PROMOTE VIRAL LATENCY IN INFECTED MACROPHAGES**
Timothy Hanley, Laura J. Martins, Vicente Planelles
- 336 SMYD5 ACTIVATES HIV-1 TRANSCRIPTION AND IS UPREGULATED BY Tat AND USP11**
Daniela Boehm, Victor L. Lam, Melanie M. Ott
- 337 CIRCADIEN-MODULATING COMPOUNDS INDUCE HIV REACTIVATION FROM LATENTLY INFECTED CELLS**
 **Jared Stern**, Jennifer Zerbato, Ajantha Rhodes, Sharon Lewin, Michael Roche
- 338 PHARMACOLOGIC CONTROL OF CD4+ T-CELL PROLIFERATION TO TARGET HIV-1 PERSISTENCE**
Emily A. Innis, Callie Levinger, Matthew A. Szaniawski, Elizabeth S. Williams, José Alcamí, Alberto Bosque, Joshua Schiffer, Mayte Coiras, Adam Spivak, Vicente Planelles
- 339 IRF7 REGULATES HIV-1 LATENCY REVERSAL INDEPENDENT OF CYTOKINE SIGNALING BLOCKADE**
 **Ifeanyi J. Ezeonwumelu**, Edurne Garcia-Vidal, Bruna Oriol-Tordera, Marta Ruiz-Riol, André Gohr, Marta Massanella, Bonaventura Clotet, Roger Badia, Eva Riveira-Muñoz, Ester Ballana
- 340 NFκB BINDING MOTIF GENOTYPES IN PROVIRAL PROMOTERS ACROSS HIV-1 SUBTYPES**
Ha Eun Lim, Pragya Khadka, Erika Benko, Colin Kovacs, Ronald Galiwango, Paul Buule, Taddeo Kityamuweesi, Andrew Redd, Steven J. Reynolds, Thomas Quinn, Jessica Proddger, R. Brad Jones, Guinevere Q. Lee
- 341 IDENTIFICATION OF SYNERGISTIC COMBINATIONS OF HIV SILENCING PROMOTING FACTORS**
Zichong Li, Warner Greene, for the Hope Collaboratory
- 342 miRNA-103 MODULATES CCR5 AND AFFECTS ESTABLISHMENT OF HIV-1 LATENCY IN CD4+ T CELLS**
 **Nicolas Bellini**, Robert Lodge, Tram N. Pham, Jaspreet Jain, Cécile Tremblay, Jean-Pierre Routy, Alon Herschhorn, Thomas T. Murooka, Eric A. Cohen
- 343 POTENT TARGETED ACTIVATOR OF CELL KILL (TACK) MOLECULES ELIMINATE HIV-INFECTED CELLS**
Carl J. Balibar, Daniel J. Klein, Beata Zamlynny, Tracy L. Diamond, Zhiyu Fang, Carol Cheney, Marina Bukhtiyarova, Yangsi Ou, Min Xu, Abdellatif ElMarrouni, John F. Fay, Shih Lin Goh, Daria Hazuda, Bonnie Howell, Antonella Converso
- 344 GENOME-WIDE CRISPR INHIBITION SCREEN IDENTIFIES A NEW HIV-1 SILENCING FACTOR SLTM**
Rachel Kim, Savannah F. Pedersen, Jack A. Collora, Ya-Chi Ho
- 345 DASATINIB PREVENTS HIV INFECTION OF MACROPHAGES AND REDUCE THE INFLAMMATORY POTENTIAL**
Sara Rodríguez-Mora, Guiomar Casado, Lorena Vigón, Juan Cantón De Seoane, Fernando Ramos-Martín, Miguel Cervero, María Aranzazu Murciano-Antón, Adam Spivak, José Alcamí, Vicente Planelles, **Mayte Coiras**

346 CRISPR-Cas9—MEDIATED EXONIC DISRUPTION DELIVERED BY LNP FOR HIV-1 ELIMINATION



Mahmudul Hasan, Jonathan Herskovitz, Milankumar Patel, Farah Shahjin, Bhavesh D. Kevadiya, Howard E. Gendelman

Poster Session-E05 IMMUNE PRESSURES ON THE HIV RESERVOIR 2:00 PM MT - 3:30 PM MT

367 HIV ENVELOPE DIVERSITY AND SENSITIVITY TO bNABs ACROSS STAGES OF ACUTE AND EARLY HIV

Laurie VanderVeen, Brian Moldt, Lisa Selzer, Jiani Li, PC Parvangada, Jintanat Ananworanich, Trevor A. Crowell, Joseph J. Eron, Eric S. Daar, Richard H. Haubrich, Romas Geleziunas, Joshua Cyktor, John W. Mellors, Christian Callebaut, for the AIDS Clinical Trials Group A5354 Study Team

368 FUNCTIONAL MDSCs ARE MAINTAINED DURING ART AND PRECLUDE HIV-1 RESERVOIR REACTIVATION



Ana Gallego Cortés, Carla Serra, Judith Grau-Expósito, Joan Rey Cano, Jordi Navarro, Adrià Curran, Joaquin Burgos-Cibrian, Paula Suanzes, Vicenç Falcó, Meritxell Genescà, Maria José Buzón

369 ROVER: REDIRECTOR OF VACCINE-INDUCED EFFECTOR RESPONSES FOR HIV-1 TARGET CELL KILLING



Christina V. Konrad, Emma F. Iversen, Jesper D. Gunst, Ida Monrad, Lars Østergaard, Ole Søgaard, Mariane H. Schleimann, Martin Tolstrup

370 TARGETED DELIVERY OF BCL2 INHIBITORS SENSITIZES HIV+ CELLS TO ELIMINATION BY CTL

Andrea Gramatica, Ozgun Kocabiyik, Rachel S. Resop, Ali Danesh, Dennis C. Copertino, Alberto Bosque, Darrell Irvine, R. Brad Jones

371 THE LATENT SIV RESERVOIR IS ESTABLISHED INDEPENDENT OF CYTOTOXIC LYMPHOCYTE CONTROL



Maura Statzu, Andrew Wong, Julia B. McBrien, Jin Wang, Miles P. Davenport, Brandon Keele, Thomas H. Vanderford, Ann Chahroudi, Mirko Paiardini, Guido Silvestri, Deanna Kulpa

372 AUTOLOGOUS NEUTRALIZATION OF HIV RESERVOIR OUTGROWTH IS STABLE OVER TIME DURING ART



Joseph Varriale, Subul Beg, Natalie McMyn, Kwan Pui Chan, Francesco R. Simonetti, Kenneth Lynn, Pablo Tebas, Ian Frank, Karam Mounzer, Katharine J. Bar, Michael Seaman, Robert Siliciano, Janet Siliciano

373 SARS-CoV-2 mRNA VACCINATION EXPOSES LATENT HIV TO Nef-SPECIFIC CD8+ T CELLS

Eva Stevenson, Sandra Terry, Dennis C. Copertino, Louise Leyre, Adam R. Ward, Pragya Khadka, Kevin Bernard, Grant Ellsworth, Carrie Johnston, Marina Caskey, Christian Gaebler, Timothy Wilkin, Guinevere Q. Lee, R. Brad Jones

374 HODHBt SYNERGIZES WITH IL-15 TO ENHANCE THE CYTOTOXIC CAPACITY OF HIV-SPECIFIC CTL

Dennis C. Copertino, Carissa Stover, Amanda Macedo, Alberto Bosque, R. Brad Jones

375 ALTERED CELL CYCLING AND APOPTOSIS IN COLONIC MUCOSA OF IMMUNOLOGICAL NONRESPONDERS

Mari Kaarboe, Mingyi Yang, Malin H. Meyer-Myklestad, Arvind Y. Sundaram, Asle W. Medhus, Birgitte Stiksrud, Anne Ma Dyrhol-Riise, Dag Kvale, Johannes R. Hov, Marius Trøseid, Pål Aukrust, Magnar Bjørås, Dag Henrik Reikvam

Poster Session-F02 ART: EFFICACY, SWITCHES, AND TOXICITY**2:00 PM MT - 3:30 PM MT****395 PHARMACOGENETICS OF THE LATE-ONSET EFAVIRENZ NEUROTOXICITY SYNDROME (LENS)**

Roland van Rensburg, Sam Nightingale, Naeem Brey, Christine H. Albertyn, Tracy Kellermann, Jantjie J. Taljaard, Tonya M. Esterhuizen, Phumla Sinxadi, Eric Decloedt

396 CORRELATIONS OF UNDETECTABLE HIV DNA 96 WEEKS AFTER ART INITIATION DURING ACUTE HIV

Gunn Pungpapong, Phillip Chan, Denise C. Hsu, Carlo Sacdalan, Somchai Sreepleanjan, Peeriya Prueksakaew, Suteeraporn Pinyakorn, Bohyung Yoon, Sandhya Vasan, Sodsai Tovanabutra, Nittaya Phanuphak, Robert Paul, Nicolas Chomont, Serena S. Spudich, for the RV254 Study Group

397 EFFECT OF ART TREATMENT ON MACROPHAGE ACCUMULATION IN THE CNS WITH SIV

Zoey K. Wallis, Cecily Midkiff, Xavier Alvarez, Kevin S. White, Patrick Autissier, Addison Q. Amadeck, Soon Ok Kim, Cinar Sumer, Yiwei Wang, Maia Jakubowski, Andrew Miller, Kenneth Williams

398 EFAVIRENZ PLASMA LEVELS, COGNITION, AND CENTRAL NERVOUS SYSTEM SIDE EFFECTS

Alice Ranzani, Francesco Castelli, Antonio Di Biagio, Antonella D'Arminio Monforte, Antonio D'Avolio, Alessandro Soria, Francesca Bai, Emanuele Focà, Lucia Taramasso, Andrea Calcagno, Paolo Bonfanti, Giuseppe Lapadula

399 REVERSIBILITY OF CENTRAL NERVOUS SYSTEM ADVERSE EVENTS IN COURSE OF ART

Lucia Taramasso, Giancarlo Orofino, Elena D. Ricci, Barbara Menzaghi, Giuseppe V. De Socio, Nicola Squillace, Giordano Madeddu, Francesca Vichi, Benedetto M. Clesia, Chiara Molteni, Filippo Del Puente, Eleonora Sarchi, Goffredo Angioni, Antonio Cascio, Paolo Bonfanti

400 IMPACT OF INTEGRASE STRAND TRANSFER INHIBITORS ON COGNITION IN THE HAILO COHORT

Jane O'Halloran, Charles Goss, Mansi Agarwal, Sarah Cooley, Kunling Wu, Rachel Presti, Beau M. Ances, Katherine Tassiopoulos, Kristine Erlandson

Poster Session-F05 NEUROIMAGING PROFILING AND OUTCOMES**2:00 PM MT - 3:30 PM MT****416 EFFECTS OF AIR POLLUTANTS ON NEUROIMAGING MEASURES DIVERGE BY HIV STATUS**

Julie K. Wisch, Ruth Alemu, Sarah Cooley, Anna H. Boerwinkle, Alexander Rosenow, Beau M. Ances

417 DECREASED MYELIN CONTENT AND COGNITIVE PERFORMANCE IN ADULTS WITH PERINATAL HIV

Payal B. Patel, Alyssa Vecchio, Lydia Barakat, Thor Wagner, Ann J. Melvin, Jennifer Chiarella, Shannon Kolind, Michael Hoff, Adam Dvorak, Irene Vavasour, Serena S. Spudich, Christina M. Marra, Robert Paul, Swati Rane

418 CHILDHOOD TRAUMA MODIFIES BRAIN MORPHOLOGY AND COGNITION IN PEOPLE WITH HIV

Lillian Ham, Hsing-Chuan Hsieh, Erin Kelly, Xiuping Chu, Anuradha Ganesan, Gregory Utz, Ryan C. Maves, Ilyssa Silverman, Edmund Tramont, Stanley I. Rapoport, Avindra Nath, Brian Agan, Joseph Snow, Bryan R. Smith, **Suad Kapetanovic**

419 BRAIN VOLUMETRICS DIFFER BY FIEBIG STAGE IN ACUTE INFECTION

Jacob Bolzenius, Napapon Sailasuta, Andrew Belden, Phillip Chan, Carlo Saccalan, Julie Ake, Somchai Sreepleanjan, Khunthalee Benjapornpong, Denise C. Hsu, Sandhya Vasan, Torie Tsuei, Serena S. Spudich, Victor Valcour, Robert Paul, for the SEARCH 010/RV254 and SEARCH 013/RV304 Study Teams

420 INCREASED PHYSICAL STRENGTH IS ASSOCIATED WITH IMPROVED BRAIN INTEGRITY IN OLDER PLWH

Sarah Cooley, Brittany Nelson, Alexander Rosenow, Beau M. Ances

421 MACHINE LEARNING QUANTIFIES ACCELERATED WHITE MATTER AGING IN PERSONS WITH HIV

Kalen Petersen, Jeremy Strain, Sarah Cooley, Florin Vaida, Beau M. Ances

Poster Session-G03 FROM FORMULATION TO DRUG EXPOSURE TO ADHERENCE: IMPORTANT PRINCIPLES IN PHARMACOLOGY

2:00 PM MT - 3:30 PM MT

447 EVG/COBI/FTC/TAF TABLETS DISSOLVED IN TAP WATER NEAR BIOEQUIVALENT WITH WHOLE TABLETS

Craig W. Hendrix, Edward J. Fuchs, Mark Marzinke, **Sandra Abdul Massih**, Jennifer Breakey, Sasha Beselman, Ian McNicholl, Adriana Andrade

448 TRANSFORMATION OF DOLUTEGRAVIR INTO A YEAR-LONG PARENTERAL PRODRUG FORMULATION

Suyash Deodhar, Brady Sillman, Aditya Bade, Brandon Hanson, Bhagya Dyavar Shetty, Nagsen Gautam, JoEllyn McMillan, Morgan Johnston, Michellie Thurman, Yazan Alnouti, Samuel M. Cohen, Bhavesh D. Kevadiya, Siddappa N. Byrareddy, Benson J. Edagwa, Howard E. Gendelman

449 IMPACT OF HYALURONIDASE ON LONG-ACTING DRUG RELEASE PHARMACOKINETICS IN MURINE MODELS

Henry Pertinez, Amit Kaushik, Paul Curley, Usman Arshad, Eman El-Khateeb, Si-Yang Li, Charles W. Flexner, Eric Nuermberger, Andrew Owen, Nicole C. Ammerman

450 POSTMORTEM TISSUE SAMPLING TO DESCRIBE EXPOSURE OF 8 ANTI-INFECTIVES IN THE BRAIN

Melanie R. Nicol, Olivie C. Namuju, Katelyn A. Pastick, Kizito Abdusalaamu, James Fisher, Lindsey B. Collins, David R. Boulware, David Meya, Robert Lukande

451 TENOFOVIR URINE POINT-OF-CARE TEST PREDICTS VIREMIA AND DRUG RESISTANCE DURING ART

Lucas E. Hermans, Chijioke N. Umunnakwe, Samanta T. Lalla-Edward, Shane Hebel, Francois Venter, Hugo A. Tempelman, Annemarie Wensing

452 NOVEL PHASE II TRIAL DESIGN WITH STRATIFIED MEDICINE PRINCIPLES FOR TREATMENT OF TB

Marjorie Z. Imperial, Vincent Chang, Payam Nahid, Susan Swindells, Gustavo E. Velásquez, Rada Savic, Patrick P. Phillips

Poster Session-H03 ANTIRETROVIRAL THERAPY IN EXPERIENCED PATIENTS: SUSTAIN OR REGAIN SUPPRESSION
2:00 PM MT - 3:30 PM MT

- 479 LONG-ACTING CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M WEEK 152 RESULTS**
Edgar T. Overton, Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre-Marie Girard, Alexander Wong, Norma Porteiro, Carlos Español, Carolina Acupil, Asma Aksar, Yuanyuan Wang, Ronald D'Amico, Christine Talarico, Kati Vandermeulen, William R. Spreen
- 480 SWITCHING TO A nRTI-FREE 2-DRUG REGIMEN (2DR): A SUB-ANALYSIS OF THE DUALIS STUDY**
Malte B. Monin, Christiane Cordes, Schneider Jochen, Hans-Jürgen Stellbrink, Stefan H. Scholten, Björn Jensen, Heiko Jessen, Wilfried Obst, Petra Spornraft-Ragaller, Pavel Khaykin, Annamaria Balogh, Eva Wolf, Helen Binder, Christoph Spinner, Christoph Boesecke
- 481 ARCHIVED RESISTANCE AND RESPONSE TO <40 C/ML & TND: DTG/3TC FDC AT WEEK 48 IN SALSA**
Mark Underwood, Olayemi Osiyemi, Rafael Rubio, Laurent Hocqueloux, Norma Porteiro, Olaf Degen, James Oyee, Joe Horton, Chris Parry, Ruolan Wang, Myooran Sithamparanathan, Jean A. Van Wyk, Brian Wynne, Choy Man, Elizabeth Blair
- 482 2DR VS 3DR INTEGRASE INHIBITOR-BASED REGIMENS INITIATION AND CD4+/CD8+ RATIO RECOVERY**
Javier Martínez-Sanz, Raquel Ron, Elena Moreno, Matilde Sánchez-Conde, Alfonso Muriel, María Rivero, José-Ramón Blanco, Enrique Bernal, Miguel de Zárraga, María José Galindo, Eva Poveda, Gloria Samperiz, Santiago Moreno, Sergio Serrano-Villar, for the Cohort of the Spanish HIV/AIDS Research Network
- 483 MULTIOMICS PLASMA PROFILE OF SWITCHING FROM 3DR TO DOLUTEGRAVIR PLUS LAMIVUDINE**
Anna Rull, Elisa de Lazzari, Eugenia B. Negredo, Pere Domingo, Juan M. Tiraboschi, Esteve Ribera, Nadia Abdulghani, Verónica Alba, Consuelo Viladés, Joaquin Peraire, Jose M. Gatell, Jose L. Blanco, Francesc Vidal, Esteban Martinez, for the DOLAM Study Group
- 484 LOW-LEVEL HIV REPLICATION FOR DTG/3TC VS TAF-BASED REGIMEN IN TANGO THROUGH WEEK 144**
Ruolan Wang, Nisha George, Mounir Ait-Khaled, Andrew Tomlinson, James Oyee, Thomas Lutz, Olayemi Osiyemi, Miguel Górgolas, Riya Moodley, Brian Wynne, Myooran Sithamparanathan, Mark Underwood
- 485 SWITCHED VERSUS RECYCLED nRTIs IN PI-BASED SECOND-LINE REGIMENS IN EAST AFRICA**
Suzanne McCluskey, Beverly Musick, Arvind Kaimal, Francesca Odhiambo, Lameck Diero, Winnie R. Muyindike, Rita Lyamuya, Samson Okumu, Mark Siedner, Kara Wools-Kaloustian, Constantin Yiannoutsos
- 486 RESUPPRESSION AFTER VIROLOGICAL FAILURE IN DOLUTEGRAVIR AND EFAVIRENZ-BASED REGIMENS**
Kaitlyn Mccan, Francois Venter, Eric Delaporte, Simiso M. Sokhela, Charles Kouanfack, Godspower Akpomemie, M. Mpoudi-Etame, Angela Tembo, Tamara Tovar Sanchez, P. Omgba Bassega, Ambar Qavi, **Andrew Hill**

487 48-WEEK OUTCOMES AFTER PROGRAMMATIC TRANSITION TO DOLUTEGRAVIR IN UGANDA

Suzanne McCluskey, Winnie R. Muyindike, Victoria Nanfuka, Daniel Omoding, Nimusiima Komukama, Ian Barigye, Lydia Kansiime, Justus Tumusiime, Ashley Stuckwisch, Bethany Hedt-Gauthier, Vincent Marconi, Mahomed-Yunus Moosa, Deenan Pillay, Ravindra Gupta, Mark Siedner

488 EFFICACY OF TENOFOVIR-LAMIVUDINE-DOLUTEGRAVIR FOR INITIAL AND FIRST-LINE SWITCH ART

Cissy Kityo, Caitlyn McCarthy, Michael Hughes, Catherine Godfrey, Carole Wallis, Urvi Parikh, Sarita Shah, Yukari C. Manabe, George K. Siberry, Isaac Tsikhutsu, Elizabeth Woolley, John W. Mellors, Charles W. Flexner, James Hakim, for the AIDS Clinical Trials Group A5381/The Hakim Study Team

489 WITHDRAWN**490 PREDICTORS OF VIRAL SUPPRESSION FOLLOWING ENHANCED ADHERENCE COUNSELING: VISEND TRIAL**

Danielle C. Engamba, C. William Wester, Melody M. Mutinta, Alepalli P. Kumar, Bob Chirwa, Getrude Phiri, Edford Sinkala, Davies Kampamba, Mpanji Siwingwa, Nyuma Mbewe, Aggrey Mweemba, Sombo Fwoloshi, Andrew Hill, Lloyd B. Mulenga, Lameck Chirwa

491 LONG-ACTING LENACAPAVIR IN PEOPLE WITH MULTIDRUG RESISTANT HIV-1: WEEK 52 RESULTS

Onyema Ogbuagu, Sorana Segal-Maurer, Cynthia Brinson, Ploenchan Chetchotisakd, Kenneth Lichtenstein, Joseph McGowan, Andrew A. Wiznia, Kimberly Workowski, Hui Wang, Nicolas Margot, Hadas Dvory-Sobol, Martin Rhee, Jared Baeten, Jean-Michel Molina

Poster Session-H04 FIRST-LINE THERAPY, LOW-LEVEL VIREMIA, AND ADHERENCE**2:00 PM MT - 3:30 PM MT****492 FEASIBILITY AND VIRAL RESPONSE TO TREATING ACUTE/EARLY HIV IN A MULTINATIONAL STUDY**

Eric S. Daar, Justin Ritz, Lu Zheng, Jintanat Ananworanich, Cecelia Kanyama, Susan J. Little, Susan E. Cohn, Sharon A. Riddler, Ann C. Collier, Robert Coombs, Lawrence Fox, Javier R. Lama, Trevor A. Crowell, for the AIDS Clinical Trials Group (ACTG) A5354 Study Team

493 LONG-TERM OUTCOMES OF DOLUTEGRAVIR AND EFAVIRENZ-400 AS FIRST-LINE ART IN CAMEROON

Mireille Mpoudi Ngole-Etame, Tamara Tovar Sánchez, Pierrette Omgba-Basega, Justin Désiré Olinga, Eric Mimbe, Michel Foalem, Raphaël Pelloquin, Marie Varloteaux, Marcel Tongo, Martine Peeters, Jacques Reynes, Alexandra L. Calmy, Eric Delaporte, Charles Kouanfack, for the NAMSAL ANRS 12313 Study Group

494 B/F/TAF 5-YEAR OUTCOMES IN TREATMENT-NAIVE ADULTS

David A. Wohl, Anton Pozniak, Kimberly Workowski, Debbie Hagins, Eric S. Daar, Chloe L. Orkin, Ellen Koenig, Karam Mounzer, Samir Gupta, Hailin Huang, Rima K. Acosta, Jason Hindman, Jared Baeten, Hal Martin, Paul E. Sax

495 HIV-1 RNA DECAY IN SEMEN AND RECTUM WITH DTG PLUS 3TC VERSUS BIC/FTC/TAF

Arkaitz Imaz, Sofia Scevola, Jordi Niubo, Pere Domingo, Guillermo Verdejo, Adrià Curran, Vicens Diaz de Brito, Juan M. Tiraboschi, Sandra Morenilla, Benito Garcia-Vidal, Irene Soriano, Daniel Podzamczar

496 ANTIRETROVIRAL THERAPY ADHERENCE IN MEDICARE FEE-FOR-SERVICE BENEFICIARIES WITH HIV

Pengxiang Li, **Girish Prajapati**, Zhi Geng, Vrushabh P. Ladage, Jean M. Arduino, Dovie L. Watson, Robert Gross, Jalpa A. Doshi

497 LOW-LEVEL VIREMIA AND VIROLOGICAL FAILURE IN HIV ANTIRETROVIRAL THERAPY

An Jing, Lao Yunfei, Tang Songyuan, Dong Xingqi, Lou Jingcheng, Li Tianshu

Poster Session-J04 HBV EPIDEMIOLOGY, TREATMENT, AND PREVENTION
2:00 PM MT - 3:30 PM MT
543 REGIONAL VARIATION IN HBV PREVALENCE IN PEOPLE LIVING WITH HIV IN BOTSWANA

Bonolo B. Phinius, Motswedi Anderson, Irene Gobe, Margaret Mokomane, Sharon Mutenga, Molly Pretorius Holme, Tendani Gaolathe, Mompoti Mmalane, Roger L. Shapiro, Joseph Makhema, Shahin Lockman, Vlad Novitsky, Max Essex, Sikhulile Moyo, Simani Gaseitsiwe

544 A RANDOMIZED TRIAL OF HBV REVACCINATION IN MSM BORN IN THE NEONATAL VACCINATION ERA

Yi-Chia Huang, Hsin-Yun Sun, Chia-Wen Li, Sung-Hsi Huang, Wen-Chun Liu, Yi-Ching Su, Sui-Yuan Chang, Wen-Chien Ko, Chien-Ching Hung

545 A LONG-ACTING TENOFOVIR PRODRUG SUPPRESSES HBV REPLICATION FOR OVER 3 MONTHS

Srijanee Das, Weimin Wang, Denise A. Cobb, Murali Ganesan, Franchesca G. Fonseca, Mohammad Ullah Nayan, Suyash Deodhar, Brandon Hanson, Edward Makarov, Howard E. Gendelman, Natalia A. Osna, Benson J. Edagwa, Larisa Y. Poluektova

546 LOW RATES OF HEPATITIS B VACCINATION AMONG HIV PATIENTS

Mamta K. Jain, Karen J. Vigil, Onkar Kshirsagar, Laura A. Hansen, Barbara S. Taylor, Mae Thamer

547 HEPATITIS B RNA AND CORE-RELATED ANTIGEN IN HIV-HBV COINFECTION

Kasha P. Singh, Jennifer Zerbato, Wei Zhao, Danny K. Wong, Gavin Cloherty, Jeffrey Gersch, Hugh Mason, Ajantha Rhodes, Peter Revill, Anchalee Avihingsanon, Jennifer Audsley, Man-Fung Yuen, Sharon Lewin

548 NEW HEPATITIS B INFECTION AMONG HIV PATIENTS: WHO IS AT RISK?

Mamta K. Jain, Karen J. Vigil, Onkar Kshirsagar, Laura A. Hansen, Barbara S. Taylor, Mae Thamer

Poster Session-J05 EXPRESSION AND PATHOGENESIS OF LIVER DISEASE

2:00 PM MT - 3:30 PM MT

549 ETIOLOGY OF LIVER DISEASE IN ADULTS WITH HIV IN LOW- AND MIDDLE-INCOME COUNTRIES

Marie K. Plaisy, Albert Minga, Gilles Wandeler, Alain Attia, Renee De Waal, Jeremy Ross, Niha Samala, Sonia Salvi, Mark H. Kuniholm, Gad Murenzi, Hugo Perrazo, Antoine Jaquet, for leDEA

550 SINGLE-CELL ANALYSIS OF THE LIVER IN HIV REVEALS PROFIBROTIC MONOCYTES/MACROPHAGES

Christopher Oetheimer, **Michael S. Wallace**, Alex S. Genshaft, Ira Fleming, Mike Vilme, Lai Ping Wong, Michael L. Dadoine, Eliana T. Epstein, Adaeze Obinelo, Ashraf Thabet, Alex K. Shalek, Ruslan Sadreyev, Gregory K. Robbins, Raymond T. Chung, Nadia Alatrakchi

551 CD4/CD8 RATIO ≥ 0.5 IS A RISK FACTOR OF ACUTE REJECTION IN HIV-INFECTED LT RECIPIENTS

Sandra Silva Arrieta, Lucia Serrano, Antonio Rafecas, Christian Manzardo, Jesus Fortun, Marino Blanes, Magdalena Salcedo, Itxarone Bilbao, Elisa Cordero, Santos Del Campo, Asuncion Moreno, Antonio Rimola, Christian Brander, **Jose M. Miro**, for the FIPSE HIV-LT Investigators

Poster Session-K04 KAPOSI SARCOMA TREATMENT AND HTLV

2:00 PM MT - 3:30 PM MT

570 ROLE OF SOCIAL SUPPORT IN DIAGNOSIS AND TREATMENT OF HIV-ASSOCIATED KAPOSI SARCOMA

Rhea Singh, **Sigrid Collier**, Aggrey Semeere, Helen Byakwaga, Miriam Laker-Oketta, Devon McMahon, Linda Chemtai, Merridy Grant, Lisa Butler, Ingrid V. Bassett, Samson Kiprono, Toby Maurer, Jeffrey N. Martin, Naftali Busakhala, Esther Freeman

571 CHARACTERISTICS OF PATIENTS ADMITTED TO THE ICU WITH KSHV-ASSOCIATED DISEASES

Megan E. Hansen, Ralph Mangusan, Kathryn Lurain, Thomas Odeny, Jomy M. George, Crystal Lu, Maura Manion, Anaida Widell, Irene Ekwede, Denise Whitby, Thomas S. Uldrick, Robert Yarchoan, Ramya Ramaswami

572 POMALIDOMIDE INDUCES T-CELL ACTIVATION AND DECREASES SENESCENCE IN KAPOSI SARCOMA

Kathryn Lurain, Mark Polizzotto, Laurie T. Krug, Kathleen M. Wyvill, Ramya Ramaswami, Robert Yarchoan, Thomas S. Uldrick, Irini Sereti

573 RISK AND PROTECTIVE FACTORS ASSOCIATED TO HTLV-1 MOTHER-TO-CHILD TRANSMISSION

Gabriela S. Prates, Arthur Paiva, Tatiane Assone, Rosa Marcusso, Jerusa V. Smith, Augusto Penalva, Jorge Casseb

574 HTLV ADULT T-CELL LEUKEMIA/LYMPHOMA: A RETROSPECTIVE STUDY IN FRENCH GUIANA 2009-2019

Karim Abdelmoumen, Kinan D. Alsibai, Mathieu Nacher, Jean-Michel Cauvin, N'Detodji-Bill Wankpo, Pauline Naudion, Caroline Misslin-Tritsch, Felix Djossou, Antoine Gessain, Lionel Galicier, Olivier Hermine, Florin Santa, Pierre Couppe, Jean-Pierre Droz, Loïc Epeboin

Poster Session-M01 WEIGHT GAIN AND ADIPOSE TISSUE BIOLOGY

2:00 PM MT - 3:30 PM MT

- 593 PREDICTED IMPACT OF ART SWITCH ON BODY MASS INDEX AMONG WOMEN WITH HIV**
Jane O'Halloran, Yuezhe Wang, Wei Jin, Mary Clare C. Masters, Raha Dastgheyb, Adaora Adimora, Margaret Fischl, Deborah Gustafson, Igbo Ofotokun, Anjali Sharma, Amanda B. Spence, Phyllis Tien, Kathleen Weber, Yanxun Xu, Leah H. Rubin
- 594 InSTI-RELATED BODY COMPOSITION DIFFERENCES IN CHRONICALLY INFECTED MLWH**
Julie K. Wisch, Sarah Cooley, Kevin E. Yarasheski, W. Todd Cade, Dominic N. Reeds, Brittany Nelson, Tricia H. Burdo, Beau M. Ances
- 595 PHARMACOGENETICS OF WEIGHT GAIN AFTER SWITCH TO INTEGRASE INHIBITOR-BASED REGIMENS**
David W. Haas, Kunling Wu, Katherine Tassiopoulos, Todd Hulgán, Jordan Lake, John Koethe, Todd Brown, Michael Leonard, Sara Bares, David Samuels, Kristine Erlandson, for the AIDS Clinical Trials Group
- 596 WEIGHT CHANGE FOLLOWING SWITCH TO DOLUTEGRAVIR IN RURAL KENYA**
 **Matthew D. Hickey**, Erick Wafula, Lucas Godoy Garraza, Sabina Ogachi, Gordon Orori, Richard O. Adede, Maya L. Petersen, Diane V. Havlir, Laura B. Balzer, James Ayieko
- 597 MACHINE LEARNING ALGORITHM TO PREDICT >5% WEIGHT GAIN IN PWH SWITCHING TO InSTI**
Giovanni Guaraldi, Federico Motta, Jovana Milic, Sara Barbieri, Licia Gozzi, Emanuele Aprile, Michela Belli, Maria Venuta, Gianluca Cuomo, Federica Carli, Giovanni Dolci, Vittorio Iadiseria, Giulia Burastero, Cristina Mussini, Federica Mandreoli
- 598 48-WEEK BODY COMPOSITION CHANGES IN PLWH SWITCHING FROM 3DR TO DTG + 3TC: DOLAM STUDY**
Esteban Martinez, Elisa de Lazzari, Adrià Curran, Pere Domingo, Eugenia B. Negredo, Nadia Abdulghani, Jose M. Gatell, Jose L. Blanco, for the DOLAM Study Group
- 599 ADIPOCYTE DIFFERENTIATION AND ANTIRETROVIRAL DRUGS: AN IN VITRO MODEL**
Maria Aurora Carleo, Angelica Perna, Pietro Rosario, Silvia Mascolo, Angela Lucariello, Giulia Palmiero, Viviana Rizzo, Anna Maria Rossomando, Alfonso Baldi, Antonio De Luca, Paolo Maggi, **Vincenzo Esposito**
- 600 METABOLIC PERTURBATIONS BY INTEGRASE INHIBITORS IN DIFFERENTIATED HUMAN ADIPOCYTES**
R. Taylor Pickering, Kaitlin M. Soden, Archana Asundi, Nina Lin
- 601 DOLUTEGRAVIR REVERSIBLY INDUCES MITOCHONDRIAL FRAGMENTATION AND TOXICITY IN VITRO**
 **Loïc C. Caloren**, Abhinav Ajaykumar, Tetiana Povshedna, Anthony Hsieh, Marie-Soleil R. Smith, Pierre Becquart, Jacqueline A. Quandt, Judy M. Wong, Helene C. Cote

Poster Session-M02 METABOLIC COMPLICATIONS

2:00 PM MT - 3:30 PM MT

602 LIPIDOMICS PROFILE OF METABOLIC SYNDROME IN WELL-TREATED PEOPLE LIVING WITH HIV

Sofie O. Villumsen, Rui Benfeitas, Andreas D. Knudsen, **Marco Gelpi**, Julie Høgh, Magda T. Thomsen, Daniel Murray, Ujjwal Neogi, Susanne D. Nielsen

603 WEEK-48 METABOLIC HEALTH AFTER SWITCH TO DTG/3TC VS CAR BY BASELINE REGIMEN: SALSA

Debbie Hagins, Cristina Mussini, Fujie Zhang, Princy N. Kumar, Laurent Hocqueloux, Nuria Espinosa-Aguilera, Christoph Wyen, James Oyee, Lori A. Gordon, Gilda Bontempo, Brian Wynne, Elizabeth Blair, Mounir Ait-Khaled, Jean A. Van Wyk

604 AGE AND OBESITY AS RISK FACTORS FOR DIABETES IN AFRICANS WITH HIV

Lisa Hamzah, Amelia Oliveira, Claire Norcross, Zoe Ottaway, Julie Fox, Burns Fiona, Andrew Ustianowski, Sarah L. Pett, Sarah Schoeman, Amanda Clarke, Caroline Sabin, Louise Goff, Frank A. Post, Cheryl Winkler, for the GEN-AFRICA Study Group

605 CO-OCCURRING OBESITY AND HIV ARE NOT ASSOCIATED WITH DIABETES MELLITUS IN SOUTH AFRICA

Itai M. Magodoro, Mongiwethu N. Dungeni, Alison C. Castle, Shakespear Mureyani, Mark J. Siedner

606 FEMINIZING HORMONAL THERAPIES WORSEN CARDIOMETABOLIC PROFILES IN TRANSGENDER WOMEN

Jordan Lake, Han Feng, Hongyu Miao, Paula Debroy, Katherine McGowan, Sabina Haberlen, Wendy Post, Shalender Bhasin, Matthew Budoff, Todd Brown

Poster Session-N03 COVID-19: MISCELLANEOUS CLINICAL AND THERAPEUTIC ISSUES

2:00 PM MT - 3:30 PM MT

636 TOCILIZUMAB (BIOSIMILAR) USE IN CYTOKINE STORM OF SEVERE COVID-19 PNEUMONIA

Nagalingeswaran Kumarasamy, Sawardekar Vinayak Maruti, Sanjiv Maheshwari, Anand Nikalje, Chirag C. Rathod, Manish K. Jain, Ashish Goyal, Naveen Chander Reddy Podduturi, Archana Gautam, Shubhadeep Sinha, Sreenivasa Chary Sriramadasu, Bala Reddy Bheema Reddy, Sheejith Kakkunnath, Pankaj Thakur, Leela Talluri

637 THE IMPACT OF COVID-19 TREATMENTS ON PATIENT OUTCOMES: A PROBABILISTIC VIEW

Bradley S. Price, Maryam Khodaverdi, Hamidreza Moradi, H Timothy Bunnell, J. Zachary Porterfield, Michael T. Vest, Susan L. Santangelo, Wesley Kimble, Alfred J. Anzalone, Jeremy Harper, Sally L. Hodder

638 ALTERED GUT MICROBIOTA AND RESPIRATORY DYSFUNCTION 3 MONTHS AFTER SEVERE COVID-19

Beate Vestad, Thor Ueland, Tøri V. Lerum, Tuva B. Dahl, Kristian Holm, Andreas Barratt-Due, Anne Ma Dyrhol-Riise, Birgitte Stiksrud, Hedda B. Hoel, Bente Halvorsen, Annika E. Michelsen, Ole H. Skjønberg, Pål Aukrust, Johannes R. Hov, Marius Trøseid

- 639 CAPSULE ENDOSCOPY FINDINGS IN PATIENTS WITH SEVERE SARS-CoV-2 INFECTION: PILOT STUDY**
Daniela Garrido-Rodríguez, **Fernanda Torres-Ruiz**, Gerardo Blanco-Velasco, Amy B. Peralta-Prado, Isabel León-Rodríguez, Julio C. Lara-Muñoz, William C. Lara-Vazquez, Dulce M. López-Sánchez, Gonzalo Salgado Montes de Oca, Santiago Ávila-Ríos
- 640 HIV AND SARS-CoV-2 INFECTION AND OUTCOMES IN THE MID-ATLANTIC US**
Amanda B. Spence, Sameer Desale, Jennifer Lee, Princy N. Kumar, Xu Huang, Stanley E. Cooper, Stephen Fernandez, Seble Kassaye
- 641 USE OF CORTICOSTEROIDS TO MANAGE HOSPITALIZED PATIENTS WITH COVID-19 IN ZAMBIA**
Peter Minchella, Sombo Fwoloshi, Duncan Chanda, Davies Kampamba, Megumi Itoh, Khozya D. Zyambo, Jonas Hines, Suilanji Sivile, Simon Agolory, Lloyd B. Mulenga
- 642 VARIABLES ASSOCIATED WITH HOSPITALIZATION DUE TO COVID-19 IN PEOPLE LIVING WITH HIV**
Fernanda Rombini, **Jamile Ballivian**, Diego Cecchini, Liliana Calanni, Fabricio Morales, Elena Obieta, Laura Morganti, Claudia Migazzi, Maria L. Yantorno, Maria Marta Greco, Rosana Cuini, Martin Hojman, Diana Pinto, Isabel Cassetti, for the COVIDARE Study Team
- 643 ZINC DEFICIENCY IS INDEPENDENTLY ASSOCIATED WITH INCREASED COVID-19 DISEASE SEVERITY**
 **Christian F. Mouchati**, Sokratis N. Zisis, Jared C. Durieux, Sarah Scott, Beth Smith, Danielle Labbato, Grace A. McComsey
- 644 MENSTRUATION IRREGULARITIES AMONG REPRODUCTIVE-AGE WOMEN DURING THE COVID-19 PANDEMIC**
Emily M. Cherenack, Ana S. Salazar, Patricia Raccamarich, Violeta J. Rodriguez, Alejandro Mantero, Sophia F. Gerard, Marissa Maddalon, Deborah Jones Weiss, Nichole R. Klatt, Maria L. Alcaide

Poster Session-001 NOVEL MYCOBACTERIAL DIAGNOSTICS AND BIOMARKERS

2:00 PM MT - 3:30 PM MT

- 645 CRISPR-DETECTED CELL-FREE DNA FOR PEDIATRIC TB DIAGNOSIS AND TREATMENT RESPONSE**
Sylvia LaCourse, Zhen Huang, Joshua Stern, Jaclyn Escudero, Lisa Marie Cranmer, Irene Njuguna, Elizabeth Maleche-Obimbo, Dalton C. Wamalwa, Christopher Lyon, Grace John-Stewart, Tony Hu
- 646 MYCOBACTERIA-SPECIFIC CD4 T CELLS IN CHILDREN LIVING WITH HIV BEFORE AND AFTER ART**
Cheryl Day, Wendy E. Whatney, Lisa Marie Cranmer, Irene Njuguna, Sylvia LaCourse, Jaclyn Escudero, Cecilia S. Lindestam Arlehamn, Loren Sasser, Cyrus Mugo, Hellen Moraa, Elizabeth Maleche-Obimbo, Dalton C. Wamalwa, Grace John-Stewart
- 647 POTENTIAL USE OF URINE LF-LAM IN DIAGNOSING ACTIVE TB IN THAI HIV-POSITIVE ADULTS**
Chawisar Janekrongtham, Rangsim Lolekha, Anchalee Avihingsanon, Niorn Ariyothai, Rom Luengwattanapong, Patsaya Mookleemas, Chonticha Kittinunvorakoon, Chuenkamol Sethaputra, Supanee Jirajariyavej, Sasiwimol Ubolyam, Chris Fujitnirun, Sureerat Watcharasuwanseree, Thitisant P. Na Ayuthaya, Sanny Northbrook, Cheewanan Lertpiriyasuwat

648 HIGHLY PERFORMANT MULTIPLEX PCR FOR TB AND NTM INFECTIONS IN PERSONS WITH HIV

Yeya dit Sadio Sarro, Bassirou Diarra, Bocar Baya, Ousmane Kodio, Fanta Sanogo, Djakaridja Daniogo, Ibrahim B. Diallo, Mohamed Tolofoudie, Chad J. Achenbach, Seydou Doumbia, Babafemi O. Taiwo, Robert Murphy, Sally M. McFall, Mamoudou Maiga

649 BLOOD-BASED PATHOGEN AND HOST BIOMARKER SIGNATURES THAT PREDICT TB TREATMENT OUTCOMES

Marjorie Z. Imperial, George Sigal, Anu Mathew, Leah Jarlsberg, Patrick P. Phillips, Jon Jacobs, Mingyue Wang, Tatiana Plisova, Christopher Campbell, J. Lucian Davis, William Whitworth, Jeff Schorey, David Lewinsohn, Rada Savic, Payam Nahid

650 IMPAIRED DLCO CORRELATES WITH REDUCED TOTAL LUNG GLYCOLYSIS AFTER TB TREATMENT

Patrick De Marie C. Katoto, Sandra Mukasa, Karen Wolmarans, Antoneta Mashinyira, Reto Guler, Friedrich Thienemann

Poster Session-P05 HIV INFECTION AND PREVENTION IN PREGNANCY
2:00 PM MT - 3:30 PM MT
700 EVALUATION OF CAB-LA SAFETY AND PK IN PREGNANT WOMEN IN THE BLINDED PHASE OF HPTN 084

Sinead Delany-Moretlwe, James Hughes, Xu Guo, Brett Hanscom, Craig W. Hendrix, Jennifer Farrior, Rebecca H. Berhanu, Alex R. Rinehart, Susan L. Ford, James F. Rooney, Adeola Adeyeye, Raphael J. Landovitz, Myron S. Cohen, Mina C. Hosseinipour, Mark Marzink

701 RECENT HIV INFECTION AMONG PREGNANT WOMEN FROM 2 NATIONAL SURVEYS IN SOUTH AFRICA

Selamawit A. Woldesenbet, Mireille Cheyip, Tendesayi Kufa-Chakezha, Carl Lombard, Samuel Manda, Kassahun Ayalew, Adrian Puren

702 HIV TEST-POSITIVITY IN PREGNANT AND POSTNATAL WOMEN RETESTED IN NAMPULA, MOZAMBIQUE

Chloe A. Teasdale, Michelle Choy, Fatima Tsiouris, Eduarda Pimental de Gusmao, Etelvino Banqueiro, Nicole Flowers, Marilena Urso, Mirriah Vitale, Elaine J. Abrams

703 PREGNANCY IN WOMEN WITH HIV IN A TUBERCULOSIS-PREVENTIVE THERAPY TRIAL

Priya Singh, Lawrence Moulton, Grace Link Barnes, Amita Gupta, Reginah Msandiwa, Richard E. Chaisson, Neil A. Martinson

704 PrEP CONTINUATION AND OBJECTIVE ADHERENCE IN PREGNANT/POSTPARTUM SOUTH AFRICAN WOMEN

Dvora Joseph Davey, Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashele, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Lubbe Wiesner, Jennifer Norman, Landon Myer

705 PREGNANCY AND BIRTH OUTCOMES IN PrEP-EXPOSED & UNEXPOSED PREGNANT SOUTH AFRICAN WOMEN

Dvora Joseph Davey, Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashele, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Landon Myer

Poster Session-Q03 REAL-WORLD OUTCOMES IN PEDIATRICS**2:00 PM MT - 3:30 PM MT****719 SEVERE IMMUNE SUPPRESSION AND RETENTION AMONG INFANTS IN SOUTH AFRICA****Gabriela E. Patten**, Nosisa Sipambo, Karl-Günter Technau, Jonathan Euvrard, Nathan Ford, Mary-Ann Davies**720 HIGH PREVALENCE OF HIV DRUG RESISTANCE AMONG NEWLY DIAGNOSED CHILDREN 0-18 MONTHS****Immaculate Mutisya**, Leonard Kingwara, Jacques Muthusi, Evelyn Ngugi, Lazarus Momanyi, Frankline Mboya, Sasi Jonnalagadda, Winfred Nyanya, Grace Akinyi, Kimberly D. McCarthy, Abraham Katana, Lucy Nganga, Marc Bulterys**721 LIVING: 48-WEEK DATA ON LPV/r PELLETS IN 990 CHILDREN IN RESOURCE-LIMITED SETTINGS**Dalton C. Wamalwa, Victor Musiime, Adeodata R. Kekitiinwa, Juliet Mwanga-Amumpaire, Rachel N. Musoke, Joseph K. Mbuthia, Elizabeth Maleche-Obimbo, Winstone M. Nyandiko, Elizabeth A. Bukusi, Maja Weisser, Nzovu Ulenga, **Mariama Diallo**, Vishal Goyal, Alistair Swanson, for the LIVING Study Team**722 HIGH DRUG RESISTANCE AND NEED FOR ART CHANGE IN CHILDREN WITH VIRAL FAILURE IN KENYA****Lisa Abuogi**, Patrick Oyaro, Katherine K. Thomas, Bhavna Chohan, Evelyn Brown, Emericah C. Kariuki, Bilal S. Ahmed, James Wagude, Eunice Kinywa, Irene Mukui, Leonard Kingwara, Boaz Oyaro, Lisa M. Frenkel, Rena Patel**723 EBV AND CMV VIREMIA PREDICT INCREASED MORTALITY IN HOSPITALIZED CHILDREN WITH HIV****Lasata Shrestha**, Irene Njuguna, Donghoon Lee, Elizabeth Maleche-Obimbo, Michael Boeckh, Emily R. Begnel, Daisy J. Chebet, Judith A. Onyango, Lisa Marie Cranmer, Meei-Li Huang, Barbra A. Richardson, Grace John-Stewart, Dalton C. Wamalwa, Jennifer Slyker**724 PEDIATRIC AND ADOLESCENT RETENTION TRENDS ACROSS AGE BANDS DURING COVID-19 PANDEMIC****Ziyanda T. Makaba**, Claire Serrao, Zamazamela P. Shelembe, Refilwe Mosome, Vimbainashe Sigauke, Dhirisha Naidoo**725 IMPACT OF ECONOMIC EMPOWERMENT ON ART ADHERENCE IN HIV-POSITIVE ADOLESCENTS IN UGANDA****Samuel Kizito**, Proscovia Nabunya, Flavia Namuwonge, Josephine Nabayinda, Joshua Kiyangi, Jennifer Nattabi, Fred Ssewamala**Poster Session-Q05 PK, SAFETY, AND ACCEPTABILITY OF NEW AGENTS FOR CHILDREN AND YOUTH****2:00 PM MT - 3:30 PM MT****732 EXTENDED SAFETY AND PK OF ANTI-HIV MONOCLONAL Ab VRC07-523LS IN HIV-EXPOSED INFANTS****Coleen K. Cunningham**, Edmund Capparelli, Elizabeth J. McFarland, Petronella Muresan, Charlotte Perlowski, Dwight E. Yin, Jack Moye, Sai Majji, Lynette Purdue, Paul A. Harding, Adrian McDermott, John R. Mascola, Barney S. Graham, for the IMPAACT P1112 Team

- 733 SUBOPTIMAL LOPINAVIR EXPOSURE ON 8-HOURLY LPV/r 4:1 IN HIV/TB-COINFECTED CHILDREN**
Chishala Chabala, Anna Turkova, Monica Kapasa, Kristen C. Lebeau, Kevin M. Zimba, Lubbe Wiesner, Khozva D. Zyambo, Louise C. Choo, Chalilwe Chungu, Joyce C. Lungu, Angela M. Crook, Veronica Mulenga, Diana Gibb, Helen McIlleron, for the SHINE Trial Team
- 734 TAF/TFV PHARMACOKINETICS WHEN GIVEN WITH PI/InSTI ART IN THE CHAPAS-4 PEDIATRIC TRIAL**
 **Hylke Waalewijn**, Alexander Szubert, Lubbe Wiesner, Chishala Chabala, Mutsa Bwakura-Dangarembizi, Shafic Makumbi, Joan Nangiya, Vivian Mumbiro, Veronica Mulenga, Victor Musiime, David M. Burger, Diana Gibb, Helen McIlleron, Angela Colbers, for CHAPAS4
- 735 PHARMACOKINETICS OF ABACAVIR IN AFRICAN CHILDREN <14 KG DOSED PER WHO WEIGHT-BANDS**
 **Suthunya Chupradit**, Dalton C. Wamalwa, Elizabeth Maleche-Obimbo, Adeodata R. Kekitiinwa, Juliet Mwanga-Amumpaire, Elizabeth A. Bukusi, Winstone M. Nyandiko, Joseph K. Mbuthia, Alistair Swanson, Tim R. Cressey, Baralee Punyawudho, Victor Musiime, for LIVING Study Team
- 736 PHARMACOKINETICS/SAFETY OF DTG, ABC/3TC DISPERSIBLE TABLETS IN THAI CHILDREN <20 KG**
Athiporn Premgamone, Suwaporn Anugulruengkitt, Noppadol Wacharachaisurapol, Chayapa Phasomsap, Monta Tawan, Thidarat Jupimai, Chutima Saisaengjan, Yardpiroon Tawon, Tim R. Cressey, Thanyawee Puthanakit
- 737 IMPAACT 2019: PK & SAFETY OF DISPERSIBLE ABC/DTG/3TC IN CHILDREN WITH HIV 6 TO <14 KG**
Kristina M. Brooks, Jennifer Kiser, Yasha Rani, Gaerolwe Masheto, Faezah Patel, Iris Mustich, Barbara Heckman, Mark Lojacono, Dwight E. Yin, Sai Majji, Hardik Chandasana, Helena Rabie, Patricia Flynn, for the IMPAACT 2019 Study Team
- 738 SAFETY AND PK OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN ADOLESCENTS**
Carolyn Bolton Moore, Edmund Capparelli, Katherine Calabrese, Brookie M. Best, Shawn Ward, Cindy McCoig, Herta Crauwels, Allison Agwu, Pearl Samson, Barbara Heckman, Susan L. Ford, Adeola Adeyeye, Andres Camacho-Gonzalez, Jack Moye, **Aditya H. Gaur**
- 739 ADOLESCENT AND PARENT EXPERIENCES WITH LONG-ACTING INJECTABLES IN THE MOCHA STUDY**
Elizabeth D. Lowenthal, Jennifer Chapman, Katherine Calabrese, Ryan Milligan, Allison Agwu, Andres Camacho-Gonzalez, Christiana Smith-Anderson, Jared Kneebone, Cindy McCoig, Conn M. Harrington, Rodica Van Solingen-Ristea, Adeola Adeyeye, Jack Moye, Carolyn Bolton Moore, Aditya H. Gaur

Poster Session-R02 FACTORS ASSOCIATED WITH SURVIVAL IN PEOPLE WITH HIV

2:00 PM MT - 3:30 PM MT

- 761 LIFE EXPECTANCY AFTER HIV DIAGNOSIS: UNITED STATES, 2008-2018**
Azfar-E-Alam Siddiqi, Anna Satcher Johnson, Angela Hernandez, Xiaohong Hu, Ruiguang Song
- 762 SURVIVAL AMONG HIV-POSITIVE VETERANS BEFORE AND AFTER THE VA OPT-OUT TESTING POLICY**
Kartavya J. Vyas, Vincent Marconi, Jodie L. Guest

- 763 MORTALITY RATES WITH OR WITHOUT InSTI THERAPY IN SUBGROUPS OF PWH: 2009-2018**
Keri N. Althoff, Elizabeth Humes, Parastu Kasaie, Cameron Stewart, Emily P. Hyle, Peter F. Rebeiro, Katherine Kooij, Maile Y. Karris, Vincent Marconi, Ank Nijhawan, Marina B. Klein, M John Gill, Joseph J. Eron, Richard Moore, for the North American AIDS Cohort Collaboration on Research and Design of IeDEA
- 764 ASSOCIATIONS OF MODERN INITIAL ANTIRETROVIRAL DRUG REGIMENS WITH ALL-CAUSE MORTALITY**
Adam Trickey, Lei Zhang, Suzanne M. Ingle, Antonella Castagna, Piotr Cichon, Pere Domingo, Sophie Grabar, Mina Psychogiou, Marta Rava, Peter Reiss, Christopher T. Rentsch, Melchor Riera, Michael J. Silverberg, Caroline Sabin, Jonathan A. Sterne
- 765 REDUCTIONS IN MORTALITY RISK AFTER STARTING ART IN 2010-2019 VERSUS 1995-2003**
Lei Zhang, Suzanne M. Ingle, M. John Gill, Ard van Sighem, Robert Zangerle, Enrico Girardi, Matthias Cavassini, Greer Burkholder, Derek D. Satre, George Adamis, Amy Justice, Sophie Grabar, John Koethe, Heidi Crane, Jonathan A. Sterne
- 766 EXCESS LIFE-YEARS LOST ASSOCIATED WITH HOSPITALIZATION FOR MENTAL ILLNESS**
Yann Ruffieux, Mpho Tlali, Anja E. Wettstein, Gary Maartens, John Joska, Morna Cornell, Leigh Johnson, Nicky Maxwell, Veronika W. Skrivanova, Mary-Ann Davies, Matthias Egger, Andreas D. Haas
- 767 PLASMA RENALASE AND ALL-CAUSE MORTALITY IN PEOPLE WITH AND WITHOUT HIV**
John Chang, Kaku So-Armah, Xiaojia Guo, Amy Justice, Gary Desir

Poster Session-R03 HIV CARE OUTCOMES

2:00 PM MT - 3:30 PM MT

- 768 CARE AND VIRAL SUPPRESSION AFTER HIV DIAGNOSIS IN US METROPOLITAN AREAS: 2019**
Shacara Johnson Lyons, Anna Satcher Johnson, Jianmin Li
- 769 HIV CARE OUTCOMES AMONG FOREIGN-BORN PERSONS WITH DIAGNOSED HIV INFECTION: 2019**
Tebitha Mawokomatanda, Sonia Singh, Eduardo Valverde
- 770 DECLINE IN CD4+ COUNTS AND RISK OF SEVERE MORBIDITY IN PLHIV AFTER INITIATING cART**
 **Maria Choufany**, Laurence Weiss, Alain Makinson, Hélène Roul, Jean-Michel Livrozet, Valérie Pourcher, Giovanna Melica, Christophe Rioux, Jean-Paul Viard, Esaïe Marshall, Sophie Grabar, Dominique Costagliola
- 771 EFFECT OF AIDS DRUG ASSISTANCE PROGRAM VARIABILITY ON TIMELY ART & VIRAL SUPPRESSION**
 Julia Thome, David B. Hanna, Angela Parcesepe, Keri N. Althoff, Jonathan A. Colasanti, Heidi Crane, Audrey L. French, Stephen Gange, Kelly Gebo, Nancy A. Hessol, Michael A. Horberg, Richard Moore, Michael J. Silverberg, **Peter F. Rebeiro**, for the North American AIDS Cohort Collaboration on Research and Design of IeDEA
- 772 THE IMPACT OF CHURN ON HIV OUTCOMES IN A SOUTHERN UNITED STATES CLINICAL COHORT**
Srinivasa Nithin Gopalsamy, Vincent Marconi, Wendy S. Armstrong, Jonathan A. Colasanti

- 773 CHARACTERIZING GEOSPATIAL MOBILITY AMONG PLWH IN TENNESSEE AND ITS IMPACT ON HIV CARE**
Aima A. Ahonkhai, Aihua Bian, Natalie Robbins, Laurie Maurer, Kate Clouse, Leslie Pierce, Jessica M. Perkins, Steven A. Wernke, Bryan Shepherd, Meredith R. Brantley
- 774 LATINOS WITH HIV IN DC: AN INTERSECTIONAL APPROACH EXPLORING HIV HEALTH OUTCOMES**
Leah Varga, Morgan Byrne, Marinella Temprosa, Michael A. Horberg, Carlos Rodriguez-Diaz, Anne Monroe, Amanda Castel, for the DC Cohort Executive Committee
- 775 EFFECT OF SOCIAL DETERMINANTS OF HEALTH ON UNCONTROLLED HIV INFECTION**
Jason S. Melo, Nancy A. Hessol, Sharon Pipkin, Ling Hsu
- 776 MENTAL HEALTH DISORDERS IN PEOPLE WITH HIV AND THE EFFECTS ON THE HIV CARE CONTINUUM**
 **Raynell Lang**, Jiafeng Zhu, Kristen McArthur, Michael A. Horberg, David J. Grelotti, Kalysha Closson, Viviane D. Lima, Angela Parcesepe, Paul S. Nestadt, Reena Camoens, Mona Loutfy, Judith Cook, Joseph Goulet, Keri N. Althoff, for the North American AIDS Cohort Collaboration on Research and Design of IeDEA
- 777 PATTERNS OF SUBSTANCE USE AND MENTAL HEALTH SYMPTOMS AMONG PEOPLE WITH HIV IN CARE**
Anthony T. Fojo, Catherine R. Lesko, Nikki Shen, Jarratt D. Pytell, Richard Moore, Marybeth McCauley, Heidi Hutton, Edward R. Cachay, Heidi Crane, Katerina Christopoulos, Michael Saag, Kenneth H. Mayer, Brian W. Pence, Geetanjali Chander, Bryan Lau
- 778 IMPACT OF METHAMPHETAMINE USE ON VIRAL LOAD BY GENDER AMONG PEOPLE WITH HIV**
Rob J. Fredericksen, Robin M. Nance, Lydia N. Drumright, Bridget M. Whitney, Stephanie A. Ruderman, Jimmy Ma, Andrew W. Hahn, Edward R. Cachay, Geetanjali Chander, Jeffrey M. Jacobson, Kenneth H. Mayer, Sonia Napravnik, Amanda Willig, Heidi Crane
- 779 VIRAL SUPPRESSION BY 3 MONTHS OF DIAGNOSIS AS AN INDICATOR OF PROGRESS IN HIV CARE**
Sierra Upton, Irina Tabidze, Jeff Lauritsen, Mark S. Dworkin
- 780 VIRAL SUPPRESSION AMONG PERSONS ENROLLED IN HIV RECENT INFECTION SURVEILLANCE: ZAMBIA**
Zaena Tessema, Elyssa Stoops, Aaron Shibemba, Lumbani Phiri, Simon Agolory, Kennedy Nkwemu, Samuel Yingst, Dailes Nsofwa, Leigh Tally, Peter Minchella, Melissa Arons, Canditra McLemore, Kemba N. Lee

Poster Session-T01 DETECTING RECENT INFECTIONS

2:00 PM MT - 3:30 PM MT

- 803 ANALYSIS OF RECENT INFECTION AMONG PERSONS NEWLY DIAGNOSED WITH HIV IN NIGERIA**
Moses Katbi, Adefisayo Adedoyin, Amobi Onovo, Adeoye Adegboye, Rachel Goldstein, Helina Meri, Angela Agweye, Pamela Gado, Amalachukwu Ukaere, David Onime
- 804 EVALUATION OF HIV-1 RECENCY ASSAYS AMONG PROSPECTIVELY OBSERVED HIV-1 SEROCONVERSIONS**
Stephanie Cox, Christoph Carter, Alex Kintu, Christian Callebaut, Jared Baeten, Moupali Das

805 NEAR-UNIVERSAL COVERAGE OF RECENT HIV TESTING IN RURAL UGANDA: POPULATION-BASED STUDY

Holly Nishimura, Ruth Young, Joseph G. Rosen, Nora S. West, Joseph Ssekasanvu, Robert Ssekubugu, Fred Nalugoda, Gertrude F. Nakigozi, Steven J. Reynolds, Larry W. Chang, David Sserwadda, Joseph Kagaayi, M. Kate Grabowski

Poster Session-T02 UNDERSTANDING AND STRENGTHENING HIV DIAGNOSIS AND MONITORING

2:00 PM MT - 3:30 PM MT

806 HIGH POSITIVITY AMONG CLIENTS OF A VIRTUAL HIV TESTING STRATEGY IN INDIA

Jade Bell, Allison M. McFall, Jalpa H. Thakker, Ajay K. Enugu, Viswanathan Arumugam, Rose Pollard, Vikrant Gupta, Aditya Singh, Samit Tandon, Harsh Agarwal, Aylur K. Srikrishnan, Subash Ghosh, Shruti H. Mehta, Sunil S. Solomon, Sangeeta Kaul

807 FACEBOOK ADVERTISEMENTS COST PER NEW HIV DIAGNOSIS USING ROUTINE AND TARGETED MODELS

John Hanna, Ank Nijhawan, Christoph U. Lehmann, Richard Medford

808 INTEGRATION OF HIV AND HCV SERVICES WITH MEDICATION FOR OPIOID USE DISORDER IN THE US

Eshan U. Patel, Becky L. Genberg, Xianming Zhu, Noa Krawczyk, Shruti H. Mehta, Aaron Tobian

809 PARTNER VIOLENCE, DISTRESS, AND HIV TESTING IN HETEROSEXUALLY ACTIVE ADULTS IN THE US

Cassandra O. Schember, Susan Cha, Meredith R. Brantley, Peter F. Rebeiro, Samantha A. Mathieson, Jack Marr, April Pettit, for the National HIV Behavioral Surveillance Study Group

810 HIV DIAGNOSIS AND LINKAGE TO CARE IN PARTNERS OF KEY POPULATION IN NIGERIA

Amobi Onovo, Kalaiwo Abiye, Angela Agweye, Godwin Emmanuel, Olivia Keiser

811 CHARACTERISTICS OF HEALTH FACILITIES ASSOCIATED WITH LOW HIV VIRAL LOAD COVERAGE

Fatima D. Mili, Jennifer F. Favaloro, Mackenzie Hurlston Cox, Shiraishi W. Ray, Larry Westerman, Amitabh P. Adhikari, Jessica Stephens, Heather Alexander, Erin Rottinghaus Romano

812 PATIENT-COLLECTED DRIED BLOOD SPOTS PROVIDE ACCURATE MEASUREMENT OF HIV VIRAL LOAD

Torin T. Schaafsma, Katherine K. Thomas, Heidi Van Rooyen, Maryam Shahmanesh, Stephen Asiimwe, Meighan Krows, Philip Joseph, Thulani Ngubane, Kombi Sausi, Nsika Sithole, Jared Baeten, Connie L. Celum, Alastair Van Heerden, Ruanne Barnabas, for the DO ART Study Team

813 INCREASED KNOWLEDGE OF HIV STATUS AMONG YOUTH: RESULTS OF YATHU YATHU RANDOMIZED TRIAL

Bernadette Hensen, Sian Floyd, Mwelwa Phiri, Albertus Schaap, Lucheka Sigande, Melvin Simuyaba, Lawrence Mwenge, Rosemary Zulu-Phiri, Louis Mwape, Sarah Fidler, Richard Hayes, Musonda Simwinga, Helen Ayles



Poster Session-T05 APPLYING SARS-CoV-2 TESTS IN PRACTICE

2:00 PM MT - 3:30 PM MT

- 823 UTILITY OF COVID-19 POINT-OF-CARE ANTIGEN TESTS IN LOW-MIDDLE INCOME SETTINGS**
Ameena Goga, Elizabeth S. Mayne, Kubashni Woeber, Simbarashe Takuva, Duduzile Nsiband, Molebogeng Lekalakala, Shameem Jaumdally, Portia Mutevedzi, Helena Vreede, Brodie Daniels, Clement Kufe, Keertan Dheda, Kamy Chetty, Glenda E. Gray, for the SA COVID-19 POC Study Team
- 824 POINT-OF-CARE ANTIBODY TESTS FOR COVID-19: FIELD-BASED PERFORMANCE, SOUTH AFRICA**
Ameena Goga, Elizabeth S. Mayne, Kubashni Woeber, Simbarashe Takuva, Duduzile Nsiband, Molebogeng Lekalakala, Shameem Jaumdally, Portia Mutevedzi, Helena Vreede, Brodie Daniels, Clement Kufe, Keertan Dheda, Kamy Chetty, Glenda E. Gray, for the SA COVID-19 POC Study Team
- 825 PERFORMANCE OF SARS-CoV-2 ANTIBODY ASSAYS IN A NATIONAL SEROSURVEY IN SOUTH AFRICA**
Sizulu Moyo, Adrian Puren, Leickness C. Simbayi, Khangelani Zuma, Nompumelelo Zungu, Mirriam Fortuin, Zinhle Brukwe, Beverley Singh, Tarylee Reddy, Edmore Marinda, Sean Jooste, Penny Moore, Lynn Morris, Thomas Rehle, for the National COVID-19 Antibody Survey Team
- 826 PREPANDEMIC SARS-CoV-2 SEROPOSITIVITY AMONG PREGNANT WOMEN: ZAMBIA, 2017-2018**
Mpanji Siwingwa, **Jonas Hines**, Sombo Fwoloshi, Samuel Yingst, Peter Minchella, Adam Wolkon, Gershon Chongwe, Simon Agolory, Lloyd B. Mulenga
- 827 SARS-CoV-2 RAPID ANTIGEN DIAGNOSTICS: COMBINED ANALYSIS OF 8 MATHEMATICAL MODELS**
Karla Therese L. Sy, Joshua M. Chevalier, Alvin X. Han, Sarah J. Girdwood, Mariet Benade, Megan Hansen, Naushin Huq, Amy Toporowski, Anna Bershteyn, Colin A. Russell, Brooke Nichols, for the ACT-Accelerator Rapid Antigen Diagnostic Modelling Consortium
- 828 ESTIMATION OF SARS-CoV-2 CUMULATIVE INCIDENCE: AN APPLICATION OF MIXTURE MODELING**
Rifa Khan, **Matt Hitchings**, Eshan U. Patel, Aylur K. Srikrishnan, Mark Anderson, K. S. Kumar, Amy Wesolowski, Syed H. Iqbal, Mary A. Rodgers, Shruti H. Mehta, Gavin Cloherty, Derek A. Cummings, Sunil S. Solomon

Poster Session-V04 EARLY PHASE STUDIES OF HIV VACCINES, bNABs, AND NEXT-GENERATION PrEP

2:00 PM MT - 3:30 PM MT

- 854 EFFECT OF ANTIMICROBIALS ON PENILE BACTERIAL DENSITY AND FORESKIN INFLAMMATION**
Tony Pham, Ronald M. Galiwango, Daniel Park, Juan Enrique Salazar, Brenda Okech, Victoria M. Biribawa, Juliet Mpendo, Moses Muwanga, Aaron Tobian, Jessica Prodder, Rupert Kaul, Cindy Liu, for the APM Trial Group
- 855 IN SITU FORMING IMPLANTS WITH CABOTEGRAVIR FOR ULTRA-LONG-ACTING PrEP**
Ivana Massud, Martina Kovarova, Andres Wong-Sam, Chuong Dinh, Eric Edwards, Victoria Mrotz, James Mitchell, Walid Heneine, Isabella Young, Roopali Shrivastava, J. Victor Garcia-Martinez, Charles Dobard, Gerardo Garcia-Lerma, Rahima Benhabbour

856 PHASE I TRIAL OF SUBCUTANEOUSLY ADMINISTERED VRC07-523LS AND PGT121

Sharana Mahomed, Nigel Garrett, Edmund Capparelli, Farzana Osman, Tanuja Gengiah, Dersere Archary, Cheryl Baxter, Penny Moore, Quarraisha Abdool Karim, Dan Barouch, Patricia E. Fast, John R. Mascola, Julie E. Ledgerwood, Lynn Morris, Salim S. Abdool Karim

857 A PHASE I CLINICAL TRIAL WITH A CONSENSUS SEQUENCE-BASED NATIVE-LIKE HIV-1 Env TRIMER

Emma Reiss - Stafford, Mathieu A. Claireaux, Karlijn van der Straten, Guistiniano V. Kerster, Wouter Olijhoek, Neeltje A. Kootstra, Rob Hurks, Antje Heit, Dietmar Katinger, Robin Shattock, Marit J. van Gils, Rogier W. Sanders, Godelieve De Bree

858 TAF/EVG DUAL-COMPARTMENT INSERT EFFICACY AGAINST RECTAL SHIV TRANSMISSION IN MACAQUES

Natalia Makarova, Tyana Singletary, M. M. Peet, James Mitchell, Angela Holder, Chuong Dinh, Maria Mendoza, Yi Pan, Walid Heneine, Gerardo Garcia-Lerma, Meredith Clark, James Smith, Gustavo Doncel

859 EXPECTATIONS OF PREVENTIVE BENEFITS & HIV-RELATED RISK BEHAVIORS IN HPTN069/ACTG5305

Jeremy Sugarman, Brian Weir, Chen Dun, Roy M. Gulick, Timothy Wilkin, Kenneth H. Mayer, Marybeth McCauley, Kevin P. Weinfurt

860 LONG-ACTING LENACAPAVIR PROTECTS AGAINST INTRAVENOUS CHALLENGE WITH SIMIAN-TROPIC HIV

Adrienne E. Swanstrom, Bing Lu, Kelly Wang, Jim Zheng, Matthew W. Breed, Kristin E. Killoran, Joshua Kramer, Jorden L. Welker, Paul Bieniasz, Theodora Hatzioannou, Robert Gorelick, Wade Blair, Stephen Yant, Jeffrey D. Lifson, **Gregory Q. Del Prete**

Poster Session-V05 COVID-19 TRACING, VACCINES, AND EFFECT OF TDF ON COVID-19 SEVERITY
2:00 PM MT - 3:30 PM MT

861 EVALUATION OF THE COVID-19 CONTACT TRACING PROGRAM IN KING COUNTY, WA, USA

Hannah N. Collins, Matthew R. Golden, Rachel W. Kubiak, Tigran Avoundjian, Eli Kern, Elizabeth Meacham, Megan Baldwin, Sarah Stewart, Julia Hood

862 WITHDRAWN**863 SARS-CoV-2 VACCINE EFFECTIVENESS FOR IN-HOSPITAL MORTALITY: ZAMBIA, 2021**

Jonas Hines, Duncan Chanda, Peter Minchella, Sombo Fwoloshi, Megumi Itoh, Davies Kampamba, Khozya D. Zyambo, Suilanj Sivile, Francis D. Mwansa, Kennedy Malama, Simon Agolory, Lloyd B. Mulenga

864 STOPCoV: SAFETY AND EFFICACY OF PREVENTATIVE COVID VACCINES

Sharon Walmsley, Leah Szadkowski, Rosemarie Clarke, Rizani Ravindran, Anne-Claude Gingras, for the STOPCOV Research Team

865 PROPORTION OF PLWH NOT VACCINATED FOR COVID-19 IN ITALY AND PREDICTORS

Alessandro Tavelli, Stefania Cicalini, Diletta Barbanotti, Spinello Antinori, Daniela Segala, Giovanni Guaraldi, Marta Guastavigna, Claudia Lazzaretti, Massimo Puoti, Francesca Ceccherini-Silberstein, Antonella Castagna, Enrico Girardi, Antonella D'Arminio Monforte, Andrea Antinori, for the Icona Study Group

866 EFFECTIVENESS OF COVID-19 VACCINATION AMONG PEOPLE LIVING WITH HIV DURING AN OUTBREAK

Kuan-Yin Lin, Pei-Ying Wu, Wang-Da Liu, Hsin-Yun Sun, Chien-Ching Hung, Shan-Chwen Chang

867 TENOFOVIR DISOPROXIL FUMARATE AND SEVERITY OF COVID-19 IN PEOPLE WITH HIV INFECTION

Julia Del Amo, Rosa Polo, Santiago Moreno, Esteban Martinez, Alfonso Cabello Úbeda, José A. Iribarren, Adrià Curran, Juan Macias, Marta Montero, Carlos Dueñas, Ana Mariño, Asun Diaz, Jose R. Arribas, Inma Jarrín, Miguel Hernán

868 HUMORAL IMMUNE RESPONSE AFTER COVID-19 VACCINATION IN PEOPLE LIVING WITH HIV

Linda Wittkop, Paul Loubet, Mathieu Chalouni, Karine Lacombe, Valérie Pourcher, Alain Makinson, Pierre-Olivier Girodet, David Chirio, Maeva Lefebvre, Catherine Mutter, Xavier De Lamballerie, Julie Longobardie, Axel Levier, Jean-Daniel Lelièvre, Odile Launay

Poster Session-X02 THE TANGLED WEB: SEXUAL AND REPRODUCTIVE HEALTH AND HIV RISK
2:00 PM MT - 3:30 PM MT
872 SEXUAL HEALTH CLINIC OUTCOMES AND PrEP LINKAGE IN A LARGE URBAN EMERGENCY DEPARTMENT

Aniruddha Hazra, Ruby Massey, Michelle Moore, Damaris Garcia, Richard Rodgers, Jessica Schmitt

873 DISCORDANT SYPHILIS ANTIBODY TESTING AND HIV RISK IN THE BRONX, NEW YORK

Nisha M. Patel, Uriel R. Felsen, Martin F. Packer, Mindy S. Ginsberg, Eric A. Meyerowitz

874 INNATE IMMUNITY PREDICTORS OF HIV RISK LINKED TO GENITAL HERPES

Yashini Govender, Charles Morrison, Pai Lien Chen, Xiaoming Gao, Hidemi S. Yamamoto, Tsungai Chipato, Sharon Anderson, Robert Barbieri, Robert Salata, Gustavo Doncel, **Raina Fichorova**

875 GENITAL MICROBIOME AND TENOFOVIR LEVELS IN TRANSGENDER MEN AND CISWOMEN ON ORAL PrEP

Jill Blumenthal, Mackenzie L. Cottrell, Sheldon Morris, Maile Y. Karris, Stephen A. Rawlings, Leah Burke, Sara Gianella, Antoine Chaillon

876 IMPACT OF NONVALENT ANTI-HPV VACCINATION ON ORAL PAPILLOMAVIRUS INFECTION

Roberto Rossotti, Alice Nava, Chiara Baiguera, Maria C. Moioli, Diana Fanti, Federico D'Amico, Elvira Inglese, Daniele Calzavara, Chiara Vismara, Simona Bossolasco, Andrea M. Tamburini, Massimo Cernuschi, Francesco Scaglione, Massimo Puoti

877 A RISK SCORE TO FACILITATE TARGETED STI DIAGNOSTIC TESTING IN YOUNG KENYAN WOMEN

Victor Omollo, Pamela Murnane, Renee Heffron, Lara Kidoguchi, Zachary O. Kwen, Elizabeth A. Bukusi, Connie L. Celum, Craig R. Cohen

878 BACTERIAL VAGINOSIS PRIOR TO AND DURING FIRST PREGNANCY IN KENYAN AGYW AT RISK OF HIV

Lynda M. Oluoch, Alison C. Roxby, Nelly R. Mugo, Kenneth Ngunjiri, Kenneth Tapia, Bhavna Chohan, Catherine Kiptinness, Anna Wald, Stacy Selke, Melody Wang, Murugi Micheni, Stephen Gakuo, Edith Kimani, Linet Makena

879 HIV-ASSOCIATED IMMUNE BIOMARKERS IN WOMEN AND GIRLS FOLLOWING SEXUAL VIOLENCE

Eleanor Capozzi, Katherine M. Anderson, Brittany A. Wood, Fernando Cabezas Mejia, Maile Y. Karris, Alexandra Fernandez-Desoto, Mimi Ghosh, Jamila K. Stockman

880 INCREASED HIV TARGET CELLS IN FGT DURING FOLLICULAR PHASE OF HIV SERONEGATIVE WOMEN

Sakthivel Govindaraj, Tyree Staple, Gina Bailey Herring, Marisa R. Young, Christina Mehta, Alicia K. Smith, Lisa Haddad, Vijayakumar Velu

**Poster Session-Y01 VIRAL LOAD MEASUREMENT AND SUPPRESSION
2:00 PM MT - 3:30 PM MT****887 IMPROVING TIME TO VIRAL SUPPRESSION: 5 YEARS POST-IMPLEMENTATION OF RAPID ART START**

Stephen Gurley, Jonathan Y. Huang, Sean Evans, Alexander Commanday, Melanie Strahm, Laura Carter-Williams, Katrina Barnes, Lisa Roland, Wendy S. Armstrong, Minh Ly T. Nguyen, Jonathan A. Colasanti

888 INCREASED HIV VIRAL SUPPRESSION DURING COVID-19 AMONG US URBAN PEOPLE WITH HIV

Matthew A. Spinelli, Noelle LeTourneau, Dave Glidden, Ling Hsu, Matthew D. Hickey, Elizabeth Imbert, Mireya Arreguin, Jennifer Jain, Jon J. Oskarsson, Susan P. Buchbinder, Mallory Johnson, Diane V. Havlir, Katerina Christopoulos, Monica Gandhi

889 WITHDRAWN**890 LINKAGE TO CARE AND TIME TO VIRAL SUPPRESSION IN PWH IN SPAIN: 2004-2020**

Belen Alejos, Cristina Díez, María José Galindo, Juan C. Lopez, Victoria Hernando, Oskar Ayerdi, María M. Alonso, Vicente Estrada, Juan A. Pineda, Alvaro Mena, María Novella Mena, David Dalmau, Inma Jarrín, **Juan Berenguer**, for the Cohort of the Spanish AIDS Research Network

891 RCT OF A MULTISECTORAL AGRICULTURAL INTERVENTION TO IMPROVE HIV AND HEALTH OUTCOMES

Craig R. Cohen, Elly Weke, Edward A. Frongillo, Lila A. Sheira, Rachel L. Burger, Adrienne R. Mocello, Pauline Wekesa, Shari Dworkin, Kate Scow, Harsha Thirumurthy, Starley R. Shade, Lisa Butler, Elizabeth A. Bukusi, Sheri D. Weiser

892 VIRAL LOAD MONITORING IN PUBLIC SECTOR CLINICS IN RURAL SOUTH AFRICA

Collins Iwuji, Lusanda Mazibuko, Meg Osler, Tshwaraganang Modise, Dickman Gareta, Siphephelo Dlamini, Patrick Gabela, Nompumelelo Khoza, Thabani Mtshali, Mark Siedner, Kathy Baisley, Andrew Boule, Kobus Herbst

893 INNOVATION TO ACHIEVE THE SECOND 95 AMIDST COVID-19 IN KEY POPULATION IN NIGERIA

Bolanle Oyeledun, Obioma Azurunwa, Christian Onyia, Collins Imarhiagbe, Francis Ogirima, Ezinne Akinola, Pius Izere-Christopher, Inyang Ayo, Evelyn Urueye, Emeka Kanebi

894 GENERIC DARUNAVIR AND DOLUTEGRAVIR ARE COST-EFFECTIVE IN SECOND-LINE ART

Jennifer Campbell, Janne Estill, Zachary Panos, Joseph Harwell, Marta Prescott, Paul Domanico, Carolyn Amole

895 TRANSITIONING WOMEN TO PREFERRED TLD REGIMEN IS LAGGING IN SUB-SAHARAN AFRICA

Neha Shah, Allahna Esber, Nicole Dear, Sean Cavannaugh, Michael Iroezindu, Emmanuel Bahemana, Hannah Kibuuka, John Owuoth, Jonah Maswai, Valentine Singoei, Trevor A. Crowell, Christina Polyak, Julie Ake, for the AFRICOS Study Group

Poster Session-Y02 HIV INCIDENCE, TESTING, AND LINKAGE
2:00 PM MT - 3:30 PM MT
896 HIV TEAMS AS TOOL TO IMPROVE THE HIV TESTING CASCADE IN HOSPITALS: #AWARE.HIV PROJECT

Carlijn Jordans, Kathryn S. Hensley, Jeroen J. van Kampen, Femke P. Mollema, Elisabeth H. Gisolf, Rachida El Moussaoui, Gonneke Hermanides, Anna Roukens, Robert-Jan Sips, Zoltán Szilávik, Renee N. Finkenflügel, Bart J. Rijnders, Annelies Verbon, Casper Rokx, for the #aware.hiv Project Group

897 PARTNER TESTING WITH HIV SELF-TEST DISTRIBUTION BY UGANDAN PREGNANT WOMEN WITH HIV

Andrew Mujugira, Gabrielle Stein, Agnes Nakyanzi, Jade Boyer, Deborah Donnell, Faith Naddunga, Paul Ssendiwalwa, Juliet Kyomugisha, Juliet Erone, Michelle Bulterys, Monisha Sharma, Monique A. Wyatt, Norma Ware, Connie L. Celum

898 CONTRIBUTIONS TO THE DECLINE IN HIV INCIDENCE AMONG GBM IN THE UK: A MODELLING STUDY

Valentina Cambiano, Fiona Lampe, Alec Miners, Sheena McCormack, Noel Gill, Graham Hart, Kevin Fenton, Marc Thompson, Gus Cairns, Valerie Delpeche, Alison Rodger, Andrew N. Phillips

Poster Session-Y03 RETENTION AND VIRAL SUPPRESSION
2:00 PM MT - 3:30 PM MT
899 HIV CARE OUTCOMES BY PLACE OF BIRTH AMONG HISPANIC/LATINO PERSONS WITH HIV INFECTION

Sonia Singh, Tebitha Mawokomatanda, Eduardo Valverde

900 FIDELITY OF UNIVERSAL HIV TEST AND TREATMENT (UTT) IMPLEMENTATION IN SOUTH AFRICA

Jabulani Ncayiyana, Radoslaw Panczak, Per Von Groote, Matthias Egger

- 901 IMPACT OF AGING IN HIV ON COVID-19 OUTCOMES VIA A MATCHED STUDY**
Siyuan Guo, Jiajia Zhang, Xueying Yang, Sharon Weissman, Bankole A. Olatosi, Rena Patel, Xiaoming Li
- 902 SIMILAR SHORT-TERM OUTCOMES WITH SAME-DAY ART INITIATION VS RAPID ART INITIATION**
Yi-Chia Huang, Chia-Jui Yang, Yuan-Ti Lee, Hsin-Yun Sun, Chin-Shiang Tsai, Nan-Yao Lee, Po-Huang Liu, Hung-Jen Tang, Chen-Hsiang Lee, Chi-Ying Lin, Chien-Ching Hung, for the Taiwan HIV Study Group
- 903 RETENTION IN HIV CARE IN RURAL SOUTH AFRICA USING DATA HARMONIZATION APPROACHES**
Collins Iwuji, Kathy Baisley, Dickman Gareta, Theresa Smit, Mark Siedner, Kobus Herbst
- 904 WITHDRAWN**
- 905 RETURN TO CARE AFTER INTERRUPTION IN TREATMENT IN SOUTH-CENTRAL UGANDA**
Alice Kisakye, Edward N. Kankaka, Joseph Kabanda, Bill Elur, Rose B. Nakityo, Steven J. Reynolds, M. Kate Grabowski, Maria Wawer, Ronald Gray, Larry W. Chang, Fred Nalugoda, Gertrude F. Nakigozi, Joseph Kagaayi, David Serwadda
- 906 SPATIAL HETEROGENEITY IN TREATMENT INTERRUPTION AND RETURN IN HIV PROGRAM IN UGANDA**
Edward N. Kankaka, Alice Kisakye, Francis X. Wasswa, Fred Nalugoda, Joseph Kabanda, Grace Namayanja, Steven J. Reynolds, M. Kate Grabowski, Maria Wawer, Ronald Gray, Larry W. Chang, Gertrude F. Nakigozi, Joseph Kagaayi, David Serwadda
- 907 IMPACT OF BRAZILIAN HEALTH POLICIES ON GENDER/AGE GAPS IN HIV TREATMENT INDICATORS**
Felipe Krakauer, Julie Somogyi, Fernanda M. Rick, Alexandre A. Ferreira, Vivian I. Avelino-Silva
- 908 POSITIVE PATHWAYS: IMPLEMENTATION TRIAL FOR HIV RETENTION IN CARE**
Michael Wohlfeiler, Rachel P. Weber, Laurence Brunet, Jennifer S. Fusco, Christine Uranaka, Quateka Cochran, Monica Palma, Tammeka Evans, Carl Millner, Gregory P. Fusco
- 909 MODELING THE IMPACT AND COST-EFFECTIVENESS OF INTERVENTIONS FOR RETENTION IN HIV CARE**
Anna Bershteyn, Lise Jamieson, Hae-Young Kim, Masabho P. Milali, Edinah Mudimu, Debra ten Brink, Rowan Martin-Hughes, Sherrie L. Kelly, Andrew N. Phillips, Loveleen Bansal-Matharu, Valentina Cambiano, Paul Revill, Gesine Meyer-Rath, Brooke Nichols
- 910 LONGITUDINAL ANALYSIS OF ADAP UTILIZATION: 2008-2018**
Kathleen A. McManus, Andrew Strumpf, Brian Sun, Amber Steen, Tim Horn, Auntrice Hamp, Amy Killelea, Olivia Liu, Elizabeth T. Rogawski McQuade

911



VIRAL LOAD BEFORE SWITCHING TO DOLUTEGRAVIR & ASSOCIATION WITH HIV TREATMENT OUTCOMES

Matthew L. Romo, Jessie Edwards, Aggrey Semeere, Beverly Musick, Mark Urassa, Francesca Odhiambo, Lameck Diero, Charles Kasozi, Gad Murenzi, Patricia Lelo, Annette H. Sohn, Kara Wools-Kaloustian, Denis Nash, for leDEA

POSTER SESSIONS BY CATEGORY

Note, abstracts that were submitted in categories designated with the letters C, S, U, and W were integrated into other sessions.

A. Virology of HIV or SARS-CoV-2

- A01 INFECTION AND ENVELOPE (Monday)
- A02 IMMUNE CELL INFECTION AND RESPONSES (Tuesday)
- A03 VIRUS REPLICATION AND HOST FACTORS (Wednesday)

B. Pathogenesis of HIV or SARS-CoV-2: Human Studies and Animal Models

- B01 NONHUMAN PRIMATE MODELS OF HIV INFECTION (Monday)
- B02 SARS-CoV-2 PATHOGENESIS (Monday)
- B03 CORRELATES OF SARS-CoV-2 OUTCOMES (Tuesday)
- B04 HIV TRANSMISSION (Monday)
- B05 HIV REPLICATION IN VIVO (Tuesday)
- B06 OUTCOMES OF HIV INFECTION (Wednesday)
- B07 HIV INFECTION AND INFLAMMATION (Wednesday)

C. HIV-Associated Tumor Viruses

D. Host Immune Responses, Vaccines, and Immunotherapies: HIV or SARS-CoV-2

- D01 HIV VACCINES (Monday)
- D02 SARS-CoV-2 VACCINES (Monday)
- D03 HIV IMMUNOLOGY: T CELLS (Tuesday)
- D04 SARS-CoV-2 IMMUNOLOGY: B CELLS AND ANTIBODIES (Wednesday)
- D05 HIV IMMUNE THERAPY (Wednesday)
- D06 SARS-CoV-2 VACCINE RESPONSES IN SPECIAL POPULATIONS (Wednesday)
- D07 SARS-CoV-2 IMMUNE THERAPY (Wednesday)
- D08 HIV IMMUNOLOGY: NK CELLS AND CYTOKINES (Monday)
- D09 SARS-CoV-2 IMMUNOLOGY: T CELLS, NK CELLS, AND CYTOKINES (Tuesday)
- D10 EBOLAVIRUS VACCINES (Monday)

E. HIV Reservoirs, Latency, and Curative Strategies Including Therapeutic Vaccines and Gene Therapy

- E01 SINGLE-CELL ANALYSES OF HIV RESERVOIRS (Tuesday)
- E02 MECHANISMS OF HIV LATENCY: MAINTENANCE AND REVERSAL (Wednesday)
- E03 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND (Monday)
- E04 CONTROLLERS AND POST-TREATMENT CONTROLLERS (Monday)
- E05 IMMUNE PRESSURES ON THE HIV RESERVOIR (Wednesday)
- E06 DYNAMICS OF HIV RESERVOIRS AND VIRAL REBOUND (Tuesday)

F. Neuropathogenesis and Neurologic Complications of HIV, SARS-CoV-2, or Both in Adults

- F01 CNS RESERVOIRS, REGULATION, AND ESCAPE (Tuesday)
- F02 ART: EFFICACY, SWITCHES, AND TOXICITY (Wednesday)
- F03 HIV, SIV, AND SARS-CoV-2 NEUROPATHOGENESIS MODELING (Monday)
- F04 BLOOD AND CSF BIOMARKERS OF BRAIN INTEGRITY AND FUNCTION (Monday)
- F05 NEUROIMAGING PROFILING AND OUTCOMES (Wednesday)
- F06 NEUROCOGNITION: PREDICTIONS, TRAJECTORIES, AND THERAPEUTICS (Tuesday)

G. Clinical Pharmacology in Adults

- G01 WHAT'S NEW IN PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS (Monday)
- G02 HIV PREVENTION AND MUCOSAL COMPARTMENT PHARMACOLOGY (Tuesday)
- G03 FROM FORMULATION TO DRUG EXPOSURE TO ADHERENCE: IMPORTANT PRINCIPLES IN PHARMACOLOGY (Wednesday)

H. Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 in Adults

- H01 CLINICAL TRIALS OF THERAPY FOR SARS-CoV-2: ANTIVIRALS AND IMMUNE MODIFIERS (Tuesday)
- H02 NEW ANTIVIRALS FOR SARS-CoV-2: ACTIVITY IN VITRO AND IN VIVO (Tuesday)
- H03 ANTIRETROVIRAL THERAPY IN EXPERIENCED PATIENTS: SUSTAIN OR REGAIN SUPPRESSION (Wednesday)
- H04 FIRST-LINE THERAPY, LOW-LEVEL VIREMIA, AND ADHERENCE (Wednesday)
- H05 NOVEL AGENTS: INTRIGUING RESULTS (Monday)

I. Resistance of HIV or SARS-CoV-2 to Small Molecules and Antibodies in Adults

- I01 PROFILING THE SENSITIVITY OF HIV TO NEUTRALIZING ANTIBODIES IN VIVO (Monday)
- I02 IMPACT OF HIV MUTATIONS ON FITNESS, DRUG RESISTANCE, AND TREATMENT RESPONSE (Monday)
- I03 NEW TECHNOLOGIES TO DETECT HIV DRUG RESISTANCE (Tuesday)
- I04 TRANSMITTED HIV DRUG RESISTANCE (Tuesday)

J. Hepatitis Viruses and Liver Complications in Adults

- J01 FATTY LIVER: NAFL, MAFL, AND NASH (Monday)
- J02 HCV TREATMENT AND DISEASE (Tuesday)
- J03 HCV ELIMINATION AND CARE CASCADE (Tuesday)
- J04 HBV EPIDEMIOLOGY, TREATMENT, AND PREVENTION (Wednesday)
- J05 EXPRESSION AND PATHOGENESIS OF LIVER DISEASE (Wednesday)

K. AIDS-Related Malignancies

- K01 CANCER RISK, TREATMENT, AND EPIDEMIOLOGY (Monday)
- K02 CERVICAL CANCER AND ANAL CANCER: PREVALENCE AND SCREENING (Tuesday)
- K03 BASIC SCIENCE OF HPV, KSHV, AND HIV-ASSOCIATED LYMPHOMAS (Tuesday)
- K04 KAPOSI SARCOMA TREATMENT AND HTLV (Wednesday)

L. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy

- L01 RISK FACTOR AND INFLAMMATORY MEDIATORS OF CARDIOVASCULAR DISEASE (Monday)
- L02 HYPERTENSION, HEART FAILURE, AND OTHER CARDIOVASCULAR DISEASE OUTCOMES (Tuesday)

M. Other Complications of HIV Infection and Antiretroviral Therapy in Adults

- M01 WEIGHT GAIN AND ADIPOSE TISSUE BIOLOGY (Wednesday)
- M02 METABOLIC COMPLICATIONS (Wednesday)
- M03 OTHER COMORBIDITIES (Tuesday)
- M04 FRAILTY AND SLEEP DISTURBANCES (Monday)
- M05 BIOMARKERS AND COMORBIDITIES (Monday)

N. Clinical Complications of COVID-19 Disease in Adults

- N01 POSTACUTE SEQUELLAE OF SARS-CoV-2 INFECTION (Monday)
- N02 NEUROCOGNITIVE MANIFESTATIONS OF COVID-19 (Tuesday)
- N03 COVID-19: MISCELLANEOUS CLINICAL AND THERAPEUTIC ISSUES (Wednesday)

O. Tuberculosis and Other Opportunistic Infections, Including the Impact of HIV or SARS-CoV-2 in Adults

- O01 NOVEL MYCOBACTERIAL DIAGNOSTICS AND BIOMARKERS (Wednesday)
- O02 PHARMACOLOGIC RELATIONSHIPS ASSOCIATED WITH TB DRUGS AND OUTCOMES (Tuesday)
- O03 TB EPIDEMIOLOGY, TREATMENT, AND IMPLEMENTATION SCIENCE (Tuesday)
- O04 NOVEL INSIGHTS IN CRYPTOCOCCAL MENINGITIS EPIDEMIOLOGY, TREATMENT, AND OUTCOMES (Monday)
- O05 CMV AND FUNGAL OPPORTUNISTIC INFECTIONS (Monday)

P. Maternal and Fetal HIV or SARS-CoV-2: Transmission, Prevention, Treatment, Pregnancy, and Postpartum Maternal Health

- P01 COVID-19 IN MOTHERS AND THEIR CHILDREN (Tuesday)
- P02 HIV, ART, AND PREGNANCY OUTCOMES: EPIDEMIOLOGY AND MECHANISMS (Tuesday)
- P03 EVOLVING INSIGHTS: MTCT RISK TO MATERNAL HEALTH (Monday)
- P04 NEW PERSPECTIVES ON THE HEALTH OF CHILDREN EXPOSED TO HIV IN UTERO (Monday)
- P05 HIV INFECTION AND PREVENTION IN PREGNANCY (Wednesday)

Q. HIV, SARS-CoV-2, or Both in Infants, Children, and Adolescents

- Q01 TIMING OF AND TESTING FOR HIV IN INFANTS, CHILDREN, AND YOUTH (Monday)
- Q02 EARLY TREATMENT AND HIV RESERVOIRS IN CHILDREN (Tuesday)
- Q03 REAL-WORLD OUTCOMES IN PEDIATRICS (Wednesday)
- Q04 COMORBIDITIES AND COMPLICATIONS OF HIV AND ART IN CHILDREN AND YOUTH (Monday)
- Q05 PK, SAFETY, AND ACCEPTABILITY OF NEW AGENTS FOR CHILDREN AND YOUTH (Wednesday)
- Q06 ALL THINGS COVID-19 IN CHILDREN (Tuesday)

R. Epidemiology of HIV in Adults

- R01 SARS-CoV-2 EPIDEMIOLOGY (Tuesday)
- R02 FACTORS ASSOCIATED WITH SURVIVAL IN PEOPLE WITH HIV (Wednesday)
- R03 HIV CARE OUTCOMES (Wednesday)
- R04 HIV CLUSTERS AND OUTBREAKS (Monday)
- R05 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION (Tuesday)
- R06 HIV EPIDEMIOLOGY (Monday)

S. Epidemiology of COVID-19

T. HIV Testing in Adults: New Diagnostics, Population Studies, and Scale-Up

- T01 DETECTING RECENT INFECTIONS (Wednesday)
- T02 UNDERSTANDING AND STRENGTHENING HIV DIAGNOSIS AND MONITORING (Wednesday)
- T03 HIV DIAGNOSTICS (Tuesday)
- T04 ADVANCES IN SARS-CoV-2 DIAGNOSTICS (Monday)
- T05 APPLYING SARS-CoV-2 TESTS IN PRACTICE (Wednesday)

U. COVID-19 Testing: New Diagnostics for Virus, Viral Variants, and Antibodies; Testing in Various Populations; and Scale-Up

V. HIV Prevention Interventions in Adults

- V01 PrEP: SERVICES, COST-EFFECTIVENESS, BONE LOSS, AND ARV RESISTANCE (Monday)
- V02 PrEP IN ADOLESCENTS AND PREGNANT PEOPLE (Tuesday)
- V03 HIV PREVENTION: NALTREXONE, PEP, AND PrEP FOR TRANSGENDER PEOPLE (Tuesday)
- V04 EARLY PHASE STUDIES OF HIV VACCINES, bNabs, AND NEXT-GENERATION PrEP (Wednesday)
- V05 COVID-19 TRACING, VACCINES, AND EFFECT OF TDF ON COVID-19 SEVERITY (Wednesday)

W. COVID-19 Prevention Interventions in Adults**X. Contraception, Sexually Transmitted Infections, and Reproductive Health in Adults**

- X01 SEXUAL AND REPRODUCTIVE HEALTH IN THE TIME OF COVID-19 (Monday)
- X02 THE TANGLED WEB: SEXUAL AND REPRODUCTIVE HEALTH AND HIV RISK (Wednesday)
- X03 THE PLOT THICKENS: SEXUAL AND REPRODUCTIVE HEALTH ISSUES IN PEOPLE WITH HIV (Tuesday)

Y. Implementation and Scale-Up of Prevention and Treatment for HIV and Impact of COVID-19 on HIV-Related Programs

- Y01 VIRAL LOAD MEASUREMENT AND SUPPRESSION (Wednesday)
- Y02 HIV INCIDENCE, TESTING, AND LINKAGE (Wednesday)
- Y03 RETENTION AND VIRAL SUPPRESSION (Wednesday)
- Y04 SUBSTANCE USE (Tuesday)
- Y05 HIV PREVENTION (Tuesday)
- Y06 MENTAL HEALTH AND STIGMA (Tuesday)
- Y07 HIV AND SURVIVAL (Monday)
- Y08 COVID-19 AND HIV (Monday)

With the virtual nature of the conference, the symposia sessions have been scheduled for the following week on February 22, 23, and 24.

LIVE SYMPOSIA SESSIONS BY DAY

TUESDAY, FEBRUARY 22, 2022

Symposium-1 GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION

CME

8:30 AM MT - 10:00 AM MT

Target Audience: This session is directed to persons interested in the process of HIV maturation.

Level of Knowledge: It is assumed that the participants are familiar with the basic steps of HIV replication.

Objectives: At the completion of the session, participants will be able to:

- Describe the role of intasomes in proviral integration
- Describe the principles of the HIV assembly and maturation process
- Describe the composition, structure, and function of the HIV capsid

Conveners

Theodora Hatzioannou, *The Rockefeller University, New York, NY, USA*

Frank Kirchhoff, *Ulm University Medical Center, Ulm, Germany*



51 HIV-1 MATURATION - NEW VIEWS OF AN EXTRAORDINARY METAMORPHOSIS

8:30

John A. Briggs, *Max Planck Institute of Biochemistry, Martinsried, Germany*



52 NEW ROLE FOR INTEGRASE IN VIRAL MATURATION

8:50

Sebla B. Kutluay, *Washington University in St Louis, Saint Louis, MO, USA*



53 STRUCTURE, ASSEMBLY, AND FUNCTIONAL ROLE OF THE INTASOME IN HIV REPLICATION

9:10

Dmitry Lyumkis, *Salk Institute for Biological Sciences, La Jolla, CA, USA*



9:30 LIVE QUESTIONS AND ANSWERS

Symposium-2 INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER?

CME

10:15 AM MT - 11:45 AM MT

Target Audience: This session is directed to clinicians, epidemiologists, pharmacologists, and virologists who are interested in postnatal HIV prophylaxis.

Level of Knowledge: It is assumed that the participants are familiar with the fundamentals of mother-to-child transmission of HIV.

Objectives: At the completion of the session, participants will be able to:

- Describe how postnatal prophylaxis works
- List the complexities of prevention strategies and where improvements could be made
- Recognize different possible strategies for postnatal prophylaxis in the future

Conveners

Sharon Nachman, *State University of New York at Stony Brook, Stony Brook, NY, USA*

Tim R. Cressey, *Chiang Mai University, Chiang Mai, Thailand*



54 SETTING THE STAGE: POSTNATAL PROPHYLAXIS TO REDUCE NEW PEDIATRIC INFECTIONS

10:15

Claire Thorne, *University College London, London, UK*



55 ANTIRETROVIRALS FOR PREVENTION: FROM ADULTS TO BABIES

10:35

Martina Penazzato, *World Health Organization, Geneva, Switzerland*



56 SPEED DIALING NEONATES TO THE IDEAL POSTNATAL PROPHYLAXIS REGIMEN

10:55

Adrie Bekker, *Stellenbosch University, Cape Town, South Africa*



11:15 LIVE QUESTIONS AND ANSWERS

Symposium-3 BRINGING CHOICE TO HIV PREVENTION

CME

12:00 PM MT - 1:30 PM MT

Target Audience: This session is directed to researchers, clinicians, and translational scientists interested in the delivery of choices of methods for HIV prevention and how the uptake of these can be improved.

Level of Knowledge: It is assumed that the participants are familiar with recent developments in the development of HIV prevention modalities.

Objectives: At the completion of the session, participants will be able to:

- Describe new HIV prevention options and the issues around their delivery
- Identify factors that influence the uptake of new prevention options
- Identify strategies that can be used in service delivery to increase uptake of new prevention technologies

Conveners

Sharon L. Hillier, *University of Pittsburgh Medical Center, Pittsburgh, PA, USA*

James A. McIntyre, *Anova Health Institute, Johannesburg, Gauteng, South Africa*



57 PREPARING FOR THE PLATE OF PREVENTION OPTIONS: HOW CAN WE DELIVER?

12:00

Hyman Scott, *San Francisco Department of Public Health, San Francisco, CA, USA*



58 BUILDING BACK BETTER: PUBLIC HEALTH SYSTEMS, PUBLIC TRUST, AND THE PrEP PIPELINE

12:20

Kenyon Farrow, *PrEP4ALL, New York, NY, USA*



59 APPLYING LESSONS ON EFFICACY AND AUTONOMY FROM CONTRACEPTION TO PrEP

12:40

Dominika Seidman, *University of California San Francisco, San Francisco, CA, USA*



1:00 LIVE QUESTIONS AND ANSWERS

WEDNESDAY, FEBRUARY 23, 2022

Symposium-4 THE HIV RESERVOIR: CREATION, SELECTION, MAINTENANCE, AND REVERSAL

CME

8:30 AM MT - 10:00 AM MT

Target Audience: This session is directed to scientists and clinicians who are interested in understanding the mechanisms by which HIV persists during antiretroviral therapy.

Level of Knowledge: It is assumed that the participants are familiar with the concepts of HIV persistence and latency.

Objectives: At the completion of the session, participants will be able to:

- Explain the concept of intact and defective proviruses
- Describe the mechanisms by which some proviruses are selected after prolonged therapy and the dynamics of the HIV reservoir
- Describe novel approaches used to target and eliminate latent and replication-competent HIV

Conveners

Katharine J. Bar, *University of Pennsylvania, Philadelphia, PA, USA*

Nicolas Chomont, *Université de Montréal, Montreal, Canada*



107 THE HIV-1 PROVIRAL LANDSCAPE: WHAT HAVE WE LEARNED?

8:30

Sarah Palmer, *The Westmead Institute for Medical Research, Westmead, Australia*



108 ROLE OF SELECTION PRESSURES AND IMMUNE RESPONSES IN SHAPING THE PERSISTENT RESERVOIR

8:50


Francesco R. Simonetti, *The Johns Hopkins University, Baltimore, MD, USA*



109 NOVEL IMMUNOTHERAPY-BASED CURE INTERVENTIONS

9:10

Mirko Paiardini, *Emory University, Atlanta, GA, USA*



9:30 LIVE QUESTIONS AND ANSWERS

Symposium-5 TUBERCULOSIS: NEW STRATEGIES IN THE TREATMENT OF THE WORLD'S OLDEST EPIDEMIC

CME

10:15 AM MT - 11:45 AM MT

Target Audience: This session is directed to researchers, clinicians, epidemiologists, and public health professionals familiar with tuberculosis and its pathogenesis, epidemiology, complications, treatment, and prevention.

Level of Knowledge: It is assumed that the participants are familiar with the basic principles of epidemiology, treatment, and prevention of drug-susceptible and drug-resistant tuberculosis.

Objectives: At the completion of the session, participants will be able to:

- Describe new data related to regimens and strategies to shorten treatment duration for drug-susceptible and drug-resistant tuberculosis
- Identify factors associated with treatment success with shorter course regimens for treatment of drug-susceptible and drug-resistant tuberculosis
- Identify promising new or novel agents under investigation for the treatment of tuberculosis

Conveners

Constance A. Benson, *University of California San Diego, San Diego, CA, USA*

William J. Burman, *Denver Public Health, Denver, CO, USA*



110 TREATMENT SHORTENING FOR DRUG-SUSCEPTIBLE TB: WHERE ARE WE AND WHAT'S NEXT?

10:15

Susan Dorman, *Medical University of South Carolina, Charleston, SC, USA*



111 A NEW ERA FOR TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS

10:35

David Moore, *London School of Hygiene & Tropical Medicine, London, UK*



112 THE PROMISE OF NEW DRUGS AND LONG-ACTING INJECTABLES FOR TB TREATMENT AND PREVENTION

10:55

Eric L. Nuermberger, *The Johns Hopkins University, Baltimore, MD, USA*



11:15 LIVE QUESTIONS AND ANSWERS

Symposium-6 SEXUALLY TRANSMITTED INFECTIONS: REVERSING THE TIDE

CME

12:00 PM MT - 1:30 PM MT

Target Audience: This session is directed to clinicians, researchers, and public health professionals interested in the state of the science and epidemiology of sexually transmitted infections (STIs).

Level of Knowledge: It is assumed that the participants are familiar with basic terminology and science for STIs.

Objectives: At the completion of the session, participants will be able to:

- Describe the current epidemiology of STIs in the United States
- Describe the underlying science behind STI vaccine development and evaluation
- Describe the current state of the science for several STI vaccines
- Explain the core science and practical issues behind preexposure prophylaxis (PrEP) for STIs
- List the current STIs and antimicrobial agents being evaluated for STI PrEP

Conveners

Connie L. Celum, *University of Washington, Seattle, WA, USA*

Jonathan Mermin, *Centers for Disease Control and Prevention, Atlanta, GA, USA*



113 THE STATE OF STI EPIDEMICS AND RESPONSE IN THE UNITED STATES

12:00

Leandro Mena, *Centers for Disease Control and Prevention, Atlanta, GA, USA*



114 CURRENT AND FUTURE RESEARCH IN STI VACCINES

12:20

Sinead Delany-Moretlwe, *Wits Reproductive Health and HIV Institute, Johannesburg, South Africa*



115

12:40

**SEXUALLY TRANSMITTED INFECTIONS
PROPHYLAXIS, IS THIS THE ANSWER?****Elizabeth A. Bukusi**, *Kenya Medical Research Institute,
Nairobi, Kenya*

1:00

LIVE QUESTIONS AND ANSWERS

THURSDAY, FEBRUARY 24, 2022

**Symposium-7 IMMUNE PROTECTION IN THE FIELD:
RAISING THE STAKES**

CME

8:30 AM MT - 10:00 AM MT

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the implications of recent advances in HIV prevention, and where the field is headed.

Level of Knowledge: It is assumed that the participants are familiar with the principles of passive and active vaccination for the prevention of HIV and other diseases.

Objectives: At the completion of the session, participants will be able to:

- Assess the current state of the HIV passive immunity field
- Explain the promise and limitations of mRNA vaccines
- Describe the recent progress in antibody germline targeting HIV immunogens

Conveners

Penny Moore, *University of the Witwatersrand, Johannesburg, South Africa*

Huldrych F. Günthard, *University Hospital Zurich, Zurich, Switzerland*



149 LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL?

8:30

Carolyn Williamson, *University of Cape Town, Cape Town, South Africa*



150 PUSHING THE ENVELOPE: mRNA VACCINES FOR COVID-19, HIV AND OTHER PATHOGENS

8:50

Drew Weissman, *University of Pennsylvania, Philadelphia, PA, USA*



151 JUMP-STARTED IMMUNE RESPONSE: NOW, HOW TO TEACH BREADTH?

9:10

William R. Schief, *Scripps Research Institute, La Jolla, CA, USA*



9:30 LIVE QUESTIONS AND ANSWERS

Symposium-8 HIV AND AGING

CME

10:15 AM MT - 11:45 AM MT

Target Audience: This session is directed to clinical and translational researchers studying HIV and aging and multi-morbidity in people with HIV.

Level of Knowledge: It is assumed that the participants are familiar with the increased burden of age-related multimorbidity in people with HIV.

Objectives: At the completion of the session, participants will be able to:

- Identify age-related complications that are (and are not) increased in people with HIV as well as the spectrum of morbidity in people who start antiretroviral therapy early versus late
- Identify basic mechanisms that might mediate the increased burden of age-related morbidity in people with HIV
- Identify measures of frailty and how they can be integrated into clinical trials

Convener

Peter W. Hunt, *University of California San Francisco, San Francisco, CA, USA*

**Panelists**

Jules Levin, *National AIDS Treatment Advocacy Project, New York, NY, USA*

Venita Ray, *Positive Women's Network, Oakland, CA, USA*



152 **CLINICAL EPIDEMIOLOGY OF AGING AND COMORBIDITY WITH HIV INFECTION: A GLOBAL PERSPECTIVE**

10:15

Mark Siedner, *Harvard Medical School, Boston, MA, USA*



153 **POTENTIAL BIOLOGIC MECHANISMS OF AGING IN HIV**

10:35

Nicholas Funderburg, *The Ohio State University, Columbus, OH, USA*



154 **INTEGRATING FRAILTY AND FUNCTIONAL OUTCOMES INTO CLINICAL TRIALS**

10:55

Kristine Erlandson, *University of Colorado, Denver, CO, USA*



11:15 **LIVE QUESTIONS AND ANSWERS**

Symposium-9 HIV PREVENTION IN SPECIAL POPULATIONS **CME**
12:00 PM MT - 1:30 PM MT

Target Audience: This session is directed to physicians, physician assistants, nurse practitioners, registered nurses, and other clinical decision-makers involved in HIV prevention care and research.

Level of Knowledge: It is assumed that the participants have a solid, working knowledge of HIV prevention and disease management.


Objectives: At the completion of the session, participants will be able to:

- Describe the unique challenges and barriers to HIV prevention success experienced in key populations (people who use drugs, transgender persons, and sex workers)
- Describe the current state of the science on approaches to HIV prevention among these key populations
- List the clinical best practices as well as research and current data gaps in HIV prevention for these key populations

Conveners

Jessica E. Justman, *Columbia University, New York, NY, USA*

Raphael J. Landovitz, *University of California Los Angeles, Los Angeles, CA, USA*



155 **A COMPREHENSIVE APPROACH TO HIV PREVENTION IN PEOPLE WHO USE SUBSTANCES**

12:00

Adam W. Carrico, *University of Miami, Miami, FL, USA*



**156 TAILORING HIV PREVENTION STRATEGIES FOR
12:20 THE UNIQUE NEEDS OF TRANSGENDER AND
 NONBINARY PEOPLE**

Sari L. Reisner, *Brigham and Women’s Hospital, Boston,
MA, USA*



**157 HIV PREVENTION APPROACHES TAILORED TO
12:40 INDIVIDUALS ENGAGED IN SEX WORK**

Frances M. Cowan, *Liverpool School of Tropical Medicine,
Harare, Zimbabwe*



1:00 LIVE QUESTIONS AND ANSWERS

ABSTRACT PROCESS

Scientific Categories

Basic Science

- A. Virology of HIV or SARS-CoV-2
- B. Pathogenesis of HIV or SARS-CoV-2: Human Studies and Animal Models
- C. HIV-Associated Tumor Viruses
- D. Host Immune Responses, Vaccines, and Immunotherapies: HIV or SARS-CoV-2
- E. HIV Reservoirs, Latency, and Curative Strategies Including Therapeutic Vaccines and Gene Therapy
- F. Neuropathogenesis and Neurologic Complications of HIV, SARS-CoV-2, or Both in Adults

Clinical

- G. Clinical Pharmacology in Adults
- H. Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 in Adults
- I. Resistance of HIV or SARS-CoV-2 to Small Molecules and Antibodies in Adults
- J. Hepatitis Viruses and Liver Complications in Adults
- K. AIDS-Related Malignancies
- L. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
- M. Other Complications of HIV Infection and Antiretroviral Therapy in Adults
- N. Clinical Complications of COVID-19 Disease in Adults
- O. Tuberculosis and Other Opportunistic Infections, Including the Impact of HIV or SARS-CoV-2 in Adults
- P. Maternal and Fetal HIV or SARS-CoV-2: Transmission, Prevention, Treatment, Pregnancy, and Postpartum Maternal Health
- Q. HIV, SARS-CoV-2, or Both in Infants, Children, and Adolescents

Epidemiology/Public Health

- R. Epidemiology of HIV in Adults
- S. Epidemiology of COVID-19
- T. HIV Testing in Adults: New Diagnostics, Population Studies, and Scale-Up
- U. COVID-19 Testing: New Diagnostics for Virus, Viral Variants, and Antibodies; Testing in Various Populations; and Scale-Up
- V. HIV Prevention Interventions in Adults
- W. COVID-19 Prevention Interventions in Adults
- X. Contraception, Sexually Transmitted Infections, and Reproductive Health in Adults
- Y. Implementation and Scale-Up of Prevention and Treatment for HIV and Impact of COVID-19 on HIV-Related Programs

For more information, visit the [CROI Abstract Categories](#) webpage. Note, abstracts that were submitted in categories designated with the letters C, S, U, and W were integrated into other categories.

Presenter Responsibilities

Visit the [Invited Presenter](#), [Oral Abstract Presenter](#), and [Poster Presenter](#) webpages for information regarding presenter responsibilities.

Abstract Review Process

For information, visit the [Abstract Guidelines and Submission](#) webpage.

Statistics for Abstracts

General Abstracts Submitted	1508
General Abstracts Accepted	860
General Oral Abstracts Accepted	92
General Poster Abstracts Accepted	768
Late-Breaking Abstracts Submitted	72
Late-Breaking Abstracts Accepted	38
Late-Breaking Oral Abstracts Accepted	17
Late-Breaking Poster Abstracts Accepted	21
Total Abstracts Submitted	1580
Total Abstracts Accepted	898

Abstracts Related to SARS-CoV-2 or Special Study Populations

SARS-CoV-2	214
Adolescents	48
Men Who Have Sex With Men (MSM)	94
People Who Inject Drugs (PWID)	39
Transgender Men or Women	37
Women	130

Authors have noted specific populations as the focus of their study, if applicable.

INDEX OF STUDIES RELATED TO WOMEN

The following index lists abstracts that the authors have noted women or women's issues as the focus of the study. This index was developed for attendees with an interest in these issues. We encourage you to refer to the Virtual Program for other presentations that may address this subject.

MONDAY, FEBRUARY 14, 2022

- 27 **UNIVERSAL HEPATITIS C VIRUS SCREENING IN PREGNANCY: THE JUICE IS WORTH THE SQUEEZE**
- 28 **HBIG-FREE STRATEGY TO PREVENT HBV MOTHER-TO-CHILD TRANSMISSION: ANRS TA PROHM STUDY**
- 29 **THE IMPACT OF COVID-19 ON ADVERSE BIRTH OUTCOMES IN BOTSWANA BY HIV STATUS**
- 37 **GUT MICROBIOTA, PLASMA METABOLOMICS, AND ATHEROSCLEROSIS IN HIV INFECTION**
- 41 **HPV GENOTYPING IN STUDY OF ADJUNCTIVE VACCINE FOR TREATMENT OF CERVICAL DYSPLASIA**
- 193 **SARS-CoV-2 SPIKE PROTEIN DESTABILIZES MICROVASCULAR HOMEOSTASIS**
- 211 **VAGINAL PROTEOME ALTERATIONS ASSOCIATED WITH HIV ACQUISITION IN THE VOICE TRIAL**
- 212 **VAGINAL MICROBIOME PROFILES IN YOUNG WOMEN AT RISK FOR HIV INFECTION**
- 213 **STROMAL FIBROBLASTS FROM FEMALE GENITAL TRACT DIMINISH THE IN VITRO EFFICACY OF PrEP**
- 304 **SEX DIFFERENCES IN CYTOKINE PROFILES DURING SUPPRESSIVE ANTIRETROVIRAL THERAPY**
- 352 **BEAT2: peg-IFN- α 2b + 3BNC117 AND 10-1074 KEEPS HIV AT <20 C/ML DURING 26 WEEK ATI**
- 410 **DECREASING CNS MYELOID ACTIVATION RELATES TO DECREASING NEURODEGENERATION IN HIV**
- 415 **MtDNA HAPLOGROUPS AND COGNITIVE FUNCTION IN BLACK AND HISPANIC WOMEN WITH HIV**
- 509 **HIV DRUG RESISTANCE IN WOMEN RANDOMIZED TO DTG VS EFV OR TDF VS TAF IN PREGNANCY**
- 511 **LOW-LEVEL RESISTANCE MUTATIONS CORRELATE WITH HIV THERAPY FAILURE IN PREGNANT WOMEN**
- 512 **CHANGES IN THE HIV-1 3'-PPT IN PATIENTS FAILING DOLUTEGRAVIR IN BRAZIL**
- 520 **NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS**
- 554 **USING NEXT-GENERATION SEQUENCING TO DETECT GENES RELATED TO CANCER IN WOMEN WITH HIV**
- 577 **SUBCLINICAL ATHEROSCLEROSIS AND IMMUNE ACTIVATION AMONG US FEMALES VS MALES WITH HIV**
- 578 **INFLAMMATORY CLUSTERS PREDICT MULTIMORBIDITY AND CVD IN PEOPLE WITH HIV ON ART**
- 619 **ASSOCIATION OF SLEEP DISRUPTION WITH KYNURENINE PATHWAY ACTIVATION IN WOMEN WITH HIV**
- 684 **PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION**

- 685 **WITHDRAWN**
- 686 **PBPK MODELING OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN PREGNANCY**
- 687 **PREGNANCY HEMOGLOBIN A1c AND GLUCOSE WITH DTG VS EFV, TDF VS TAF: IMPAACT 2010**
- 688 **WEIGHT GAIN WITH RALTEGRAVIR VS EFAVIRENZ DURING PREGNANCY**
- 689 **GESTATIONAL WEIGHT GAIN IN SOUTH AFRICAN PREGNANT WOMEN LIVING WITH HIV**
- 690 **UNIQUE PROFILE OF INFLAMMATION AND IMMUNE ACTIVATION IN PREGNANT US WOMEN WITH HIV**
- 695 **PREDICTORS OF NEURODEVELOPMENT IN HIV-EXPOSED–UNINFECTED INFANTS**
- 699 **IDENTIFYING HIV-POSITIVE MOTHERS AND EXPOSED INFANTS IN MATERNAL CHILD SERVICES**
- 710 **COMMUNITY-BASED, PEER-LED SRH SERVICES INCREASE COVERAGE IN AYP (YATHU YATHU TRIAL)**
- 729 **MENTAL HEALTH DISORDERS IN HIV-POSITIVE ADOLESCENTS AND YOUTHS: DATA FROM MOZAMBIQUE**
- 731 **WEIGHT GAIN AMONG ADOLESCENTS ON DOLUTEGRAVIR: A REAL CONCERN?**
- 782 **PHYLOGENETIC TRACKING OF HIV EPIDEMIC GROWTH IN QUEBEC FROM 2014 TO 2020**
- 829 **DIFFERENCES IN SEXUAL HEALTH CLINIC SERVICES BY AGE AND GENDER IN METROPOLITAN BOSTON**
- 941 **SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH**
- 942 **IMPACT OF COVID OUTBREAK ON PREVENTION AND CARE FOR HIV AND STIs AT A LARGE HOSPITAL**

TUESDAY, FEBRUARY 15, 2022

- 65 **HIV-1 REMISSION WITH CCR5Δ32Δ32 HAPLO-CORD TRANSPLANT IN A US WOMAN: IMPAACT P1107**
- 77 **PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH RIFAMPICIN THERAPY IN ACTG A5375**
- 80 **LONG-ACTING INJECTABLE FOR PREVENTION OF HIV AND UNPLANNED PREGNANCY**
- 82 **PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING**
- 86 **COUNTERFACTUAL ESTIMATION OF CAB-LA EFFICACY AGAINST PLACEBO USING EXTERNAL TRIALS**
- 88 **CHOICE AND ADHERENCE TO DAPIVIRINE RING OR ORAL PrEP BY YOUNG AFRICAN WOMEN IN REACH**
- 90 **DETECTING RECENT HIV INFECTIONS IN OUTPATIENT DEPARTMENTS: A MULTI-COUNTRY ANALYSIS**
- 92 **THE IMPACT OF FREE ANTIRETROVIRAL THERAPY FOR NONCITIZEN PREGNANT WOMEN IN BOTSWANA**
- 106 **TREATMENT OF ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS TO PREVENT ANAL CANCER**
- 205 **TGF-β2 IS ASSOCIATED WITH ASYMPTOMATIC/MILD SARS-CoV-2 INFECTION DURING PREGNANCY**
- 262 **INVESTIGATING ANTIGEN-INDEPENDENT CD8+ T-CELL ENFORCEMENT OF HIV LATENCY**

- 427 A NOVEL COMORBIDITY INDEX PREDICTS COGNITIVE CHANGE IN PEOPLE WITH CHRONIC HIV
- 440 ANTI-INFECTIVES' PENETRATION IN UPPER AND LOWER FEMALE GENITAL TISSUES
- 538 PROGRESS TOWARD HCV MICROELIMINATION AMONG HIV-POSITIVE PATIENTS IN TAIWAN
- 561 PREVALENCE AND SEVERITY OF HPV-ASSOCIATED ANAL DISEASE IN PWH YOUNGER THAN 35
- 563 GENITAL AND ANAL CYTOLOGY: HPV COTESTING RESULTS FROM 381 WOMEN LIVING WITH HIV
- 564 EVALUATING HPV TESTING FOR CERVICAL CANCER SCREENING IN FOUR COUNTRY'S HIV PROGRAMS
- 591 IMPAIRED RESPONSE OF MEMORY TREG TO HDL IS ASSOCIATED WITH HIGHER CARDIOVASCULAR RISK
- 658 SEX DIFFERENCES IN LATENT TUBERCULOSIS INFECTION AMONG CLOSE CONTACTS IN BRAZIL
- 670 HIV AND SARS-CoV-2 INFECTION AMONG POSTPARTUM KENYAN WOMEN AND THEIR INFANTS
- 671 ADVERSE PREGNANCY OUTCOMES ASSOCIATED WITH COVID-19 INFECTION IN WESTERN KENYA
- 672 SARS-CoV-2 INFECTION AND PREGNANCY IN AFRICA: A 6-COUNTRY RETROSPECTIVE COHORT STUDY
- 673 LONGITUDINAL SARS-CoV-2 ANTIBODY RESPONSE IN PREGNANCY AND TRANSPLACENTAL TRANSFER
- 674 IMMUNE SYSTEM PROFILE AND CYTOKINE LEVELS OF SARS-CoV-2 IN PREGNANCY AND NEWBORNS
- 675 NEUTRALIZING ANTIBODY RESPONSE AND TRANSPLACENTAL TRANSFER IN COVID-19 IN PREGNANCY
- 676 IMPAACT 2032: REMDESIVIR PK & SAFETY IN PREGNANT AND NON-PREGNANT WOMEN WITH COVID-19
- 677 NEURAL TUBE DEFECTS AND PRENATAL EXPOSURE TO DOLUTEGRAVIR: UNITED STATES, 2008-2019
- 678 BIRTH OUTCOMES FOLLOWING PRENATAL EXPOSURE TO DOLUTEGRAVIR: THE DOLOMITE-EPPICC STUDY
- 679 RISK-BENEFIT TRADE-OFF FOR PREGNANCY AND INFANT OUTCOMES: DTG, EFV, TAF, AND TDF
- 680 ADVERSE OUTCOMES IN SUBSEQUENT PREGNANCIES IN THE IMPAACT 2010 TRIAL
- 681 SOME *InSTIs* INDUCE TOXICITY AND DIFFERENTIATION IN HUMAN EMBRYONIC STEM CELLS
- 682 IMPACT OF MATERNAL HIV/HBV COINFECTION ON PREGNANCY AND INFANT OUTCOMES
- 683 HIV-RELATED DIFFERENCES IN PLACENTAL IMMUNOLOGY: DATA FROM THE PRACHITi COHORT
- 749 DAY-TO-DAY IMPACT OF COVID-19 ASSOCIATED WITH RISK OF OVERDOSE: C3PNO COHORT FINDINGS
- 787 EMPIRICAL ESTIMATES OF ADULT HIV INCIDENCE ACROSS 12 COUNTRIES IN SUB-SAHARAN AFRICA
- 788 EDUCATION AND HIV RISK: EVIDENCE FROM 12 SUB-SAHARAN AFRICAN COUNTRIES, 2015-2018
- 795 HIV INCIDENCE AND IMPACT OF INTERVENTIONS IN FEMALE SEX WORKERS IN MENA
- 802 AUTHORSHIP INEQUALITIES IN GLOBAL HEALTH RESEARCH INITIATIVE

- 842 A TOOL TO ASSESS HIV PREVENTION READINESS OF ADOLESCENT GIRLS AND YOUNG WOMEN
- 845 PrEP USE PERSISTENCE AMONG KENYAN WOMEN WHO INITIATED PrEP DURING PREGNANCY
- 846 ORAL PrEP USE AMONG SOUTH AFRICAN WOMEN WITH PLANS FOR PREGNANCY
- 847 GEOGRAPHIC CLUSTERING AND PROGRESS IN PrEP USE AMONG WOMEN IN THE US: 2012-2019
- 884 DOUBLE-DOSE ETONOGESTREL CONTRACEPTIVE IMPLANT OVERCOMES INTERACTION WITH EFVIRENZ
- 885 DISPARITIES IN PRENATAL SYPHILIS RISK AMONG PREGNANT WOMEN LIVING WITH HIV IN BRAZIL
- 886 SCREENING OF STIs IN PREGNANCY AND PREGNANCY OUTCOMES IN WOMEN WITH AND WITHOUT HIV
- 914 SUBSTANCE USE TREATMENT UTILIZATION AMONG WOMEN WITH AND AT RISK FOR HIV IN THE SOUTH
- 915 RANDOMIZED TRIAL OF PATIENT ACTOR TRAINING TO IMPROVE PrEP SERVICES FOR AGYW IN KENYA
- 922 DEFERRING CREATININE CLEARANCE TESTING TO SUPPORT PrEP UPTAKE IN YOUNG WOMEN
- 925 PrEP DISCONTINUATION AMONG WOMEN IN US COMMUNITY HEALTH CENTERS

WEDNESDAY, FEBRUARY 16, 2022

- 121 PHASE IIB EFFICACY TRIAL OF MOSAIC HIV-1 VACCINE REGIMEN IN AFRICAN WOMEN: IMBOKODO
- 135 DOLUTEGRAVIR WITH RECYCLED nRTIs IS NONINFERIOR TO PI-BASED ART: VISEND TRIAL
- 143 CDC'S DIRECT-TO-CONSUMER DISTRIBUTION OF 100,000 HIV SELF-TESTS
- 144 HIV SELF-TESTING UNCOVERS HIGH BURDEN OF HIDDEN INFECTIONS IN INDIA
- 145 HIGH HIV SELF-TESTING OF MALE PARTNERS OF WOMEN LIVING WITH HIV IN RURAL SOUTH AFRICA
- 146 SIX-MONTH PrEP WITH HIV SELF-TESTING TO IMPROVE DELIVERY KENYA: A RANDOMIZED TRIAL
- 226 SURVIVAL AND DISEASE PROGRESSION IN ART-NAÏVE LTNP WITH UNDETECTABLE HIV-REPLICATION
- 227 METABOLIC SHIFTS POTENTIATE ACCELERATED AGING IN SUCCESSFUL LONG-TERM HIV TREATMENT
- 271 LOSS OF TOLERANCE AND ANERGY IN HUMAN PERIPHERAL B CELLS DURING SARS-CoV-2 INFECTION
- 283 PROMOTING RESIDENT MEMORY CD8+ T-CELL PHENOTYPES TO ENHANCE HIV RESERVOIR ELIMINATION
- 373 SARS-CoV-2 mRNA VACCINATION EXPOSES LATENT HIV TO Nef-SPECIFIC CD8+ T CELLS
- 447 EVG/COBI/FTC/TAF TABLETS DISSOLVED IN TAP WATER NEAR BIOEQUIVALENT WITH WHOLE TABLETS
- 486 RESUPPRESSION AFTER VIROLOGICAL FAILURE IN DOLUTEGRAVIR AND EFVIRENZ-BASED REGIMENS
- 490 PREDICTORS OF VIRAL SUPPRESSION FOLLOWING ENHANCED ADHERENCE COUNSELING: VISEND TRIAL
- 494 B/F/TAF FIVE-YEAR OUTCOMES IN TREATMENT-NAÏVE ADULTS

573	RISK AND PROTECTIVE FACTORS ASSOCIATED TO HTLV-1 MOTHER-TO-CHILD TRANSMISSION
593	PREDICTED IMPACT OF ART SWITCH ON BODY MASS INDEX AMONG WOMEN WITH HIV
598	48-WEEK BODY COMPOSITION CHANGES IN PLWH SWITCHING FROM 3DR TO DTG + 3TC: DOLAM STUDY
644	MENSTRUATION IRREGULARITIES AMONG REPRODUCTIVE-AGE WOMEN DURING THE COVID-19 PANDEMIC
700	EVALUATION OF CAB-LA SAFETY AND PK IN PREGNANT WOMEN IN THE BLINDED PHASE OF HPTN 084
701	RECENT HIV INFECTION AMONG PREGNANT WOMEN FROM 2 NATIONAL SURVEYS IN SOUTH AFRICA
702	HIV TEST-POSITIVITY IN PREGNANT AND POSTNATAL WOMEN RETESTED IN NAMPULA, MOZAMBIQUE
703	PREGNANCY IN WOMEN WITH HIV IN A TUBERCULOSIS-PREVENTIVE THERAPY TRIAL
704	PrEP CONTINUATION AND OBJECTIVE ADHERENCE IN PREGNANT/POSTPARTUM SOUTH AFRICAN WOMEN
705	PREGNANCY AND BIRTH OUTCOMES IN PrEP-EXPOSED & UNEXPOSED PREGNANT SOUTH AFRICAN WOMEN
719	SEVERE IMMUNE SUPPRESSION AND RETENTION AMONG INFANTS IN SOUTH AFRICA
736	PHARMACOKINETICS/SAFETY OF DTG, ABC/3TC DISPERSIBLE TABLETS IN THAI CHILDREN <20 KG
763	MORTALITY RATES WITH OR WITHOUT InSTI THERAPY IN SUBGROUPS OF PWH: 2009-2018
770	DECLINE IN CD4+ COUNTS AND RISK OF SEVERE MORBIDITY IN PLHIV AFTER INITIATING cART
778	IMPACT OF METHAMPHETAMINE USE ON VIRAL LOAD BY GENDER AMONG PEOPLE WITH HIV
813	INCREASED KNOWLEDGE OF HIV STATUS AMONG YOUTH: RESULTS OF YATHU YATHU RANDOMIZED TRIAL
856	PHASE I TRIAL OF SUBCUTANEOUSLY ADMINISTERED VRC07-523LS AND PGT121
859	EXPECTATIONS OF PREVENTIVE BENEFITS & HIV-RELATED RISK BEHAVIORS IN HPTN069/ACTG5305
867	TENOFOVIR DISOPROXIL FUMARATE AND SEVERITY OF COVID-19 IN PEOPLE WITH HIV INFECTION
872	SEXUAL HEALTH CLINIC OUTCOMES AND PrEP LINKAGE IN A LARGE URBAN EMERGENCY DEPARTMENT
874	INNATE IMMUNITY PREDICTORS OF HIV RISK LINKED TO GENITAL HERPES
875	GENITAL MICROBIOME AND TENOFOVIR LEVELS IN TRANSGENDER MEN AND CISWOMEN ON ORAL PrEP
877	A RISK SCORE TO FACILITATE TARGETED STI DIAGNOSTIC TESTING IN YOUNG KENYAN WOMEN
878	BACTERIAL VAGINOSIS PRIOR TO AND DURING FIRST PREGNANCY IN KENYAN AGYW AT RISK OF HIV

879	HIV-ASSOCIATED IMMUNE BIOMARKERS IN WOMEN AND GIRLS FOLLOWING SEXUAL VIOLENCE
880	INCREASED HIV TARGET CELLS IN FGT DURING FOLLICULAR PHASE OF HIV SERONEGATIVE WOMEN
895	TRANSITIONING WOMEN TO PREFERRED TLD REGIMEN IS LAGGING IN SUB-SAHARAN AFRICA
897	PARTNER TESTING WITH HIV SELF-TEST DISTRIBUTION BY UGANDAN PREGNANT WOMEN WITH HIV
907	IMPACT OF BRAZILIAN HEALTH POLICIES ON GENDER/AGE GAPS IN HIV TREATMENT INDICATORS

INDEX OF PRESENTING AUTHORS

The following index list presenting authors as of January 17, 2022. Changes to presenting authors after that date are not reflected.

-A-

Abdelmoumen, Karim 574
 Abdelwahab, Mahmoud T. 655
 Abdul Massih, Sandra 447
 Abela, Irene A. 124
 Abu-Raddad, Laith J. 49, 759
 Abuogi, Lisa 722
 Adeniji, Opeyemi S. 280
 Ahmed, Amina 744
 Ahonkhai, Aima A. 773
 Akelo, Victor 671
 Akinola, Ezinne P. 893
 Akpan, Uduak 489
 Akullian, Adam 794
 Alagaratnam, Jasmini 127
 Alba, Diana L. 36
 Alessandri-Gradt, Elodie 501
 Alessio, Loredana 540
 Alford, Kate 422
 Ali, Ali M. 656
 Alrubayyi, Aljawharah 306
 Althoff, Keri N. 763
 Ambike, Shubhankar 180
 Amick, Alyssa K. 831
 Ances, Beau M. 416, 420, 594
 Antar, Annukka A.R. 383
 Anthony-Gonda, Kim 278
 Antinori, Andrea 291
 Armani-Tourret, Marie 357
 Armengol, Victor D. 128
 Arribas, Jose R. 460
 Atehortua, Laura O.F. 591
 Atindaana, Edmond 378
 Atoyebi, Shakir A. 686
 Aung, Htein Linn 425
 Ayles, Helen 710

-B-

Baker, Owen R. 820
 Bakewell, Nicholas 622
 Balasubramanian, Ruchita 916
 Balibar, Carl J. 343
 Ballivian, Jamile 642
 Bardon, Ashley 923
 Bares, Sara 633
 Barry, Michael 841
 Beauchamp, Geetha 842
 Beaudoin-Bussi eres, Guillaume 301
 Beck, Evan 818, 819
 Bedrossian, Rita A. 621
 Begnel, Emily R. 670
 Bell, Jade 806
 Bellini, Nicolas 342
 Benhabbour, Rahima 445
 Benito, Jos   M. 258
 Benmassaoud, Amine 519
 Bennett, Brady W. 847
 Berenguer, Juan 531, 890
 Bershteyn, Anna 909

Bertagnolli, Lynn N. 443
 Berton, Mattia 436
 Bissa, Massimiliano 236
 Blasi, Maria 194
 Blumenthal, Jill 84, 875
 Boehm, Daniela 336
 Boesecke, Christoph 924
 Bohlius, Julia 560
 Bolzenius, Jacob 419
 Bonacci, Robert A. 786
 Bonett, Stephen 869
 Bono, Valeria 206
 Boopathy, Archana V. 237
 Borobia, Alberto 463
 Boswell, Kristin L. 317
 Bowler, Scott 202
 Boyce, Ceejay L. 509
 Brenner, Bluma G. 782
 Brinkman, Kees 292
 Brooks, Kelsie 199
 Brooks, Kristina M. 431, 676, 737
 Brummel, Sean 679
 Brunet-Ratnasingham, Elsa 313
 Bryson, Yvonne 65
 Buck, Amanda M. 320
 Bulterys, Michelle 695
 Burdorf, Rachel M. 511

-C-

Cai, Yanhui 349, 363
 Calmy, Alexandra L. 941
 Caloren, Lo  c C. 601
 Cambiano, Valentina 898
 Cambou, Mary C. 675
 Campbell, Jennifer 894
 Capa, Laura 226
 Capozzi, Eleanor 879
 Casazza, Joseph P. 498
 Caskey, Marina 140
 Castagna, Antonella 865
 Castel, Amanda 940
 Castilho, Jessica L. 885
 Castleman, Moriah J. 271
 Cavallari, Eugenio Nelson 567
 Chabala, Chishala 733
 Chaisson, Lelia H. 657
 Chakrabarti, Lisa A. 322
 Chammartin, Fr  d  rique 295
 Chang, Jennifer J. 142
 Chang, John 767
 Chang, Joseph C. 840
 Chang, Vincent 437, 661
 Chappell, Catherine A. 27, 884
 Chatterjee, Debashree 253
 Chaudhuri, Shaoli 946
 Chavez, Pollyanna R. 143
 Chawki, Sylvain 441
 Cheema, Jaskaran S. 542
 Chemaitelly, Hiam 795
 Chen, Yaokai 74, 669

Chen, Yaozong 300
 Cherenack, Emily M. 644
 Cherkos, Ashenafi S. 694
 Chew, Kara W. 284
 Chinula, Lameck 687
 Chirairo, Harugumi 147
 Choufany, Maria 770
 Chupradit, Suthunya 735
 Cindi, Zinhle 439
 Clark, Kolin 356
 Climent, Nuria 223
 Clipman, Steven J. 784
 Cohen, Craig R. 891
 Coiras, Mayte 345
 Coleman, Megan 850
 Collier, Sigrid 570
 Collins, Hannah N. 861
 Collora, Jack A. 329
 Compton, Alex A. 22
 Conrado, Daniela J. 461
 Copertino, Dennis C. 374
 Corbeau, Pierre 207
 Corbett, Craig 424
 Corley, Michael J. 394
 Cornelisse, Vincent J. 921
 Coutinho, Conrado M. 688
 Cox, Stephanie 804
 Cross, Gail B. 76
 Crowell, Trevor A. 387
 Cunningham, Coleen K. 732
 Cysique, Lucette A. 634

-D-

Daar, Eric S. 492
 Dagotto, Gabriel 252
 Dahourou, D  sir   Lucien 728
 Daly, Michele B. 444
 Das, Srijaanee 545
 Dash, Prasanta K. 588
 Dashti, Amir 64
 Day, Cheryl 646
 de la Court, Feline 919
 DeJesus, Edwin 429
 Dekker, Jose 507
 Del Amo, Julia 867
 Del Prete, Gregory Q. 860
 Delany-Moretlwe, Sinead 700
 Deleage, Claire 19, 376
 Deodhar, Suyash 448
 Dhummakupt, Adit 714
 Di Chiara, Costanza 276
 Di Gennaro, Francesco 729
 Diakparomre, Ogheneochuko E. 871
 Diallo, Mariama 721
 Diaz-Martinez, Janet 525
 Dickinson, Laura 100
 Diez-Fuertes, Francisco 267
 Dillon, Stephanie 220
 Ding, Shilei 169
 Dirajlal-Fargo, Sahera 727
 Dittmer, Dirk P. 568
 Doctor, Jessica 35

Dolci, Giovanni 303
 Domínguez-Rodríguez,
 Sara 717
 Donnell, Deborah 86
 Doshi, Shradha J. 747
 Drammeh, Bakary 89
 Du, Li 172
 Dubé, Mathieu 326
 Dufour, Caroline 67, 327
 Durieux, Jared C. 610
 Durstenfeld, Matthew S. 99

-E-

Eden, Arvid 131
 Ellis, Ronald J. 414, 427
 Ellsworth, Grant 41
 Elsbernd, Kira 708
 Emery, Ann L. 184
 Engamba, Danielle C.M. 490
 Erlandson, Kristine 34
 Eshleman, Susan 95
 Esmailzadeh, Elmira 162
 Esposito, Vincenzo 599
 Esteban-Cantos, Andrés
 218
 Evans, Ceri 268
 Evering, Teresa H. 626
 Ezeonwumelu, Ifeanyi
 J. 339

-F-

Fairlie, Lee 680
 Falcinelli, Shane D. 334
 Farr Zuend, Christina 211
 Fennell, Christina 92
 Ferrari, Ludovica 290
 Ferré, Valentine M. 297, 299
 Fichorova, Raina 874
 Fichtenbaum, Carl J. 520
 Files, Jacob K. 263
 Filipkowski, Alexandra
 M. 584
 Fink, Douglas 612
 Fischer, Tracy 404
 Fisher, Katie 377
 Fittje, Pia 305
 Flores Ortega, Ricardo E. 72
 Fojo, Anthony T. 777, 943
 Fox, Howard S. 393
 Fox, Julie 849
 Frasca, Federica 310, 741
 Fredericksen, Rob J. 778
 Freeman, Michael L. 592
 Frouard, Julie 330
 Fulda, Evelynne S. 50

-G-

Gabuzda, Dana 407
 Gaebler, Christian 361
 Gaisa, Michael M. 563
 Gaitan, Noah C. 514
 Gallardo-Cartagena, Jorge
 A. 97
 Gallay, Philippe 478
 Gallego Cortés, Ana 368
 Gandhi, Aditya R. 930
 Gantner, Pierre 388
 Garcia, Federico 516
 Gaur, Aditya H. 738
 Gebre, Makda 254
 Gelpi, Marco 602
 George, Ashley F. 213

Gharbharan, Arvind 467
 Ghosn, Jade 628
 Gianella, Sara 304, 358
 Giovenco, Danielle 944
 Giron, Leila B. 332, 553
 Godot, Véronique 248
 Goga, Ameena 823, 824
 Golden, Matthew R. 148
 Gonzalez, Gabriel 312
 Gonzalez Perez, Juan 862
 Goonetilleke, Nilu 285
 Gopalsamy, Srinivasa Nithin
 772
 Gordon, David E. 476
 Gourdelier, Manon 181
 Govindaraj, Sakthivel 880
 Gramatica, Andrea 370
 Gray, Glenda E. 47, 121
 Grinsztejn, Eduarda 662
 Gross, Robert 613
 Groves, Nicholas S. 21
 Grudda, Tanner 71
 Guaraldi, Giovanni 521, 597
 Gudipati, Smitha 815
 Gummerson, Elizabeth 788
 Guo, Ling 799
 Guo, Siyuan 901
 Gupta, Samir 138
 Gurley, Stephen 887
 Gutiérrez Chamorro, Lucía
 282

-H-

Haas, David W. 438, 595
 Hagemann, Kerri 321
 Hagins, Debbie 603
 Hamill, Matthew M. 881
 Hamm, Sebastian 296
 Hampshire, Karly 789
 Hamusonde, Kalongo 801
 Hamzah, Lisa 604
 Hanley, Timothy 335
 Hanna, John 807
 Hansen, Megan E. 571
 Hartana, Ciputra A. 712
 Hasan, Mahmudul 346
 Hastie, Elizabeth 666
 Hazra, Aniruddha 872
 He, Xuan 119, 245
 Heck, Craig J. 922
 Heffron, Renee 927
 Helmold Hait, Sabrina 287
 Hendrix, Craig W. 83
 Henrard, Sophie 428
 Hensen, Bernadette 813
 Herce, Michael E. 913
 Hermans, Lucas E. 451
 Herrera, Carolina 442
 Herschhorn, Alon 158
 Hickey, Matthew D. 596
 Hikichi, Yuta 161
 Hill, Andrew 486
 Hill, Kristi C. 837
 Hines, Jonas 586, 826, 863
 Hitchings, Matt 828
 Ho, Ya-Chi 69
 Hoang, Timothy 25
 Hoffmann, Christian 513
 Holguín, Africa 756
 Hoover, Karen W. 852
 Horberg, Michael A. 98

Hosek, Sybil 844
 Hu, Zixin 506
 Huang, Ya-Lin A. 832, 833
 Huang, Yi-Chia 544, 902
 Huck, Daniel M. 583
 Hudson, Alana G. 536
 Humphrys, Daniel 163
 Hung, Chien-Ching 538
 Hunt, Peter W. 552

-I-

Imaz, Arkaitz 495
 Imperial, Marjorie Z. 452,
 649
 Ingiliz, Patrick 539
 Innis, Emily A. 338
 Irie, Whitney 925
 Ismail, Jeeda 581
 Iwuji, Collins 892, 903
 Izquierdo-Useros, Nuria 183

-J-

Jackson-Gibson, Maya 29
 Jacobs, Jana L. 198
 Jain, Mamta K. 546, 548
 Jalloh, Sallieu 170
 Janekrongtham, Chawisar
 647
 Janssens, Julie 325
 Jantarabenjakul, Watsamon
 243
 Jao, Jennifer 696, 726
 Jayaweera, Dushyantha
 464
 Jiang, Danting 209
 Jilg, Nikolaus 105, 459
 Jimenez Leon, Maria Reyes
 359
 Jing, An 497
 Jo, Stephanie 554
 Johnson, Samuel D. 191
 Johnson Lyons, Shacara 768
 Jones, R. Brad 373
 Jordan-Paiz, Ana 222
 Jordans, Carlijn 896
 Joseph, Jessica 564, 709
 Joseph, Sarah B. 381
 Joseph Davey, Dvora 145,
 704, 705
 Juelg, Boris 139
 Justman, Jessica E. 46

-K-

Kaarboe, Mari 375
 Kagan, Ron M. 821
 Kakande, Elijah 75
 Kalayjian, Robert 412
 Kallianpur, Asha R. 406, 616
 Kamkwala, Asante R. 409
 Kankaka, Edward N. 906
 Kanyama, Cecelia 663
 Kapetanovic, Suad 418
 Katbi, Moses 803
 Katoto, Patrick De Marie
 C. 650
 Kavuma, Paul 889
 Ke, Ruian 178
 Kearney, Brian P. 470
 Kenny, Grace 274
 Kettelhut, Aaren E. 219
 Killian, Rose 141
 Kim, Eun Hye G. 331

- Kim, Manse 651
 Kim, Rachel 344
 Kimball, Anne A. 835
 Kincer, Laura 130
 King'e, Maureen M. 693
 Kisakye, Alice 905
 Kityo, Cissy 488
 Kizito, Samuel 725
 Kleinman, Adam J. 354
 Knudsen, Andreas D. 576
 Koepke, Lennart 309
 Kohler, Pamela 915
 Kohli, Anita 102
 Kong, Weili 18, 171
 Konrad, Christina V. 369
 Kostaki, Evangelia G. 783
 Kourtis, Athena 677
 Kovarova, Martina 210, 446
 Krakauer, Felipe 907
 Krishnan, Sonya 660
 Kronfli, Nadine 750
 Kubjane, Mmamapudi 659
 Kufa-Chakezha, Tendesayi 920
 Kuguel, Sebastián G. 283
 Kuhn, Louise 715
 Kulpa, Deanna 123
 Kumarasamy, Nagalingeswaran 101, 636
- L-**
 LaCourse, Sylvia 645, 673, 698
 Laeremans, Thessa 286
 Lahiri, Cecile D. 232
 Lake, Jordan 527, 606
 Lambrechts, Laurens 328
 Landovitz, Raphael J. 96
 Lang, Raynell 614, 776
 Larsen, Anna 845
 Lee, Eunok 319
 Leeme, Tshepo B. 665
 LeeVan, Elyse 791
 Leroy, Laury Anne 239
 Lesko, Catherine R. 945
 Letendre, Scott L. 133
 Li, Jonathan 379
 Li, Michael J. 932
 Li, Rui 333
 Li, Shuyi 706
 Li, Xinyi 790
 Li, Yifan 275
 Li, Yijia 203, 364
 Li, Yunqi 230
 Li, Zichong 341
 Lier, Audun J. 848
 Lim, Ha Eun 340
 Limanaqi, Fiona 173
 Lin, Kuan-Yin 866
 Ling Hu, Ted 757
 Lingas, Guillaume 455
 Littlefield, Katherine M. 316
 Liu, Albert 82
 Lo, Janet 134
 Loerinc, Leah 562
 Lopez, Paul G. 160
 Lowenthal, Elizabeth D. 739
 Lu, Maolin 167
 Lurain, Kathryn 572
 Lwin, Hay Mar Su 582
- M-**
 Ma, Jimmy 537
 Ma, Tongcui 20
 Macatangay, Bernard J.C. 260, 261, 281
 Macdonald, Pippa J. 85
 Macias, Juan 518
 Madlala, Hlengiwe P. 689
 Magan, Mahad 800
 Magodoro, Itai M. 605
 Mahomed, Sharana 856
 Makaba, Ziyanda T. 724
 Makarova, Natalia 858
 Mallarino-Haege, Christina 215
 Mancebo Pérez, Cristina 565
 Maness, Nicholas 240
 Marathe, Gayatri J. 535
 Margot, Nicolas 508
 Martin, Holly A. 386
 Martín Alonso, Samara 186
 Martin Carbonero, Luz 529
 Martinez, Esteban 598, 942
 Martinez, Miguel A. 182
 Martínez-Sanz, Javier 482
 Martinot, Martin 758
 Massud, Ivana 855
 Masters, Mary Clare C. 620, 937
 Mastroso, Ilaria 132, 466, 630
 Mathad, Jyoti S. 683
 Mathews, Saumi 390
 Matovu, Flavia K. 682
 Matthews, Lynn T. 846
 Matthews, Randolph P. 432
 Mawokomatanda, Tebitha 769
 Mayer, Kenneth H. 939
 Mazzotta, Valentina 462
 McAlpine, Lindsay S. 635
 McCluskey, Suzanne 485, 487, 515
 McGettrick, Padraig 578
 McKinnon, John 468
 McLaughlin, Angela 839
 McManus, Kathleen A. 910
 Mdluli, Thembi 324
 Meade, Christina S. 413
 Mélade, Julien 176
 Melo, Jason S. 775
 Menétréy, Caroline 528
 Mikaeloff, Flora 623
 Mili, Fatima D. 811
 Milic, Jovana 522, 629
 Miller, Rachel L. 781
 Mills, Edward J. 453
 Min, Alice K. 402
 Min Han, Win 526, 615
 Minchella, Peter 641
 Miro, Jose M. 551
 Mitchell, Julie 392
 Mizushima, Daisuke 918
 Mngqibisa, Rosie 77
 Moallef, Soroush 749
 Mocroft, Amanda 534, 559
 Mogere, Peter A. 817
 Möller, Isabela 760
 Molto, Jose 435
 Momplaisir, Florence 751
- Monardo, Roberta 302
 Monin, Malte B. 480
 Montaner, Luis J. 503
 Montanha, Maiara C. 654
 Montano, Mauricio 26
 Moore, Amelia E.B. 609
 Moraleda, Cinta 822
 Morris, Sheldon 851
 Mota, Talia M. 262
 Mouchati, Christian F. 643
 Moyo, Sizulu 825
 Moysi, Eirini 264
 Mpoudi Ngole-Etame, Mireille 493
 Muecksch, Frauke 125
 Mugarra, Christopher 904
 Mujigira, Andrew 897
 Mulenga, Lloyd B. 135
 Muñoz-Basagoiti, Jordana 475
 Musoke, Lewis S. 585
 Mussini, Cristina 465
 Muthoga, Charles 664
 Mutisya, Immaculate 720
 Muyindike, Winnie R. 653
 Mwangi, Winfred 685
- N-**
 Nachega, Jean 672
 Nance, Robin M. 587
 Nayrac, Manon 241
 Ncayiyana, Jabulani 900
 Nchioua, Rayhane 23
 Neary, Jillian 384
 Negi, Riya 204
 Neilan, Anne M. 829
 Nekhai, Sergei 208
 Nelson, Bryan S. 718
 Neogi, Ujjwal 227
 Ngure, Kenneth 88, 146
 Nguyen, Thuy 382
 Nicol, Melanie R. 450
 Nicolas, Alexandre 294
 Nishimura, Holly 805
 Niyomnatham, Suvimol 244
 Nleya, Bokani 159
 Nomah, Daniel Kwakye 469
 Novitsky, Vlad 517
 Nyang'wa, Bern-Thomas 79
 Nyemba, Dorothy C. 886
- O-**
 O'Brien, Meagan P. 104
 O'Connor, Megan A. 192
 O'Halloran, Jane 400, 593
 O'Shea, Jesse 94
 Obregon-Perko, Veronica 188
 Odeny, Thomas 556
 Ogbe, Ane T. 288
 Ogbuagu, Onyema 491
 Ollerton, Matthew T. 214
 Oluoch, Lynda M. 878
 Ombajo, Loice A. 136
 Omollo, Victor 877
 Onovo, Amobi 810, 936
 Ortblad, Katrina 928
 Ortiz, Alexandra 120
 Overton, Edgar T. 479, 607, 746

-P-

Pagani, Isabel 168
 Pahus, Marie H. 504
 Pal, Virender K. 185
 Palefsky, Joel 106
 Pan, David Z. 458
 Panigrahi, Soumya 193
 Pasca, Sergiu 575
 Patel, Eshan U. 754, 808
 Patel, Nisha M. 873
 Patel, Payal B. 417
 Patel, Rena 33
 Patel, Suhani 798
 Pathak, Rajiv 177
 Paton, Nicholas 137
 Patten, Gabriela E. 719
 Peetluk, Lauren S. 652
 Peluso, Michael J. 631
 Perdomo-Celis, Federico 257
 Pereira Ribeiro, Susan 205
 Perez, Stephen 44
 Perez-Gomez, Alberto L. 314
 Persaud, Deborah 31
 Pertinez, Henry 449
 Petersen, Kalen 421
 Peterson, Tess 589
 Pham, Thao 430
 Pham, Tony 854
 Pham, Tram N.Q. 353
 Phinius, Bonolo B. 543
 Pickering, R. Taylor 600
 Pitman, Matthew C. 355
 Plaisly, Marie K. 549
 Platt, Laura 793
 Plaza-Jennings, Amara 391
 Podany, Anthony T. 78
 Popoola, Victor O. 792
 Post, Frank A. 608
 Pourcher, Valérie 289
 Poveda, Eva 225
 Powers, Jenna S. 70
 Prajapati, Girish 496
 Prates, Gabriela S. 573
 Premgamone, Athiporn 736
 Price, Bradley S. 637
 Price, Jennifer 523
 Prodger, Jessica L. 269
 Pungpapong, Gunn 396
 Puray-Chavez, Maritza N. 164

-R-

Rahman, Mohammad Arif 238
 Raju, Sarath 611
 Rallón, Norma 366
 Ramakrishnan, Aditi 914
 Ramos Amador, Jose Tomas 742
 Ranzani, Alice 398
 Rapoud, Delphine 912
 Rebeiro, Peter F. 771
 Reeves, Daniel B. 713
 Reiss - Stafford, Emma 857
 Requena, Maria B. 532
 Reverté Calvet, Laia 201
 Rhodehouse, Kyle 365
 Richard, Jonathan 217

Riebensahm, Carlotta 524
 Riggs, Patricia K. 408
 Riitho, Victor 234
 Rist, Michael P. 569
 Rodríguez Galet, Ana 816
 Rodriguez-Centeno, Javier 624
 Rogando, Andrea C. 619
 Roh, Jamin 200
 Romo, Matthew L. 911
 Rosás-Umbert, Miriam 122
 Rosenberg, Nora E. 787
 Rossotti, Roberto 876
 Routhu, Nanda Kishore 251
 Rovito, Roberta 196
 Rowan, Sarah E. 752
 Roy, Upal 625
 Royston, Léna 579
 Rubin, Leah H. 423
 Ruffieux, Yann 557, 558, 766
 Rull, Anna 483
 Russell, Magdalena 707

-S-

Sainz, Talia 730, 731
 Saito, Suzue 90
 Salahuddin, Syim 40
 Saluzzo, Simona 555
 Salvadori, Nicolas 814
 Salvino, Joseph M. 477
 Sánchez-Conde, Matilde 618
 Sánchez-Gaona, Nerea 307
 Santiago, Mario L. 24
 Santinelli, Letizia 221
 Santos, José Ramón 510
 Sardo, Luca 190
 Sarro, Yeya dit Sadio 648
 Schaafsma, Torin T. 812
 Schember, Cassandra O. 809
 Schenck, Jessica K. 401
 Schneider, Jeffrey 255
 Schnure, Melissa 830
 Schumacher, Christina 870
 Schynkel, Tinus 187
 Scordio, Mirko 566
 Scribner, Curtis L. 474
 Segeral, Olivier 28
 Seiger, Kyra W. 68
 Selim, Michelle 935
 Serero, Jordana 533
 Shah, Neha 895
 Shapiro, Adrienne E. 103
 Shapiro, Roger L. 32
 Sharma, Ashish A. 270
 Shen, Grace 580
 Shiau, Stephanie 690, 716
 Shrestha, Lasata 723
 Shrestha, Ram 929
 Shrivastava, Shikha 249
 Sibude, Jeanne 684
 Siddiqi, Azfar-E-Alam 761
 Sieg, Scott F. 265
 Sigel, Keith 561
 Silverberg, Michael J. 39
 Simbayi, Leickness C. 753
 Simonetti, Francesco R. 385
 Simons, Lacy M. 179
 Simpson, Jennifer 256
 Singh, Amit Kumar 259

Singh, Kasha P. 547
 Singh, Priya 703
 Singh, Sonia 43, 899
 Skaathun, Britt 785
 Skipper, Caleb 667
 Sklutuis, Rachel 389
 Skrivankova, Veronika W. 802
 Smith, Marie-Soleil R. 681
 Smith, Robert A. 500
 Smith-Anderson, Christiana 740
 Sobieszczuk, Magdalena E. 81
 Solomon, Sunil S. 93
 Sorrentino, Leonardo 311
 Sowah, Leonard 530
 Spence, Amanda B. 640
 Spinelli, Matthew A. 888
 Stansfield, Sarah 836
 Statzu, Maura 371
 Stern, Jared 337
 Stranix-Chibanda, Lynda 30
 Strizki, Julie M. 471
 Su, Hang 277
 Suanzes, Paula 668
 Sugarman, Jeremy 859
 Sun, Hsin-Yun 541
 Sun, Jing 48, 617
 Sun, Yinghui 938
 Sy, Karla Therese L. 827
 Søgaaard, Ole 62

-T-

Tagarro, Alfredo 711, 745
 Taiwo, Babafemi O. 454
 Tamargo, Javier A. 748
 Taramasso, Lucia 399
 Tauzin, Alexandra 242
 Tavasoli, Azin 410
 Teasdale, Chloe A. 699, 702
 Tebas, Pablo 352
 Tessema, Zaena 780
 Thakker, Jalpa H. 144
 Thorne, Claire 678
 Tiecco, Giorgio 883
 Tietjen, Ian 473, 499
 Tipoe, Timothy L. 266
 Titanji, Boghuma K. 590
 Tomalka, Jeffrey A. 118
 Tomescu, Costin 279
 Toribio, Mabel 38
 Torre, Peter 697
 Torres-Ruiz, Fernanda 639
 Touloumi, Giota 797
 Toy, Junine 948
 Trickey, Adam 764
 Trinité, Benjamin 273
 Trunfio, Mattia 411

-U-

Umvilighozo, Gisele 224
 Underwood, Mark 481
 Upton, Sierra 779

-V-

Vadaq, Nadira 228, 229
 van der Straten, Karlijn 272
 van Doren, Vanessa E. 882
 van Duyn, Rachel 175
 van Kampen, Jeroen J.A. 512

van Rensburg, Roland 395
 van Santen, Daniela K. 73
 Vance, David 426
 VanderVeen, Laurie 367
 Vanetti, Claudia 174
 Varga, Leah 774
 Varriale, Joseph 372
 Vázquez Alejo, Elena 674
 Veenhuis, Rebecca T. 129
 Vega-Ramirez, Hamid 933
 Veloso, Valdilea 838
 Ventura, John D. 351
 Verdejo-Torres, Odette 405
 Vergori, Alessandra 293, 632
 Verma, Mohit 246
 Vestad, Beate 638
 Vhembo, Tichaona 692
 Vigón, Lorena 315
 Viox, Elise G. 189
 Visseaux, Benoît 197, 755
 Vitale Andrade, Joana 298
 Volpe, Karen E. 415
 Vyas, Kartavya J. 762

-W-

Waalewijn, Hylke 734
 Wada, Paul Y. 658
 Wafula, Andrew W. 926
 Walker-Sperling, Victoria E.K. 63
 Wallace, Michael S. 550
 Wallis, Zoey K. 397
 Walmsley, Sharon 864
 Wang, Fan 440
 Wang, Qiankun 360
 Wang, Ruolan 484
 Wang, Yiran 212

Wang, Yuhuan 457
 Wang, Zheng 37
 Ward, Adam R. 231
 Watson, Eric S. 627
 Webb, Bradon 456
 Weber, Elijah 434
 Wedrychowski, Adam 362
 Wei, Yulong 308
 Weinberger, Leor 472
 Weisberg, Matthew A. 796
 Weiser, Sheri D. 931
 Wettstein, Anja E. 934
 White, Jennifer A. 380
 White, Kevin S. 403
 Williams, Mark 743
 Wittkop, Linda 868
 Wohl, David A. 494
 Wohlfeiler, Michael 908
 Woldemeskel, Bezawit A. 318
 Woldeesenbet, Selamawit A. 701
 Wu, Vincent H. 66
 Wu, Xinsheng 947

-X-

Xu, Ziyang 235

-Y-

Yaffe, Zak A. 691
 Yagnik, Bhrugu 348
 Yazdanpanah, Yazdan 323
 Yeung, Stephen T. 195
 Young, Isabella 80
 Young, Ruth 91
 Yu, Jingyou 247
 Yuan, Zhe 350
 Yurkovetskiy, Leonid 166

-Z-

Zabaleta, Nerea 250
 Zablocki-Thomas, Laurent D. 347
 Zacharopoulou, Penny 505
 Zanni, Markella V. 577
 Zaunders, John 126
 Zeballos Rivas, Diana Reyna. 843
 Zech, Fabian 165
 Zewdie, Kidist Belay. 87
 Zhang, Haeyoung 433
 Zhang, Lei 765
 Zhang, Weiying 233
 Zhao, Connie A. 216
 Zhou, Shuntai 45
 Zhu, Weiming 834, 853
 Ziegelbauer, Joseph 42
 Zucker, Jason 917

NOTES

[illegible]

[illegible]

SCHEDULE AT A GLANCE

General Information

CROI 2022 Schedule February 12-16 (with symposia)

Live Program • February 12 - 16, 2022

Time	Saturday, February 12, 2022	Sunday, February 13, 2022	Monday, February 14, 2022
8:00 AM MT START	W-1 SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES (8:30 AM -12:30 PM)	OPENING SESSION (8:30-10:45 AM) MARTIN DELANEY PRESENTATION <i>WE'RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION</i> BERNARD FIELDS LECTURE <i>VACCINE STRATEGIES FOR HIV-1 AND COVID-19</i> N'GALY-MANN LECTURE <i>HIV RESEARCH: GENERATING EVIDENCE TO ADVANCE PUBLIC HEALTH POLICIES IN BRAZIL</i> THE COVID-19 EPIDEMIC IN THE UNITED STATES: A DISCUSSION WITH DR ROCHELLE P. WALENSKY	P-1 MONDAY (8:30 - 9:30 AM) • HIV NONPROTEIN MODELS FOR PATHOGENESIS AND CURATION • CHILDREN AND UNINFECTED ACTION
9:45 AM MT			ORAL ABSTRACTS (11:45 AM)
11:00 AM MT		CONCURRENT TECHNICAL WORKSHOPS (11:00 AM -1:00 PM) W-2 FRONTIERS IN LABORATORY TECHNOLOGIES W-3 CASE-BASED LIVER WORKSHOP W-4 CLINICAL TRIAL DESIGN AND ANALYSIS	0-1 TARGETS OF VIRAL INFECTION 0-2 MATERNAL AND NEWBORN INFECTIONS 0-3 MALIGNANCY AND COMORBIDITIES 0-4 EVOLVING HIV AND S
12:00 PM MT			CONCURRENT SESSIONS (12:00 PM)
12:30 PM MT			11 VIRAL SUPPRESSION: THE FACE OF RESPONSIVE VACCINES 12 COVID-19: CONSENSUS AND CONTROVERSY 13 (COVID-19) MANDATORY PRESENT, FORWARD
1:00 PM MT			
1:15 PM MT			NETWORKING OPPORTUNITIES FOR INVESTIGATORS
2:00 PM MT			LIVE CHAT SESSION WITH PRESENTERS
3:30 PM MT			
END			

Live Symposia Program • February 22 - 24, 2022

Time	Tuesday, February 22, 2022	Wednesday, February 23, 2022
8:30 AM MT START	CONSECUTIVE SYMPOSIA SESSIONS (8:30 AM - 1:30 PM) 5-1 GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION (8:30 - 10:00 AM)	CONSECUTIVE SYMPOSIA SESSIONS (8:30 AM - 1:30 PM) 5-4 THE HIV RESERVOIR: CRUCIAL FOR MAINTENANCE, AND REVERSAL
10:15 AM MT	5-2 INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER? (10:15 - 11:45AM)	5-5 TUBERCULOSIS: NEW STRATEGIES FOR THE WORLD'S OLDEST ENEMY
12:00 PM MT	5-3 BRINGING CHOICE TO HIV PREVENTION (12:00 -1:30 PM)	5-6 SEXUALLY TRANSMITTED INFECTIONS (12:00 -1:30 PM)
1:30 PM MT		
END		

Schedule at a Glance

(Continues on February 22, 23, and 24)

Monday, February 14, 2022	Tuesday, February 15, 2022	Wednesday, February 16, 2022
P-1 PLENARY SESSION (8:30-9:30 AM) HUMAN PRIMATE FOR STUDIES OF VIRUS INFECTION: PREVALENCE, PERSISTENCE, AND REVERSAL NEW INSIGHTS INTO HIV RNA BIOLOGY UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE	P-2 TUESDAY PLENARY SESSION (8:30-9:30 AM) NEW INSIGHTS INTO HIV RNA BIOLOGY UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE	P-3 WEDNESDAY PLENARY SESSION (8:30-9:30 AM) NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTION PAST AND FUTURE OF HIV VACCINES
ORAL ABSTRACT SESSIONS (9:45-11:45 AM) 0-5 HIV RESERVOIRS AND CURE STRATEGIES 0-6 TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HEPATITIS 0-7 HIV PREVENTION: FROM THE BENCH TO POPULATION 0-8 GLOBAL PERSPECTIVES ON HIV TESTING, TREATMENT, AND PREVENTION 0-9 SARS-CoV-2 ANTIVIRALS AND OUTCOMES	ORAL ABSTRACT SESSIONS (9:45-11:45 AM) 0-5 HIV RESERVOIRS AND CURE STRATEGIES 0-6 TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HEPATITIS 0-7 HIV PREVENTION: FROM THE BENCH TO POPULATION 0-8 GLOBAL PERSPECTIVES ON HIV TESTING, TREATMENT, AND PREVENTION 0-9 SARS-CoV-2 ANTIVIRALS AND OUTCOMES	ORAL ABSTRACT SESSIONS (9:45-11:45 AM) 0-10 IMMUNE RESPONSES TO HIV AND SARS-CoV-2 IN TREATMENT, PREVENTION, AND PATHOGENESIS 0-11 CROSSING THE CNS BORDER: HIV, SIV, AND SARS-CoV-2 0-12 HIV ANTIVIRALS AND OUTCOMES 0-13 SHIFTING PARADIGMS IN HIV TESTING
CONCURRENT INTERACTIVE SESSIONS (12:00-1:00 PM) 14 LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND 15 WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK?	CONCURRENT INTERACTIVE SESSIONS (12:00-1:00 PM) 14 LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND 15 WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK?	CONCURRENT INTERACTIVE SESSIONS (12:00-1:00 PM) 16 CHIMERIC ANTIGEN RECEPTORS (CARs): WHAT'S NEXT? 17 HIV CONTROVERSIES: CASE-BASED APPROACH TO PATIENTS WHO ARE TREATMENT OR PREVENTION EXPERIENCED 18 IMPACT OF VIRAL LOAD IN TRANSMISSION AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION
NETWORKING SESSIONS FOR NEW INVESTIGATORS (1:15-1:55 PM) SPECIAL SESSION: ANAL CANCER PREVENTION AND MANAGEMENT (1:15-2:00 PM)	NETWORKING SESSIONS FOR NEW INVESTIGATORS (1:15-1:55 PM) SPECIAL SESSION: ANAL CANCER PREVENTION AND MANAGEMENT (1:15-2:00 PM)	NETWORKING SESSIONS FOR NEW INVESTIGATORS (1:15-1:55 PM)
LIVE CHAT SESSIONS WITH POSTER PRESENTERS (2:00-3:30 PM)	LIVE CHAT SESSIONS WITH POSTER PRESENTERS (2:00-3:30 PM)	LIVE CHAT SESSIONS WITH POSTER PRESENTERS (2:00-3:30 PM)

Thursday, February 24, 2022
CONSECUTIVE SYMPOSIUM SESSIONS (8:30 AM-1:30 PM) 5-7 IMMUNE PROTECTION IN THE FIELD: RAISING THE STAKES (8:30-10:00 AM) 5-8 HIV AND AGING (10:15-11:45 AM) 5-9 HIV PREVENTION IN SPECIAL POPULATIONS (12:00-1:30 PM)